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INTRODUCTION
1.1 The history on the discovery and nomenclature of Insulin-like Growth Factors
The existence of insulin-like growth factors (IGFs) in blood was fi rst recog-
nized by Wiliam D. Salmon Jr. and Wiliam H. Daughaday in 1956 [1]. Exam-
ining the role of pituitary-regulated growth-stimulating substances, these 
authors demonstrated that a growth hormone (GH) dependent factor in serum 
could stimulate labeled sulfate (35SO4) incorporation into chondroitin sulfate 
(cartilage) in vitro. In line with their fi ndings, Salmon and Daughaday initially 
designated this factor as ‘sulfation factor’ [1]. Comparative studies were also 
performed in vivo. Hypophysectomy of rats markedly reduced labeled sulfate 
incorporation into chondroitin sulfate of epiphyseal cartilage, whereas injec-
tions of pituitary extracts and purifi ed bovine GH effectively restored 35SO4 
incorporation [2,3]. The observations that the direct effect of bovine GH on 
costal cartilage was minimal, whereas serum from hypophysectomized rats 
treated with bovine GH stimulated 3H-thymidine incorporation into cartilage 
led to the postulation that GH utilized the intermediary substance sulfation 
factor [4,5].
In 1963 a second line of research reported excess insulin-like activity (ILA) 
in normal serum. In this study Froesch et al. used an adipose tissue bioas-
say in which glucose uptake and net gas exchange were used as metabolic 
indexes of ILA in serum. They showed that in fasting subjects only 7% of 
serum ILA could be neutralized by insulin specifi c blocking antibodies [6]. 
Based on these fi ndings Froesch et al. introduced the term ‘non-suppressible 
insulin-like activity (NSILA)’. 
In a third line of investigation Dulak and Temin described a polypeptide 
fraction produced by a cell line derived from fetal rat liver cells [7]. Dulak and 
Temin called this fraction ‘multiplication-stimulating activity (MSA)’ as it was 
able to stimulate growth of chicken embryo fi broblast in vitro [7,8]. 
As it became clear that sulfation factor and NSILA had similar (if not identi-
cal) actions, Daughaday and colleagues proposed the term ‘somatomedin’ as 
offi cial designation for sulfation factor in 1972. An important argument for 
this; the accumulating evidence of sulfation factor/NSILA being an important 
mediator of GH (also known as somatotropin) induced actions [5]. 
In the following years it was found that somatomedin/NSILA actually con-
sisted of a family of at least two peptides (respectively somatomedin A and 
C) [9-11]. The amino acid sequences of both polypeptides were published 
by Rinderknecht and Humbel in 1978 [12]. Moreover, in 1981 Marquard and 
colleagues showed that rat MSA differed only a few amino acids from human 
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somatomedin A [13]. As the structure of all proteins closely resembled that 
of pro-insulin, these proteins were offi cially renamed as Insulin-like growth 
factor I (IGF-I) and II (IGF-II) respectively in 1987 [14].
1.2 Evolutionary and structural aspects of insulin-like proteins
1.2.1  The insulin protein superfamily
Together with insulin, IGF-I and IGF-II are members of the so-called insulin 
protein superfamily [15]. This superfamily is comprised of small proteins that 
show similarity at the levels of their primary and tertiary structure. The primary 
peptide sequence of each family member is characterized by three domains; 
a carboxyl A chain joined to an amino terminal B chain by an intervening C 
chain (B-C-A) [15]. 
The insulin superfamily is an ancient family. Insulin and/or insulin-like 
proteins have been described in unicellular eukaryotes [16] as well as in primi-
tive species (e.g. insects, tunicates, annelids, and others) [15-19]. Throughout 
evolution, the prototypical domain structure of these proteins appears to 
have been well conserved: especially the B and A chains share relatively high 
sequency homology between species and exhibit a pattern of distinct and 
highly conserved cysteine motifs which characterize the family. For instance, 
the motif (CC-3X-C-8X-C) present in the A peptide has been termed the so-
called insulin signature [15].
In mammals the insulin protein superfamily originally comprised of four 
members: insulin, IGF-I, IGF-II, and relaxin. Relaxin was identifi ed in the 
1920s by Frederick Hisaw from serum of female guinea pigs as a factor that 
induced widening of the birth canal [20]. In addition relaxin has been found 
to have a variety of other roles, e.g. endometrial differentiation during embryo 
implantation, stimulation of angiogenesis, wound healing and lactation and 
being a modulating factor in cardiovascular responses [21]. Additional mem-
bers of the insulin superfamily have been identifi ed more recently, being 
predominantly expressed in tissues of the reproductive system [15]; Leydig 
insulin-like peptide precursor 3 or INSL3 [22], early placenta insulin-like pep-
tide, placentin or INSL4 [23,24], relaxin/insulin-like factor 2 or INSL5 [25] and, 
relaxin/insulin-like factor 1 or INSL6 [26,27]. Of all the members of the insulin 
protein family, insulin and the IGFs are the most closely related members in 
terms of primary structure and biological activities (see below) [28].
Based on their type of target receptors, the members of the insulin protein 
superfamily can be roughly divided in two distinct groups; those that acti-
vate specifi c tyrosine kinase receptors (insulin, IGF-I and IGF-II), and those 
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that act through G-protein-coupled seven transmembrane receptors (GPCR) 
(relaxin H1, H2 and INSL3-6). Two orphan leucine-rich repeat-containing 
G-protein-coupled receptors, LGR7 and LGR8, have been identifi ed as being 
relaxin receptors [15].
1.2.2 Structural and evolutionary aspects of IGF proteins
The term insulin-like growth factor (IGF) was proposed to denote a class of 
proteins whose structure was highly similar to that of pro-insulin [29,30]. The 
mature human IGF-I protein consists of 70 amino acids with a molecular weight 
of 7.65 kDa [12]. It is synthesized and cleaved from a larger prepro-molecule 
(prepro-IGF-I), containing classic A,B,C and D domains, together with a 48 
amino acid signal peptide and a carboxy-terminal extension (E) peptide. The 
signal and E peptide are cleaved off during processing of the mature IGF-I 
peptide [31]. In contrast to insulin, the mature IGF-I protein retains the C 
peptide and the extended carboxy terminal D-domain, thereby remaining a 
contiguous amino acid chain (Figure 1). In general, human IGF-I, IGF-II and 
insulin have approximately 50% of their amino acids in common [31]. The 
human IGF-I protein shares 48% amino acid sequence homology with human 
pro-insulin [12,30]. The A and B domains of IGF-I and insulin share up to 
60-70% of their amino acids [29]. The mature human IGF-II protein consists 
of 67 amino acids with a molecular weight of 7.5 kD [32]. Like IGF-I, it is also 
synthesized mainly in the liver and cleaved from a larger prepro-molecule 
Insulin IGF-I
Figure 1. Figure of human insulin and IGF-I. The mature insulin peptide is composed of an 
A-region (black) linked to a B-region (light grey) by cysteine bridges (dashed lines). IGF-I 
and IGF-II (not shown) are also composed of an A and B region, but contain two extra 
regions compared to insulin; the C (dark grey) region between the B and A domains and 
the D region (open lines) at the C-terminus. Adapted from Brzozowski et al. Biochemistry 
2002; 41:9389-9397 and LeRoith et al. 1992, 116(10):854-62.
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(prepro-IGF-II), containing A,B,C and D domains, an amino acid signal pep-
tide and a carboxy-terminal extension (E) peptide [15]. In humans IGF-II has 
about 70% structure homology with IGF-I [32]. 
The high amino acid sequence homology and the overlap of biological 
activities (see below) between IGFs and insulin suggests a high probability of 
an evolutionary link between these hormones. Complementary DNAs encod-
ing prepro-IGF-I have been cloned from several vertebrate species including 
mammals, birds (e.g. chicken), amphibians and fi sh (e.g. salmon) [33]. Focus-
ing on primates, IGF-I amino acid sequences are strongly conserved; with 
the exception of new word monkeys (e.g. Callithrix jacchus or Marmoset) 
the sequences of all the mature primate IGF-Is are identical to that of human. 
Also mature dog IGF-I is identical to that of man. In addition, the existence of 
IGF-I, IGF-II and insulin as distinct proteins occurs in all vertebrates except 
for the primitive jawless fi sh (Agnatha). Concerning jawless fi sh, although 
separate IGF and insulin genes have been described in these organisms, there 
are no separate genes for IGF-I and IGF-II [34]. Amphioxus, a protochordate 
expresses a hybrid insulin/IGF molecule. This strongly suggests that IGFs 
diverged from the line of insulin evolution at an early stage of vertebrate evo-
lution, antedating the primitive jawless vertebrates [35]. From these studies 
the hypothesis emerged that duplications of an ancestral insulin(-like) gene, 
that functioned primarily as a “mitogenic” growth factor, allowed insulin to 
develop as a primarily metabolic regulator while the mitogenic activity was 
retained by the IGF gene [36].
1.3 The human IGF-I-gene 
IGF-I is encoded by a single gene copy that in man resides on the long arm 
of chromosome 12 (12q 22–24.1). It comprises six exons spanning a region 
of about 85 kilo base-pairs (kb) [37]. A schematic overview of the IGF-I gene 
is shown in Figure 2. IGF-I gene expression is initiated from either one of 
two promoter regions (P1 and P2, respectively exons 1 and 2) in a tissue 
specifi c manner. In the liver and the kidney IGF-I transcription is initiated 
mainly from P2 and is highly GH dependent, whereas in other tissues P1 is the 
most important initiation site [33]. Exons 1, 2, 5 and 6 are alternatively spliced. 
Exons 1 and 3 and exons 2 and 3 code for the signal peptides, whereas exons 
3 and 4 code for the mature protein. The signal peptide is later cleaved off. 
Exons 5 and 6 encode distinct so-called carboxy-terminal E regions, of which 
there is no equivalent in insulin. Within the inactive pre-pro-IGF-I precursors 
these E-regions play an important role in the maturation of the IGF-I peptide. 
For human IGF-I three different E-domains (Ea (35 residues), Eb (77 residues) 
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and Ec) result from differential splicing of the transcript [33]. Specifi c biologi-
cal activities have been reported from each E-domain, which however goes 
beyond the scope of this thesis.
1.3.1 IGF-I gene polymorphisms
A polymorphism is defi ned as a variation in the nucleotide sequence of 
genomic DNA that is too common to be due merely to a new mutation, 
thereby having a prevalence of at least 1 percent. Within the IGF-I gene 
region two common classes of polymorphisms are present: variable number 
of tandem repeats (VNTR) and single nucleotide polymorphisms (SNPs). 
VNTRs consist of a repetitive number of small nucleotide sequences (ranging 
from one to several) of which the array length can vary. SNPs are defi ned as 
a single nucleotide substitution by another nucleotide and have a genomic 
frequency in average of 1 per 100-1000 nucleotides. Another familiar concept 
in the research fi eld focused on genetic variation is linkage disequilibrium 
(LD), being the co-occurrence of closely linked areas (or alleles) more 
5’ 3’
P1
1exon 2
P2
5 63 4
55.9 Kb 16.9 Kb
untranslated
coding for prepro-IGF-I
coding for mature IGF-I
2.67 Kb
76.2 Kb
4.52 Kb 1.5 Kb 15.4 Kb
84.6 Kb
78.1 Kb
62.9 Kb
78.3 Kb
101398227
101398454
101393551
101393707
101337417
101337598
101313809
101320474
101336067
101335740
Figure 2. Schematic overview of the human IGF-I gene. The human IGF-I gene is located on 
chromosome 12 and comprises of six exons (1-6). Exon 1 and 2 respectively contain the two 
promoter regions from which RNA transcription is initiated (P1 and P2). Several IGF-I  mRNA 
precursors have been isolated. Five of these are shown in this fi gure ranging from ~63 to ~85 
Kb. Exons 5 and 6 give rise to the 3’ untranslated region (3’UTR) from which three different 
E-domains are transcribed. All mRNA transcripts give rise to the same IGF-I molecule. This 
mature IGF-I protein is encoded by exons 3 and 4. In grey the chromosomal positions are 
shown. Also distance between exons is shown.
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commonly than expected by chance only. The explanation for this is that 
genomic recombination during meiosis does not occur at random throughout 
the length of the genome, but at certain privileged sites. Thus, areas without 
these recombination sites are relatively well conserved and thereby tend to 
be inherited together as one block. A combination of such LD blocks give rise 
to haplotypes. An advantage of this approach is that to ‘cover’ the variation 
within a haplotype it may not be necessary to determine all polymorphisms 
within the region spanned by the LD blocks within that haplotype, but only 
those that ‘tag’ this variation. Such SNPs are therefore called tagging SNPs. 
This possibility exists because of the HapMap project, an international project 
investigating LD blocks throughout the genome and in different ethnicities 
(http://www.hapmap.org/). 
In the last decade there has been done extensive research in the fi eld of 
genetic polymorphisms, including numerous studies focusing on IGF-I gene 
polymorphisms/haplotypes, with outcomes ranging from associations with 
levels to complex diseases like diabetes and cancer. It is therefore impossible 
to cover all of this information. A few studies will be highlighted that are to 
some extent of interest in relation to studies included in this thesis. Vaessen 
et al. found in 900 Caucasian elderly participants of the Rotterdam study that 
variance in length of a VNTR microsatellite (ca-repeat) polymorphism at -1 kb 
of the IGF-I gene P1 promoter was associated with several phenotypes [38]. 
Absence of the commonest 192-base pair allele was associated with reduced 
serum IGF-I levels, reduced height, an increased risk of type 2 diabetes mel-
litus (OR 1.7, 95% CI 1.1–2.7) and MI (OR 1.7, 95% CI 1.1-2.5) later on in life. 
Others however could not replicate these fi ndings in another study cohort 
[39]. In a case-control study by Nielsen et al. comprising 694 type 2 diabetics 
(DM type 2) and 218 glucose-tolerant control subjects no associations were 
found between the lack of the common promoter allele and DM type 2. The 
common wild-type allele of the P1 promoter polymorphism was associated 
with increased levels of fasting serum triglycerides in glucose-tolerant whites 
[40]. Rietveld et al. studied this VNTR polymorphism in 346 individuals of the 
Rotterdam study in relation to the age-related decline of total IGF-I levels [41]. 
They found that homozygous carriers of the common allele demonstrated 
signifi cant decline in serum IGF-I with age as observed in the general popula-
tion, whereas heterozygous and non-carriers did not. An identical pattern was 
observed for levels of IGFBP-3. The authors concluded that the P1 promoter 
ca-repeat polymorphism might directly or indirectly infl uence GH-mediated 
regulation of IGF-I secretion. Hovind et al. published a prospective follow-up 
study of a cohort of 277 patients with newly diagnosed type 1 diabetes. They 
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found that subjects with the variant type of the P1 IGF-I ca-repeat polymor-
phism had, during follow-up, a higher risk of development of microalbumin-
uria (MA) compared subjects with the wild type genotype (192/192). A similar 
fi nding was reported by Rietveld et al. in 1069 participants of the Rotterdam 
study, in which it was shown that in the presence of abnormal glucose toler-
ance a higher risk for MA was observed in variant carriers compared to carriers 
of the wild type genotype of this IGF-I gene polymorphism [42].
In a large case-control study in premenopausal women Patel et al. studied 
IGF-I haplotypes bases on tagging SNPs in relation to IGF-I, IGFBP-1 and 
IGFBP-3 levels and risk on breast cancer [43]. Thirty tagging SNPs were ana-
lyzed to cover most common haplotypes, including four haplotype blocks for 
IGF-I and three for IGFBP-1 and IGFBP-3. Certain IGF-I SNPs were associated 
with change in circulating total IGF-I levels. SNPs in IGF-I block 1 (covering 
the promoter region) were most closely associated with circulating total IGF-I 
levels; the variant alleles were signifi cantly associated with higher circulating 
IGF-I levels (trend p = 0.0075 for rs7965399 and p = 0.0262 for rs35767). Cer-
tain IGFBP-3 SNPs were associated up to 12% change in circulating IGFBP-3 
levels. Logistic regression analyses however found no signifi cant associations 
between breast cancer and individual SNPs or haplotypes in located within 
the regions spanning the IGF-I, IGFBP-1, or IGFBP-3 genes. 
1.4 The IGF system and its functional properties in health and disease
The IGF system is a complex molecular network acting in an endocrine, para-
crine and autocrine fashion. Traditionally it includes two growth factors (IGF-I 
and IGF-II), six IGF-binding proteins (IGFBP-1 to -6), nine IGFBP-related 
proteins (IGFBP-rPs) and two cell surface receptors (IGF-IR and the IGF-II 
mannose-6-phosphate receptor (M-6-PR). The IGF-IR functions as biological 
target for both IGF-I and IGF-II. A schematic overview of the IGF system is 
shown in Figure 3 [32]. Figure 3 also shows insulin and the insulin receptor 
(IR), this because of the close relationship between IGFs and insulin as well as 
between their receptors, both qua structure and function. Indeed, it has been 
shown that IGFs and insulin can bind each other’s receptors, and also hybrids 
of the IGF-IR and the IR exist (see below). 
The axis in which IGFs have major participation is characterized by its 
pleiotrophic functions; it is involved in cell growth, proliferation, differentia-
tion and cell survival as well as in the regulation of glucose, fat and protein 
metabolism. In this way the IGF system affects nearly every organ system in 
the body [32]. Figure 4 summarizes most of the established functions of IGF-I.
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1.4.1 The original Somatomedin Hypothesis: ‘the endocrine paradigm’
Originally IGF-I was recognized as part of a classical endocrine hormone 
system being dominated by hypothalamic/pituitary factors, thereby regulat-
ing growth and tissue differentiation [44]. In vitro studies showed that IGF-I 
stimulates cell growth and differentiation in nearly all systems [45]. In vivo 
it was found that human fetal serum had readily detectable concentrations 
of somatomedins/IGFs [46-51], that fetal tissues possessed cell membrane 
somatomedin/IGF receptors of relatively high affi nity [47], and that somato-
medin levels in cord serum correlated with size at birth [52].
EXTRA-CELLULAR
CELL MEMBRANE
INTRA-CELLULAR
IGF-I
Receptor
Insulin
Receptor
subtype A/B
Hybrid
Receptor
IGF-II
Receptor
IGF-IIGF-II Insulin IGF-II
IGFBP1 IGFBP2 IGFBP3 IGFBP4 IGFBP5 IGFBP6 IGFBPrp
ALS
IGFBP protease
ALS
Figure 3. Schematic overview of the IGF system. Classically the IGF system is composed of 
two Insulin Like Growth Factors (IGF-I (black)  and IGF-II (grey)), six high affi nity Insulin-
Like Growth Factor Binding Proteins (IGFBP-1 to -6), several related IGFBPs (IGFBPrp), 
IGFBP proteases and two receptors; the IGF-I receptor (IGF-IR) and the IGF-II receptor. 
All IGFBPs can bind both IGF-I and IGF-II (however with different binding affi nity for 
some).  Only the unbound forms of IGFs are thought to interact with the IGF-IR and the 
IGF-II receptor. Only the IGF-IR is bioactive, and next to IGF-I also binds IGF-II. Next to 
IGFs also insulin and  the insulin receptor (IR) are shown. As IGFs and insulin as well as 
the IGF-IR and the IR share high sequence homology they are able to bind and activate 
each other’s cognate receptors but with different affi nity (denoted by the thickness of the 
arrows). Interestingly, several IGF-IR/IR hybrid receptors are known which can be bound by 
both IGFs and insulin.
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IGF-I was thought being almost solely produced by the liver upon GH stim-
ulation, itself produced by the pituitary in a pulsatile fashion. To some extent, 
GH also stimulates the production of IGF-II, as IGF-II levels are decreased 
about 20% on average in GH-defi ciency [32]. The synthesis and pulsatory 
secretion of GH by the pituitary is infl uenced by several hypothalamic and 
pituitary factors [53]. Two transcription factors PROP1 and PIT1, that regulate 
the differentiation of pituitary cells into somatotrophs during embryogen-
esis, stimulate GH synthesis and its release by the pituitary. In addition, GH 
release is stimulated by transduction signal, activated by the binding of GH 
releasing hormone (GHRH) to the GHRH receptor. Ghrelin, produced in the 
hypothalamic arcuate nucleus and acting through the growth hormone secre-
tagogue receptor, also stimulates the release of GH [54]. Growth hormone 
binds specifi cally to the GHR and thereby mediates the production of IGF-I 
by the liver [55]. The regulation of IGF-I production by GH appears to be 
mediated entirely by signalling through the Janus kinase (JAK) 2 pathway, 
via the phosphorylation of the transcription factor, signal transducer and 
activator of transcription (STAT) 5b [56]. Via the circulation IGF-I reaches its 
target tissues (e.g. bone, cartilage and muscle). In return, IGF-I inhibits GH 
secretion, thereby providing a negative feedback loop within the IGF system 
[57]. Thus, while it was recognized that IGFs had high structural similarity with 
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Figure 4. Overview of the main known functions of IGF-I.
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insulin - suggesting a metabolic function – at fi rst instance the general idea 
predominated that the functional role of IGFs was primarily to act as growth 
factors in an endocrine fashion. This idea has been postulated as the original 
somatomedin hypothesis [44]. 
1.4.2 The Somatomedin Hypothesis 50 years later: ‘the endocrine paradigm 
revised’
1.4.2A Growth/development
Today - more than half a century after the discovery of IGF-I - it has become 
clear that the original endocrine paradigm about the GH/IGF system as 
described is insuffi cient [44,55]. First evidence for this came from D’Ercole and 
collegues in 1980 who published data about extra hepatic IGF-I production. 
In these studies, the authors showed production of IGF-I in addition to liver 
tissue by different explants of fetal mouse tissues solely cultured in serum free 
medium (e.g. lung, brain, kidney and intestine). From this it was concluded 
that this evidence of local/peripheral IGF-I production strongly suggested 
autocrine/paracrine effects of IGFs [58]. Studies on IGF-I mRNA expression 
patterns in different species supported the idea of wide spread IGF-I produc-
tion: it was found that the IGF-I gene was expressed in almost all (if not all) 
mammalian tissues, being not only limited to embryonic tissues, but also in 
the post-natal phase [59,60]. Furthermore it was found that not solely the liver, 
but also other tissues were able to produce IGF-I upon GH stimulation: in 
hypophysectomized rats being injected with GH IGF-I specifi c mRNA expres-
sion could be induced in multiple non-hepatic tissues (e,g. skeletal muscle, 
lung, heart, kidney and white adipose tissue) [61,62]. 
In 1982 the original paradigm of circulating IGF-I as an important compo-
nent for longitudinal growth was challenged signifi cantly by fi ndings by Isak-
son et al. [63]. In their studies the authors showed that unilateral infusion of 
human GH into the cartilage growth plate of hypophysectomized rats resulted 
in signifi cant longitudinal growth of bone at the respective site, but no effect 
was observed in the contralateral limb. Similar results were obtained by others 
[64,65]. Although the suggestion has been made that GH has direct, non-IGF-I 
dependent, proliferative effects on growth plate germinal zone cells - which 
indeed has been observed by others [66,67] - the dwarfi sm phenotype of igf-I / 
IGF-IR null mice clearly shows the signifi cance of IGF-I effects in longitudinal 
growth [68,69]. In addition, it was found that IGF-I knockout mice are even 
smaller than GHR knockout mice [70]. Also in humans it has been found that 
IGF-I gene deletion results in a phenotype that is undisputedly dominated by 
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an extreme short stature [71]. The IGF system is thus intimately involved in 
prenatal and postnatal growth, although production of both IGF-I and IGF-II 
in utero is essentially independent of GH. Through an, as yet, unidentifi ed 
molecular ‘switch’, IGF-I production at around the time of birth transitions 
from its GH-independent mode to a profoundly GH-dependent mode [56].
The contribution of paracrine/autocrine IGF production in relation to 
growth/development was emphasized by Yakar et al. who studied mouse 
models in which liver-specifi c IGF-I gene deletion could be introduced. In 
these models circulating GH levels were increased up to 4-fold and circulating 
IGF-I levels were decreased to about 25% in the knockout mice compared to 
the wild-type. Surprisingly, body length, femoral length and weight of organs 
did not differ between liver-specifi c knockouts and wild-type littermates 
[72,73]. It has to be noticed, however, that circulating free IGF-I levels were 
found to be normal in liver-specifi c IGF-I knockout (LID) mice. Interestingly, 
LID mice show a 4-fold increase in serum insulin levels and abnormal glucose 
clearance after insulin injection. Furthermore the insulin insensitivity in the 
LID mice was shown to be muscle specifi c. Recombinant human IGF-I treat-
ment of the LID mice caused a reduction in insulin levels and an increase in 
insulin sensitivity [74]. 
Based on the above, not surprisingly, the question was raised whether the 
endocrine/circulating component of the IGF system is of signifi cance in relation 
to organism growth/development. However, it was shown that if circulating 
levels of IGF-I dropped to 10-15% of normal by knocking out the acid-labile 
subunit (ALS; see below) next to the IGF-I gene in mice, the linear growth 
of this mouse model was reported to be signifi cantly reduced. The proximal 
growth plates of the tibiae of these double knockout mice were smaller in 
total height as well as in the height of the proliferative and hypertrophic zones 
of chondrocytes. There was also a 10% decrease in bone mineral density and 
about 35% decrease in cortical thickness in these mice. The authors concluded 
that a certain threshold concentration of circulating IGF-I is necessary for nor-
mal bone growth and development [75]. Ueki et al. reported in ALS defi cient 
mice that GH effects (body weight gain, linear growth) mediated by endo-
crine IGF-I were largely dependent on the absence of ALS, whereas the GH-
dependent stimulation of IGF-I expression in liver, adipose tissue and skeletal 
muscle was unaffected. Recently, Wu et al. introduced another interesting 
mouse model. In order to further determine the function of endocrine versus 
tissue produced IGF-I they developed the KO-HIT mice which have no tissue 
IGF-I but exhibit increased serum IGF-I levels due to hepatic over-expression. 
The authors showed that in the total absence of tissue IGF-I, elevated levels of 
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serum IGF-I could support normal body size at puberty and postpubertal ages, 
but were insuffi cient to fully develop the female reproductive system [76].
In conclusion: It has become clear that the IGF system is widely spread 
throughout the body where it has both endocrine and paracrine/autocrine 
properties. Up to 70% of circulating IGF-I is produced by the liver. Paracrine/
autocrine IGF has a large contribution in the regulation of growth/develop-
ment and reproduction, although endocrine IGF also has input of signifi cance. 
GH and IGF-I have both dependent and solitary effects on growth. However, 
normal postnatal growth requires the combined actions of GH and IGF-I [77]. 
1.4.2B  Metabolic aspects of IGFs and their counteractions on GH effects
The original somatomedin hypothesis mainly addressed the mitogenic aspects 
of IGFs (e.g. growth/differentiation) [44]. However, IGFs were originally 
(also) identifi ed by their insulin-like effects (referred to as NSILAs) suggest-
ing IGFs having important metabolic functions/effects [6]. Indeed, IGFs share 
high sequence homology with pro-insulin (see paragraph 1.2.2 in this thesis). 
In paired euglycemic clamp studies, Boulware et al. showed that IGF-I, when 
compared to insulin, had almost identical effects on glucose uptake, glucose 
production, plasma free fatty acid concentrations, and fat oxidation rates [78]. 
Similar to insulin, IGF-I stimulates peripheral glucose uptake [78-80], inhibits 
gluconeogenesis, enhances adipogenesis and inhibits proteolysis, although it 
appears to be less effective than insulin [81,82]. The effects of IGF-I on muscle 
and total body glucose metabolism have been studied extensively in animals 
studies [79,80,83,84] and have been confi rmed in humans [78,85-90]. Concern-
ing support of evidence for the lipogenic properties of IGF-I: most leading 
observations come from studies of treatment of GH-insensitive subjects with 
IGF-I. In such subjects Laron et al. have shown that long-term recombinant 
IGF-I therapy (up to 12 years) increased body adipose tissue to 2-3 fold of the 
normal values [91].
In line with the metabolic actions of IGFs, nutrition has been recognized as 
a major determinant of circulating IGF levels, but also of its actions. Nutritional 
deprivation decreases hepatic IGF-I production by diminishing IGF-I gene 
expression and increases the clearance and degradation of serum IGF-I through 
changes in the levels of circulating IGFBPs [92]. Decreased levels of total IGF-I 
have been observed in states of undernutrition, including marasmus, anorexia 
nervosa, celiac disease and HIV infection [92-94], whereas IGF-I levels rise 
when malnourished patients are refeeded [95,96]. One of the nutritional fac-
tors that is clearly associated with IGF-I activity is protein intake. Elevated 
protein intake is able to prevent the mentioned IGF-I decrease in hypocaloric 
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states [97], whereas protein restriction leads to target organ insensitivity for 
IGF-I [98,99]. An interesting observation in this fi eld comes from Schurch et 
al. in a double-blind placebo-controlled study in elderly individuals with a 
recent hip fracture and low total IGF-I levels [100]. The authors observed that 
a daily protein repletion (20 g) for 6 months resulted in increased total IGF-I 
and IGFBP-3 levels within 1 week (and later on also in prealbumin and IgM), 
increased muscle strength and lowered incidence of medical complications 
(e.g. infections). The authors hypothesized that protein intake might improve 
immune status through restoration of IGF-I actions on the immune system. 
Indeed IGF-I has been shown to stimulate proliferation of immune cells and 
modulates immunoglobulin secretion [101]. Next to protein intake, the car-
bohydrate content of the diet is also a major determinant of responsiveness 
of IGF-I to GH and might be even of superior importance; while the protein 
intake is able to increase IGF-I in the presence of adequate energy, there is 
a threshold energy requirement below which optimal protein intake fails to 
raise IGF-I after fasting [92].
The physiological effects of GH are complex and pleiotrophic. Amongst 
the metabolic effects of GH are gluconeogenesis, ketogenesis and lipolysis, 
all being opposite to those of IGFs [55]. Thus, the original suggestion that GH 
exerts its effects on non-osseous tissues through IGF-I (or IGF-II) as mediator 
does not hold completely: e.g. effects of IGF-I on muscle and other tissues are 
the opposite of those of GH itself. Kaplan and Cohen described an augmenta-
tive/counteractive system for GH-IGF. ‘Because IGFs have insulin-like effects 
that stimulate protein synthesis and inhibit proteolysis while countering the 
hyperglycemic and lipolytic effects of GH, this mechanism serves to enhance 
the anabolic effects of GH’ [55].
1.4.3 IGF binding proteins in relation to IGF-dependent and independent actions
Unlike insulin, which circulates in an unbound form, IGFs circulate in the 
plasma complexed to a group of IGF specifi c binding proteins (IGFBPs). The 
IGFBPs circulate in molar excess of the IGFs. In this way over 99% of present 
IGFs in the circulation are bound, meaning less than 1% of IGFs circulates in 
a free form [32,102].
Six high affi nity IGFBPs are known, referred to as IGFBP-1 to -6, of which 
IGFBP-1 to -3 are more abundant in serum, whereas IGFBP-4 to -6 are more 
tissue specifi c and show low circulatory levels (Table 1). In humans, all six 
IGFBPs share about 50% amino acid sequence homology, with the highest 
degree of homology in the N- and C-terminal regions. The IGFBP genes share 
a common structural organization; four conserved exons are located within 
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these genes ranging from 5 kb (IGFBP-1) to more than 30 kb (IGFBP-2 and 
IGFBP-5) [103,104]. A conserved amino-terminal domain contains six disulfi de 
bonds in all IGFBPs except for IGFBP-6, which has fi ve (Table 1). Important 
IGF-binding residues are found in the amino-terminal domain, as well as in 
the carboxy terminal domain. The central domain of the IGFBPs shows essen-
tially no structural conservation among any members of the family [104,105].
IGFBPs are found in the circulation in an unbound form or in complex with 
IGFs; the binary complex. IGFBP-3 and IGFBP-5 also form ternary complexes, 
consisting of a binary complex of the respective IGFBP with IGFs in complex 
Table 1: Overview of the Insulin-like Growth Factor Binding Proteins 
Binding 
Protein
Chromosome Molecular 
Weight 
(kDa)
Amino 
acid 
residues
Modulation 
of IGF action
Relative IGF 
affi  nity
Comments
IGFBP-1 7 28 234 Inhibition 
and/or 
Potentiation 
I > II Regulated by insulin
RGD sequence
Phosphorylated
Integrin binding
IGFBP-2 2 34 289 Inhibition I < II Major IGFBP in semen
RGD sequence
Heparin binding
IGFBP-3 7 29 264 Inhibition 
and/or 
Potentiation
I = II Major IGFBP in serum
Regulated by GH
ALS binding
N-glycosylation
Phosphorylated
Insulin binding
Inhibition of IR-
autophosphorylation
Inhibition of mitogenesis
Heparin binding
Cell binding
Nuclear localization
IGFBP-4 17 26 237 Inhibition I = II N-glycosylation
2 extra cysteines
IGFBP-5 2 29 252 Potentiation I < II Major IGFBP in bone
ALS binding
Phosphorylated
Heparin binding
Cell binding
Nuclear localization
IGFBP-6 12 28 216 Inhibition I < II Mainly present in CSF
O-glycosylation
2 less cysteines
This table was modifi ed after: Sue M. Firth and Robert C. Baxter: Cellular Actions of the 
Insulin-Like Growth Factor Binding Proteins, Endocrine Reviews, 2001, 23(6):824–854, 
Sujatha Rajaram, David J. Baylink, and Subburaman Mohan: Endocrine Reviews 1997 18(6): 
801–831 and Calum Livingstone: Insulin-like growth factor-related proteins and diabetic 
complications, The British Journal of Diabetes and Vascular Disease, 2003, 3(5): 326-331.
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with a leucine-rich glycoprotein termed the acid labile subunit (ALS) [106,107]. 
Free or binary-complexed IGFBPs are believed to exit the circulation rapidly, 
whereas ternary complexes appear to be essentially confi ned to the vascular 
compartment [108-110].
Being originally recognized as (passive) circulating transport proteins for 
IGF-I and IGF-II, IGFBPs are now recognized as playing a variety of roles 
in the circulation, the extracellular environment and even inside the cell: 1. 
IGFBPs extend half-life of circulating IGFs by preventing their degradation by 
proteolysis. The half-life of unbound/free IGF-I has been reported to be in the 
range of less than 10 minutes [111]. However, when forming a ternary com-
plex with IGFBP-3 and ALS, the half-life of IGF-I is extended to approximate 
12-16 hours [112]. 2. IGFBPs predominate distribution and bio-availability of 
IGFs, thereby modulating IGF interaction with the IGF-IR [113]. In general 
IGFBPs are thought to inhibit IGF actions most probably by binding com-
petition with the IGF target receptors. IGFBPs have also been shown to be 
able to potentiate IGF action presumably by facilitating IGF delivery to target 
tissues [32,114,115]. Although multiple studies describe the potentiating and 
inhibiting actions of IGFBPs on IGF activity, currently there is no unifying 
mechanism that explains these opposite actions. 3. In addition to IGF related/
dependent actions, IGFBPs also have been shown to have their own intrinsic 
bioactivity by binding nuclear receptors (e.g. inhibition of growth and induc-
tion of apoptosis by IGFBP-3) [105,115,116]. Interestingly in this respect, in the 
genome all IGFBPs are in close proximity to the Homeobox gene clusters. Hox 
genes are coding for DNA binding proteins that are involved in the regulation 
of organism morphogenesis. The possibility has been postulated that IGFBPs 
and Hox genes originate from ancestral single genes that underwent controlled 
duplication and translocation, suggesting evolutionary linkage [32,117-119].
1.4.3A IGF actions in relation to IGFBP-1
Insulin-like growth factor binding protein 1 became the fi rst characterized 
member of the IGF binding proteins [120-122]. Next to that of IGFBP-3, the 
human IGFBP-1 gene is located on chromosome 7 (7p14-p12), in close prox-
imity to the Hox-A gene [123-125]. IGFBP-1 is a 25-28 kDa protein. Twelve 
N-terminal and 6 C-terminal cystein residues, which are conserved in mam-
malian IGFBP-1 sequences and other IGFBPs, are important for IGF binding 
[104]. IGFBP-1 is produced in the liver, kidneys and decidua and the ovary 
[126]. Serum levels of IGFBP-1 are highly dependent on metabolic factors/
status, and thereby highly fl uctuate in accordance with food intake. The high-
est levels of circulating IGFBP-1 levels are found in a fasting state (>100 ng/
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dL) inducing a peak at night, and the lowest after food intake (<10 ng/dL) [32]. 
Next to high intra-individual variation, IGFBP-1 levels also vary considerably 
between healthy subjects [127]. In relation to other IGFBPs, IGFBP-1 is thus 
unique in having dramatically variable kinetics in the circulation [126].
The main determinant of IGFBP-1 levels is insulin, through inhibition of 
hepatic IGFBP-1 gene transcription probably via hepatic nuclear factor 3 
(HNF3) [126,128]. In this way IGFBP-1 is involved in the regulation of glucose 
metabolism. Low circulating levels of IGFBP-1 indeed have been associated 
with glucose tolerance, features of the metabolic syndrome and insulin resis-
tance, obesity and the development of cardiovascular disease [129-133]. It has 
been found that in situations of severe stress (e.g. infection, trauma, surgery 
and burn injury) the relation between IGFBP-1 and insulin diminishes. Cyto-
kine control of IGFBP-1 production may be an explanation for these observa-
tions [134,135]. In addition to insulin, IGF-I and IGF-II probably also inhibit 
IGFBP-1 production, whereas glucagon and especially glucocorticoids are 
important stimulatory factors for IGFBP-1 production [126].
In relation to IGF function, IGFBP-1 appears to be a primary and acute 
determinant of IGF-I bioavailability [105]. It has been suggested that IGFBP-1 
facilitates IGF-I transport to the extra vascular compartment, thus thereby 
potentially increasing IGF-I availability/activity in the target tissues [102].
Both potentiating and inhibitory effects of IGFBP-1 on IGF-I actions have 
been described. The positive or negative modulation of IGF-I bioavailability 
by IGFBP-1 is thought to be related to the phosphorylation status of serine 
residues [32,105,136]. The affi nity of phosphorylated human IGFBP-1 for IGF-I 
is six-fold higher than for the nonphosphorylated protein [136]. In humans, 
phosphorylated forms in general inhibit IGF-I actions, whereas dephosphory-
lated IGFBP-1 has stimulatory activity [120,137,138]. The impacts of IGFBP-1 
phosphorylation on its function in vivo are however uncertain.
1.4.3B IGF actions in relation to IGFBP-3
IGFBP-3 is the major IGFBP in human serum. Its molecular weight varies from 
29 kDa (nonglycosylated) to 44 kDa due to the possibility of glycosylation 
[139]. IGFBP-3 forms in which various N-glycosylation sites have been altered 
by mutagenesis reveal that decreasing glycosylation tends to increase cell sur-
face association [140]. The functional implications of this are not certain how-
ever. Like IGFBP-1, IGFBP-3 can be secreted as a phosphoprotein, which in 
contrast to IGFBP-1 does not affect IGF-I binding capacity, however [141]. GH 
is the main regulator of IGFBP-3 production by the liver. Other stimulators are 
Michael BW2.indd   26 27-11-09   11:11
Introduction and Aim of the Thesis 27
interleukin-1, tumor necrosis factor-alpha, transforming growth factor-beta, 
retinoic acid, parathormone , estradiol, glucocorticoids and p53 [32].
Being the most abundant IGFBP, the major IGF transport function can be 
attributed to IGFBP-3, binding about 75-90% of circulating IGFs. In healthy 
adults, about 90% of IGFBP-3 circulates in the ternary 150 kD complex which 
cannot cross the vascular endothelium [104]. The circulating levels of IGFBP-3 
are dependent on age, being low at birth and peaking at puberty after which 
they decrease in further life [139]. 
The relationship between IGFs and IGFBP-3 is highly complex. Inhibit-
ing actions predominate, however IGF potentiating actions by IGFBP-3 have 
been demonstrated in several studies and have been reviewed extensively 
[32,104,105,139]. In general, in vitro studies show that IGFBP-3 in solution 
decreases (growth) stimulatory effects of IGFs via high affi nity sequestration 
of the ligands. The affi nity of IGF to IGFBP-3 is higher than to the IGF-IR 
[142], thereby preventing IGF-IR interaction. In contrast, preincubation of 
cells with IGFBP-3 followed by IGF-I treatment has been found to enhance 
the presentation of IGF to the IGF-IR. Several concepts have been reported: 
IGFBP-3 cell association and processing to a form of reduced IGF affi nity 
[143,144], IGFBP-3 induced protection of cells from IGF-I mediated IGF-IR 
down-regulation [145], mediation of IGF actions by IGFBP-3 through the 
phosphatidyl inositol 3 (PI3)-kinase pathway [146] and/or release of IGFs from 
IGFBP-3 via specifi c proteases for IGFBP-3 [147,148]. Interestingly, 5 amino 
acids present in a 18-residue basic domain (containing a heparin-binding 
motif) that is implicated in IGFBP-3 cell binding play an important role in ALS 
binding. From this it may be speculated that the endothelial cell surface and 
ALS compete for the same residues on IGFBP-3, a process that is involved in 
the dissociation of the ternary complex and the release of IGFs [104]. 
1.4.4 IGF Receptors
The IGF receptor family comprises two trans-membrane proteins. Most actions 
of both IGF-I and IGF-II are mediated through the type I IGF receptor (IGF-
IR), being the cognate receptor for these ligands [32]. IGF-II also binds the 
mannose-6-phosphate receptor with high affi nity. Most studies demonstrate 
that this receptor, having no intrinsic activity, functions mainly as a scavenger 
for IGF-II [32,149]. 
IGFs also have binding capacity for the insulin receptor (IR). A segment 
localized to the C-terminus of the IR α-subunit is subject to tissue-specifi c 
alternative splicing, thereby resulting in two IR isoforms, the IR-A (minus exon 
11) and IR-B, respectively. IGF-II has been reported to bind the IR isoform A 
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with high affi nity. Therefore, IGF-II might use both the IGF-IR and the IR-A 
to exert its effects. Hybrid receptors, formed by one IR hemicomplex and 
one IGF-IR hemicomplex, have been observed [150,151]. Functional studies 
suggest that these hybrids behave like IGF-IR homotetramers rather than as IR 
homotetramers. IR/IGF-IR hybrid receptors bind IGF-I with an affi nity similar 
to that of the IGF-IR, whereas they bind insulin with a much lower affi nity 
[152,153]. The IR isoform in hybrid receptors does not affect affi nity of IGF-I, 
IGF-II and insulin for hybrid receptors [154]. Hence, hybrid receptors may 
play a role in switching signaling from insulin to IGF-I (Table 2). Very recently 
a review has been published about this interesting subject by Belfi ore et al 
[155]. 
1.4.4A  Structure of the IGF-IR
The IGF-IR is a member of the insulin tyrosine kinase class of cell-surface 
receptors, together with the IR and the orphan insulin receptor-related recep-
tor [156]. The human IGF-IR gene is located on chromosome 15q26 and 
encodes a single polypeptide of 1367 amino acids (440 kDa) that is constitu-
tively expressed in most tissues. However, IGF-IRs are very low expressed in 
liver or adipose tissue, in contrast to IRs [157].
The IGF-IR shares approximately 70% amino acid sequence homology with 
the IR, and their genes exhibit obvious homology in terms of size and exon 
organization. The IGF-IR is synthesized as single-chain pre-proreceptor, with 
a 30-residue signal peptide that is cleaved co-translationally. Proreceptors 
are glycosylated, folded and dimerized by chaperone proteins. In the Golgi 
apparatus the receptors are processed at a tetrabasic Arg-Lys-Arg-Arg furin-
protease cleavage site to generate the α (130–135 kDa) and β (90–97 kDa) 
subunits of the mature receptor [158].
The mature IGF-IR consists of two disulfi de αβ-half receptors, linked by 
disulfi de bridges, giving rise to the mature α2β2-heteroterameric holoreceptor 
Table 2. Receptor subtypes of the IGF system
Homotetramers Hybrids
Receptor IR-B/IR-B IR-A/IR-A IGF-IR/IGF-IR IR-B/IR-A IR-B/IGF-IR IR-A/IGF-IR
Name IR-B IR-A IGF-IR HIR-AB HR-B HR-A
Ligand(s) Insulin Insulin IGF-I Insulin IGF-I IGF-I
IGF-II IGF-II IGF-II IGF-II IGF-II
Insulin
Adapted from Belfi ore A, Frasca F, Pandini G, Sciacca L, Vigneri R: Insulin receptor isoforms 
and insulin receptor/insulin-like growth factor receptor hybrids in physiology and disease. 
Endocr Rev 2009;30:586-623.
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even in the absence of ligand. The extracellular α-subunits, containing cyste-
ine-rich regions, form the binding site for IGFs [159]. The β-subunits cross the 
cell membrane, being extracellularly linked to the α-subunits, while the intra-
cellular region of the β-subunits possesses tyrosine kinase activity. The kinase 
domain of the IGF-IR shares 85% homology with that of the IR, and the ATP 
binding cleft is 100% conserved. IGF-IR activation leads to autophosphory-
lation on tyrosines 1131, 1135 and 1136 in the kinase domain, followed by 
phosphorylation of juxtamembrane tyrosines and carboxy-terminal serines. 
This is followed by recruitment of specifi c docking intermediates, including 
insulin-receptor substrate-1 (IRS-1) and SH2 containing protein (Shc). These 
molecules link the IGF-IR to diverse signalling pathways.
1.4.4B IGF-IR signaling pathways
Two main well known signaling pathways are activated through the IGF-IR; 1) 
the lipid kinase phosphatidylinositol-3-kinase (PI3K) / V-akt murine thymoma 
viral oncogene homolog 1 (AKT1) pathway (AKT1 is also known as protein 
kinase B (PKB)) - and 2) the Ras / Mitogen-Activated Protein Kinase (MAPK) 
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Figure 5. Schematic overview of the IGF-IR signaling pathways. After activation of the IGF-
IR by binding of IGF-I or –II, the autophosphorylation process of the kinase subunits leads 
to phosphorylation of adaptor proteins. Two main intracellular pathways are activated, the 
RAS-ERK-MAPK pathway and the PI3/AKT pathway. Both pathways are described in detail 
in the text of paragraph 1.4.4B.
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pathway [160]. A schematic diagram of these pathways is illustrated in Figure 
5. In addition the IGF-IR can modify calcium-dependent signaling pathways 
[160,161].
PI3K-AKT pathway: IRS-1 plays a key role in transmitting signals from the 
IGF-IR to intracellular pathways PI3K / AKT and ERK / MAPK pathways [162]. 
IGF-IR tyrosine phosphorylation induces binding of IRS-1 to the tyrosine 
kinase catalytic unit through its src homology 2 domain (SH2). Tyrosine-
phosphorylated IRS-1 interacts with PI3Ks - also having a SH2 domain - that 
catalyze the conversion of phosphatidylinositol 4,5-bisphosphate (PIP2) to 
phosphatidylinositol 3,4,5-trisphosphate (PIP3) [163]. PIP3 binds AKT1 and 
phosphoinositide dependent kinase-1 (PDK-1). PDK-1 is a crucial kinase 
for activation of both AKT1 and subtypes of protein kinase C (PKC). The 
importance of PDK-1 has been demonstrated by experiments in homozygous 
knock-out mice, which die during early embryonic development [164]. Acti-
vated PKCs and AKT1 facilitate glucose transporter-4 (GLUT4) translocation 
from GLUT4 vesicles to the membrane, thereby enhancing glucose uptake 
[165]. The serine-threonine protein kinase AKT1 froms a key protein in IGF-IR 
signaling. AKT1 phosphorylates and inactivates several cytoplasmatic pro-
teins (Figure 5). Next to GLUT4 translocation AKT1 mediates glucose (and 
protein) homeostasis via inhibition of glycogen synthase kinase-3 (GSK3), 
thereby indirectly promoting glycogen (and protein) synthesis [165,166]. A 
primary function of AKT1 is phosphorylation of B-cell lymphoma 2 (Bcl-2)-
associated death promoter (BAD), thereby inhibiting its pro-apoptotic prop-
erties. Phosphorylation of BAD results in dissociation of the anti-apoptotic 
proteins Bcl-2 and B-cell lymphoma-extra large (Bcl-xl) from the BAD-Bcl2-
Bcl-xl complex [167]. Active AKT1 also inhibits pro-apoptotic members of the 
forkhead transcription factor family (FOXO) by phosphorylation [168]. Brunet 
et al. showed that human FKHR1 - also known as FOXO1 – is a direct target 
of AKT1 preventing FHKR1 induced apoptosis via genes such as Fas ligand 
[169]. Trough activation of Inhibitor of ΚB (I-ΚB) kinases (IKKs), AKT1 allows 
the dissociation of nuclear factor kappa-light-chain-enhancer of activated B 
cells (NF-ΚB) from I-ΚB. In the nucleus NF-ΚB acts as an transcription factor 
which activates several including anti-apoptotic genes [170,171]. The serine/
threonine protein kinase mammalian target of rapamycin (mTOR) is also 
a AKT1 target directly or indirectly (by blocking mTOR inhibitor Tuberous 
sclerosis protein 2 (TSC2)) [172,173]. Via several downstream targets mTOR 
stimulates cell growth, cell proliferation, cell motility, cell survival, protein 
synthesis, and transcription.
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Ras/ERK pathway: IGF-IR activation can also lead to activation of a com-
plex composed of SH2 containing protein (Shc), growth factor receptor 
bound protein-2 (GRB2) and the guanine nucleotide exchange factor ‘son of 
sevenless’ (SOS). The activated SHC-GRB2-SOS complex activates the small 
GTPase Ras which initiates sequential phosphorylation cascades involving 
serine/threonine kinase Raf, MAPK Kinases (MEK1/2), and extracellular 
signal-regulated kinases (ERK) or MAPK. An endpoint of the Ras / MAPK 
pathway is modifi cation of transcription factor activity, such as activation of 
Elk transcription factors [174]. This target pathway of IGF-IR signaling has 
been mostly associated with cell proliferation, differentiation and migration, 
but in some cases can also inhibit apoptosis [160]. In accordance with AKT1, 
ERKs can inhibit apoptosis via phosporylation of BAD and can indirectly 
stimulate mTOR activity (Figure 5).
1.5 The IGF system, aging and longevity
Aging is characterized by a diminished capacity to control homeostasis, 
which associates with an increased susceptibility to develop life-threatening 
diseases and disabilities, such as cancer, cardiovascular disease, diabetes 
and neurodegenerative disorders. A signifi cant and increasing proportion of 
the population is elderly, especially in the developed countries, making it of 
increasing importance to gain insights on how aging predisposes individuals 
to disease. Interestingly, peculiar metabolic characteristics are endowed in 
long-lived people. Some of these include lower than expected body mass 
index, fasting plasma glucose, plasma insulin/IGF-I, insulin resistance as well 
as preserved pancreatic B-cell function [175].
In the last two decades the insulin/IGF signaling pathway has been of 
great interest in relation to organism aging and longevity, including that of 
humans. Transduction of insulin/IGF signals may be critical determinants of 
lifespan in lower rank organisms. Genetic studies performed in the nematode 
Caenorhabditis elegans identifi ed insulin/insulin-like (receptor) pathway 
genes (age-I, daf-2, daf-16 and ins-7) as regulators of its lifespan [176-179]. 
Daf-2 encodes the nematode homologue of the insulin/insulin-like receptors 
in mammals. Disruption of the insulin/IGF-I like daf-2 pathway signifi cantly 
extended lifespan of these organisms up to 30-100% dependent on the 
mutation [180]. Soon afterwards, it was shown that the evolutionary highly 
conserved insulin/insulin-like pathways also infl uence lifespan in yeast and 
insects in a comparative way [181-183]. Referring to the later organisms, 
the fruit fl y Drosophila melanogaster insulin-like receptor gene (InR) is a 
homologue of C.elegans daf-2 and mammalian insulin receptors. Although 
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genotypes homozygous for mutant InR have been reported to be lethal, 
several heteroallelic combinations of InR alleles produce viable adults with 
a dwarfi sm phenotype [184]. Measurement of basal and insulin stimulated 
kinase activity indicated that InRp5545 (P-element insertion in exon-1) and 
InRE19 alleles both resulted in reduced receptor signaling function. Tatar et 
al. found the heteroallelic, hypomorphic InRp5545/InRE19 genotype to live 
85% longer than wild-type controls. Interestingly sexual dimorphism existed 
as this was only true in female fl ies [183]. InRp5545/InRE19 males had higher 
mortality as early adults but reduced mortality at late ages.
To study the insulin/IGF signaling in relation to mammalian longevity 
several rodent models have been used [180]. Of interest are heterozygous 
models of GH/IGF-I defi ciency and IGF-IR knockouts. Both Snell (PIT-1 muta-
tion [185]), and Ames (PROP-1 mutation [186]) mice demonstrate GH/IGF-I 
defi ciency, a dwarfi sm phenotype and increased longevity in both males and 
females relative to wild-type controls [187,188]. Results have to be interpreted 
with caution however; next to GH/IGF-I multiple other primary endocrine 
defi ciencies (prolactin, TSH) and hormonal/metabolic changes (insulin sensi-
tivity, glucocorticoids) are present in Snell and Ames mice which could be of 
importance in relation to organism longevity [180]. Analogous to Drosophila 
melanogaster, IGF-IR and IR homozygous knock-out mice are not vital, but 
die at or shortly after birth due to respiratory insuffi ciency and metabolic 
complications [68]. Holzberger et al. developed a IGF-IR mutant mouse model 
(IGF-IR+/-) harboring heterozygous deletion of exon 3. This exon is coding 
for the ligand binding domain of the IGF-IR and deletion resulted in 50% 
reduction in receptor levels [189-191]. Post-natal growth curves did not differ 
between IGF-IR+/- and wild-type littermates, and only slight differences devel-
oped afterwards being in favor of wild-type controls and more pronounced 
in males than in females. Fertility, consumption and energy expenditure were 
unaffected. Survival analysis revealed a signifi cantly longer lifespan in IGF-
IR+/ - mice compared to wild-types, but this was only signifi cant in females 
(+33%). Interestingly IGF-IR+/- mice displayed increased resistance towards 
methyl viologen-induced intracellular oxidative stress. Again these results 
showed the same sex-dimorphic pattern [189].
Since genetic alterations in IGF-I/insulin (or homologous) signaling path-
ways seem to infl uence longevity in organisms, ranging from yeast to rodents, 
the question was raised whether the low insulin/IGF-I signaling paradigm is 
also applicable to human longevity. Findings are characterized by controversy 
and studies are limited (also due to ethical limits). Both isolated GH defi ciency 
and GH overproduction in acromegaly have been associated with reduced 
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lifespan [192,193]. However, individuals with GH insensitivity or Laron syn-
drome (GHR resistance) have a dwarfi sm phenotype with high GH and low 
IGF-I levels which is not obviously associated with reduced or increased 
lifespan [194]. In a study performed in healthy centenarians, Paolisso et al. 
observed circulating IGF-I levels being equal to subjects aged over 75 years, 
whereas centenarians had lower IGFBP-3 levels. They suggested that in cen-
tenarians the bioavailability of IGF-I is enhanced despite its lower levels [195]. 
Ruiz-Torres et al. studied the pattern of sex-specifi c decline of IGF-I levels 
with age in 205 individuals aged 19-93 years. In contrast to women, decline in 
IGF-I levels with advancing age in men showed a higher slope in individuals 
aged <55 years and a lower slope onwards. They concluded that the regres-
sion line observed in aged men was artifi cially modifi ed by mortality since the 
lowest IGF-I levels measured were higher than those predicted, suggesting 
increased mortality among men with relatively low circulating IGF-I levels 
[196]. 
Other information comes from studies on genetic variability at the loci of 
insulin and IGF-I/II genes. Insulin/IGF gene polymorphisms in relation to 
human longevity were fi rst studied in the region spanning the insulin-IGF-II 
loci. De Luca et al. reported that restriction enzyme determined FokI-AvaII 
haplotypes were found to associate with longevity in Italian centenarians, 
however this was only found in men [197]. Whether and how this polymor-
phism is involved in altered insulin/IGF activity, however, is not known. In 
the Ashkenazi ethnic group an association was found between an ApaI IGF-II 
polymorphism and longevity, but here only in females [198]. In contrast no 
association between variability at the insulin gene locus and lifespan was 
observed in an aging Dutch population in the Leiden 85-plus study [199]. At 
the human IR locus a haplotype was associated with longevity in a group of 
Japanese subjects older than 105 years [200]. Bonafè et al. found genotypic 
combinations at codon 1013 of IGF-IR and at −359 bp from the starting codon 
of phosphoinositide-3-OH kinase (PI3KCB) were associated with longevity 
and with low IGF-I plasma levels in Italian centenarians [201]. The synonymous 
polymorphism (rs2229765) in the IGF-IR gene consists of a G to A transition 
leading to the amino acid change Glu>Glu. Recently, Albani et al. studied this 
IGF-IR gene polymorphism into more detail within another Italian population 
[202]. They found that males showed an age-related increase in the A-allele 
of rs2229765 and a change in the plasma level of IGF-I, which dropped sig-
nifi cantly after 85 years of age (85+ group; A/A homozygous subjects had the 
lowest plasma IGF-1 level). Whether this polymorphism effects IGF-IR activity 
was however not reported.
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Together these observations suggest that the insulin/IGF-I system might 
be involved in longevity, although results are sparse and sometimes confl ict-
ing especially for studies in man. Furthermore, information on how certain 
factors infl uence IGF-I bioactivity in relation to human survival is absent and 
prospective data (which is of course very diffi cult to obtain in the elderly) are 
not available.
1.6  IGF-I and insulin sensitivity, diabetes mellitus and cardiovascular disease
1.6.1 Insulin sensitivity, obesity and diabetes mellitus type 2
Several observations suggest that IGF-I plays a primary role in insulin physi-
ology. Liver-specifi c IGF-I defi cient (LID) mice - characterized by their low 
circulating IGF-I levels - have high GH levels, glucose intolerance and insulin 
resistance [203]. Also, mice with disturbed IGF-IR function display features 
of severe insulin resistance and early onset of type 2 diabetes mellitus (DM 
type 2) [204], whereas over-expression of these receptors in skeletal muscle 
produces a less severe phenotype [205]. Mechanisms that could explain these 
observations are IGF-I-induced enhancement of peripheral insulin actions via 
IGF-IR signaling (e.g. skeletal muscle) and/or suppression of pituitary GH 
secretion. Another interesting observation in this fi eld comes from pancreatic 
β-cell specifi c IGF-IR knock-out mice, which show severely impaired insulin 
secretion upon glucose stimulation compared to controls, which is accompa-
nied by glucose intolerance [206,207].
The role of IGF-I in relation to insulin sensitivity has also been recognized 
in humans. A rare state of IGF-I defi ciency related to a homozygous partial 
deletion in the IGF-I gene is associated with severe insulin resistance which 
was normalized after administration of IGF-I [208,209]. Using clamp studies 
Cusi et al. showed that in healthy subjects IGF-I enhanced insulin sensitivity 
in the fasting state [210]. In addition, several studies showed that administra-
tion of IGF-I (either alone or in combination with IGFBP-3) improved insulin 
sensitivity in healthy subjects [78,85,89,203,211], in those with existing insulin 
resistance [212,213] as well as in subjects with DM type 2 [214,215].
Although these studies point towards a signifi cant role of IGF-I in glucose 
homeostasis, there is lack of unanimity when assessing studies focusing on the 
relationship between the IGF-axis and obesitas and/or DM type 2. It is well 
known that especially obese subjects are prone to develop DM type 2. Some 
studies have reported increased circulating total IGF-I levels in obese subjects 
and type 2 diabetics [216,217]. However, several other studies reported IGF-I 
levels within the (lower) normal range in obesity-related DM type 2 [218-221]. 
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Conversely, lower circulating total IGF-I levels have been associated with 
poorer glycaemic control in DM type 2 [222]. In addition, low circulating IGF-I 
levels also have been found to be independently associated with the presence 
of features of the metabolic syndrome, including insulin resistance [223]. For 
levels of free IGF-I a different profi le has been found, being relatively high in 
obese subjects with and without DM type 2 when compared to non-diabetic 
lean controls [224]. Obesity also affects IGF-II, IGFBP-2 and IGFBP-3; circulat-
ing total and free IGF-II are relatively high in obese subjects, as is IGFBP-3, 
which tend to further rise if type 2 DM is present. In contrast, IGFBP-2 levels 
are decreased in subjects with obesitas and are even lower in those having type 
2 DM [224]. In contrast to measures of IGF-I, those of GH and IGFBP-1 show 
more clear patterns in relation to obesity and/or insulin resistance. Obesity 
is associated with GH hyposecretion and reduced synthesis and circulating 
levels of IGFBP-1 are observed in states of insulin resistance, such as obesity 
[131,225,226]. Elevated serum levels of free IGF-I and -II are likely to increase 
the feedback inhibition of the pituitary GH secretion and this provides an 
explanation for the hyposecretion of GH in obese subjects. Still, despite 
GH hyposecretion, obese subjects show no sign of GHD [224]. Actually it is 
thought that obese subjects are GH hypersensitive since short-term treatment 
with low dose GH has been shown to increase serum total IGF-I signifi cantly 
more in obese than in lean subjects [227]. The increased responsiveness to GH 
in obese subjects could be explained by an up-regulated hepatic GHR density, 
as circulating GH-binding protein (GHBP), which originates from cleavage of 
the extracellular part of the GHR, is elevated in obese subjects [224,228].
Prospective data about the association between the risk of DM type 2 and 
the IGF-axis are limited. Sandhu et al. found an inverse relationship between 
circulating total IGF-I levels and the risk of DM type 2 after an average follow-
up of 4.5 years among about 600 subjects aged 45-65 years [229]. Those hav-
ing IGF-I levels above the median had half the risk of DM type 2 compared to 
those below the median.
1.6.2 The IGF-axis in relation to cardiovascular disease
An enormous number of studies has been published that focused on the ques-
tion whether and (if so) how the IGF system is associated with the risk of 
cardiovascular disease (CVD). The link between IGF-I and CVD comes from 
observations that subjects with primary GH defi ciency and those with acro-
megaly are characterized by increased mortality attributable to CVD [230-232]. 
In general, previous studies point to IGF-I as a pro-atherogenic mediator. For 
instance, IGF-I has been shown to stimulate growth and migration of vascular 
Michael BW2.indd   35 27-11-09   11:11
C
ha
pt
er
 1
36
smooth muscle cells (VSMC) [233-235], and these cells express high numbers 
of both IGF-IR and IGF-IR/IR hybrids [90]. More recently, it has been shown 
that activation of the PI3K/AKT pathway potentiates platelet aggregation 
[102,103]. On the other hand there are several studies that claim opposite 
effects for IGF-I in the development of atherosclerosis. Tumor necrosis factor 
α (TNFα), a pro-atherogenic factor, produced by activated macrophages in 
atherosclerotic plaques has been shown to actively inhibit IGF-I gene expres-
sion [236]. In addition, IGF-I may have directly benefi cial effects on the vas-
cular system through stimulation of nitric oxide production (activated AKT1 
stimulates endothelial nitric oxide synthase) [237]. Third, insulin resistance 
has been convincingly linked to hypertension, obesity, dyslipidemia and 
cardiovascular disease [238]. Therefore, via its benefi cial effects on glucose 
homeostasis and insulin sensitivity (as described in paragraph 1.6.2) IGF-I 
could have important anti-atherosclerotic effects.
Several observational studies report signifi cant associations between low 
circulating total and/or free IGF-I levels and increased risk of CVD [132,239-
242]. Low circulating total IGF-I has been correlated with increased risk of 
MI and AP [243-245]. In a nested case-control study within a prospective 
study Juul et al. measured total circulating IGF-I and IGFBP-3 in individuals 
who on average had a diagnosis of ischemic heart disease (IHD, N=231) 7.6 
years after blood sampling and in age and sex matched controls [242]. The 
authors reported that subjects in the lowest quartile of total IGF-I at baseline 
on average had a 1.94 (95% CI 1.03-3.66) times higher risk of IHD during the 
15 years of follow-up when compared to those in the highest quartile. For 
individuals in the highest quartile of IGFBP-3 this was 2.16 (1.18-3.95) times 
higher than those in the lowest quartile. Individuals with low IGF-I and high 
IGFBP-3 showed a relative risk of 4.07 (1.48-11.22) of having IHD compared 
to controls. The authors concluded that IGF-I may infl uence the development 
of IHD, in which individuals with low levels of total IGF-I and high IGFBP-3 
levels are at risk.
1.7 Measurement of IGF-I: IGF-I immunoassays and IGF-I bioassays
1.7.1 Immunoassays to determine total circulating IGF-I levels
All assays for measurement of circulating IGF-I were initially conventional 
radioimmunoassays (RIA). These assays are based on competition between a 
fi xed amount of radiolabeled IGF-I, a fi xed of IGF-I specifi c antibodies and a 
variable amount of IGF-I in the (unknown) blood sample. As almost all IGF-I in 
blood is bound with high affi nity to IGFBPs techniques have been developed 
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to remove or inactivate IGFBPs to overcome assay interference [246]. The gold 
standard technique for removal of IGFBPs is that of acid gel fi ltration column 
chromatography [247]. Limitations of applicability of this technique are sample 
volume expansion, reproducibility and labor intensiveness [248]. A widely 
used method of IGFBP removal has been acid/ethanol precipitation [249]. By 
use of this technique IGF-I is especially extracted from IGFBPs, which form a 
ternary complex with ALS (IGFBP-3 and IGFBP-5). Smaller IGFBPs, however, 
(e.g. IGFBP-1) remain in the sample and this still can produce signifi cantly 
residual signal interference, especially in pathophysiological conditions (e.g. 
diabetes) [250]. To minimize this problem, Blum et al. developed a method 
that utilized addition of IGF-II to saturate remaining IGFBP binding capacity 
for IGF-I after acid/ethanol precipitation [251]. Most of the currently used IGF-I 
immunoassays have a 2-step antibody design, rather than using competitive 
binding assays. An IGF-I capture antibody is linked to a solid phase (e.g. 
beads, microparticles, coated tube), whereas a second labeled IGF-I antibody 
- directed against another epitope of the IGF-I molecule than the capture anti-
body – is used for detection. The read-out technique used is dependent on the 
type of label linked to the detection antibody; radioactive nuclide (immuno-
radiometric assay (IRMA)), enzyme (enzyme-linked immunoabsorbant assay 
(ELISA)) [252], chemiluminescent molecules (Chemiluminescence immunoas-
say (CLIA)). Of notifi cation, although in theory these assays have the potential 
to eliminate IGFBP interference without necessity of IGFBP extraction and 
saturation techniques, they can still be potentially altered by the presence of 
IGFBPs [248,253]. Furthermore other determinants such as the utilized IGF-I 
standard or antibodies, as well as sample storage conditions may have impact 
on assay outcomes [248,254-256].
1.7.2 Free IGF-I assays
In line with the generally accepted idea that only the unbound IGF-I molecule 
is biologically active, assays have been developed to measure free IGF-I. Early 
methods for determination of free IGF-I were based on neutral size-exclusion 
chromatography, neutral high pressure liquid chromatograph (HPLC) and 
reverse phase chromatography [224]. It was however widely acknowledged 
that chromatography distorted the equilibrium between free and bound IGF-I 
and thereby grossly overestimated levels of unbound peptide [257].
Later Frystyk et al. developed an assay in order to determine free IGF-I lev-
els in human serum. In this assay they used an ultrafi ltration method, in which 
serum is fi ltered at a low-centrifugal force across a membrane allowing passage 
of unbound IGFs but not of IGFBPs. This is followed by a sandwich assay to 
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analyze IGF-I concentration in the ultrafi ltrate compartment [258,259]. At the 
same time, another method for determination of free IGF-I was published by 
Takada et al. using an IRMA method [260]. In both assays temperature turned 
out to be an important determinant. Using the ultrafi ltration method free IGF-I 
levels measured at 37°C were considerably higher compared to those mea-
sured at 5°C [259]. Frystyk et al. compared both methods. They found that the 
direct IRMA technique, next to temperature, was highly sensitive to incubation 
time. Furthermore it was realized that the free IGF-I levels measured by the 
direct IRMA were higher than those measured by the ultrafi ltration method. 
This because the capture antibody used in the direct IRMA method next to 
binding unbound IGF-I probably also extracted IGF-I from IGFBPs [261]. 
While the relevance of free IGF-I to IGF activity is debated, it was found that 
circulating free rather than total IGF-I levels regulate the negative feedback 
loop with GH [262]. Thus, while these assays offer the possibility to determine 
the unbound fraction of circulating IGF-I, they are technically diffi cult to per-
form and outcomes are dependent on the type of assay used.
1.7.3 IGF-I Bioassays and the IGF-I Kinase Receptor Activation Assay (KIRA)
As counts for numerous biological systems - including for the IGF system - 
extracellular biological information is integrated at a cellular level through cell 
surface receptors. Receptor activation then leads to activation and / or inhibi-
tion of target signalling cascades, which eventually lead to cellular endpoint 
responses (e.g. proliferation, differentiation, survival, product secretion / 
uptake or apoptosis). A bioassay is essentially any technique that assesses the 
bioactivity of a given ligand by measuring its induction of a certain response 
by an intact cell. Outcomes (‘responses’) that are generally used in bioassays 
include proliferation, differentiation, survival, product secretion, fl uores-
cence, cytotoxicity or apoptosis. All of these responses used in traditional 
bioassays are downstream events, initiated by the stimulation of a receptor by 
its ligand(s). In case of IGFs classical bioassays have been based on sulfate 
and 3H-thymidin incorporation into cartilage [2,5,263] and proliferation of 
BALBc 3T3 fi broblast cells [264-266] or MCF- 7 human breast adenocarcinoma 
cells [267,268]. However, the weakness of these IGF-I bioassays lies within 
the assessment of cellular responses that are far downstream of the IGF-IR 
signaling cascade. This opens the possibility of interference or cross-links by 
alternative pathways that may lead to the same cellular response. In addition, 
in these assays IGF-I bioactivity might be biased by endogenous production 
of IGFs, IGFBPs, proteases or other factors produced by the read-out system 
due to long duration of ligand exposure. Thus, from the above the cautious 
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conclusion could be drawn that immunoassays also have been introduced to 
estimate IGF-I bioactivity due to the lack of alternative methods (bioassays) 
that met acceptable performance criteria to be available for measurement of 
IGF bioactivity in larger settings. It can thus be stated that the (additive) value 
and performance of bioassays in general greatly depends on their underlying 
design. As with immunoassays, performance of bioassays should be critically 
subjected to general assay terms as sensitivity, specifi city and assay variability, 
but even more important, they should also provide meaningful and additive 
information of biological signifi cance by coming as close as possible to the in 
vivo situation.
In 1999 Sadick et al. published a novel strategy for a rapid bioassay that in 
theory can be applied to every member of the tyrosine kinase receptor super 
family. This method was therefore termed as kinase receptor activation assay 
(KIRA). It employs a two-plate system, one cell culture plate for stimulation of 
intact cells, followed by receptor solubilization and a second plate for recep-
tor capture and analysis of tyrosine phosphorylation by ELISA [269]. In this 
way the KIRA assay can be defi ned essentially as monospecifi c in that only the 
response of the receptor is determined for which it is designed [269].
In case of IGFs, the IGF-IR forms the key structure by connecting the 
extracellular IGF system to its intracellular targets. In this way, biological 
information harbored by the IGF system is integrated and translated into 
intracellular events at the level of the IGF-IR. Activation of the IGF-IR leads 
to conformational changes, allowing autophosphorylation of the intracellular 
kinase domains. Thereby IGF-IR autophosphorylation – the fi rst intracellular 
event, only initiated by ligands able to activate the IGF-IR – forms the most 
specifi c intracellular target, that could be used to assess bioactivity generated 
by the IGF system. Based on the KIRA principle, Chen et al. refi ned an IGF-I 
KIRA developed by Sadick et al. and validated it for measurement of IGF-I 
bioactivity in human serum. As a biological read-out system, they used human 
embryonic renal cells (293 EBNA) stabile transfected with cDNA encoding the 
full-length human IGF-IR gene. Figure 6 shows a scheme of the IGF-I KIRA 
procedure designed by Chen et al.
The IGF-I KIRA uses a short (15-min) sample incubation time, and this mini-
mizes the possible time for the cells to produce IGFBPs and proteases that may 
interfere with the ligand activity during sample incubation. In contrast to IGF 
immunoassays IGFBPs are not removed from serum samples, but are allowed 
to modulate IGF-IR activation via inhibition and/or delivery-of IGFs at physi-
ological conditions as happens in vivo. Qua performance Chen et al showed 
that the IGF-I KIRA is highly sensitive, specifi c (cross-reactivity of insulin, 
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insulin analogs, and proinsulin was less than 1%; IGF-II cross-reactivity was 
12%), and accurate (intra- and inter-assay coeffi cients of variation were about 
7 and 15% respectively). In addition, co-incubation of recombinant IGF-I with 
increasing concentrations of IGFBP-1, -2, or -3 dose dependently reduced 
the IGF-I KIRA signal, showing that the IGF-I KIRA is sensitive for IGFBP 
modulation. Analysis of serially diluted serum samples showed that the sig-
nal was relatively independent of the dilution up to 1:20. Receptor-binding 
experiments with iodinated IGF-I further showed that IGF-IR-binding affi nity 
for IGF-II and insulin was more than 10 and 200 times lower, respectively, 
than that for IGF-I.
By quantifi cation of IGF-IR activation, the IGF-I KIRA is based on a dif-
ferent methodological principle when compared to IGF-I immunoreactive 
Scheme of the IGF-I KIRA assay
293 EBNA
IGF-IR cells
Cell culture in DMEM
with 10% FCS (24 hrs)
day 1
15 min
stimulation
Lysate transfer
to 2nd plate
day 2
IGF-IR capture antibody
coating  (2nd plate)
Switch of culture
medium to DMEM
with 1% HSA (24 hrs)
Cell Lysis
Antibody 1 Antibody 2
P
P EUR
Capturing of IGF-IR followed by detection
of phosphorylation status
IGF-IR
day 3 day 4
Serum
Figure 6. Schematic overview of the IGF-I Kinase Receptor Activation Assay (IGF-I KIRA). 
The assay is a 4-day procedure. On day 1 human embryonic kidney cells stabile transfected 
with the human IGF-IR are cultured in 48 well culture plates (200,000 cells per well) in 
medium containing 10% fetal calf serum (FCS). On day 2 the medium is replaced by me-
dium containing 1% human serum albumin (HSA). A second 96 well plate is coated with an 
human IGF-IR capture antibody (MAD1). On day 3 cells are stimulated with serum for 15 
minutes and then cells are lysed. Lysate is transferred to the washed 96 well plate that was 
coated with MAD1 on day 2. On day 4 the 96 well plate is washed and a second antibody 
is added (PY20), specifi cally recognizing phosphorylated residues located at the kinase 
domains of the IGF-IR. The PY20 antibody contains an europium label that can be detected 
by a time resolved fl uorometer.
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assays [270]. Theoretically IGF-I KIRA measurements represent the outcome 
of the sum of all factors that modify IGF-IR activation, especially those factors 
that directly modulate interactions between IGF-I and the IGF-IR (IGFBPs, 
IGFBP proteases). This makes the IGF-I KIRA method a new and scientifi cally 
interesting tool to study IGF-I bioactivity.
1.7.4 IGF-I bioactivity; what’s in a name?
As the IGF-IR by far has the highest affi nity for IGF-I and outcomes of unknown 
serum samples are plotted against known concentrations of recombinant 
IGF-I as a reference, the method was named ‘IGF-I KIRA’, and its outcomes 
‘circulating IGF-I bioactivity’. However, IGF-II also binds and acts through 
the IGF-IR. Therefore it is to be expected that results of the IGF-I KIRA are 
also infl uenced by circulating IGF-II. As described, the contribution of IGF-II 
to the IGF-I KIRA signal was about 12% when compared to IGF-I at equal 
concentrations [270]. The contribution of IGF-II to IGF-I bioactivity could be 
biologically signifi cant in vivo since circulating IGF-II levels are higher than 
those of IGF-I and do not decline with age as does IGF-I [252]. 
One could argue that sensitivity to IGF-II is a disadvantage of the IGF-I 
KIRA. This argument indeed holds when this phenomenon is interpreted as 
interference of IGF-II in the assay. On the other hand, the general aim of a 
bioassay is to give insight in the function of a biological system and not of 
single system parameters as such. Thus, when applied to the IGF system, 
input of IGF-II in the IGF-I KIRA results can also be seen as an advantage and 
should therefore not be ignored. In this way no biological information is lost 
about the regulation of IGF system biology when studied in relation to health 
and disease.
 In conclusion, it is thus recognized by the author that the term IGF-I bioac-
tivity is very well defendable (and from an historical point of view respected 
in this thesis), but when looked at in more detail it does not completely cover 
all of what is actually assessed by use of this bioassay; namely bioactivity 
that is generated through IGF-IR activation, being independent of the ligand 
(IGF-I or IGF-II and to some extend insulin) that facilitates this.
1.7.5 Studies on IGF-I bioactivity
At the moment of writing this thesis several studies have been published in 
which IGF-I bioactivity was studied. An overview of these studies will be 
given in this paragraph without discussing every detail.
In 8 GH-defi cient (GHD) and 8 healthy age-matched controls Kanaley et al. 
studied whether exercise-induced GH release and administration affected the 
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circulating IGF-system [271]. Blood samples were drawn at baseline, during 
and post-excercise (45 min of cycle ergometer exercise. IGFBP-1 rose at 75 
min post-exercise in all groups, and IGFBP-2 and -3 increased signifi cantly 
over time in GHD subjects, but no change in IGF-I bioactivity was found dur-
ing exercise or recovery in either group although there was a trend for a slight 
decrease in IGF-I bioactivity post-exercise.
Gravholt et al. studied the effects on the GH/IGF-system in 23 women with 
Turner’s syndrome (TS) before and during hormone replacement therapy 
(HRT) in comparison to 24 healthy age-matched women [272]. They showed 
that while immunoreactive IGF-I was normal, IGF-I bioactivity was decreased 
in TS. Although during HRT both the basal increased IGFBP-3 proteolytic 
activity and decreased levels of IGFBP-3 carried within ternary complex were 
normalized, this did not affect IGF-I bioactivity in TS patients on HRT.
In an in vitro setting Møller et al. investigated the effect of six different gly-
cosaminoglycans (GAGs) on serum levels of free IGF-I and IGF-II, bioactive 
IGF-I, total IGF-I, and IGFBPs [273]. Second, the effect of heparin was studied 
in serum from 10 pregnant and 10 post partum women, 8 normal subjects and 
8 patients with type 1 DM. Basal free and bioactive IGF-I where signifi cantly 
higher in pregnant women, but lower in type 1 diabetics when compared to 
controls. In diabetics total IGF-I was also signifi cantly decreased. All GAGs 
signifi cantly increased levels of free IGF-I in a dose-dependent manner, 
whereas total immunoreactive IGF-I and IGFBP levels remained unchanged. 
Heparin strongly increased free and bioactive IGF-I in all tested sera. This was 
most pronounced in sera of pregnant women and less in subjects with type 1 
diabetics.
In a case-control study Chen et al. studied changes in circulating total, free, 
and bioactive IGF-I as well as in IGFBP-1 and -2, and IGFBP-1-bound IGF-I 
(binary complex) during an oral glucose tolerance test (OGTT) in 7 patients 
with liver cirrhosis and 7 matched healthy controls for age and BMI [274]. 
Blood samples were drawn at 0, 30, 60, 90, 120, 150, and 180 min. Baseline 
levels of total (-47%), free (-36%), and bioactive IGF-I (-51%) were signifi -
cantly lower, while IGFBP-1 (+268%) was higher in liver cirrhotic patients. 
Despite unchanged concentrations of total and free IGF-I, bioactive IGF-I 
declined signifi cantly, together with levels of IGFBP-1, IGF-I:IGFBP-1 binary 
complex and IGFBP-1 saturation index, after OGTT in patients with liver cir-
rhosis and the same tendency was observed in healthy subjects. The authors 
hypothesized this may be caused by the observed higher levels of unsaturated 
IGFBP-1, as well as the faster disappearance of ‘readily dissociable IGF-I’ 
present in IGF-I:IGFBP-1 binary complexes.
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Laursen et al. established a model to analyze the regulatory network includ-
ing the IGF-IR, IGF-I and -II, IGFBP-4 and -5 and their specifi c proteolytic 
enzyme pregnancy-associated plasma protein-A (PAPP-A) [275]. They showed 
that in cells treated with the respective IGFBPs in excess of IGF-I, a substan-
tially higher level of IGF-IR activation was observed with IGFBP-4 compared 
with IGFBP-5, whereas when using equimolar amounts of these IGFBPs and 
IGF there was almost no difference. However, the progress of proteolysis was 
by far more pronounced in the second experiment. Binding analyses showed 
tighter binding of IGFs to intact IGFBP-5 than IGFBP-4. To test the hypothesis 
that proteolysis of IGFBP-4 occurred only after cleavage of IGFBP-5, IGF-IR 
activity was analyzed in relation to cleavage of wild-type IGFBP-4 or -5 and 
variants resistant to proteolytic activity. Indeed, proteinase-resistant IGFBP-5 
completely blocked the release of bioactive IGFs from wild-type IGFBP-4.
Støving et al. published a longitudinal case-control study that focused on 
the relation between circulating IGF-I bioactivity and IGF-binding capacity 
(IGFBP-1/IGF-I binary complex formation) in patients with anorexia nervosa 
(AN) at different stages and in different subtypes of the disease [276]. The 
study was performed in 45 women with AN and 24 age-matched healthy 
controls. Despite increased IGFBP-1 concentrations, levels of IGFBP-1/IGF-I 
were normal in AN. Circulating IGF-I bioactivity was signifi cantly decreased 
in patients with restricting and binge-purging subtypes of AN compared to 
controls. This was also the case for total and free IGF-I. Furthermore all three 
IGF-I parameters increased signifi cantly after weight gain during 2–6 months. 
Furthermore, in AN patients, the three IGF-I measurements were tightly corre-
lated. The authors concluded that in AN circulating total and free IGF-I levels 
mirrored IGF-I bioactivity.
Recently, Karl et al. published a cross-sectional study in a cohort of 44 
normally active healthy young women to examine associations between fac-
tors reportedly associated with free and total IGF-I levels and bioactive IGF-I 
[277]. Regression models predicting bioactive IGF-I demonstrated that 61% 
of the variation in IGF-I bioactivity could be attributed to concentrations of 
total and free IGF-I, and IGFBP-1, -2 and -3. Age and alcohol intake were 
negatively correlated to all three IGF-I parameters. Estradiol and progesterone 
levels were positively correlated with both free and bioactive IGF-I levels. 
IGF-I bioactivity solitary showed a negative relationship with body fat and 
a positive relationship with habitual selenium intake. Only free IGF-I was 
positively associated with habitual isofl avone intake. The authors concluded 
that alcohol intake may blunt physiologic actions of the IGF-axis, that female 
sex-hormones may infl uence the IGF-I axis and that although IGF-I bioactivity 
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was not associated with total energy intake, associations with selenium and 
isofl avone intake may refl ect a positive association between protein intake 
and the IGF-I axis.
In another study Frystyk et al. analyzed the relationship between IGF-I 
bioactivity and obesity in 34 healthy women [278]. Of them 11 were lean, 12 
overweight, and 11 obese. Bioactive IGF-I, IGFBP-1 and GH were measured 
in 6h pools of serum. Mean 24h GH, peak stimulated GH and total IGF-I levels 
were inversely associated with BMI, whereas IGF-I bioactivity and IGFBP-3 
levels were not. Total IGF-I was signifi cantly reduced in obese subjects com-
pared to those having overweight. IGF-I bioactivity showed a comparable 
trend but it was not signifi cant. Percent bioactive IGF-I [(bioactive/total IGF-
I) x 100] was signifi cantly higher in obese than both lean and overweight 
subjects. Based on results not fi tting their hypothesis the authors concluded 
that in obesity normal IGF-I activity is maintained and could be mediated by 
enhanced sensitivity to GH at the level of the liver.
AIM OF THE THESIS
1.8 Aim and Outline of the Thesis
The general aim of the research presented in this thesis is to evaluate whether 
circulating IGF-I bioactivity measured by the IGF-I-KIRA has the potential 
to produce new insights in the functional properties of the circulating IGF-I 
system in relation to human aging, health and disease.
Chapter 2: In order to determine the relation between circulating IGF-I 
bioactivity and circulating total IGF-I levels we measured IGF-I bioactivity 
in serum of a healthy study population of blood donors in which total IGF-I 
levels had been determined by use of fi ve different IGF-I immunoassays. 
Dependency of this relation on the type of methodology used to measure 
circulating total IGF levels was evaluated. In addition, normal values of circu-
lating IGF-I bioactivity were determined in the healthy population.
Chapter 3: The IGF system has been linked to organism survival. Therefore 
we studied the relationship between circulating total, free and bioactive IGF-I 
and human survival in an prospective study of elderly men. The main ques-
tion was whether IGF-I bioactivity, being based on another methodological 
and theoretical principle than measurements of circulating immunoreactive 
IGF-I levels could provide new information in this fi eld of research.
Chapter 4: The IGF system is greatly affected in individuals with chronic 
renal failure (CRF), especially in those that are in need of dialysis. Total IGF-I 
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has been suggested as a suitable marker for nutritional status in CRF patients, 
which are in general characterized by undernutrition. In this study we ana-
lyzed whether measures of total and bioactive IGF-I were affected by nutrition 
enriched dialysates in CRF patients on chronic abdominal peritoneal dialysis 
(CAPD). 
Chapter 5: As IGF-I immunoassays are dependent on the interaction 
between IGF-I and highly specifi c antibodies in theory these measurements 
can be negatively or positively disturbed by the presence of serum hetero-
philic antibodies that interact with either the capture or the detection antibody 
or with both. Although this type of assay disturbance has been recognized 
for many immunoassays this has never been described for IGF-I immunoas-
says. In chapter 5 we describe to our best knowledge the fi rst case in the 
literature of heterophilic antibody interference of an IGF-I immunoassays. We 
also studied whether the IGF-I KIRA was sensitive for heterophilic antibody 
interference. 
Chapter 6: Insulin and IGF activity are thought to infl uence each other’s 
actions. In this respect IGF-I and or IGFBP levels have been studied in relation 
to glucose homeostasis, insulin resistance, diabetes mellitus and the metabolic 
syndrome (MS). In a cross-sectional study we analyzed whether and (if so) 
how circulating IGF-I bioactivity was related to glucose homeostasis, insulin 
resistance and to the MS in a group of individuals randomly selected from a 
population study.
Chapter 7: Several studies have found associations between IGF-I gene 
polymorphisms and circulating levels of total IGF-I. In a subcohort of the 
Rotterdam study whether single nucleotide polymorphisms (SNPs) and haplo-
types of the IGF-I gene were related to levels of circulating total and bioactive 
IGF-I. Furthermore we also studied whether these polymorphisms/haplotypes 
were related to the development of MI and/or AP in the study population.
Chapter 8 covers the general discussion and the future perspectives. 
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ABSTRACT
Background: IGF-I immunoassays are primarily used to estimate IGF-I bio-
activity. Recently, an IGF-I specifi c Kinase Receptor Activation Assay (KIRA) 
has been developed as an alternative method. However, no normative values 
have been established for the IGF-I KIRA.
Objective: To establish normative values for the IGF-I KIRA in healthy adults. 
Design: Cross-sectional study in healthy non-fasting blood donors. 
Study participants: 426 healthy individuals (310 M, 116 F; age range: 18 – 79 yrs)
Main outcome Measures: IGF-I bioactivity determined by the KIRA. Results 
were compared with total IGF-I, measured by fi ve different IGF-I immunoas-
says. 
Results: Mean (± SD) IGF-I bioactivity was 423 (± 131) pmol/L and decreased 
with age (β = -3.4 pmol/L/yr, p < 0.001). In subjects younger than 55 yrs mean 
IGF-I bioactivity was signifi cantly higher in women than in men. Above this 
age this relationship was inverse, suggesting a drop in IGF-I bioactivity after 
menopause. This drop was not refl ected in total IGF-I levels. IGF-I bioactivity 
was signifi cantly related to total IGF-I (rs varied between 0.46 – 0.52; P-values 
< 0.001). 
Conclusions: We established age-specifi c normative values for the IGF-I KIRA. 
We observed a signifi cant drop in IGF-I bioactivity in women between 50 and 
60 years, which was not perceived by IGF-I immunoassays. The IGF-I KIRA, 
when compared to IGF-I immunoassays, theoretically has the advantage that it 
measures net effects of IGF-binding proteins on IGF-I receptor activation. How-
ever, it has to be proven whether information obtained by the IGF-I KIRA is 
clinically more relevant than measurements obtained by IGF-I immunoassays.
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INTRODUCTION
Fifty years ago Salmon and Daughaday discovered a factor in serum which 
stimulated sulphate incorporation by cartilage in vitro [1]. This unknown 
factor, then called sulphation factor or somatomedin-C, was later renamed 
insulin-like growth factor-I (IGF-I) [2,3]. After generation of highly specifi c 
antibodies for IGF-I, it became possible to develop immunoassays for the 
assessment of circulating IGF-I levels [4-6]. Today, these IGF-I immunoassays 
are clinically widely used to assess IGF-I bioactivity in humans and are appli-
cable to measure large numbers of blood samples.
In the circulation about 99% of circulating IGF-I is bound to six high affi nity 
IGF-binding proteins (IGFBPs) [7]. IGFBPs interfere with antibody binding to 
IGF-I and therefore, in virtually all common IGF-I immunoassays an extrac-
tion method has to be used in order to remove these IGFBPs [8,9]. Remain-
ing IGFBPs or their fragments may interfere and produce falsely increased 
or decreased circulating total IGF-I levels [10]. This latter phenomenon may 
especially occur in pathological conditions [11]. 
Another problem is that large differences in absolute circulating levels 
of total IGF-I are observed between different commercially available IGF-I 
immunoassays [8,12]. Recently it was suggested that this variability in assay 
performance and the use of inappropriate reference ranges undermine the 
applicability of international consensus criteria in local practice [11]. Never-
theless, introduction of IGF-I immunoassays has been proven to be useful in 
the diagnosis and treatment of acromegaly [13].
The IGFBPs are considered to regulate IGF-I bioavailability [7,14]. How-
ever, the commonly used IGF-I immunoassays in fact ignore the effects of 
IGFBPs on the interactions between IGF-I and the IGF-I receptor [10]. Frystyk 
et al. recently developed a kinase receptor activation assay (KIRA) specifi c for 
IGF-I [15,16]. This IGF-I KIRA quantifi es phosphorylation of tyrosine residues 
of the activated IGF-I receptor (IGF-IR) as a measure for IGF-I bioactivity 
in serum [17]. In contrast to commonly used IGF-I immunoassays, the IGF-I 
KIRA is sensitive for modifi cations of IGF-IR activation by circulating IGFBPs 
and IGFBP-proteases [15,18]. Therefore, the IGF-I KIRA method might be 
an important advancement in measuring circulating IGF-I bioactivity, which 
could enhance insights in the IGF-I system both in normal and pathological 
conditions. 
The aim of the present study was to establish normative values for the IGF-I 
KIRA in the healthy population. Results of the IGF-I KIRA were compared 
Michael BW2.indd   67 27-11-09   11:12
C
ha
pt
er
 2
68
with circulating total IGF-I levels obtained by fi ve commonly used IGF-I 
immunoassays [19].
RESEARCH DESIGN AND METHODS
Subjects and measurements
The study population has been described previously [19]. Briefl y, morning 
serum samples were taken from healthy non-fasting blood donors (N = 426; 
females N = 116). Age ranged from 18 to 79 years (median: 44 yrs). Height and 
weight were measured and the body mass index (BMI) was calculated. Mean 
± SD for BMI was 25.3 ± 3.9 kg/m2 (range: 15.8 – 42.2). All participants gave 
informed consent. The Ethics Committee of the Charité Humboldt University 
(Berlin, Germany) had approved this study. 
Total IGF-I Immunoassays
Five different immunoassays were used to measure total circulating IGF-I in 
the healthy population. Three of these assays were immunometric assays, 
whereas two were conventional radioimmunoassays (RIAs). The following 
immunoassays were used: Assay A: IGF-I RIA, an in-house assay at University 
Children’s Hospital, Tuebingen, Germany; Assay B: IGF-I RIA-CTTM, Mediag-
nost, Tuebingen, Germany; Assay C: Diagnostic Systems Laboratories (DSL) 
2800 Active® IGF-I-IRMA, Sinsheim, Germany; Assay D: Nichols Advantage® 
Chemiluminiscence IGF-I Immunometric assay, Nichols Institute Diagnostics, 
San Juan Capistrano, CA, USA.; Assay E: IGF-I CIA, Immulite®, Diagnostic 
Products Corp. (DPC). In all immunoassays recombinant human IGF-I was 
used as standard. After acidifi cation an excess of IGF-II was used to eliminate 
residual interference with IGFBPs. For four of these immunoassays (Assays 1, 
2, 3 and 4), the age-related reference ranges for circulating total IGF-I in this 
study population have been previously published [19]. Intra- (a) and inter- (b) 
assay coeffi cients of variation varied between (a) 3.1 − 7.0% and (b) 3.8 − 8.8% 
respectively [19]. Total IGF-I levels are expressed as nmol/L (to convert total 
IGF-I levels into μg/L, values have to be divided by 0.131). 
IGF-I Kinase receptor activation assay (IGF-I KIRA) 
Circulating IGF-I bioactivity was measured using an in-house IGF-I kinase 
receptor activation assay as was previously described [15]. This assay uses 
human embryonic renal cells stably transfected with cDNA of the human IGF-
IR gene (293 EBNA IGF-IR). Cells were a kind gift from Prof. Pierre de Meyts, 
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(Receptor Biology Laboratory, Hagedorn Research Institute, Novo Nordisk, 
Gentofte, Denmark). After 48 ours of culture, cells were stimulated at 37°C 
with either recombinant IGF-I standards (Austral Biologicals, San Ramon, 
CA) or 10-fold diluted serum samples for 15 minutes and lysed afterwards. 
Crude lysates were transferred to a sandwich assay. For capture a monoclonal 
antibody directed against the human IGF-IR (MAD1, 1μg/well, Novozymes 
Gropep, Adelaide, Australia) was used. As tracer an europium-labelled mono-
clonal anti-phosphotyrosine antibody (PY20, Perkin-Elmer Life Sciences) was 
used. Contents were read in a time-resolved fl uorometer (Victor2 multilabel 
counter, Perkin-Elmer, Groningen, The Netherlands). Assays were performed 
in 48 well plates. IGF-I standards, 2 control samples, and unknown serum 
samples were included in duplicate on every plate. Intra-assay CV was 5.6%. 
The inter-assay CVs were respectively 6.8% and 12.6% for the two control 
samples, which averaged (mean ± SD) 414 ± 28 pmol/L and 1146 ± 144 
pmol/L (N = 60 plates), respectively. Circulating IGF-I bioactivity is expressed 
as pmol/L (to convert IGF-I bioactivity into μg/L, values have to be divided 
by 131). Serum samples used in the IGF-I KIRA were kept at -80°C and had 
been thawed ones. From previous unpublished data we know that repetitive 
freezing and thawing of serum samples (up to several times) does not change 
results of the IGF-I KIRA. IGF-I KIRA measurements were performed 5 years 
after initial collection of serum.
To test whether estradiol (E2) affects results of the IGF-I KIRA we per-
formed the following experiment; Serum was collected from a healthy male 
individual. Infl uence of estradiol (E2) was tested by adding 500 or 1000 pM 
fi nal concentration to recombinant IGF-I standards and/or to a 1/10 diluted 
serum sample. Recombinant IGF-I standards and a 1/10 dilution of the serum 
to which no E2 was added were used as controls.
Statistical Analysis
Data were analyzed using SPSS for Windows, release 12.0 (SPSS, Chicago, 
Illinois) unless otherwise reported. For IGF-I bioactivity measurements means 
± SD, medians, and the 95% confi dence intervals (95% CI) are presented. 
The Kolmogorov-Smirnov test with the Dallal-Wilkinson-Lilliefors correction 
(K-S test) and the D’Agustino and Pearson omnibus test (A-P test: GraphPad 
version 5.0, GraphPad Software, Inc., San Diego) were used to test data for 
normality of distribution. When no normality of distribution was found, 
data were log-transformed. Correlations between IGF-I bioactivity and total 
IGF-I are presented as Spearman correlation coeffi cients (rs). Nonparametric 
Mann-Whitney or Wilcoxon rank sum tests were used to compare IGF-I levels 
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between men and women categorized by age. Linear regression was used to 
calculate the relationship between IGF-I bioactivity and age. The coeffi cient 
of variation (CV) was calculated by using the formula: (SD/mean) × 100%. 
This CV standardizes the relative spread in data between IGF-I assays, so that 
a sensible comparison can be made. Curve estimation and regression analysis 
were performed to determine whether age-related changes were best fi tted by 
a linear, exponential or polynomial function. Where more than one function 
was signifi cant, the one with the highest R2 value was considered the best 
fi tting model. A P value < 0.05 was considered statistically signifi cant. 
RESULTS
Circulating IGF-I bioactivity was almost normally distributed (untransformed 
data: K-S test; p = 0.07, A-P test; p = 0.04, (Figure 1A)). Log-transformation of 
IGF-I bioactivity levels did not improve normality of the data distribution (log-
transformed data: K-S test; p = 0.0001, A-P test; p < 0.0001). In contrast, circu-
lating total IGF-I levels showed an asymmetric distribution in all fi ve studied 
IGF-I immunoassays (untransformed data: K-S and A-P tests; p < 0.0001 for 
all immunoassays (Figure 1B – 1F)). After log-transformation of total IGF-I 
levels a normal distribution (K-S and A-P test: p > 0.05) was obtained in three 
out of fi ve IGF-I immunoassays (data not shown). (Total IGF-I assays that 
did not show a normal distribution after log transformation were: DSL IGF-I 
IRMA (K-S test; p = 0.003, A-P test; p = 0.005) and Nichols IGF-I CIA (K-S test; 
p = 0.03 and A-P test; p = 0.02). Linear correlation and regression coeffi cients 
between the measurements of IGF-I immunoassays are shown in Table 1.
To estimate the spread in the data of IGF-I in the study population, we cal-
culated the coeffi cient of variation (CV). The CV for the IGF-I KIRA was 31% 
and thereby lower than for the fi ve studied IGF-I immunoassays (Mediagnost 
IGF-I RIA: 34%, In-house IGF-I RIA: 36%, DPC IGF-I CIA: 42%, Nichols IGF-I 
CIA: 45%, DSL IGF-I IRMA: 48%, respectively). 
Mean (± SD) circulating IGF-I bioactivity was 423 (± 131) pmol/L and 
ranged from 57 to 875 pmol/L. In Table 2 mean values of circulating IGF-I bio-
activity are presented after stratifi cation for age. IGF-I bioactivity decreased 
signifi cantly with age, which was best fi tted by a linear model (slope β = -3.4 
pmol/L/yr, (95% CI: -4.5 – -2.5); p < 0.001). There was no signifi cant differ-
ence in β (p = 0.16) between men (β = -2.9 pmol/L/yr (95% CI: -3.8 – -1.9); 
p < 0.0001) and women (β = -4.6 pmol/L/yr (95% CI: -6.0 – -3.3); p < 0.001) 
(Figure 2)). With one exception (Nichols), the age-related decreases in total 
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IGF-I were best fi tted by polynomial (quadratic) functions (data not shown). 
The decrease of total IGF-I with age measured by the total IGF-I CIA (Nichols) 
was best fi tted by a linear model (β = -0.48 nmol/L/yr, (95% CI: -0.54 – -0.42); 
p < 0.001).
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Figure 1. Distribution of IGF-I measurements in the study population: (A) IGF-I KIRA; (B) 
IGF-I RIA, an in-house assay at University Children’s Hospital, Tuebingen, Germany; (C) 
IGF-I RIA-CTtm, Mediagnost; (D) IGF-I-IRMA 2800 Active®, DSL; (E) IGF-I CIA, Nichols 
Advantage®; (F) IGF-I CIA, Immulite® DPC. Data obtained by the IGF-I KIRA showed an 
almost normal distribution, in contrast to IGF-I immunoassays for which data were skewed 
leftwards. An ideal bell-shaped normal distribution curve is shown in each plot.
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Overall, there were no gender specifi c differences in mean IGF-I bioactivity 
(men: mean = 420 pmol/L, (95% CI: 405 – 435) vs. women: mean = 433 (95% 
CI: 409 – 458); p = 0.36 (adjusted for age and BMI, Table 3)).
In subjects younger than 55 yrs, mean IGF-I bioactivity was signifi cantly 
higher in women than in men (men (N = 207) mean = 436 pmol/L, (95% CI: 
418 – 454) vs. (women (N = 76): mean = 484 (95% CI: 455 – 513); p = 0.007, 
(Figure 3)). Above the age of 55 years this relationship was opposite and 
mean IGF-I bioactivity in women was signifi cantly lower than in men (men 
(N = 103) mean = 387 pmol/L, (95% CI: 366 – 408) vs. women (N = 40): mean 
337 (95% CI: 313 – 361); p = 0.008). Table 3 shows means for IGF-I bioactivity 
in men and women stratifi ed for age. In all fi ve IGF-I immunoassays there 
were no gender-specifi c differences in mean circulating total IGF-I levels 
before age 55 yrs. Above age 55 years mean circulating total IGF-I levels were 
signifi cantly lower in women than in men in all IGF-I immunoassays (data not 
Table 1: Linear regression equations: comparison of the relation between fi ve IGF-I im-
munoassays
Dependent 
variable(Y)
Independent variable (X)
A B C D
A  ***
B R2 
Y
= 0.85
= 2.20x + 0.97
***
C R2 
Y
= 0.85
= 1.43x – 5.38
R2 
Y
= 0.80
= 1.32x – 5.58
***
D R2 
Y
= 0.82
= 1.52x – 3.20
R2 
Y
= 0.75
= 1.37x – 2.96
R2 
Y
= 0.87
= 1.01x + 3.54
***
E R2 
Y
= 0.87
= 1.45x – 2.60
R2 
Y
= 0.91
= 1.41x – 4.19
R2 
Y
= 0.86
= 0.93x + 4.57
R2 
Y
= 0.81
= 0.84 + 3.36
Regression models are based on total IGF-I levels expressed as nmol/L. In all models 
correlation was signifi cant (P < 0.001 for all). IGF-I immunoassays: (A) IGF-I RIA, an in-
house assay at University Children’s Hospital, Tuebingen, Germany; (B) IGF-I RIA-CTTM, 
Mediagnost; (C) IGF-I-IRMA 2800 Active®, DSL; (D) IGF-I CIA, Nichols Advantage®; (E) 
IGF-I CIA, Immulite® DPC.
Table 2: Age-related reference ranges for IGF-I bioactivity in healthy adults (N = 426)
Age 
(years)
Number 
(N)
Mean 
(pmol/L)
SD Median
(pmol/L)
5th 
percentile
95th 
percentile
< 24 38 527 139 528 287 747
25 - 34 66 476 140 461 254 763
35 - 44 100 432 132 428 212 666
45 - 54 79 411 122 402 253 643
55 - 64 103 385 108 383 191 566
> 65 40 344 081 343 173 468
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shown). The statistically signifi cant drop in IGF-I bioactivity in women around 
age 55 years was not observed for all fi ve IGF-I immunoassays. 
Circulating IGF-I bioactivity was signifi cantly related to circulating total IGF-I 
levels (rs varied between 0.46 – 0.52, p < 0.001 for all fi ve IGF-I immunoassays, 
Figure 4A – 4E). Mean circulating IGF-I bioactivity calculated as percentage 
of total IGF-I averaged 1.8 to 2.4% (in-house RIA: 2.4% (0.42 – 5.82) (median 
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Figure 2. IGF-I bioactivity levels according to age. IGF-I bioactivity decreased signifi cantly 
with age in both men (  ) and women (). Linear regression lines for men ( ) and women 
( ) are shown.
Table 3: Age-related reference ranges for IGF-I bioactivity in healthy individuals: men vs. 
women 
Age (years) Men Women P-value
Number 
(N)
Mean 
(pmol/L)
SD Number 
(N)
Mean 
(pmol/L)
SD
18 - 79 310 420 131 117 433 131 0.36*
< 24 31 510 138 7 602 126 0.13**
25 - 34 46 470 150 20 489 119 0.47**
35 - 44 70 417 140 30 467 106 0.04**
45 - 54 60 396 106 19 461 150 0.008**
55 - 64 79 400 110 24 332 083 0.009**
> 65 24 344 093 16 344 063 0.50**
*Adjusted for age and BMI. **Adjusted for BMI.
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(range)), Mediagnost: 2.2% (0.34 – 5.2), DSL: 2.3% (0.33 – 9.1), Nichols: 1.8% 
(0.32 – 5.88) and DPC: 1.8% (0.29 – 5.38). This calculated bioactive IGF-I frac-
tion increased signifi cantly with age for all fi ve IGF-I immunoassays (β varied 
between 0.010% – 0.033% per year; p < 0.001 for all). Figure 5A-E shows the 
calculated bioactive fraction for all fi ve IGF-I immunoassays per age category 
in men and women. IGF-I bioactivity was not related to height, weight or BMI, 
whereas total IGF-I levels were positively related to height (r varied between 
0.17 – 0.23, p < 0.003 for all), and negatively to BMI (rs varied between - 0.24 
and -0.20, p < 0.001 for all).
No direct effects of two different concentrations of estradiol (500 and 1000 
pmol/L) could be detected when added to the IGF-I reference dilutions or 
spiked to serum (Table 4). 
*
*
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Figure 3. Mean circulating IGF-I bioactivity according to age categories and sex. Mean cir-
culating IGF-I bioactivity levels in women ( ) differed signifi cantly from men ( ), being 
higher in age groups 35-44 years (p = 0.04), and 45-54 years (p = 0.008) and lower in age 
group 55-64 years (p = 0.009). Between 50 and 60 years of age there was a drop in mean 
circulating IGF-I bioactivity in women. Overall, before 55 years of age circulating IGF-I bio-
activity in women was signifi cantly higher, and after this age signifi cantly lower when com-
pared to men. Data are presented as mean ± SEM. *Signifi cant difference between men and 
women within an age category. **Signifi cant difference between men and women before or 
after age 55 years.
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Figure 4. Relations between circulating IGF-I bioactivity measured by the IGF-I KIRA vs. 
circulating total IGF-I measured by fi ve different IGF-I immunoassays to measure total IGF-I: 
(A) IGF-I RIA, an in-house assay at University Children’s Hospital, Tuebingen, Germany; 
(B) IGF-I RIA-CTTM, Mediagnost; (C) IGF-I-IRMA 2800 Active®, DSL; (D) IGF-I CIA, Nichols 
Advantage®; (E) IGF-I CIA, Immulite® DPC.
Michael BW2.indd   75 27-11-09   11:12
C
ha
pt
er
 2
76
1.0
2.0
3.0
4.0
< 24 25-34 35-44 45-54 55-64 > 65
Age categories (years)
men
women
0
A
IG
F
-I
 b
io
ac
ti
vi
ty
 /
 T
o
ta
l I
G
F-
I (
%
)
0
1.0
2.0
3.0
4.0
men
women
< 24 25-34 35-44 45-54 55-64 > 65
Age categories (years)
B
IG
F
-I
 b
io
ac
ti
vi
ty
 /
 T
o
ta
l I
G
F-
I (
%
)
1.0
2.0
3.0
4.0
< 24 25-34 35-44 45-54 55-64 > 65
Age categories (years)
men
women
0
C
IG
F
-I
 b
io
ac
ti
vi
ty
 /
 T
o
ta
l I
G
F-
I (
%
)
1.0
2.0
3.0
4.0
< 24 25-34 35-44 45-54 55-64 > 65
Age categories (years)
men
women
0
D
IG
F
-I
 b
io
ac
ti
vi
ty
 /
 T
o
ta
l I
G
F-
I (
%
)
1.0
2.0
3.0
4.0
< 24 25-34 35-44 45-54 55-64 > 65
Age categories (years)
men
women
0
E
IG
F
-I
 b
io
ac
ti
vi
ty
 /
 T
o
ta
l I
G
F-
I (
%
)
Figure 5. Mean bioactive fraction per age category (A) IGF-I RIA, an in-house assay at 
University Children’s Hospital, Tuebingen, Germany; (B) IGF-I RIA-CTTM, Mediagnost; C) 
IGF-I-IRMA 2800 Active®, DSL; D) IGF-I CIA, Nichols Advantage®; E) IGF-I CIA, Immulite® 
DPC. In all assays the bioactive fraction increased signifi cantly with age in both men and 
women (P < 0.001 for all).
Table 4: IGF-I bioactivity in male serum spiked with different concentrations of estradiol
Serum sample IGF-I Bioactivity (pmol/L)
(based on control reference)
IGF-I Bioactivity (pmol/L)
(based on reference with E2)
1000 pM E2 137 130
500 pM E2 138 131
No E2 added 148 140
E2 = estradiol, pM = picomolar. Next to the serum, also one series of IGF-I reference was 
spiked with equimolar concentrations of E2.
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DISCUSSION
To our knowledge this is the fi rst study that reports age-specifi c normative 
ranges of circulating IGF-I bioactivity in the healthy population obtained by 
the IGF-I KIRA. These normative values are based on measurements in more 
than 400 normal subjects with age ranging from 18 – 79 yrs. These age-specifi c 
normative ranges will be helpful to interpret whether IGF-I bioactivity is nor-
mal, increased and/or decreased in subjects with pathological conditions like 
acromegaly and GH defi ciency. 
Currently used IGF-I immunoassays have indeed yielded important and 
biologically meaningful information about the IGF-I system [20]. However, 
many problems have been reported when IGF-I immunoassays were used 
in clinical practice [13]. Attempts to resolve these problems have focused on 
methods of separating IGF-I from its binding proteins (IGFBPs) prior to IGF-I 
measurements. Although there have been many technologies developed to 
eliminate interference of IGFBPs, in many IGF-I immunoassays, remaining 
IGFBPs or BP fragments may still interfere and produce falsely increased or 
decreased circulating total IGF-I levels [21]. This latter effect may especially be 
of importance in pathophysiologic states accompanied by signifi cant changes 
in IGFBP levels, such as diabetes mellitus and renal failure [21]. For example, 
Chestnut and Quarmby showed that while the correlation between IGF-I 
immunoassays was high in sera of healthy individuals, there was a lack of 
correlation between immunoassays when sera from individuals with diabetes 
were analysed [8]. 
IGF-I immunoassays only determine the immunoreactive properties of the 
IGF-I molecule, rather than its actual biological effect [22]. The separation of 
IGF-I from the IGFBPs prior to the IGF-I measurements ignores in fact the 
important modulating effects of IGFBPs on IGF-I bioavailability. However, 
clinicians are generally interested in the biological effects of IGF-I [22]. 
An important reason for using IGF-I immunoassays has been the lack of 
reliable IGF-I bioassays [10,16]. Previous IGF-I bioassays were based on 
downstream signalling events (e.g. sulphate incorporation by cartilage, cell 
proliferation and survival), but they often suffered from high variability and 
long assay duration [16,23,24]. Moreover, these IGF-I bioassays often had a 
lack of specifi city and were labour-intensive. An ideal assay for assessing 
IGF-I bioactivity should be easily quantifi able, highly sensitive and based on 
a signal specifi cally transmitted by the IGF-IR [25]. In this respect, the IGF-I 
KIRA comes close to an ideal IGF-I bioassay as it directly targets the acti-
vated IGF-IR, requires only small volumes of serum, has a short incubation 
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time, is sensitive to the modifying infl uences of circulating IGFBPs and 
IGFBP-proteases and has an overall precision that is fully comparable to the 
traditional IGF-I immunoassays [15,16,18]. However, the KIRA is still more 
labour-intensive than immunoassays. In addition, we realize that IGF-I KIRA 
measurements were performed with serum and therefore obtained results 
do not necessarily refl ect net IGF-I bioactivity present in the extra-vascular 
tissues. 
Interestingly, IGF-I immunoassays that did not utilize removal of IGFBPs 
have been described previously in literature (5). These older assays for IGF-I 
were not considered useful for clinical practice, as it was assumed that IGFBP 
interference was a priori bad for determination of IGF-I (9). However, this 
opens the possibility that the results of these older IGF-I assays might cor-
relate better with IGF-I KIRA results than do modern IGF-I immunoassays, 
which prior to its measurement extract IGF-I from IGFBPs. 
Circulating IGF-I bioactivity showed a wide inter-individual variability 
among subjects in every age group. The CV of the IGF-I KIRA within the study 
population (a standardized measure of relative spread in data) was lower than 
that for total IGF-I. Since a lower magnitude of CV is considered to refl ect 
a better reliability (precision) of measurements, this suggests that the IGF-I 
KIRA in this respect performs at least equal to IGF-I immunoassays.
IGF-I bioactivity was positively related to total IGF-I in all studied IGF-I 
immunoassays. Interestingly, for all IGF-I immunoassays the observed corre-
lation coeffi cients were relatively low and comparable. Our results show that 
the observed relation between total IGF-I and IGF-I bioactivity is independent 
of the type of immunoassay that is used to determine circulating total IGF-I 
levels. In addition, these results suggest that the IGF-I KIRA produces new 
information about the IGF-I system, which differs from that obtained by IGF-I 
immunoassays. However, the physiological importance of this difference 
remains to be clarifi ed.
Circulating IGF-I bioactivity decreased signifi cantly with age. The decline 
of IGF-I bioactivity with age was less steep than that observed for circulating 
total IGF-I levels. As a consequence the mean calculated fraction of IGF-I bio-
activity over total IGF-I increased slightly but signifi cantly with age. Although 
the cross-sectional study design does not refl ect the intra-individual rate of 
change of IGF-I bioactivity, a possible explanation for this latter observation 
is that IGF-I bioactivity becomes less-GH dependent with aging than total 
IGF-I levels. Another explanation could be that the relative increase in IGF-I 
bioactivity with age refl ects a compensatory mechanism to overcome an age-
dependent relative IGF-IR resistance. Third, also circulating IGF-II levels could 
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be involved. In contrast to IGF-I, circulating levels of IGF-II do not decrease 
after puberty but remain stable throughout life [26]. Chen et al. showed that 
the 293 EBNA IGF-IR cells respond not only to IGF-I but also to IGF-II, which 
has a cross-reactivity of 12%, to the IGF-I KIRA compared to IGF-I [15]. This 
opens the possibility that the relative contribution of IGF-II to the IGF-I KIRA 
signal increases with aging. 
Remarkably, before age 55 years of age, the mean IGF-I bioactivity was 
signifi cantly higher in women than in men, while after this age an inverse 
relationship was observed. This signifi cant drop in IGF-I bioactivity in women 
between the age of 50 and 60 years was not refl ected in total IGF-I levels. 
Although we do not have information about age of menopause in the studied 
women, we speculate that the observed decrease in IGF-I bioactivity after age 
55 years of age is related to changes in estrogens levels [27-29]. This could 
explain why women had a relatively higher mean IGF-I bioactivity than men 
before 55 years, but also why mean IGF-I bioactivity was lower in women 
than in men after this age.
In conclusion, in the present study we established age-specifi c normative 
values for circulating IGF-I bioactivity levels in the healthy adult population. 
The IGF-I KIRA produces new information about the circulating IGF-I system 
that differs from that obtained by IGF-I immunoassays. Whether this informa-
tion is clinically more relevant than measurement of circulating total IGF-I 
levels in the diagnosis and/or treatment of GH disorders is at present unclear. 
However, the establishment of these normative reference values for IGF-I 
bioactivity is the fi rst step to answer these questions in the near future.
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ABSTRACT
Background: Low IGF-I signaling activity prolongs lifespan in certain animal 
models, but the precise role of IGF-I in human survival remains controversial. 
The IGF-I kinase receptor activation assay (IGF-I KIRA) is a novel method 
for measuring IGF-I bioactivity in human serum. We speculated that deter-
mination of circulating IGF-I bioactivity is more informative than levels of 
immunoreactive IGF-I.
Objective: To study IGF-I bioactivity in relation to human survival. 
Design: Prospective observational study.
Setting: A clinical research center at a university hospital.
Study participants: 376 healthy elderly men (aged 73 to 94 years).
Main outcome Measures: IGF-I bioactivity was determined by the IGF-I KIRA. 
Total and free IGF-I were determined by IGF-I immunoassays. Mortality was 
registered during follow-up (mean 82 months).
Results: During the follow-up period of 8.6 years 170 men (45%) died. Survival 
of subjects in the highest quartile of IGF-I bioactivity was signifi cantly better 
than in the lowest quartile, both in the total study group (HR = 1.8, (95% 
CI: 1.2 − 2.8, p = 0.01) as well as in subgroups having a medical history of 
cardiovascular disease (HR = 2.4 (95% CI: 1.3 − 4.3, p = 0.003) or a high 
infl ammatory risk profi le (HR = 2.3 (95% CI: 1.2 − 4.5, p = 0.01). Signifi cant 
relationships were not observed for total or free IGF-I.
Conclusion: Our study suggests that a relatively high circulating IGF-I bioac-
tivity in elderly men is associated with extended survival and with reduced 
cardiovascular risk.
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INTRODUCTION
Insulin-like growth factor I (IGF-I) has important anabolic and mitogenic 
effects, and is involved in mechanisms of function, maintenance, and repair 
of many tissues [1]. Involvement of IGF-I in the process of aging has been 
studied extensively in the last two decades. Studies in invertebrates have sug-
gested that disruption of signalling pathways similar to the IGF-I pathway 
extends lifespan [2-5]. Growth hormone/IGF-I defi cient mice and rats have 
increased longevity compared to controls [3,6,7]. Also, decreased IGF-I recep-
tor (IGF-IR) signalling activity in female heterozygous knockout mice was 
shown to retard the process of aging [8]. However, the precise role played by 
IGF-I in human survival remains controversial [9].
IGF-I is part of a complex system consisting of two growth factors (IGF-I 
and IGF-II), at least six high-affi nity IGF binding proteins (IGFBP-1 to -6) 
and several IGFBP proteases [1,10]. It is believed that only 0.5-1% of total 
IGF-I levels circulates in a free form, whereas about 99% of circulating IGF-I 
is bound by IGFBPs. Only free IGF-I is considered to interact with the IGF-IR 
[11].
Most of what is known about regulation of IGF-I in the circulation is based 
on measurements using specifi c IGF-I immunoassays. Since IGFBPs interfere 
with the accurate determination of IGF-I by immunoassay, various techniques 
have been developed to remove IGFBPs from samples or neutralize their 
infl uence on IGF-I immunoreactivity [11,12]. However, it is important to note 
that IGFBPs are important modulators of IGF-I bioactivity [1]. IGFBPs are able 
to alter IGF-I bioactivity without changing the extractable concentrations of 
total IGF-I [11]. 
Recently, a highly sensitive and IGF-I specifi c kinase receptor activation 
assay (IGF-I KIRA) was developed to determine IGF bioactivity in human serum 
[13,14]. This bioassay determines the ability of circulating IGF-I to activate the 
IGF-IR by quantifi cation of intracellular receptor auto-phosphorylation upon 
IGF-I binding. Unlike an immunoassay, the IGF-I KIRA does not disregard 
modifying effects of IGFBPs and IGFBP proteases on the interaction between 
IGF-I and the IGF-IR (15, 16). Therefore, the IGF-I KIRA method is a new tool 
that could help broaden our understanding of the IGF-I system in humans, in 
both normal and pathological conditions.
The objective of the present study was to investigate whether IGF-I bioactiv-
ity was related to survival in a cohort of healthy elderly men. In addition, we 
studied the relationship between IGF-I bioactivity and cardiovascular disease 
(CVD) in this cohort.
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RESEARCH DESIGN AND METHODS
Study Population
The design of the Zoetermeer study, a prospective cohort study conducted 
in clinically healthy independently living Caucasian elderly men, has been 
reported previously [15]. Individuals were drawn from the municipal register 
of Zoetermeer, the Netherlands. Inclusion criteria were male sex, age ≥ 70 
years and a suffi cient physical and mental status to visit the study center inde-
pendently. The Medical Ethics Committee of the Erasmus MC approved the 
study. Out of 1567 invited men, 403 participated and gave written informed 
consent. At baseline, medical histories were obtained from all participants, 
and serum samples were collected from 376 individuals. General practitioners 
were contacted about the status of participants in subsequent years. Cause 
of death was derived from death certifi cates and could only be verifi ed in 
a limited number of subjects. The maximum follow-up time was 8.6 years. 
Information on nonfatal events was not registered. 
Anthropometric measurements
Height and weight were measured. Systolic (SBP) and diastolic (DBP) blood 
pressures were measured in duplicate. Hypertension was defi ned as SBP > 
160 mmHg and/or DBP > 90 mmHg or antihypertensive treatment. Lean body 
mass and fat mass were measured using dual-energy X-ray absorptiometry 
(Lunar Corp., Madison, Wisconsin) [16]. 
Assays
At baseline, a venous blood sample was collected after an overnight fast. 
Serum and plasma aliquots were stored immediately after processing at -40°C. 
Total IGF-I levels were measured by radioimmunoassay (RIA) (Mediagnost 
GmbH, Tübingen, Germany) [17]. Intra-assay and inter-assay coeffi cients of 
variation (CVs) were 1.6% and 6.4%, respectively. Free IGF-I levels were mea-
sured by a non-competitive, two-site immunoradiometric assay (Beckman 
Coulter, Inc., Webster, Texas). Intra-assay and inter-assay CVs were 10.3% 
and 10.7% respectively. IGFBP-1 and IGFBP-3 levels were determined by 
specifi c RIA as previously described [17]. For IGFBP-1 and IGFBP-3, intra-
assay CVs were 3.4% and 1.9%, respectively, and inter-assay CVs were 8.1% 
and 9.2%, respectively. Insulin was measured by a commercially available RIA 
(Medgenix Diagnostics, Brussels, Belgium). Intra-assay and inter-assay CVs 
were 8.0% and 13.7%, respectively. Immunoassays were performed soon after 
sample collection (in 1998) to reduce the possibility of analyte degradation. 
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Insulin sensitivity was calculated according to the Homeostasis Model 
Assessment (HOMA) model 2 (HOMA Calculator v2.2, Oxford Centre for 
Diabetes, Endocrinology and Metabolism). Total and high-density lipoprotein 
(HDL) cholesterol and triglycerides were measured using a commercially 
available kit [15]. Low-density lipoprotein (LDL) cholesterol levels were calcu-
lated. C-reactive protein levels (CRP) were determined with a highly sensitive 
method (hs-CRP) using a latex-enhanced immunoephelometric assay on a BN 
II analyzer (Dade Behring, Liederbach, Germany). 
IGF-I Kinase receptor activation assay (IGF-I KIRA)
IGF-I bioactivity was measured using an in-house IGF-I KIRA as previously 
described [13]. Human embryonic renal cells (293 EBNA, Invitrogen, Ger-
many) stably transfected with copy DNA of the human IGF-IR gene were used 
as read-out after stimulation with either recombinant IGF-I standards (Austral 
Biologicals, San Ramon, CA) or 1/10 diluted serum samples. IGF-I standards, 
two control samples, and serum samples from study participants were mea-
sured in duplicate on each culture plate. Intra-assay and inter-assay CVs were 
6.0% and 10.9%, respectively. IGF-I KIRA measurements were performed in 
2005. There are no data on the effects of long-term storage on sample IGF-I 
activity in the KIRA assay. However, since all samples were analyzed follow-
ing an equal period of storage, any variable effect of storage time is likely 
removed. 
Statistical Analysis
Data were analyzed using SPSS for Windows, release 12.0 (Chicago, Illinois). 
Only data from the 376 participants for whom serum samples were available 
were included in the analyses. The Shapiro-Wilk test was used to test normality 
of variables (data were considered to be normally distributed when p > 0.05). 
For data that did not meet the criteria for normality, logarithmic transformations 
were applied. Baseline characteristics are presented as means ± SD, medians 
with 25th and 75th percentiles (P25 − P 75), or numbers. Correlation coeffi cients 
(rs) between IGF-I parameters were calculated using non-parametric tests 
(Spearman’s correlation coeffi cient). Univariate general linear models were 
used to calculate adjusted differences in means of variables between groups 
(F-tests were used to evaluate signifi cance). Linear regression was used to 
calculate the relation between IGF-I bioactivity and age. A multiple linear 
regression model was used to test equality of slopes (IGF-I bioactivity = B0 
+ B1 ⋅ age + B2 ⋅ Z + B3 ⋅ age ⋅ Z + E), where Z = 1 for non-survivors; Z = 0 for 
survivors and E denoting independent, identically normally distributed error 
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terms. IGF-I bioactivity and free IGF-I were calculated as percentage of total 
IGF-I according to the formula: X (pmol/L) / total IGF-I (pmol/L) x 100% (X = 
IGF-I bioactivity or free IGF-I level, respectively).
Cox proportional hazard models were used to analyse survival (Wald tests 
were used to evaluate signifi cance of variables in the hazard model). The 
time-to-event variable was specifi ed as time from baseline examination to 
death denoted in months. Individuals who did not have an event during the 
time that the subject was part of the study (N = 206) were censored. Continu-
ous IGF-I risk factors were grouped (group 1: ≤ 25th, group 2-3: 25th − 75th 
and group 4: ≥ 75th percentiles) and used as categorical covariates in survival 
analyses. For all IGF-I parameters risk was calculated relative to the high-
est quartile. Within the fi nal model, age, BMI, smoking, SBP, diabetes, LDL 
and HDL were considered possible confounders and were used as baseline 
time-constant covariates. Both crude and adjusted hazard ratios (HR) were 
estimated. Assumptions of proportionality of hazards were verifi ed by graphi-
cal inspection. To control for confounding by cardiovascular disease (CVD) 
or infl ammatory risk status, crude data were stratifi ed and survival analysis 
was repeated as described previously. To correct for CVD, crude data were 
stratifi ed into two groups split by the presence (N = 133) or absence (N = 242) 
of prevalent CVD. Presence of CVD was defi ned as having a medical history 
of MI or cerebrovascular disease, and/or being treated or having symptoms 
of AP, congestive heart failure or claudicatio intermittens [15]. To correct for 
infl ammatory risk status continuous baseline hs-CRP levels were split at 3 
mg/L, resulting in subjects with a low to medium infl ammatory risk profi le 
(IRP) (hs-CRP ≤ 3 mg/L, N = 238) and subjects with a high IRP (hs-CRP > 3 
mg/L, N = 138) [18,19]. Survival analysis using IGF-I risk groups as categorical 
covariates was performed in IRP and CVD strata as described previously.
In general: cause of death was based on death certifi cates that could not 
be verifi ed in the majority of subjects. Therefore, cause of death was not 
controlled for in all Cox proportional hazard models. Trends across IGF-I risk 
groups were based on models with linear effect of the risk factors (Armit-
age trend test). Two-sided P-values are reported and P-values < 0.05 were 
considered statistically signifi cant.
RESULTS
Baseline characteristics of participants, categorized by survivors (N = 206, 
(55%)) and non-survivors (N = 170, (45%)), are shown in Table 1. Mean age 
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at baseline was 77.7 ± 3.5 (mean ± SD) years (range, 73 to 94). Mean time to 
death was 81.9 months (range, 3 to 103). 
Baseline levels of IGF system parameters are shown in Table 2. Overall, 
IGF-I bioactivity and free IGF-I levels accounted for 2.6% (range, 0.2−5.9) 
and 0.6% (range, 0.2 − 2.9) of circulating total IGF-I levels, respectively (p < 
0.001). These fractions were not signifi cantly correlated with each other (rs = 
0.04, p = 0.48). At baseline, only mean IGFBP-1 levels differed signifi cantly 
between survivors and non-survivors (Table 2). In addition, the mean calcu-
lated bioactive IGF-I fraction was signifi cantly higher in survivors compared 
to non-survivors (mean ± SEM: 2.7 ± 0.06% vs. 2.4 ± 0.07%, adjusted for age p 
= 0.04), whereas the calculated mean free IGF-I fraction did not differ between 
these groups (p = 0.62). Also the mean total IGF-I / IGFBP3 ratio did not differ 
between survivors and non-survivors (adjusted for age p = 0.21).
Table 1. Baseline characteristics of survivors and non-survivors in the study cohort (N = 376)
Variable          Survivors
        (N = 206)
  Non-Survivors
       (N = 170)
P-value
Mean (SD)
Age (year) 77.1 (3.0) 78.5 (3.9) < 0.001
BMI (kg/m2) 25.8 (2.9) 25.2 (3.0) 0.29
Lean mass (kg) 52.3 (5.5) 51.4 (5.4) 0.21 §
Fat mass (kg) 21.3 (5.7) 21.0 (5.7)  0.84 §
SBP (mmHg) 157 (25) 156 (24)  0.85 #
DBP (mmHg) 84 (11) 83 (11) 0.49 #
Total cholesterol (mmol/L) 5.8 (1.0) 5.7 (1.1)  0.53 #
Glucose (mmol/L)  * 5.5 (1.2) 5.4 (1.0)  0.82 #
Median (P25 – P75)
Insulin (IU/L) *     8.0 (6.0 − 10.0)     8.3 (6.2 − 10.6) 0.27 #
HOMA (%S) 96 (71 − 124) 94 (75 − 124) 0.73 #
Number (%)
Smoking 37 (18%) 33 (19%) 0.89
Hypertension 114 (55%) 116 (68%) 0.01 #
Myocardial Infarction 24 (12%) 39 (23%) 0.002
Malignancy 18 (9%) 14 (8%) 0.91
Diabetes mellitus     14 (6.8%) 17 (10%) 0.30
All values are unadjusted. P values were adjusted for age. §, P values for lean mass and fat 
mass were additionally adjusted for height. #, §, P values for blood pressures, lipids, glu-
cose, insulin, HbA1c and HOMA (%S), were additionally adjusted for body mass index. ∗, 
Diabetics were excluded in the analysis of means for glucose and insulin. BMI = body mass 
index, SBP = systolic blood pressure, DBP = diastolic blood pressure, P25 – P75 = range 
between the 25th and 75th percentile, Insulin sensitivity in percentage (%S) was calculated 
according to the Homeostasis Model Assessment (HOMA) model 2 (HOMA Calculator v2.2, 
Oxford Centre for Diabetes, Endocrinology and Metabolism).
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IGF-I bioactivity was signifi cantly correlated with all studied parameters of 
the IGF system (Table 3) and to the total IGF-I / IGFBP-3 ratio (rs = 0.26, p < 
0.001). Furthermore, mean baseline IGF-I bioactivity was negatively related 
to age (slope (β) = -4.5 pmol/L/year, p = 0.01, data not shown). However, the 
rate of decline in IGF-I bioactivity with age did not differ between survivors 
(β = -3.5 pmol/L/year) and non-survivors (β = -4.1 pmol/L/year, p = 0.77). We 
found no signifi cant correlations between IGF-I bioactivity and BMI, WHR, 
lean mass, fat mass, fasting glucose or insulin (data not shown).
Survival analyses for risk factor groups (1, 2-3 and 4) of total IGF-I, free 
IGF-I and IGF-I bioactivity were performed. Hazard ratios (HR) for mortality 
rate between groups are shown in Table 4. 
Cox proportional hazard plots are shown in Figures 1A, B and C, respec-
tively. A signifi cant relationship was found between groups of IGF-I bioactiv-
ity and mortality (Table 4, Figure 1C). Subjects within the highest quartile of 
IGF-I bioactivity (group 4) had a lower mortality rate than subjects in groups 
with lower IGF-I bioactivity (groups 1 and 2-3). This remained signifi cant after 
adjustment for age, BMI, smoking, SBP, diabetes, LDL and HDL (Table 4). For 
total IGF-I and free IGF-I no signifi cant relationships were found (Table 4, 
Table 2. Means at baseline of parameters of the IGF-I system in the total study population, 
in survivors and in non-survivors after follow-up
Mean or geometric mean (CI 95%)
Variable  Unit All subjects 
(N = 376)
Survivors 
(N = 206)
Non-Survivors 
(N = 170)
P-value*
IGF-I 
Bioactivity pmol/L 333 (320 − 346) 344 (328 − 361) 317 (296 − 337) 0.09
Total IGF-I nmol/L 13.3 (12.9 − 13.6) 13.3 (12.7 − 13.7) 13.2 (12.6 − 13.9) 0.72
Free IGF-I pmol/L 76.2 (72.2 − 80.3) 77.0 (72.1 − 82.2) 75.4 (69.1 − 82.2) 0.58
IGFBP-1 nmol/L 1.1 (1.1 − 1.2) 1.1 (1.0 − 1.1) 1.2 (1.1 − 1.3) 0.03
IGFBP-3 nmol/L 90.5 (88.0 − 93.0) 93.4 (90.1 − 96.9) 86.7 (83.1 − 90.2) 0.20
For Free IGF-I and IGFBP-1 geometric means are shown and CI 95% intervals were cal-
culated by forward-backward log-transformation. *Age adjusted P-values were calculated 
between survivors vs. non-survivors.
Table 3. Correlation coeffi cients between parameters of the IGF system in the study popu-
lation (N = 376)
IGF-I bioactivity Total IGF-I Free IGF-I IGFBP-1
Total IGF-I - 0.49**
Free IGF-I - 0.19** - 0.37**
IGFBP-1 - 0.25** - 0.15** - 0.10*
IGFBP-3 - 0.34** - 0.52** - 0.17** - 0.23**
Correlations are presented as Spearman coeffi cients. 
*P < 0.05, **P < 0.01.
Michael BW2.indd   90 27-11-09   11:12
IGF-I Bioactivity and Human Survival 91
T
ab
le
 4
. 
E
st
im
at
ed
 h
az
ar
d
 r
at
io
s 
b
et
w
ee
n
 g
ro
u
p
s 
o
f 
IG
F-
I 
b
io
ac
tiv
ity
, 
to
ta
l 
IG
F-
I 
an
d
 f
re
e 
IG
F-
I 
in
 a
ll 
su
b
je
ct
s 
an
d
 a
ft
er
 s
tr
at
ifi 
ca
tio
n
 f
o
r 
C
V
D
 +
 
an
d
 C
V
D
- 
an
d
 I
R
P
lo
w
/m
ed
 a
n
d
 I
R
P
h
ig
h
, r
es
p
ec
tiv
el
y,
 d
u
ri
n
g 
a 
fo
llo
w
-u
p
 p
er
io
d
 o
f 
8.
6 
ye
ar
s
G
ro
up
*
A
ll 
Su
bj
ec
ts
CV
D
 -
CV
D
 +
IR
P l
ow
/m
ed
IR
P h
ig
h
H
R
CI
 9
5%
P f
or
 tr
en
d
H
R
CI
 9
5%
P f
or
 tr
en
d
H
R
CI
 9
5%
P f
or
 tr
en
d
H
R
CI
 9
5%
P f
or
 tr
en
d
H
R
CI
 9
5%
P f
or
 tr
en
d
A
. U
na
dj
us
te
d
IG
F-
I 
Bi
oa
ct
iv
ity
1
1.
8
1.
2 
− 
2.
8
1.
6
0.
9 
− 
2.
9
2.
4
1.
3 
− 
4.
3
1.
4
0.
8 
− 
2.
5
2.
3
1.
2 
− 
4.
5
2-
3 
1.
2
0.
8 
− 
1.
8
1.
4
0.
8 
− 
2.
5
1.
1
0.
6 
− 
1.
9
1.
0
0.
6 
− 
1.
6
1.
9
1.
0 
− 
3.
6
4
Re
f
…
0.
01
Re
f
…
0.
12
Re
f
…
0.
01
Re
f
…
0.
32
Re
f
…
0.
01
To
ta
l 
IG
F-
I
1
0.
9
0.
6 
− 
1.
4
0.
8
0.
4 
− 
1.
4
1.
2
0.
7 
− 
2.
1
0.
8
0.
5 
− 
1.
8
1.
0
0.
5 
− 
1.
8
2-
3
0.
6
0.
4 
− 
0.
9
0.
7
0.
4 
− 
1.
2
0.
6
0.
4 
− 
1.
1
0.
6
0.
3 
− 
0.
9
0.
9
0.
5 
− 
1.
6
4
Re
f
…
0.
36
Re
f
…
0.
29
Re
f
…
0.
92
Re
f
…
0.
12
Re
f
…
0.
25
Fr
ee
 
IG
F-
I
1
1.
1
0.
8 
− 
1.
7
1.
2
0.
7 
− 
2.
1
1.
2
0.
7 
− 
2.
2
0.
8
0.
5 
− 
1.
3
1.
8
1.
0 
− 
3.
4
2-
3 
0.
7
0.
5 
− 
1.
1
0.
8
0.
5 
− 
1.
3
0.
8
0.
5 
− 
1.
3
0.
7
0.
4 
− 
0.
9
1.
1
0.
6 
− 
2.
1
4
Re
f
…
0.
93
Re
f
…
0.
75
Re
f
…
0.
76
Re
f
…
0.
15
Re
f
…
0.
25
B.
 A
dj
us
te
d
IG
F-
I 
Bi
oa
ct
iv
ity
1 
1.
6
1.
0 
− 
2.
5
1.
3
0.
7 
− 
2.
5
2.
5
1.
4 
− 
4.
8
1.
3
0.
7 
− 
2.
3
2.
1
1.
1 
− 
4.
1
2-
3 
1.
4
0.
8 
− 
1.
8
1.
4
0.
8 
− 
2.
5
1.
2
0.
7 
− 
2.
1
1.
0
0.
6 
− 
1.
7
2.
0
1.
0 
− 
3.
8
4
Re
f
…
0.
04
Re
f
…
0.
31
Re
f
…
0.
01
Re
f
…
0.
47
Re
f
…
0.
03
To
ta
l 
IG
F-
I
1
0.
9
0.
6 
− 
1.
3
0.
8
0.
4 
− 
1.
4
1.
1
0.
6 
− 
1.
9
0.
7
0.
4 
− 
1.
3
1.
1
0.
6 
− 
2.
1
2-
3 
0.
7
0.
5 
− 
1.
0
0.
8
0.
5 
− 
1.
4
0.
6
0.
3 
− 
1.
0
0.
6
0.
4 
− 
0.
9
1.
0
0.
5 
− 
1.
9
4
Re
f
…
0.
25
Re
f
…
0.
37
Re
f
…
0.
77
Re
f
…
0.
10
Re
f
…
0.
87
Fr
ee
 
IG
F-
I
1
1.
0
0.
7 
− 
1.
6
1.
3
0.
7 
− 
2.
3
1.
1
0.
6 
− 
2.
0
0.
9
0.
5 
− 
1.
6
1.
7
0.
9 
− 
3.
4
2-
3 
0.
7
0.
5 
− 
1.
1
0.
9
0.
5 
− 
1.
5
0.
7
0.
4 
− 
1.
2
0.
6
0.
4 
− 
1.
0
1.
0
0.
6 
− 
1.
9
4
Re
f
…
0.
81
Re
f
…
0.
94
Re
f
…
0.
98
Re
f
…
0.
39
Re
f
…
0.
15
In
d
iv
id
u
al
s 
w
er
e 
gr
o
u
p
ed
 a
cc
o
rd
in
g 
to
 t
h
ei
r 
b
as
el
in
e 
le
ve
ls
 o
f 
th
re
e 
d
if
fe
re
n
t 
IG
F-
I 
p
ar
am
et
er
s 
(I
G
F-
I 
b
io
ac
tiv
ity
, 
To
ta
l 
IG
F-
I 
an
d
 F
re
e 
IG
F-
I)
. 
G
ro
u
p
 1
: 
IG
F-
I 
≤ 
25
th
 p
er
ce
n
til
e,
 G
ro
u
p
 2
-3
: 
IG
F-
I 
b
et
w
ee
n
 2
5t
h
 a
n
d
 7
5t
h
 p
er
ce
n
til
e,
 G
ro
u
p
 4
: 
IG
F-
I 
≥ 
75
th
 p
er
ce
n
til
e.
 I
n
 a
ll 
m
o
d
el
s 
gr
o
u
p
 4
 
is
 t
h
e 
re
fe
re
n
ce
 g
ro
u
p
 (
H
R
 =
 1
.0
).
 (
A
) 
U
n
ad
ju
st
ed
 m
o
d
el
s,
 (
B
) 
m
o
d
el
s 
ad
ju
st
ed
 f
o
r 
ag
e,
 B
M
I,
 s
m
o
ki
n
g,
 S
B
P,
 d
ia
b
et
es
, 
LD
L 
an
d
 H
D
L.
 C
V
D
- 
=
 
ab
se
n
ce
 o
f 
ca
rd
io
va
sc
u
la
r 
d
is
ea
se
, 
C
V
D
+
 =
 p
re
se
n
ce
 o
f 
ca
rd
io
va
sc
u
la
r 
d
is
ea
se
, 
IR
P
lo
w
/m
ed
 =
 l
o
w
 t
o
 m
ed
iu
m
 i
n
fl 
am
m
at
o
ry
 r
is
k 
p
ro
fi 
le
, 
IR
P
h
ig
h
 =
 
h
ig
h
 in
fl 
am
m
at
o
ry
 r
is
k 
p
ro
fi 
le
.
Michael BW2.indd   91 27-11-09   11:12
C
ha
pt
er
 3
92
Figure 1A and 1B respectively). In addition, when survival was analysed using 
quartiles of total IGF-I / IGFBP3 ratios no signifi cant relationship was found 
(adjusted for age p for trend = 0.41, data not shown).The data were then 
stratifi ed into subgroups with either positive (N = 133) or negative medical 
history of CVD (N = 242). Mean baseline levels of IGF-I bioactivity and all 
0 20 40 60 80 100
Follow-up time (months)
Total IGF-I A
C
u
m
u
la
ti
ve
 S
u
rv
iv
al
 (
%
)
P for trend = 0.36
40
50
60
70
80
90
100
0 20 40 60 80 100
Follow-up time (months)
Free IGF-I B
C
u
m
u
la
ti
ve
 S
u
rv
iv
al
 (
%
)
P for trend = 0.93
40
50
60
70
80
90
100
0 20 40 60 80 100
Follow-up time (months)
IGF-I Bioactivity C
P for trend = 0.01
C
u
m
u
la
ti
ve
 S
u
rv
iv
al
 (
%
)
40
50
60
70
80
90
100
Figure 1. Cox proportional hazard plots (%) for groups of (A) circulating total IGF-I levels, 
(B) circulating free IGF-I levels and (C) IGF-I bioactivity levels. P for trend only reached 
statistical signifi cance in the IGF-I bioactivity groups. Groups of IGF-I parameters: Group 1 
( ): ≤ 25th percentile; Group 2-3 ( ): between 25th and 75th percentile; Group 4 ( ): 
≥ 75th percentile. Trends across IGF-I bioactivity risk groups were based on Cox proportional 
hazard models with linear effect of the risk factor (Armitage trend test). Maximum time of 
follow-up was 103 months.
Michael BW2.indd   92 27-11-09   11:12
IGF-I Bioactivity and Human Survival 93
other measured parameters of the IGF system did not differ between these 
two CVD groups (data not shown). 
There was a signifi cant relationship between groups of IGF-I bioactivity 
and mortality in subjects with prevalent CVD (Table 4, Figure 2A). 
Subjects in the lowest quartile (group 1) of IGF-I bioactivity had a sig-
nifi cantly higher mortality rate than subjects in the highest quartile (group 4) 
(unadjusted p for trend = 0.003; adjusted p for trend = 0.004). 
For group 1 vs. 2-3 the HR for mortality rate was signifi cant (unadjusted HR 
= 2.3 (CI 95%: 1.4 − 3.8, p = 0.001); adjusted HR = 2.1 (CI 95%: 1.3 − 3.6, p = 
0.005). 
IGF-I bioactivity was signifi cantly inversely related to hs-CRP levels (rs = 
-0.17, p < 0.001, adjusted for age and BMI). Of all other measured parameters 
of the IGF-I system, only IGFBP-1 levels were signifi cantly positively corre-
lated with hs-CRP levels (r = 0.15, p = 0.04, adjusted for age and BMI). 
Using hs-CRP as a marker of infl ammation and mortality risk, we stratifi ed 
data into a subgroup with a low to medium (N = 238) and with a high (N = 
138) infl ammatory risk profi le (IRP). At baseline, mean IGF-I bioactivity was 
lower in subjects with a high IRP, than in subjects with a low to medium IRP 
(mean ± SEM: 312 ± 11.6 vs. 344 ± 7.8 pmol/L, p = 0.01, adjusted for age and 
BMI). Means of other parameters of the IGF-I system did not differ between 
IRP subgroups. 
The relationship between IGF-I bioactivity groups and mortality was sig-
nifi cant, but only in subjects with a high IRP (Table 4, Figure 2B). Subjects in 
the highest quartile (group 4) had signifi cantly better survival than subjects in 
the lowest quartile (group 1) (p = 0.01). This relationship remained signifi cant 
after adjustment for age, BMI, smoking, SBP, diabetes, LDL and HDL (p = 
0.03). Exclusion of the fi rst year of follow-up, did not affect this relationship 
as the difference in mortality rate remained signifi cant for group 1 vs. 4 (unad-
justed HR = 2.0, 95% CI: 1.1 − 4.3, p = 0.02; adjusted HR = 2.0, 95% CI: 1.0−4.0, 
p < 0.05). For group 1 vs. 2-3 the HR for mortality rate was not signifi cant 
(unadjusted HR = 1.2 (CI 95%: 0.8 − 2.0, p = 0.38; adjusted HR = 1.0 (CI 95%: 
0.6 − 1.8, p = 0.88). 
Lastly, IRP and CVD data were combined. At baseline, mean IGFBP-1 levels 
were signifi cantly higher in subjects with a positive medical history of CVD 
and/or a high IRP (N = 211) compared to individuals without prevalent CVD 
and a low/medium IRP, p = 0.004, data not shown).
A signifi cant trend for mortality rates was found across IGF-I bioactiv-
ity groups in subjects with a high IRP and/or a positive medical history of 
CVD (unadjusted p for trend = 0.003; adjusted p for trend = 0.005; Figure 
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2C). Mortality rate was highest in group 1, the quartile with the lowest IGF-I 
bioactivity (for estimated HRs see legends of Figure 2C). 
Neither total nor free IGF-I showed any signifi cant relationships with mor-
tality rate in CVD and IRP subgroups (Table 4).
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Figure 2. Crude incidence rates (number of events (deaths) per 100 person-years) are shown 
for groups of circulating IGF-I bioactivity levels according to strata of (A) absence or presence 
of a medical history of CVD (CVD - vs. CVD +, respectively), (B) low/medium or high infl am-
matory risk profi le (IRPlow/medium vs. IRPhigh, respectively) and (C) combined subgroups of 
CVD and IRP (CVD+ and/or IRPhigh vs. CVD- and IRPlow/medium). A signifi cant linear trend (*) 
between groups of IGF-I bioactivity was only found in subjects (A) with prevalent CVD, (B) 
a high IRP or (C) prevalent CVD and/or a high IRP. Figure 2C; for group 1 vs. 2-3 unadjusted 
HR = 1.5 (95% CI: 1.0 − 2.3, p < 0.05) for group 1 vs. 4: HR = 2.3 (95% CI: 1.3 − 3.8, p = 0.002); 
and for group 2 vs. 3: HR = 1.5 (95% CI: 0.9 − 2.5, p = 0.11). HRs adjusted for age, BMI, smok-
ing, SBP, diabetes, LDL and HDL were 1.4 (95% CI: 0.9 − 2.4, p = 0.15); 2.2 (95% CI: 1.3 − 3.8, 
p = 0.004); and 1.6 (95% CI: 0.9 − 2.6, p = 0.08), respectively.  
Maximum time of follow-up was 103 months. Trends across IGF-I bioactivity risk groups 
were based on Cox proportional hazard models with linear effect of the risk factor (Armitage 
trend test). Groups of IGF-I bioactivity: Group 1: IGF-I bioactivity ≤ 25th percentile; Group 
2-3: IGF-I bioactivity between 25th and 75th percentile; Group 4: IGF-I bioactivity ≥ 75th per-
centile. CVD = cardiovascular disease, IRP = infl ammatory risk profi le. IRP subgroups were 
based on hs-CRP levels: IRPlow/medium = CRP ≤ 3 mg/L, IRPhigh = CRP > 3 mg/L.
A
C
B
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DISCUSSION
This 8-year prospective study in elderly men showed that higher circulating 
IGF-I bioactivity is associated with better overall survival. Individuals in the 
lowest quartile of IGF-I bioactivity had a 1.8-fold increased mortality risk com-
pared with individuals in the highest quartile. Interestingly, for total and free 
IGF-I measurements as well as for the total IGF-I / IGFBP-3 ratios we could 
not fi nd such relationships.
Although men with lower IGF-I bioactivity might have died earlier or might 
have been excluded from the study because their physical condition (illness, 
frailty or other causes) prevented a visit to the research center [20], the strength 
of our study is its prospective design, which is likely to reduce this form of 
selection bias. 
The IGF-I KIRA was used to measure IGF-I bioactivity [13,14], which was 
signifi cantly associated with other IGF system parameters measured by immu-
noassay. However, none of these associations had correlation coeffi cients 
greater than 0.5. This suggests that, in comparison with immunoassays, the 
KIRA produces different information about circulating IGF-I. 
In most IGF-I immunoassays, various techniques are used to remove 
IGFBPs [21]. However, one of the major functions of IGFBPs is to modulate 
IGF-I bioavailability. IGFBP-1 is thought to be an important direct modulator 
of IGF-I bioactivity [10]. In our study IGF-I bioactivity correlated better with 
circulating IGFBP-1 levels than with either total or free IGF-I levels, suggest-
ing that IGFBP-1 indeed infl uences IGF-I bioactivity.
Of interest is the observed discrepancy between IGF-I bioactivity and free 
IGF-I in our study. Both parameters are believed to be informative about the 
fraction of circulating total IGF-I that interacts with the IGF-IR. Mean IGF-I 
bioactivity was signifi cantly greater than mean free IGF-I level and correlation 
between these parameters was poor. An explanation could be that the IGF-I 
KIRA is more sensitive than free IGF-I levels in estimating the concentration 
of circulating IGF-I that interacts with the IGF-IR, since the KIRA is probably 
better at detecting the modulatory effects of IGFBPs and IGFBP proteases. In 
addition, as the IGF-I KIRA measures the overall ability of serum to activate the 
IGF-IR in vitro, our data do not allow us to discriminate between the relative 
contributions of IGF-I and IGF-II to the IGF-I KIRA signal. Therefore, IGF-II 
mediated effects could also have contributed to the discrepancy between the 
IGF-I KIRA and free IGF-I levels. From previous experiments it is known that 
IGF-II has a cross-reactivity of about 12% to the IGF-IR [13]. However, as has 
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been suggested previously, from a biological point of view it is not important 
whether IGF-IR activation is caused mostly by IGF-I or IGF-II [22].
In this study a relatively high circulating IGF-I bioactivity was associated 
with a lower mortality risk. This is in contrast to results reported in animal 
studies, where low circulating IGF-I levels were associated with increased 
survival. An explanation could be that in these animal studies effects of 
IGF-I on the rate of aging were studied during lifelong exposure, whereas 
our study only provides insight into IGF-I activity towards the end of life. 
In addition, insulin and IGF-I have very different functions and signalling 
pathways in mammals compared with their homologs in lower species (e.g. 
C. elegans and Drosophila). Furthermore, lifespan in humans is measured in 
decades as opposed to months or days in rodents, fl ies and nematodes [23]. 
Another explanation could be that catabolism and/or a systemic infl ammatory 
response as a consequence of subclinical (undiagnosed) diseases may have 
induced resistance to IGF-I production. It could be that in our study low IGF 
bioactivity may not be a cause but rather an effect, serving as a reporter for 
disease or catabolism. 
Humans have the potential to live for over 100 years and the precise inter-
actions of all factors that infl uence aging is complex. In the Western world 
cardiovascular disease (CVD) and cancer are the most important determinants 
of human survival. Although cancer is also a common cause of death in animal 
models used to study longevity, CVD is not and is more specifi c to humans. 
When we stratifi ed for the presence or absence of CVD, we found that low 
IGF-I bioactivity was an important independent risk factor for mortality rate 
in individuals with CVD. Interestingly, comparative results were found when 
data were stratifi ed according to IRP (based on CRP levels), and the observed 
trend became even stronger when both groups were combined. 
Of note, CRP is a non-specifi c marker of systemic infl ammatory responses 
and has emerged as the most powerful predictor of mortality due to CVD 
events among eleven other biomarkers [19]. In our study CRP levels were 
signifi cantly inversely related to IGF-I bioactivity and positively to IGFBP-1. 
Although a decline in IGF-I bioactivity, as previously discussed, could be a 
component of the hormonal alterations that occur in any illness or catabolic 
state (37), the difference in mortality rate between the highest and the lowest 
quartile of IGF-I bioactivity in our study remained signifi cant when all mor-
talities in the fi rst year of follow-up were excluded from the analyses. Thus, 
undiagnosed illness or catabolic states at baseline probably did not cause the 
relationship between IGF-I bioactivity and survival. 
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Interestingly, there are different clinical models that support the negative 
regulation of CRP and other infl ammatory markers by GH/IGF-I administration 
[24,25] For example, Sesmilo et al. found low levels of CRP in patients with 
active acromegaly, which rose when IGF-I levels normalized after administra-
tion of a GH receptor antagonist [26]. Verma et al. found that CRP negatively 
infl uences proliferation, differentiation and survival of isolated endothelial 
progenitor cells in vitro and their ability to produce nitric oxide (NO), whereas 
for IGF-I opposite effects have been reported [27,28]. Altogether these fi nd-
ings point to the possibility of a relationship between IGF-I bioactivity, CRP 
and CVD. However, it remains to be seen whether reduced IGF-I bioactivity 
is an endocrine contributor to mortality risk or simply an epiphenomenon 
related to overall health/resistance to infl ammation.
In conclusion, this prospective study provides evidence that low circulat-
ing IGF-I bioactivity in elderly men is associated with increased mortality, 
especially in those individuals in which an age-related pro-infl ammatory state 
exists, with its attendant higher risk of mortality from CVD. Remarkably, for 
total and free IGF-I measurements we could not fi nd such relationships. Com-
pared to IGF-I immunoassays the IGF-I KIRA may offer the unique possibility 
of measuring the net modulating effects of IGFBPs and IGFBP proteases on 
IGF-IR activation by bioactive IGF-I available in human serum. In this respect, 
our study suggests that determination of IGF-I bioactivity may help to clarify 
the controversies that exist about the precise role of IGF-I in human survival.
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ABSTRACT
Background: Inadequate food intake plays an important role in the develop-
ment of malnutrition in continuous ambulatory peritoneal dialysis (CAPD) 
patients. 
Aim of the study: To investigate in CAPD patients whether circulating insulin-
like growth factor-I (IGF-I) bioactivity may offer a more sensitive index to 
acute nutritional interventions than total IGF-I. 
Methods: An open-label, randomized, crossover study of 2 days -with one-
week interval- was performed in 12 CAPD patients in the fed state to compare 
a mixture of amino acids (Nutrineal 1.1%) plus glucose (AA plus G) (Physi-
oneal 1.36 to 3.86%) dialysate versus G only as control dialysate. Fed-state 
conditions were created by identical liquid hourly meals. IGF-I bioactivity was 
measured by the kinase receptor activation assay (IGF-I KIRA); Total IGF-I 
was measured by immunoassay. 
Results: In the fed state both after AA plus G as well as after G dialysis IGF-I 
bioactivity increased compared to baseline, while no changes in circulating 
total IGF-I levels were observed in both treatment arms. However, the increase 
in IGF-I bioactivity was only signifi cant after AA plus G dialysis (p=0.02). 
Conclusions: Our results provide evidence that in CAPD patients changes in 
circulating IGF-I bioactivity are associated with nutrient intake and that IGF-I 
bioactivity rather than total IGF-I is involved in acute responses to nutritional 
interventions in CAPD patients. 
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INTRODUCTION
Malnutrition is a major complication of continuous ambulatory peritoneal 
dialysis (CAPD) and is associated with increased morbidity and mortality 
[1]. Insulin-like growth factor-I (IGF-I) is produced in tissues throughout the 
body under the infl uence of growth hormone (GH). In addition, nutrition 
is one of the main regulators of circulating IGF-I [2,3]. Circulating IGF-I has 
been proposed as a valid sensitive marker of (mal) nutrition in subjects on 
CAPD, which may have advantages above serum albumin and other markers 
of nutritional state [4-7]. On the other hand, reduced bioavailability of IGF-I 
may play a role in decreasing muscle protein synthesis [8].
The GH-IGF-I axis shows major changes in chronic renal failure (CRF). 
Despite elevated GH levels, IGF-I secretory rate by the liver is reduced in CRF, 
possibly as a result of hepatic GH resistance [9]. There is also a resistance to 
IGF-I action, which may be the result of circulating inhibitors [8]. The amount 
of these circulating inhibitors increases in patients with CRF along with the 
decrease in glomerular fi ltration rate [10].
Circulating IGF-I bioactivity measured by “classic” bioassays has been 
reported to be low in CRF [11]. Since these “classic” bioassays suffered from 
high variability as well as long assay duration, IGF-I bioactivity is at present 
almost exclusively estimated by immunological determinations of total IGF-I. 
In contrast, circulating total IGF-I levels measured by immunoassays have 
been reported as normal or elevated in CRF. However, the results of IGF-I 
immunoassays may not necessarily correspond to the fraction of IGF-I being 
accessible to the IGF-I receptor [12]. 
Recently a rapid and accurate IGF-I bioassay was developed as alternative 
to the “classic” bioassays, named the kinase receptor activation assay (IGF-I 
KIRA) [12,13]. The IGF-I KIRA quantifi es phosphorylation of tyrosine residues 
of the activated IGF-I receptor (IGF-IR) as a measure for IGF-I bioactivity in 
serum. In contrast to commonly used IGF-I immunoassays, the IGF-I KIRA 
is sensitive for modifi cations of IGF-IR activation by circulating Insulin-like 
Growth Factor Binding Proteins (IGFBPs) and IGFBP-proteases [12,14]. 
We hypothesized that measuring circulating IGF-I bioactivity by the IGF-I 
KIRA method could help to enhance our insights in the alterations of the IGF-I 
system in CAPD patients. Considering that a substantial portion of patients 
undergoing CAPD have insuffi cient protein and calorie intake due to anorexia, 
we previously evaluated in CAPD patients the metabolic effects of dialysate 
containing amino acids with glucose (AA plus G) and observed that this solu-
tion improved protein metabolism both in fasting [15] and in fed [16] patients on 
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peritoneal dialysis. From the same study we here evaluate whether circulating 
IGF-I bioactivity is a more sensitive index to monitor acute responses to nutri-
tional interventions than total IGF-I. In addition, in these CAPD patients we 
compared basal IGF-I bioactivity and total IGF-I in relation to nutritional status.
METHODS
Study population
Twelve patients on CAPD were recruited from the Peritoneal Dialysis Unit 
of the Erasmus Medical Center (Erasmus MC). Inclusion criteria were: stable 
patients, who were on peritoneal dialysis for more than 3 months and a weekly 
total Kt/V>1.7 (Total Kt/V= urea clearance per week (Kt) divided by urea 
distribution volume (V), as delivered by peritoneal dialysis plus residual renal 
function). Exclusion criteria were peritonitis, other infections or infl ammatory 
diseases in the previous 6 weeks, malignancy, and life expectancy less than 6 
months. The Medical Ethics Committee of the Erasmus MC approved the study 
and informed consent was obtained from all patients. 
Study design
The study design has been published in detail [16]. Briefl y, an open-label, ran-
domized, crossover study of 2 days with one-week interval was performed.
On the 2 study days, all patients came at 08.00 a.m. into the hospital and 
stayed at the Department of Nephrology of the Erasmus MC. Dialysis was 
performed during daytime for 9 h, while the patients consumed a liquid diet 
comparable in nitrogen and energy content in their habitual diet (Figure 1). 
The total food volume was divided into 11 equal portions (Figure 1). The fi rst 
two meal portions were given at half-hourly intervals, and the remaining nine 
portions were given at hourly interval thereafter (Figure 1).
For dialysis either dialysate that contained a mixture of amino acids and 
glucose (AA plus G) (Nutrineal 1.1% plus Physioneal 1.36% to 3.86%; Baxter 
BV, Utrecht, the Netherlands) or dialysate that contained glucose only (G) 
was used. The AA plus G dialysate was obtained by mixing one bag of 2.5 L of 
Nutrineal 1.1% (containing 27.5 g of AA) and four bags of 2.5 L of Physioneal 
1.36% to 3.86% G (see [16] for more details). The night before the study days, 
all patients underwent dialysis with Extraneal. Because metabolic steady-state 
conditions are not achieved with a standard CAPD scheme, six daytime dialy-
sate exchanges on the 2 study days were performed using an automatic cycler 
(HomeChoice, Baxter B.V.). 
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Blood Measurements
At 8.20 a.m. two catheters were inserted into superfi cial veins of both arms. 
Baseline blood samples were collected before starting the oral feeding. Blood 
samples for IGF-I parameters were taken before the fi rst dialysate exchange 
(fasting state) and at the end of the study (Figure 1). Circulating IGF-I bioactiv-
ity was measured using an in-house IGF-I kinase receptor activation assay 
as previously described [17]. This latter assay is based on another principle 
than IGF-I immunoassays [13,17]. Briefl y, IGF-I binding to the IGF-I receptor 
(IGF-IR) results in autophosphorylation of tyrosine residues located within 
the intracellular kinase domain, being the fi rst step in the intracellular signal 
cascade. The IGF-I KIRA uses human embryonic renal cells stably transfected 
with cDNA of the human IGF-IR gene (293 EBNA IGF-IR) and quantifi es 
phosphorylation of tyrosine residues of the IGF-IR to assess IGF-I bioactivity. 
Serum total IGF-I was measured by a solid-phase, enzyme-labeled chemilumi-
nescent immunometric assay (CLIA) Immulite 2000 IGF-I supplied by Siemens 
Medical Solutions Diagnostics, Los Angeles, USA. 
Both IGF-I bioactivity and total IGF-I levels were compared with the age-
specifi c normative range values for IGF-I. Reference values for IGF-I bioactiv-
ity and total IGF-I have been published in previous reports [17,18]. Both for 
IGF-I bioactivity and total IGF-I individual Z-scores were calculated using the 
following formula: Z-score = (x–average x/S.D.) where x is the actual IGF-I 
bioactivity or IGF-I level, average x is the mean IGF-I bioactivity or IGF-I level 
at that age, and S.D. is standard deviation for the mean at that age. 
0 60 120 180 240 300 360 420 480 540 min-60
AA plus G-dialysate or G-dialysate
Time
IGF IGF
Liquid
Food
Blood
Sampling
Figure 1. Schematic diagram of the study-day protocol.
   Portions of the liquid food, the fi rst two portions given half-hourly and thereafter 
hourly.
  Time points of blood sampling for IGF-I
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Insulin was measured by a chemiluminescent immunometric assay (Immu-
lite 2000 Insulin; Siemens Medical Solutions Diagnostics, Los Angeles, USA). 
Amino acids were measured by ion-exchange chromatography on a Bio-
chrome 20 amino acid analyzer with ninhydrin detection (Biochrome, Cam-
bridge, UK). Serum glucose, creatinine, albumin, prealbumin, and transferrin 
were performed by standard laboratory methods. Residual renal function 
was derived as the mean of renal urea and creatinine clearance (ml/min) and 
derived from PD adequest 2.0 software Baxter.
Other measurements
Body mass index (BMI) was defi ned as weight divided by the square of height 
(kg/m2). Subjective global assessment (SGA) as described by Detsky et al. is 
based on clinical parameters [19]. Patients were classifi ed according to their 
nutritional status into three categories: A: good nutritional status; B: moder-
ate malnutrition; C: severe malnutrition. The Protein Equivalent of Nitrogen 
Appearance normalized (nPNA) was evaluated by the urea kinetic model (PD 
Adequest 2.0 software, Baxter) [16]. 
Effects on protein metabolism were studied using whole-body protein turn-
over (WBPT). Previously we performed an open-label randomized crossover 
study on 2 days with 6 days interval comparing the effect of AA plus G dialy-
sate with dialysate containing only G [16]. For the present study we used data 
on WBPT, which were all derived from our previously performed study [16].
Statistical analysis
Data are expressed as medians with ranges unless otherwise indicated.
All variables were tested using the Shapiro-Wilk- test for normality. When 
no normality of distribution was found, data were log-transformed. One-way 
ANOVA was used to test differences between subjects with different SGA clas-
sifi cations. The Wilcoxon Signed Rank test was used to compare outcomes in 
IGF-I parameters and other variables between before and after dialysis. The 
paired T- test was used to compare differences between the two treatment 
regimens (AA plus G versus G dialysis). Pearson ‘s correlation coeffi cients 
were calculated to assess the associations between variables. Pearson ‘s 
correlation coeffi cients for IGF-I were calculated after adjustment for age. 
A P-value of 0.05 or less was considered statistically signifi cant. Data were 
analyzed using SPSS 15 for Windows (SPSS Inc., Chicago, IL).
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RESULTS
In Table 1 the baseline characteristics of the study population are presented. 
According to the SGA classifi cation, 4 out of 12 patients were moderately 
malnourished. The mean BMI of these latter 4 patients tended to be lower 
and the time on peritoneal dialysis was longer than that of patients with a 
good nutritional status, but these differences were not statistically signifi cant 
(Table 1). At baseline albumin, prealbumin and transferring levels did not 
differ between subjects with different SGA classifi cations. 
In subjects with a good nutritional status (SGA A) Z-scores for circulating 
total IGF-I were in the upper half of the normal range (Table 2; Figure 2). 
Z-scores for total IGF-I exceeded the normal range (i.e Z-score >2.0 SD) in 
patients with moderate malnutrition (SGA B) (Table 2). The differences in 
total IGF-I between both groups were not statistically signifi cant (Table 2; 
Figure 2). 
Mean circulating IGF-I bioactivity did not differ between patients with SGA 
A and SGA B (Table 2; Figure 2). Z-scores for IGF-I bioactivity were in the 
lower half of the normal range (Table 2; Figure 2). Three subjects (two classi-
fi ed as SGA B) had IGF-I bioactivity outside and below the normal range (i.e. 
Z- score <2.0 SD) (Table 2). IGF-I bioactivity was not signifi cantly related to 
total IGF-I (r = 0.50, p = 0.10). 
Table 1. Characteristics of 12 patients (4 females) in the basal state stratifi ed for nutritional 
status by SGA
SGA A (n=8; 3F) SGA B (n=4; 1F) P-value
Median Range Median Range
Age (yrs) 57.5 (35 – 63) 53.7 (33 – 70) 0.85
BMI (kg/m2) 26.8 (23.7 – 32.6) 22.9 (21.4 – 32.8) 0.37
Residual renal function
(mL/min/1.73 m2)
6 (4 – 12) 6 (4 – 11) 0.77
Time on PD (months) 8 (4 – 72) 18 (4 – 28) 0.92
Kt/V 2.6 (2.0 – 3.1) 2.0 (1.9 – 2.7) 0.08
Albumin (g/L) 39 (35 – 42) 38 (36 – 40) 0.71
Prealbumin (g/L) 0.36 (0.28 – 0.54) 0.38 (0.27 – 0.43) 0.87
Transferrin (g/L) 2.25 (1.90 – 2.70) 2.15 (2.10 – 2.60) 0.99
nPNA (g/kg/day) 0.95 (0.56 – 1.37) 0.84 (0.69 – 0.97) 0.40
Protein intake (g/kg/day) 0.99 (0.68 – 1.38) 0.83 (0.59 – 0.93) 0.14
Energy intake (kcal/kg/day) 22.8 (16.0 – 26.6) 20.1 (11.1 – 32.1) 0.71
SGA: subjective global assessment; SGA A: good nutritional status; SGA B: moderate mal-
nutrition; F = female; BMI: body mass index; PD: peritoneal dialysis; nPNA: normalized 
protein equivalent of nitrogen appearance (PD Adequest 2.0 software, Baxter)  
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Both IGF-I bioactivity and total IGF-I levels did not signifi cantly decrease 
with age (IGF-I bioactivity: r = -0.16, p = 0.63; total IGF-I levels: r = 0.30, 
p = 0.34). 
Total IGF-I levels and IGF-I bioactivity were inversely related to creatinine 
clearance, although these latter relationships missed statistical signifi cance 
(r = -0.58, p = 0.06 and r = -0.48, p = 0.11, respectively).
In the fed state both after AA plus G and after G dialysis IGF-I bioactivity 
increased compared to baseline (Table 3; Figure 3). However, the increase in 
IGF-I bioactivity was only signifi cant after AA plus G dialysis (p=0.02). Com-
pared to baseline no changes in circulating total IGF-I levels were observed in 
both treatment arms (Table 3; Figure 3). 
 In the basal state serum bicarbonate, creatinine, urea, glucose and insulin 
levels did not statistically differ between both treatment arms (data not shown). 
After dialysis insulin and glucose levels increased signifi cantly compared with 
SGA A SGA B
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Z
-s
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SGA A SGA B
Total IGF-I IGF-I Bioactivity
Figure 2. Top: Z-scores for total IGF-I after stratifi cation for SGA. Bottom: Z-scores for 
IGF-I bioactivity after stratifi cation for SGA. The line in the middle represents the 50th per-
centile of data. The boxes extend from the 25th percentile to the 75th percentile values; the 
whiskers extend from the 5th to the 95th percentile values of each group.
Table 2. IGF-I parameters of the 12 patients in the basal state
SGA A (n=8; 3F) SGA B (n=4; 1F) P-value
Median Range Median Range
Total IGFI
(nmol/L)
26.9 (11.2 – 48.2) 31.0 (18.1 – 33.0) 0.54
Z-score 1.75 (-1.30 – 4.50) 2.35 (-0.60 – 4.00) 0.36
IGF-I Bioactivity
(pmol/L)
216 (136 – 358) 211 (167 – 218) 0.41
Z-score -1.57 (-2.31 to -0.44) -1.78 (-2.18 to -1.55) 0.34
SGA: subjective global assessment; SGA  A: good nutritional status; SGA B: moderate mal-
nutrition
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baseline in both treatment arms (Table 4). After AA plus G dialysis plasma 
essential and non-essential amino acid levels signifi cantly increased com-
pared to G dialysis (data not shown). Protein loss and excretion of urea in 
dialysate did not differ with either type of dialysate (data not shown). Results 
of whole-body protein turnover after AA plus G dialysate and after G dialysate 
from this study have previously been published [16]. After AA plus G dialysate 
Table 3. IGF-I Parameters after AA plus G dialysate (A) and after G dialysate (B), respec-
tively
A] After AA plus G Dialysate
IGF-I Bioactivity (pmol/L) Total IGF-I (nmol/L)
Basal At the end 
of dialysis
Change* 
(%)
Basal At the end
of dialysis
Change* 
(%)
Median 211 251** +34 30 26 -5
Range (136 – 358) (191 – 571) (-33 – +59) (11 – 48) (10 – 43) (-15 – +21)
B] After G Dialysate
IGF-I Bioactivity (pmol/L) Total IGF-I (nmol/L)
Basal At the end of 
dialysis
Change* (%) Basal At the end
of dialysis
Change*
(%)
Median 226 251 +16 25 26 +1.5
Range (151 – 371) (177 – 533) (-52 – +52) (10 – 42) (13 – 42) (-13 – +23)
AA plus G dialysate = combined amino acids plus glucose dialysis, G dialysate = glucose 
dialysis. 
*Changes at the end of dialysis compared to baseline (= 100%) 
**P = 0.02; Paired t-test.
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Figure 3. Top: Changes in circulating total IGF-I levels in the fed state after G and after AA 
and G dialysate, respectively (Basal state = 100%).  Bottom: Changes in circulating IGF-I 
bioactivity in the fed state compared to baseline after G and after AA and G dialysate, respec-
tively (Basal state = 100%).
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leucine fl ux, leucine oxidation, protein intake and protein synthesis signifi -
cantly increased compared with G dialysate (p = 0.001, p < 0.001, p < 0.001 
and p=0.039, respectively). There were no signifi cant differences in protein 
breakdown after AA plus G dialysate and G dialysate, respectively (p = 0.346). 
In addition, overall net protein balance was not signifi cantly different between 
both treatment arms (p = 0.347). 
Both after AA plus G and after G dialysis IGF-I bioactivity was signifi cantly 
related to leucine fl ux, leucine oxidation and protein intake, but not to protein 
synthesis, protein breakdown and overall net protein balance (Table 5). More-
over, IGF-I bioactivity was not related to insulin levels at the end of dialysis 
(AA plus G: r = 0.24, p = 0.47; G: r = 0.38, p = 0.25). 
Table 4. Glucose and insulin [median (range)] in the basal state and at the end of 9h dialysis 
with AA plus G or G dialysate, respectively
Baseline
AA plus G dialysis
After
AA plus G dialysis
Baseline
G dialysis
After
G dialysis
Glucose 
(mmol/L)
4.4
(3.6 – 6.8)
5.7*
(3.6 – 12.7)
4.2
(2.1 – 6.7)
5.3*
(3.9 – 11.1)
Insulin 
(pmol/L)
106
(46 – 444)
478*
(111 – 1268)
130
(35 – 288)
454*
(172 – 950)
AA plus G dialysate = combined amino acids plus glucose dialysis, G dialysate = glucose 
dialysis. 
*P<0.05 versus baseline.
Table 5. Age-adjusted correlation coeffi cients between IGF-I and parameters of whole-
body protein turnover after AA plus G dialysate (A), and after G dialysate (B), respectively
IGF-I Bioactivity Total IGF-I
A] After AA plus G Dialysate
Flux 0.61* 0.23
Oxidation 0.71* 0.30
Intake 0.62* 0.10
Synthesis 0.37 0.10
Breakdown 0.35 0.33
Net Protein balance 0.14 -0.32
 B] After G Dialysate
Flux 0.67* 0.44
Oxidation 0.72* 0.40
Intake 0.64* 0.03
Synthesis 0.46 0.41
Breakdown 0.23 0.64*
Net Protein balance 0.20 -0.49
AA plus G dialysate = combined amino acids plus glucose dialysis, G dialysate = glucose 
dialysis. 
*P<0.05.
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There were no signifi cant relationships between total IGF-I levels and 
WBPT parameters after AA plus G dialysis (Table 5). After G dialysis total 
IGF-I levels were signifi cantly related to protein breakdown, but not other 
components of WBPT (Table 5). 
Neither basal IGF-I bioactivity nor total IGF-I levels were related to nPNA 
(IGF-I bioactivity: r = 0.37, p = 0.27; total IGF-I: r = 0.52, p = 0.09). 
DISCUSSION
The major fi nding of the present study in CAPD patients is that in the fed 
state both after AA plus G and after G dialysis circulating IGF-I bioactivity 
increased. This increase in IGF-I bioactivity occurred while no changes in cir-
culating total IGF-I levels were observed. Our observation suggests that IGF-I 
bioactivity rather than total IGF-I is involved in acute responses to nutritional 
interventions in CAPD patients.
Only after AA plus G dialysate the rise in IGF-I bioactivity was signifi cantly. 
The lack of a signifi cant rise in IGF-I bioactivity after G dialysis may be due 
to the small number of patients. Alternatively, it cannot be ruled out that the 
larger amount of AA accounts for a signifi cant rise of IGF-I bioactivity.
Previously it has been suggested that nutrients infl uence synthesis and 
action of IGF-I and its binding proteins (IGFBPs) at multiple levels [3]. Both 
protein and energy are needed for IGF-I gene expression [2,20]. Although 
protein is a very strong factor in changing hepatic IGF-I gene expression, a 
period of 9 hrs is likely too short to induce measurable changes in circulat-
ing IGF-I levels [20]. Therefore the rise in IGF-I bioactivity at the end of the 
dialysis period probably refl ects diet-induced changes in circulating IGFBP 
levels as nutrition is also a major regulator of the circulating IGFBP levels 
[2]. Dietary manipulations may change the circulating levels of IGFBPs more 
rapidly and thereby IGF-I bioactivity [2]. Although it has been found that cir-
culating IGFBP-3 concentrations are relatively constant throughout the day, 
IGFBP-1 is markedly and rapidly suppressed by nutrient intake and this effect 
is mediated primarily by increased insulin, glucose and probably amino acid 
concentrations [21-25]. Insulin may also selectively stimulate the transport of 
IGFBP-1 to the extravascular space [26]. Both mechanisms might be involved 
in the changes of IGF-I bioactivity. However, the design of our study was not 
suffi cient to disentangle which components of nutritional interventions were 
affecting the increase of IGF-I bioactivity.
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A weakness of our study could be that we did not measure the six IGFBP 
levels. Because IGFBPs control IGF-I bioavailability they are believed to exert 
both stimulatory and inhibitory effects on IGF-I actions [27]. In addition, 
IGF-I bioactivity may be further controlled by posttranslational modifi cations 
of IGFBPs (e.g. partial proteolytic degradation by specifi c IGFBP proteases 
and selective dephosphorylation) [27]. Thus the interpretation of the overall 
effects of these six IGFBPs on IGF-I activity is very diffi cult, especially in CRF 
which is characterized by substantial changes in the circulating IGF system.. 
In this respect the IGF-I KIRA assay may have an important advantage over 
measuring IGFBPs: it gives an overall and integrated picture by capturing the 
complex interactions between IGF-I, IGFBPs, proteases, and the IGF-I recep-
tor, since the IGF-I KIRA directly measures IGF-I receptor activation in vitro. 
Thus, the IGF-I KIRA probably provides a more accurate measure of IGF-I 
action in vivo than any other currently available model based on immunoas-
saysof IGFBP blood levels, since it incorporates complex interactions with 
binding proteins and proteases.
We observed no change in total IGF-I levels during dialysate administration 
in both treatment arms. In accordance with our fi ndings, Pupim et al. also 
reported no changes in total IGF-I levels during intradialytic parenteral nutri-
tion to chronic hemodialysis patients, despite a signifi cant positive effect on 
protein and energy metabolism [28].
Although there was a marked rise of plasma insulin levels in both treat-
ment arms after dialysate administration, the absence of relationship between 
insulin and IGF-I bioactivity does not support an insulin-mediated increase in 
IGF-I bioactivity.
Our results provide evidence that in CAPD patients acute changes in 
circulating IGF-I bioactivity are associated with nutrient intake and that in 
this respect IGF-I bioactivity is a more sensitive index for monitoring acute 
responses to nutritional interventions than total IGF-I.
In both treatment arms IGF-I bioactivity was positively related to leucine 
fl ux, leucine intake and leucine oxidation. The competing processes of amino 
acid deposition (synthesis for maintenance) and loss (oxidation) play an 
important role in maintaining protein metabolism [29]. If protein intake is not 
adequate, the amino acid supply is limited and oxidation is reduced to a greater 
extent than is synthesis [30,31]. Conversely, when amino acids are provided in 
excess, as probably was the case in our study, oxidation rather than synthesis 
is increased [30]. In other words, in this situation leucine oxidation is a more 
sensitive index of adequacy of amino acid intake than is protein synthesis, 
changing in proportion to protein intake [31]. Thus the positive relationships 
Michael BW2.indd   112 27-11-09   11:12
IGF-I Bioactivity and Nutrition in CAPD Patients 113
between IGF-I bioactivity, leucine fl ux, leucine intake and leucine oxidation 
in our study is consistent with our fi nding that circulating IGF-I bioactivity 
can be changed by amino acid intake: thus our study provides evidence that 
an increase in circulating IGF-I bioactivity likely is the consequence of an 
increased amino acid and/or protein intake. In favor of this, it has been found 
that changes in nitrogen balance parallel changes in IGF-I [32]. By use of a 
“classic” IGF-I bioassay it has been reported that circulating IGF-I bioactivity 
is low in subjects on HD [11]. Our study confi rms this fi nding for PD. Using 
a “classic” porcine cartilage bioassay Phillips et al. showed that circulating 
IGF-I bioactivity was reduced and they hypothesized that IGF-I bioactivity 
was depressed because of the accumulation of dialyzable inhibitors [11]. 
Some years later these dialyzable inhibitors were identifi ed as IGFBPs and 
it was demonstrated that IGF-I activity in blood samples of CRF patients was 
indeed restored after removal of IGFBPs by IGF-II chromatography [33]. Thus 
the low IGF-I bioactivity in CAPD patients in our study may directly refl ect 
sequestering of IGF-I by IGFBPs in the circulation.
Most CAPD patients in our study showed serum total IGF-I levels in the 
normal range. This observation is in line with previous studies in patients 
undergoing maintenance hemodialysis (HD) [10,33-35]. However, circulating 
total IGF-I levels exceeded even the normal range in some patients. This latter 
phenomenon was especially observed in patients with moderate malnutrition 
(SGA B). Although we did not measure IGFBP levels, previous studies have 
shown that serum of individuals with CRF contains increased levels of IGFBP-
1, IGFBP-2, fragments of IGFBP-3, IGFBP-4 and IGFBP-6 [10,34,36]. It has 
been hypothesized that these IGFBPs accumulate largely because of reduced 
clearance: elevation of their serum levels is inversely related to glomerular fi l-
tration rate [10]. When IGFBPs are present in serum in large excess and a total 
IGF-I immunoassay is utilized that is subject to even modest amount of binding 
protein interference, the measured total IGF-I levels may be artifi cially high 
[37]. This problem may be exacerbated in patients with underlying conditions, 
that lower circulating IGF-I levels (like subjects with chronic renal failure and 
moderate malnutrition), since the decrease in IGF-I as well the increase in 
IGFBPs results in more unsaturated IGFBPs and intensify the interference [37]. 
This may explain why in our study circulating total IGF-I levels exceeded the 
normal range especially in CAPD patients with moderate malnutrition.
Finally, several fi ndings in our study appeared not to be statistically signifi -
cant (e.g. comparison IGF-I parameters between groups of SGA A vs. B and 
the correlation between insulin and IGF-I bioactivity). However, this may also 
have been due to the small number of patients included in our study. 
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In conclusion, the observed acute increase in IGF-I bioactivity in the fed 
state may be related to nutrition-induced changes in circulating IGFBPs. The 
present study suggests that IGF-I bioactivity rather than total IGF-I is involved 
in acute responses to nutritional interventions in CAPD patients.
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ABSTRACT
Background: A low serum total insulin-like growth factor-I (IGF-I) is con-
sidered a diagnostic indicator of growth hormone defi ciency (GHD) in the 
presence of hypopituitarism. Introduction of immunoradiometric (IRMA) and 
chemiluminescence (CLIA) IGF-I immunoassays has introduced endogenous 
antibodies as a new source of interference. In general this goes unnoticed and 
might lead to unnecessary diagnostic and therapeutic interventions. 
Case: A 56-year-old man was referred with a decline in physical performance, 
unexplained osteopenia and weight loss of 3 kg over the past 8 months. 
Although clinical signs and symptoms were unremarkable, laboratory results 
pointed to secondary hypothyroidism and secondary hypogonadism. In 
addition, the serum total IGF-I level (CLIA; Diagnostics Products Corporation 
(DPC)) was in the low normal range. Two GH stimulation tests were per-
formed, but these tests did not support the diagnosis GHD. Moreover, IGF-I 
bioactivity measured by the Kinase Receptor Activation Assay (IGF-I KIRA) 
was normal. Interference of heterophilic antibodies was considered. After 
pretreatment with specifi c heterophilic blocking tubes (HBT), which contain 
blocking reagents to eliminate heterophilic antibodies, serum free thyroxin, 
testosterone, and IGF-I levels turned out to be normal. 
Conclusion: To our best knowledge, we here describe the fi rst case in the lit-
erature of a patient with low serum total IGF-I levels due to interference from 
heterophilic antibodies in the used IGF-I immunoassay. When confronted 
with low IGF-I levels, which do not fi t the clinical picture, interference of 
heterophilic antibodies should be considered in the differential diagnosis.
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INTRODUCTION
In 1977 the fi rst radioimmunoassay for insulin-like growth factor I (IGF-I) was 
described by Furlanetto et al. [1]. Since then, IGF-I immunoassays have been 
used to screen patients for the presence of growth hormone defi ciency (GHD) 
or acromegaly. However, when IGF-I immunoassays were applicated in larger 
groups of patients, many problems were encountered when these assays were 
used for these purposes [2]. From the start IGF-I immunoassays have suffered 
from analytical problems including their reproducibility and accuracy for the 
detection of IGF-I in human serum. 
Almost all IGF-I present in the circulation is bound to so-called insulin-like 
growth factor binding proteins (IGFBPs) [3]. As IGFBPs may interfere with 
specifi c antibody binding to IGF-I, it is considered essential for a high quality 
IGF-I immunoassay that binding protein interference is eliminated [2]. There-
fore, in virtually all IGF-I immunoassays, techniques such as acid-ethanol 
extraction or saturation with IGF-II are implemented in order to remove or to 
neutralize interference by these IGFBPs [4]. Similarly, since variability in IGF-I 
measurements can lead to erroneous conclusions, it is important that antibod-
ies utilized in IGF-I immunoassays both have high specifi city and affi nity for 
IGF-I [5].
Measurement of circulating total IGF-I levels is considered highly sensitive 
and specifi c for the diagnosis of acromegaly [6-8](6-8). A low circulating IGF-I 
level in an adult with additional pituitary hormonal defi ciencies, is considered 
highly specifi c for GH defi ciency. However, even when the most reliable 
IGF-I immunoassays are used, only in 57% of severe GHD patients (defi ned 
as a peak GH of less than 2.5 ng/mL in insulin tolerance testing) circulating 
IGF-I levels are below the 95% confi dence interval of the normal range in a 
healthy population [5]. 
The introduction of immunoradiometric (IRMAs) and chemiluminescence 
(CLIAs) IGF-I immunoassays has provided enhanced speed and sensitivity for 
IGF-I measurement and made it possible to conduct convenient total IGF-I 
determination without binding-protein interference [5]. As a consequence, 
the clinical use of IRMAs and CLIAs resulted in a reduction of the number 
of patients who require provocative GH testing. However, these new assay 
technologies may have introduced a new clinical problem when using IGF-I 
for the diagnosis and evaluation of patients with GHD. We here illustrate this 
by a case history.
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METHODS
This study was performed after obtaining patient ‘s written informed consent 
for use of his blood samples for further investigations.
Serum total IGF-I was measured by a solid-phase, enzyme-labeled che-
miluminescent immunometric assay (CLIA) Immulite 2000 IGF-I supplied 
by Siemens Medical Solutions Diagnostics (Los Angeles, USA). In this assay 
a murine anti-IGF-I coated to a solid phase (bead; capture antibody) and a 
polyclonal rabbit anti-IGF-I conjugated to alkaline phosphatase (detection 
antibody) are used. According the manufacturer IGFBP interferences are 
circumvented by an on-board predilutional and acidifi cation step (pH<3.1) 
to separate IGF-I and IGFBP-3. Once the sample is neutralized again (i.e. 
restoring pH to 7), IGFBP binding sites are blocked by adding an excess IGF-
II in order to prevent reaggregation of IGF-I and IGFBP-3. The within-assay 
coeffi cient of variation of the Immulite 2000 IGF-I varies between 3-6%. The 
level of IGF-I was expressed as nanomoles per liter (nM) and was compared 
with the age-specifi c normative range values for IGF-I. Reference values for 
IGF-I have been published in a previous report [9].
Immulite 2500 assays were used to measure the following hormonal param-
eters: Free thyroxin (Free T4) (by a solid-phase, chemiluminescent, competitive 
analog immunoassay), Thyroid Stimulating Hormone (TSH) (by a solid-phase, 
two site chemiluminescent, immunometric assay), Follicle Stimulating Hormone 
(FSH) (by a solid-phase, two site chemiluminescent, immunometric assay), 
Luteinizing Hormone (LH) (by a solid-phase, two site chemiluminescent, immu-
nometric assay), testosterone (by a solid-phase, competitive chemiluminescent 
enzyme immunoassay), cortisol (by a solid-phase, two site competitive chemi-
luminescent enzyme immunoassay) and compared with the respective norma-
tive range values for these hormones. All blood samples assayed but cortisol 
were re-measured after pretreatment with specifi c heterophilic blocking tubes 
(HBT) (Scantibodies Laboratory Inc, Santee, Ca). The HBT contains a unique 
blocking reagent composed of specifi c binders, which inactivate heterophilic 
antibodies, and allows for the rapid and simple elimination of false positive 
heterophilic interference in plasma or serum for sandwich immunoassays. Each 
tube contains enough reagent to inactivate the heterophilic antibodies in 500 
µL of sample. The reagent is in the form of a lyophilized pellet at the bottom of 
the tube. One tube was used for each sample. After pipetting each sample into 
the bottom of a tube, and mixing the sample with the reagent, each sample was 
incubated for one hour in HBT at room temperature (18º - 28º C) according the 
manufacturers' instructions (www.scantibodies.com).After pretreatment with 
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HBT blood samples were considered free from heterophilic antibody interfer-
ence. GH was measured by the Immulite 2500 using a solid-phase, two sites 
chemiluminescent, immunometric assay. 
IGF-I Kinase Receptor Activation Assay (IGF-I KIRA)
Circulating IGF-I bioactivity was measured using an in-house IGF-I kinase 
receptor activation assay (IGF-I KIRA) as was previously described [10,11]. 
The methodology of this latter assay is based on another principle than that 
of IGF-I immunoassays. Briefl y, IGF-I binding to the IGF-I receptor (IGF-IR) 
results in autophosphorylation of tyrosine residues located within the intracel-
lular kinase domain, being the fi rst step in the intracellular signal cascade. The 
IGF-I KIRA uses human embryonic renal cells stably transfected with cDNA 
of the human IGF-IR gene (293 EBNA IGF-IR) and quantifi es phosphorylation 
of tyrosine residues of the IGF-IR to assess IGF-I bioactivity. Since the IGF-I 
KIRA is based on a totally different method than IGF-I immunoassays, it has 
no susceptibility to interference by heterophilic antibodies. 
CASE HISTORY 
A 56-year-old male patient was referred to the outpatient clinic with a medi-
cal history of a decline in physical performance, forgetfulness, unexplained 
osteopenia and loss of weight (about 3 kg over the past 8 months). The patient 
had no history of previous exposure to animal proteins, but in his childhood 
he had lived on a farm and was exposed to diverse animal species. Although 
laboratory results pointed to secondary hypothyroidism and secondary hypo-
gonadism (Table 1), these diagnoses were not clearly supported by clinical 
Table 1. Results of hormonal parameters comparing the original non pretreatment assay 
results with the results obtained after pretreatment with HBT*
Normal Range Primary Result After HBT*
Free T4   (pmol/L) 9–23 <3.9 20.0
TSH (U/L) 0.35–3.50 0.50 0.35
Testosterone (nmol/L) 12–33 <0.70 22.0
LH (U/L) 0.8–7.6 1.3 1.5
FSH (U/L) 0.7–11.1 3.0 1.9
Total IGF-I (nmol/L) 8–24 9.5 16.1
IGF-I KIRA (pmol/L) 191–566 374 372
Cortisol (nmol/L) > 500 650 ND
 *After using Heterophilic Blocking Tubes (HBT, Scantibodies Laboratory Inc, USA); ND=not 
determined
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signs and symptoms. In addition, the serum total IGF-I level was within the 
lower normal range and serum cortisol level excluded adrenal insuffi ciency 
(Table 1). Two GH stimulation tests were performed, but their results did not 
support GHD (after growth hormone-releasing hormone (GHRH) stimulation: 
peak serum GH: 6.4 μg/L (normal > 5.0 µg/L); after arginine plus GHRH: peak 
serum GH 17.3 μg/L (normal > 16.5. µg/L)). Magnetic resonance imaging (MRI) 
of the brain demonstrated a normal pituitary gland with no abnormalities. 
Interference with heterophilic antibodies was considered as explanation 
for the anomalous laboratory results. After pretreatment with specifi c HBT, 
serum free T4 and testosterone turned out to be normal (Table 1). Circulating 
IGF-I bioactivity measured by the Kinase Receptor Activation Assay (IGF-I 
KIRA) prior to HBT treatment was within the normal range. Therefore we 
also considered interference of heterophilic antibodies as explanation for the 
low normal total IGF-I levels. After pretreatment with HBT, total IGF-I level 
also turned out to be normal (Table 1). When we repeated the IGF-I KIRA 
measurement in HBT treated serum, there was no evidence for interference 
of heterophilic antibodies in the IGF-I bioassay (see Table 1).
DISCUSSION
Since there was an obvious mismatch in our patient between clinical fi ndings 
and laboratory results for free T4 and testosterone, we suspected that the val-
ues of both hormones were falsely low due to interference with heterophilic 
antibodies (Figure 1). Our suspicion was confi rmed after pretreatment of the 
blood samples with HBT, since levels were in the normal range afterwards. 
The IGF-I KIRA was not susceptible to interference by heterophilic antibod-
ies. As IGF-I bioactivity measured by the IGF-I KIRA proved to be around 
the median of the normal range, interference of heterophilic antibodies was 
also considered as an explanation for the low normal serum total IGF-I levels 
as measured in the Immulite assay. Indeed, when serum of our patient was 
pretreated with HBT, the total IGF-I level also turned out to be around the 
median of the age-specifi c normal range.
Our results demonstrate that the Immulite assays for total IGF-I, free T4 
and testosterone are susceptible to interference by heterophilic antibodies. 
Although in the manufacturer ‘s manual of these assays it is mentioned that 
this type of interference may cause anomalous results, to our knowledge this 
is the fi rst report in literature that describes this phenomenon for an IGF-I 
immunoassay. 
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Interference by circulating endogenous antibodies in immunoassays is as 
old as the technique itself and is a potential problem for all assays employ-
ing immunometric assay methods [12]. Assays using either polyclonal or 
monoclonal antibodies may be affected and assays previously reported to be 
affected by heterophilic antibody interference include those for TSH, T3, T4, 
PSA, testosterone and LH [13-16]. Interference from circulating antibodies is 
specifi c for an individual patient, and these proteins have the potential to 
interfere in an unpredictable way with some (but not necessarily all) immu-
noassay tests used [17]. In accordance with this latter possibility, we did not 
fi nd any indication for heterophilic antibody interference in the serum TSH, 
LH and FSH measurements of our patient.
Most papers about heterophilic antibody interference in immunometric 
assays report an overestimation of the analyte, leading to lower concentra-
tions of the analyte after blocking treatments [18]. In these false positive 
assay outcomes, heterophilic antibodies bind both the solid phase capture 
antibody as well as the labeled antibody reagent, linking them together. So it 
appears as if the analyte in this sample is present and causing the complex. 
False negative assay results like that in our patient have also been reported in 
literature. Two mechanisms have been described: binding and blocking the 
solid-phase capture antibody, or binding and blocking the labeled antibody 
*
*
*
Particle
*
*
*
Particle
*
*
*
Particle
Normal assay False-negative assay False-negative assay
Heterophilic
antibody
Analyte
A B C
Heterophilic
antibody
Figure 1. Schematic overview of immunoassay disturbances by heterophilic antibodies. (A) 
Normal immunoassay. In most reports about heterophilic antibody interference in immuno-
assays an overestimation of the analyte is described. However, false-negative assay results 
have been reported. Two mechanisms have been described: (B) binding and blocking the 
solid-phase capture antibody (dark grey), or (C) binding and blocking the labeled antibody 
reagent (light grey) by the heterophilic antibody (black). The mechanism being responsible 
for the false-negative assay results obtained in our patient is unknown.
Michael BW2.indd   125 27-11-09   11:12
C
ha
pt
er
 5
126
reagent. However, it is unknown which mechanism was responsible for the 
falsely negative results in our patient. 
Circulating anti-animal antibodies can arise from iatrogenic and noniat-
rogenic causes [19]. Administration of mouse antibodies for therapeutic and 
imaging purposes may lead in many patients to the formation of human anti-
mouse antibodies (HAMAs) [20,21]. Such antibodies have strong affi nity for 
mouse IgG and are a major cause of immunoassay interference [20]. 
Kaplan and Levinson distinguish specifi c HAMAs from heterophilic anti-
bodies. [22,23]. Heterophilic antibodies are human antibodies of low avidity 
that show broad activity against immunoglobulins from several species. These 
antibodies can arise as a result of occupational exposure of farm workers, 
from activities such as keeping pets, ingesting animal antigens in food (like 
cow ‘s milk), vaccination, infection, or even blood transfusion [19,24,25] and 
may persist for several years [26]. The published estimates of the presence of 
heterophilic antibodies in the normal population vary between 1–80% [13,19]. 
Non-linear sample dilution has been recognized as a method to identify 
samples with interference [12,27]. However, this is not universally successful. 
If sample dilution happens to result in apparent elevation in the same range 
as the undiluted sample, interference may not be detected [28]. 
There are several methods to reduce the effects of heterophilic antibod-
ies. Addition of serum of non-immune animal species will reduce the effect 
of heterophilic antibodies in many cases [13]. This method works best when 
the species of the human anti-animal antibody is matched with non-immune 
animal serum [13]. Therefore it is routine practice for assay manufacturers 
to incorporate serum of non-immune animal species in the reagents of most 
methods. Bovine serum has been shown to be more effi cient than murine 
serum [29]. It has been suggested that heterophilic antibodies in most patients 
are bovine immunoglobulins arising from the ingestion of meat and milk [13]. 
Polymerized IgG, chemical aggregation and heat aggregation are other 
methods that have been shown to improve the ability of non-specifi c antibod-
ies to reduce interference [13,28]. 
Several blocking reagents are commercially available [18]. In our study we 
have used HBT, which contains lyophilized specifi c binders to inactivate ani-
mal antibodies [19]. A difference between values for the treated and untreated 
specimens is interpreted as evidence for heterophilic antibody interference. It 
is known that this method is not appropriate for every immunoassay. However, 
after pretreatment with HBT serum total IGF-I concentration in our patient 
turned to be like IGF-I bioactivity around the median of the normal range, 
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suggesting that HBT tubes is a suitable technique to eliminate heterophilic 
antibody interference in the Immulite 2000 IGF-I assay.
In conclusion, the Immulite total IGF-I assay method, in its present form, is 
susceptible to interference by heterophilic antibodies. Physicians should be 
aware of this phenomenon because results of circulating total IGF-I levels are 
often used as a basis for further diagnostic and therapeutic decisions.
Michael BW2.indd   127 27-11-09   11:12
C
ha
pt
er
 5
128
REFERENCES
 1. Furlanetto RW, Underwood LE, Van Wyk JJ, D'Ercole AJ: Estimation of somatome-
din-C levels in normals and patients with pituitary disease by radioimmunoassay. 
J Clin Invest 1977;60:648-657.
 2. Clemmons DR: Commercial assays available for insulin-like growth factor I and 
their use in diagnosing growth hormone defi ciency. Horm Res 2001;55 Suppl 
2:73-79.
 3. Rajaram S, Baylink DJ, Mohan S: Insulin-like growth factor-binding proteins 
in serum and other biological fl uids: regulation and functions. Endocr Rev 
1997;18:801-831.
 4. Chestnut RE, Quarmby V: Evaluation of total IGF-I assay methods using samples 
from Type I and Type II diabetic patients. J Immunol Methods 2002;259:11-24.
 5. Clemmons DR: Quantitative measurement of IGF-I and its use in diagnosing and 
monitoring treatment of disorders of growth hormone secretion. Endocr Dev 
2005;9:55-65.
 6. Baum HB, Biller BM, Katznelson L, Oppenheim DS, Clemmons DR, Cannistraro 
KB, Schoenfeld DA, Best SA, Klibanski A: Assessment of growth hormone (GH) 
secretion in men with adult-onset GH defi ciency compared with that in normal 
men--a clinical research center study. J Clin Endocrinol Metab 1996;81:84-92.
 7. Hoffman DM, Nguyen TV, O'Sullivan AJ, Baxter RC, Ho KK: Diagnosis of growth 
hormone defi ciency in adults. Lancet 1994;344:482-483.
 8. Barkan AL, Beitins IZ, Kelch RP: Plasma insulin-like growth factor-I/somatome-
din-C in acromegaly: correlation with the degree of growth hormone hypersecre-
tion. J Clin Endocrinol Metab 1988;67:69-73.
 9. Elmlinger MW, Kuhnel W, Weber MM, Ranke MB: Reference ranges for two auto-
mated chemiluminescent assays for serum insulin-like growth factor I (IGF-I) and 
IGF-binding protein 3 (IGFBP-3). Clin Chem Lab Med 2004;42:654-664.
 10. Brugts MP, Ranke MB, Hofl and LJ, van der Wansem K, Weber K, Frystyk J, Lam-
berts SW, Janssen JA: Normal values of circulating insulin-like growth factor-I 
bioactivity in the healthy population: comparison with fi ve widely used IGF-I 
immunoassays. J Clin Endocrinol Metab 2008;93:2539-2545.
 11. Chen JW, Ledet T, Orskov H, Jessen N, Lund S, Whittaker J, De Meyts P, Larsen 
MB, Christiansen JS, Frystyk J: A highly sensitive and specifi c assay for deter-
mination of IGF-I bioactivity in human serum. Am J Physiol Endocrinol Metab 
2003;284:E1149-1155.
 12. Ismail AA: A radical approach is needed to eliminate interference from endog-
enous antibodies in immunoassays. Clin Chem 2005;51:25-26.
 13. Selby C: Interference in immunoassay. Ann Clin Biochem 1999;36 ( Pt 6):704-721.
 14. Emerson JF, Ngo G, Emerson SS: Screening for interference in immunoassays. 
Clin Chem 2003;49:1163-1169.
 15. Ramaeker D, Brannian J, Egland K, McCaul K, Hansen K: When is elevated testos-
terone not testosterone? When it is an immunoassay interfering antibody. Fertil 
Steril 2008;90:886-888.
 16. Torjesen PA, Bjoro T: Antibodies against [125I] testosterone in patient's serum: a 
problem for the laboratory and the patient. Clin Chem 1996;42:2047-2048.
Michael BW2.indd   128 27-11-09   11:12
Heterophilic Antibodies and Total IGF-I Levels 129
 17. Covinsky M, Laterza O, Pfeifer JD, Farkas-Szallasi T, Scott MG: An IgM lambda 
antibody to Escherichia coli produces false-positive results in multiple immuno-
metric assays. Clin Chem 2000;46:1157-1161.
 18. Ellis MJ, Livesey JH: Techniques for identifying heterophile antibody interference 
are assay specifi c: study of seven analytes on two automated immunoassay ana-
lyzers. Clin Chem 2005;51:639-641.
 19. Kricka LJ: Human anti-animal antibody interferences in immunological assays. 
Clin Chem 1999;45:942-956.
 20. Janssen JA, Blankestijn PJ, Docter R, Blijenberg BG, Splinter TA, van Toor H, 
Schalekamp MA, Lamberts SW, Krenning EP: Effects of immunoscintigraphy 
with monoclonal antibodies in assays of hormones and tumour markers. Bmj 
1989;298:1511-1513.
 21. van Toorenenbergen AW, Hooijkaas H, Heerenbrink GK, Dufour-van den Goor-
bergh DM: Heterophilic antibody interference in a tryptase immunoassay. Clin 
Biochem 2008;41:331-334.
 22. Kaplan IV, Levinson SS: When is a heterophile antibody not a heterophile 
antibody? When it is an antibody against a specifi c immunogen. Clin Chem 
1999;45:616-618.
 23. van Toorenenbergen AW, van Daele PL, Boonstra JG: False-elevated serum 
tryptase assay result caused by heterophilic antibodies. J Allergy Clin Immunol 
2005;116:1159-1160.
 24. Andersen DC, Koch C, Jensen CH, Skjodt K, Brandt J, Teisner B: High prevalence 
of human anti-bovine IgG antibodies as the major cause of false positive reac-
tions in two-site immunoassays based on monoclonal antibodies. J Immunoassay 
Immunochem 2004;25:17-30.
 25. Ismail AA, Barth JH: Wrong biochemistry results. Bmj 2001;323:705-706.
 26. Talapatra I TD, LloydAssay D: Interference of Hormones Leading to Errone-
ous Results: Two Case Reports. Journal Indian Academy of Clinical Medicine 
2007;8:97-98.
 27. Ismail AA, Walker PL, Cawood ML, Barth JH: Interference in immunoassay is an 
underestimated problem. Ann Clin Biochem 2002;39:366-373.
 28. Bjerner J: Human anti-immunoglobulin antibodies interfering in immunometric 
assays. Scand J Clin Lab Invest 2005;65:349-364.
 29. Weber TH, Kapyaho KI, Tanner P: Endogenous interference in immunoassays in 
clinical chemistry. A review. Scand J Clin Lab Invest Suppl 1990;201:77-82.
Michael BW2.indd   129 27-11-09   11:12
Michael BW2.indd   130 27-11-09   11:12
Chapter 6 
IGF-I Bioactivity in an Elderly Population: 
Relation to Insulin Sensitivity, Insulin Levels and 
the Metabolic Syndrome 
Brugts MP1, van Duijn CM2, Hofl and LJ1, Witteman JC2, Lamberts SWJ1, 
Janssen JAMJL1. 
1Department of Internal Medicine, Erasmus MC, Rotterdam, The Netherlands
2Department of Epidemiology & Biostatistics, Erasmus MC, Rotterdam, The Netherlands.
Accepted for publication: Diabetes, 2009
Michael BW2.indd   131 27-11-09   11:12
C
ha
pt
er
 6
132
ABSTRACT
Background: There is a complex relationship between Insulin-like Growth 
Factor-I (IGF-I), IGF-binding proteins, growth hormone, and insulin. The 
IGF-I kinase receptor activation assay (IGF-I KIRA) is a novel method for 
measuring IGF-I bioactivity in human serum. We speculated that determina-
tion of IGF-I bioactivity might broaden our understanding of the IGF-I system 
in subjects with the metabolic syndrome.
Objective: To investigate whether IGF-I bioactivity was related to insulin sen-
sitivity and the metabolic syndrome.
Research Design and Methods: Cross-sectional study embedded in a random 
sample (1036 elderly subjects) of a prospective population-based cohort 
study. IGF-I bioactivity was determined by the IGF-I KIRA. Categories of glu-
cose (in)tolerance were defi ned by the 2003 ADA criteria. Insulin sensitivity 
was assessed by the homeostatic model assessment (HOMA2). The ATP-III 
defi nition of the metabolic syndrome was used. 
Results: In subjects with normal fasting glucose (NFG) and impaired fasting 
glucose (IFG) IGF-I bioactivity progressively rose with increasing insulin 
resistance (IR) and peaked at fasting glucose levels just below 7.0 mmol/L. 
In subjects with diabetes, however, mean IGF-I bioactivity dropped and was 
signifi cantly lower compared to subjects with NFG and IFG. 
Mean IGF-I bioactivity peaked when 3 criteria of the metabolic syndrome 
were present and then declined signifi cantly when 5 criteria of the metabolic 
syndrome were present. 
Conclusions: We observed that IGF-I bioactivity was related to insulin sensitiv-
ity, insulin levels, and the metabolic syndrome. Our study suggests that there 
exists a ‘Starling curve for IGF-I bioactivity’. This observation contrasts with 
previous results obtained by measuring circulating total IGF-I concentrations.
Michael BW2.indd   132 27-11-09   11:12
IGF-I Bioactivity and Insulin Sensitivity 133
INTRODUCTION
A complex relationship exists between insulin-like growth factor-I (IGF-I), 
IGF-binding proteins (IGFBPs), growth hormone (GH), and insulin. GH 
exerts potent effects on intermediary metabolism, amongst which is the ability 
to antagonize insulin actions [1]. IGF-I directly inhibits insulin secretion from 
pancreatic beta cells while it increases insulin sensitivity by GH-dependent 
and –independent mechanisms [2]. 
The relationships are even more complex: insulin appears to be neces-
sary for normal liver GH responsiveness, probably by maintaining liver GH 
receptor levels [3]. However, chronic hyperinsulinemia reduces GH receptor 
expression and signaling in the liver [4,5]. 
Unlike insulin, the majority of circulating IGF-I is bound to six IGFBPs 
which are important in determining IGF-I availability and activity [6]. 
Recently, the IGF-I specifi c kinase receptor activation assay (IGF-I KIRA) 
was developed to determine circulating IGF bioactivity [7,8]. This bioassay 
determines IGF-I bioactivity by quantifi cation of intracellular receptor auto-
phosphorylation upon IGF-I binding. Unlike IGF-I immunoassays, the IGF-I 
KIRA takes into account the modifying effects of IGFBPs on the interaction 
between IGF-I and the IGF-I receptor (IGF-IR) [9]. The aim of the present study 
was to investigate whether IGF-I bioactivity was related to insulin sensitivity, 
insulin levels, and the metabolic syndrome (MS) in an elderly population-
based cohort.
METHODS AND MEASUREMENTS
The Rotterdam study is a prospective population-based cohort study inves-
tigating incidence and risk factors of cardiovascular, neurodegenerative, 
locomotor, and ophthalmologic diseases in elderly people. Objectives and 
methods have been described in detail elsewhere [10]. Baseline measure-
ments took place in 1993. Follow-up examinations were done in 1993–94, 
1997–99, and 2002–04. For the present study blood samples were drawn and 
examinations were conducted at the third survey (1997-1999). The medical 
ethics committee of the Erasmus Medical Center approved the study and writ-
ten informed consent was obtained from all participants.
Only for participants who were not known to have diabetes, fasting blood 
samples were obtained in the morning after an overnight fast. Fasting plasma 
glucose (FPG) was determined using the Hexokinase method (Boehringer 
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Mannheim, Mannheim, Germany). The ADA-2003 criteria were used to clas-
sify categories of glucose tolerance: normal fasting glucose (NFG; FPG <5.6 
mmol/l), impaired fasting glucose (IFG; FPG 5-6–7.0 mmol/l) and diabetes 
(DM) (FPG ≥7 mmol/l) [11]. Serum total cholesterol and HDL-C were deter-
mined using an automatic enzymatic procedure (Boehringer Mannheim). 
Serum triglycerides were analyzed by Triglyceride GPO-PAP (Roche Diagnos-
tics, Mannheim Germany). Insulin was measured with an electrochemilumi-
nescence immunoassay (Roche Diagnostics; intra- and interassay CV<3.7%; 
the manufacturer indicates cross-reactivity of 20% with des-31,32-proinsulin). 
Sitting blood pressure was measured using a random-zero sphygmomanom-
eter and the mean of two readings was used for analyses. Height and weight 
were measured while wearing indoor clothes without shoes.
Circulating IGF-I bioactivity was measured using an in-house IGF-I kinase 
receptor activation assay (IGF-I KIRA) (intra-assay CV: 5.2%; interassay CV: 
12.2%) [8,12]. IGF-I bioactivity was measured in 1050 blood samples, randomly 
selected from 3792 individuals, who had participated in the third survey. IGF-I 
bioactivity was successfully measured in 1036 out of 1050 subjects. Fourteen 
subjects were excluded from analysis since the measurement of IGF-I bioactiv-
ity did not repeatedly pass defi ned acceptance criteria (intra-assay CV <10%). 
The updated Homeostasis Assessment Model (HOMA-2) was used to assess 
insulin sensitivity (%S), HOMA-IR (insulin resistance), which is the reciprocal 
of %S, and beta cell function (%B) from pairs of fasting glucose and insulin 
levels [13]. The Adult Treatment Panel III (ATP-III) criteria were used to diag-
nose the MS [14].
STATISTICAL ANALYSIS
Characteristics of the study population are presented as mean with 95% CI. 
Statistical analyses were confi ned to those subjects in which IGF-I bioactivity 
was determined. Linear regression analyses were used to assess relation-
ships of IGF-I with age. Pearson‘s correlation coeffi cients were calculated to 
assess (age-adjusted) associations between variables. Univariate analyses of 
covariance were used to compare variables stratifi ed by deciles of HOMA-IR, 
adjusted for age, gender, BMI and anti-diabetic therapy when appropriate. 
Analyses in which values were logarithmically transformed yielded similar 
results to those with untransformed data. Because interpretation of logarithmic 
data is diffi cult, non-transformed data are presented with P-values obtained 
after logarithmic transformation of data. In 904 out of 1036 subjects (87%) all 
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parameters of the MS were available; 132 subjects had one or more missing 
values and were therefore excluded from statistical analyses concerning the 
MS.
A two-sided probability of P-value <0.05 was considered statistically sig-
nifi cant. All analyses were performed with SPSS for Windows v.15 (SPSS Inc., 
2001, Chicago, IL).
RESULTS
Table 1 shows clinical characteristics of the study population. Based on 2003 
ADA criteria 697 subjects (69.7%) had NFG, 165 subjects (16.3%) had IFG and 
153 subjects (15.1%) had DM. Sixty-two subjects (6%) were known with DM of 
which 19 (1.8%) were treated with only diet, 39 (3.8%) with oral antidiabetics, 
3 (0.3%) were on insulin therapy and 1 (0.1%) subject was treated with oral 
anti-diabetics and insulin.
Mean IGF-I bioactivity was signifi cantly lower in men than in women (men: 
168.9 ± 2.5 pmol/L (mean ± SE) vs. women: 187.0 ± 3.1 pmol/L (p < 0.001, 
Table 1. Baseline characteristics of the study population (1036 subjects; 451 males)
Mean (95% CI)
Age (yrs) 72.4 (62.8 – 86.3)
Height (m) 1.66 (1.52 – 1.82)
Weight (kg) 74.6 (55.6 – 97.2)
BMI (kg/m2) 26.9 (21.5 – 33.9)
Waist (cm) 93.8 (75.2 – 111.8)
                Men 97.5 (82.4 – 112.8)
                Women 90.8 (72.8 – 110.0)
Systolic BP (mm Hg) 143.9 (112.0 – 182.0)
Diastolic BP (mm Hg) 75.3 (57.2 – 95.9)
Fasting glucose (mmol/L) 6.0 (4.7 – 8.7)
Fasting insulin (pmol/L) 176.7 (28.0 – 212.3)
HOMA-S (%)* 77.3 (22.6 – 161.0)
HOMA-IR* 1.88 (0.60 – 4.40)
HOMA-B (%)* 100.4 (45.7 – 174.9)
Total Cholesterol (mmol/L) 5.81 (4.28 – 7.45)
HDL-cholesterol (mmol/L) 1.38 (0.87 – 2.06)
Triglycerides (mmol/L) 1.48 (0.70 – 2.75)
IGF-I bioactivity (pmol/L) 180.3 (105.0 – 277.3)
BMI=body mass index; BP = blood pressure;  HDL = high-density lipoprotein.
*HOMA = Homeostasis Assessment Model (HOMA-2). This model was used to estimate 
insulin sensitivity (HOMA-S (%)), insulin resistance (HOMA-IR) and beta cell function 
(HOMA-B (%)).
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after adjustment for age and BMI). IGF-I bioactivity decreased signifi cantly 
with age in men but not in women (men: β = -0.590 pmol/L/yr, p = 0.011; 
women: β= +0.647 pmol/L/yr, p = 0.119).
There was no association between IGF-I bioactivity and fasting insulin 
(r=0.049, p = 0.206). However, when analysis was confi ned to subjects with 
NFG, IGF-I bioactivity was signifi cantly and positively related to fasting insu-
lin (r=0.096, (age-adjusted) p=0.036). IGF-I bioactivity did not differ between 
diabetic subjects with and without oral antidiabetics and/or insulin therapy 
(169 (± SE 8.7) pmol/L vs.179 (± 1.8) pmol/L, respectively; (p = 0.47)).
After adjustment for age, overall IGF-I bioactivity was inversely related 
to insulin sensitivity (r = -0.113, p = 0.003), while the relationship between 
IGF-I bioactivity and B-cell function was borderline signifi cant (r = 0.065, p = 
0.088). When subjects were stratifi ed to deciles of insulin resistance (HOMA-
IR), mean FPG and insulin levels progressively rose per increasing HOMA-IR 
decile (Figure 1 A-B). Mean FPG levels in the 10th decile (7.52 ± 0.13 mmol/L) 
met diagnostic criteria for DM. For mean IGF-I bioactivity there was a progres-
sive increase with increasing IR up to and including the 9th decile (P for trend 
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Figure 1. Mean (± SEM) fasting glucose (A), mean (± SEM) fasting insulin (B) and mean 
IGF-I bioactivity (± SEM) (C) stratifi ed per decile of HOMA-IR. Statistical differences be-
tween deciles were calculated after adjustment for age, BMI and gender. 
(A) * Pfor trend < 0.001; (B) * Pfor trend < 0.001; (C) * Pfor  trend < 0.001 and ** P = 0.005.
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= 0.003) (Figure 1C). However, IGF-I bioactivity signifi cantly dropped in the 
10th decile compared to the 9th decile (Figure 1C, p = 0.005). 
When analyses were repeated after excluding diabetics on medical therapy, 
the outcome was unaffected: IGF-I bioactivity rose signifi cantly up to and 
including the 9th decile of HOMA-IR (Pfor trend = 0.006) and it decreased signifi -
cantly in the 10th decile (9th vs. 10th decile: p = 0.010).
Mean HOMA-IR increased signifi cantly per increasing number of compo-
nents of the MS (P for trend < 0.001, adjusted for age and gender, Figure 2A). As 
expected, mean FPG levels rose progressively with an increasing number of 
components of the MS (Figure 2B). Mean fasting insulin levels were signifi -
cantly higher in subjects with 5 components of the MS than in subjects with 
4 or less components of the MS (Figure 2C). Up to a point, IGF-I bioactivity 
was also directly related to number of components of the MS, peaking when 
three components were present, and the diagnosis of the MS could be made. 
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Figure 2. Relationship between the number of components of the metabolic syndrome and 
HOMA-IR (A), mean (± SEM) fasting glucose (B), mean (± SEM) fasting insulin (C) and 
mean (± SEM) IGF-I bioactivity (D).
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However, in subjects with more than 3 components of the MS IGF-I bioactivity 
decreased signifi cantly (mean IGF-I bioactivity in subjects with 3 vs. 5 com-
ponents: p = 0.04, adjusted for age and gender) (Figure 2D). When the latter 
analysis was restricted to subjects with FPG levels <7.0 mmol/L an identical 
pattern was observed (data not shown).
DISCUSSION
The main fi nding of our study was that circulating IGF-I bioactivity progres-
sively rose with increasing severity of insulin resistance and hyperinsulinemia. 
At FPG levels just below 7.0 mmol/L, mean IGF-I bioactivity reached a plateau. 
However, in subjects with DM mean IGF-I bioactivity was signifi cantly lower 
than in subjects with NFG and IFG.
Strong evidence exists that insulin is essential for GH stimulation of hepatic 
IGF-I production [15]. Insulin defi ciency results in a decreased liver GH recep-
tor expression, which can be reversed by insulin administration [3,16]. On the 
other hand, patients with type 2 DM often exhibit reduced circulating total 
IGF-I levels. One explanation for reduced circulating total IGF-I levels in type 
2 DM is that chronic hyperinsulinemia induces GH receptor resistance [4]. 
Under experimental conditions, hyperinsulinemia reduces not only GH recep-
tor expression but also GH signaling at both receptor and postreceptor levels 
[4,5]. Although the direction of cause and effect may be diffi cult to assess in 
a cross-sectional study, this opens the possibility that the observed decline in 
IGF-I bioactivity in diabetic subjects was related to hyperinsulinemia-induced 
hepatic GH resistance.
Circulating IGFBP-1 has an inverse relationship with insulin [17]. Circulat-
ing IGFBP-1 rise and fall in response to hepatic portal blood insulin [17]. It has 
been suggested that low IGFBP-1 concentrations in insulin-resistant/hyperin-
sulinaemic states increase IGF-I bioactivity in an attempt to stimulate glucose 
uptake in muscle and other insulin-resistant cells. From the other hand: data 
in animals have showed that increased levels of IGFBP-1 can both inhibit 
IGF-I action and induce hyperglycaemia [17].
In a recent prospective study IGFBP-1 levels initially decreased when glu-
cose tolerance deteriorated, but actually increased during follow-up in those 
individuals, who developed diabetes, which probably refl ects "resistance" to 
portal blood insulin [18]. Although we did not measure IGFBP-1 levels in our 
study, the decline in mean IGF-I bioactivity in subjects with FG levels > 7.0 
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mmol/L may be thus also directly related to increasing inhibitory effects of 
elevated IGFBP-1 levels on IGF-I bioactivity. 
Several epidemiological studies have linked low circulating total IGF-I and 
increased (total) IGF-I/IGFBP-1 ratios to an increased risk of the MS [19-23]. 
An increased total IGF-I/IGFBP-1 ratio has been proposed as a surrogate 
marker of increased IGF-I bioactivity [24]. This is probably a compensatory 
mechanism to maintain normal glucose tolerance, since raised IGF-I bioactiv-
ity will improve insulin sensitivity [25]. High IGF-I bioactivity may suppress 
GH secretion as part of a negative feedback system and thereby induce lower 
total IGF-I levels [23]. This may explain why low total IGF-I levels have been 
previously reported to be associated with an increased risk of the MS [22]. 
Our study also suggests that during further progression of the MS IGF-I 
bioactivity declines. As individuals with the MS are chronically exposed to 
high circulating insulin levels, the rise in IGF-I bioactivity (see Figure 2D) in 
subjects with 1-3 components of the MS, may be due to an insulin-mediated 
suppression of IGFBP-1 levels, as discussed before. However, in subjects with 
more than 3 components of the MS, IGF-I bioactivity signifi cantly declined 
(Figure 2D). The lower IGF-I bioactivity in these latter individuals may be a 
direct consequence of the development of hepatic insulin resistance (mani-
fested by a relative increase of IGFBP-1) and hyperinsulinemia-induced GH 
resistance, as discussed above.
A limitation of our study is that no comparisons were made between circu-
lating IGF-I bioactivity and total IGF-I measurements. However, we previously 
found a weak correlation between circulating total IGF-I levels and IGF-I bio-
activity suggesting that the IGF-I KIRA produces information about the IGF-I 
system, which essentially differs from that obtained by IGF-I immunoassays 
[12]. Moreover, no information is yet available on whether 10-years sample 
storage at -80 degrees affects measurements of IGF-I bioactivity. However, 
because all samples were analyzed after an equal period of storage, any vari-
able effect of storage time is likely removed.
Another point is that we did not perform an OGTT. Therefore, it is not 
clear how many subjects had impaired glucose tolerance or even diabetes 
that was not assessed by fasting glucose alone. In addition, HOMA-IR will not 
always refl ect insulin sensitivity accurately in subjects with differing beta-cell 
function.
In conclusion, our study suggests that an individual’s insulin sensitivity and 
circulating insulin levels directly modulate IGF-I bioactivity. When IR becomes 
apparent, but glucose levels are still within the normal range, there is an initial 
rise in circulating IGF-I bioactivity. However, when glucose tolerance rises 
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to the point where IFG occurs, IGF-I bioactivity reaches a plateau. Finally, 
when blood glucose levels have risen into overt type 2 DM, circulating IGF-I 
bioactivity progressively declines. IGF-I bioactivity seems also related to the 
MS. Our study suggests that there exists a ‘Starling curve for IGF-I bioactivity’ 
(Figure 3). 
Normal insulin Hyper- Hyper- and Hypoinsulinemic
secretion insulinemia phase of Type 2 DM
Hepatic Insulin
Resistance
GH Receptor Signaling
‘The Starling Curve for IGF-I Bioactivity’
Normal
Fasting
Glucose
Impaired
Fasting
Glucose
Diabetes
Mellitus
Figure 3. The ‘Starling curve for IGF-I Bioactivity’. When glucose levels are within the 
normal range and insulin resistance increases, there is an initial compensatory hyperinsu-
linemia and rise in circulating IGF-I bioactivity. When glucose tolerance has increased to 
the point where impaired fasting glucose levels occur, IGF-I bioactivity reaches a plateau. 
When blood glucose levels rise further into a range indicating overt type 2 DM, GH sensi-
tivity progressively decreases while hepatic insulin resistance progressively increases. Both 
mechanisms contribute to a progressive reduction of IGF-I bioactivity.
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ABSTRACT
Background: IGF-I may be involved in the pathogenesis of CVD. We specu-
lated that determination of circulating IGF-I bioactivity is more informative 
than levels of immunoreactive total IGF-I. 
Objective: We examined the associations between comon genetic variations 
in the IGF-I gene in relation to levels of total and bioactive IGF-I and to risk 
on MI/AP.
Design and Measures: Analyses included 5970 subjects of the Rotterdam 
study, successfully genotyped for 18 SNPs of the IGF-I gene at baseline. Total 
IGF-I was measured in 430 subjects at baseline and IGF-I bioactivity was mea-
sured in 1036 subjects at the third survey (1997-1998). The IGF-I gene was 
characterized into 6 haplotype blocks. 
Results: Four hundred sixty eight subjects developed MI/AP during follow-up. 
Genetic variations in haplotype block 1 and block 2 were signifi cantly related 
to total IGF-I in men and women. Genetic variations in haplotype blocks 3-6 
of the IGF-I gene were related to circulating IGF-I bioactivity in men but not in 
women. Block 1 and block 2 of the IGF-I gene were also signifi cantly associ-
ated with an increased risk for MI/AP in men but not in women. All these 
relationships remained signifi cant after further adjustments. No relationships 
were observed between blocks 3-6 of the IGF-I gene and MI/AP. 
Conclusions: We observed a gender-specifi c impact of genetic variations in 
the IGF-I gene on circulating total IGF-I levels and risk on MI/AP. Although 
gender-specifi c genetic variations of the IGF-I gene were also present for 
levels of circulating IGF-I bioactivity, these variations did not appear to sub-
stantially infl uence the risk on MI/AP. 
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INTRODUCTION
Twin studies have shown that at least 40% of the interindividual variability 
in total IGF-I levels is genetically determined [1,2]. Second, IGF-I may be 
involved in the pathogenesis of cardiovascular disease (CVD) [2-4]. In humans, 
low serum IGF-I has been associated with coronary artery disease (CAD) in 
both cross-sectional and prospective studies, but results are characterized 
by inconsistency [5-9]. The possible association between total IGF-I levels 
and risk of CVD may be not real, but due to measurement errors or other 
(unknown) confounders. In addition these associations may be the result of 
reverse causation, meaning that the relation between levels of total IGF-I and 
CVD could be the result of latent disease rather than IGF-I itself. Observational 
epidemiologic studies cannot help to resolve a defi nite answer on the role 
of IGF-I in the pathogenesis of CVD. However, ‘Mendelian Randomization’-
the assortment of genes from parents to offspring that occurs during gamete 
formation and conception’-is an epidemiological approach that is less sus-
ceptible to reverse causality and confounding [10]. This approach provides a 
natural experiment for testing causal associations between circulating IGF-I 
levels and CVD risk [11]. When a polymorphism of the IGF-I gene is related to 
different levels of circulating IGF-I, and when low levels of circulating IGF-I 
are indeed a causal risk for cardiovascular disease, then one would expect 
that individuals with an IGF-I genotype associated with low IGF-I levels have 
a higher risk to develop CVD. 
The IGF-I gene contains a microsatellite polymorphism approximately 1 
kb upstream from the IGF-I gene transcription site. This IGF-I gene poly-
morphism may directly infl uence IGF-I production. Previously we reported 
within the framework of the Rotterdam study that this IGF-I gene promoter 
polymorphism was associated with circulating total IGF-I levels [12] and that 
subjects with a myocardial infarction (MI) who are variant carriers of the IGF-I 
promoter polymorphism had an increased risk of mortality [13].
Insulin-like growth factor binding proteins (IGFBPs) may also modify IGF-I 
activity. So far, most knowledge about IGF-I is based on measurements of cir-
culating total IGF-I levels by using specifi c immunoassays. Recently, a highly 
sensitive and IGF-I specifi c kinase receptor activation assay (IGF-I KIRA) was 
developed to determine IGF bioactivity in human serum [14,15]. Unlike IGF-I 
immunoassays, the IGF-I KIRA takes into account the modifying effects of 
(IGFBPs) on the interaction between IGF-I and the IGF-I –receptor. The IGF-I 
KIRA might be a new tool that could help broaden our understanding of the 
IGF-I system in humans, both in normal and pathological conditions like CVD.
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Within the frame work of the Rotterdam study we studied whether IGF-I 
gene polymorphisms/haplotypes were related to circulating to risk on CVD, 
and whether these IGF-I gene polymorphisms/haplotypes were functionally 
related to circulating total IGF-I levels and/or IGF-I bioactivity 
METHODS
The Rotterdam study is an ongoing prospective population-based cohort 
study investigating incidence and risk factors of cardiovascular, neurode-
generative, locomotor, and ophthalmological diseases in elderly people. The 
objectives and methods have been described in detail elsewhere [16]. The 
cohort includes 7.983 men and women aged 55 years and over (78% of the eli-
gible population) living in a well-defi ned suburb of the city of Rotterdam, the 
Netherlands. The baseline measurements took place until 1993. Information 
was collected on age, gender, present health status and medical history and 
blood was drawn for DNA. Follow-up examinations were done in 1993–94, 
1997–99, and 2002–04. 
The medical ethics committee of the Erasmus Medical Center approved the 
study and written informed consent was obtained from all participants.
MEASUREMENTS
At the baseline examination, information concerning medical history, medica-
tion use, and smoking behavior was obtained. Height and weight were mea-
sured and body mass index (BMI) (in kg/m2) was calculated. Diabetes mellitus 
was defi ned as the use of glucose-lowering medication and/or random serum 
glucose level 11.1 mmol/L or over. Total serum cholesterol and high-density 
lipoprotein (HDL) cholesterol were determined with an automated enzymatic 
procedure. Blood pressure was measured, with the subject in sitting position, 
at the right upper arm with the use of a random zero sphygmomanometer. 
The same methods were used for collection of follow-up data. 
Mean follow-up time since the start of the Rottterdam Study was 6.43 yrs 
(range 5.14-10.21) for participants, who were investigated at the third survey 
of the Rotterdam study (1997-1999). Information on  angina pectoris (AP) was 
obtained at the third survey by using a Dutch version of the Rose Question-
naire [17]. 
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IGF-I bioactivity was measured in blood samples drawn at the third survey 
of the Rotterdam study. Because of logistic and fi nancial restrictions, measure-
ment of IGF-I bioactivity was confi ned to about 1000 subjects. For the mea-
surement of IGF-I bioactivity 1050 subjects were at randomly selected from 
3792 individuals, who had participated in the third survey of the Rotterdam 
study and from whom blood was drawn. Fourteen subjects were excluded 
from analysis since the measurement of IGF-I bioactivity did not repeatedly 
pass defi ned acceptance criteria (intra-assay variation <10%). IGF-I bioactiv-
ity was fi nally reported for 1036 subjects. At baseline total IGF-I had been 
measured in a subsample from the fi rst baseline cohort comprising of 430 
subjects as was previously reported [12,18]. For the present study these IGF-I 
measurements were used in the analyses. 
Total IGF-I immunoassay and IGF-I Kinase Receptor Activation Assay (IGF-I KIRA)
Total IGF-I was determined by a commercially available radioimmunoassay 
(RIA; Medgenix Diagnostics, Brussels, Belgium, with intra-assay and interas-
say variation of 6.1% and 9.9%) as previously stated (18). Circulating IGF-I 
bioactivity was measured using an in-house IGF-I kinase receptor activation 
assay as was previously described [14,15]. This assay uses human embryonic 
renal cells stably transfected with cDNA of the human IGF-IR gene (293 EBNA 
IGF-IR). After 24 h of culture in serum containing medium, cells were starved 
for 24 h in medium with 0.1% albumin. Thereafter, cells were stimulated at 37°C 
with either recombinant IGF-I standards (Austral Biologicals, San Ramon, CA) 
or 10-fold diluted serum samples for 15 minutes and then lysed. Crude lysates 
were transferred to a sandwich assay. For capture a monoclonal antibody 
directed against the human IGF-IR (MAD1, Novozymes Gropep, Adelaide, 
Australia) was used. As tracer a europium-labeled monoclonal anti-phospho-
tyrosine antibody (PY20, Perkin-Elmer Life Sciences) was used. Contents were 
read in a time-resolved fl uorometer (Victor2 multilabel counter, Perkin-Elmer, 
Groningen, The Netherlands). Assays were performed in 48 well plates. IGF-I 
standards, 2 control samples, and unknown serum samples were included in 
duplicate on every plate. Intra-assay CV was 5.2%. The inter-assay CVs were 
respectively 8.2% and 12.2% for the two control samples, which averaged 
(mean ± SD) 184.7 ± 15.1 pmol/L and 1039.6 ± 126.5 pmol/L (N = 121 plates), 
respectively. Circulating IGF-I bioactivity is expressed as pmol/L (to convert 
IGF-I bioactivity into mg/L, values have to should be divided by 131). Serum 
samples used in the IGF-I KIRA were kept at -80°C and had not been thawed 
before use. IGF-I KIRA measurements were performed 9-11 years after initial 
collection of sera. 
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Follow-up procedure for cardiovascular disease
Follow-up started at the baseline examination and for the present study lasted 
until January 1st, 2006. Information on fatal and non-fatal cardiovascular 
endpoints was obtained from general practitioners and letters and discharge 
reports from medical
specialists [19]. Reported events were coded according to the International 
Classifi cation of Diseases, 10th edition (ICD-10) [20]. We defi ned incident CHD 
as MI, coronary artery bypass grafting (CABG), percutaneous transluminal 
coronary angioplasty (PTCA) and cardiac death. In identifying MIs, all avail-
able information, which included ECG, cardiac enzyme levels, and the clinical 
judgment of the treating specialist, was used. 
SNP selection and genotyping for genetic characterization
Information on SNPs that were eventually used to cover genetic variance at 
the human IGF-I gene locus are shown in the supplementary Table S1. We 
screened publicly available databases (such as dbSNP) and initially collected 
data on 8 SNPs for the insulin-like growth factor-I gene. Tagging SNPs cov-
ered the promoter regions as well as the 3’ UTR region of the IGF-I gene. In 
the promoter region we selected for our study the following SNPs: rs7965399, 
rs35765, rs35767 and rs17882264; and in the 3’UTR region: rs1520220, rs6220, 
rs6214 and rs6219. For fi ve out of the eight selected SNPs statistically signifi -
cant associations with total IGF-I has been reported in the literature [21-23].
Subsequently, microarray genotyping became available and was performed 
in the whole original Rotterdam study cohort with proper quality DNA samples 
(n=6449) using the Infi nium II HumanHap550K Genotyping BeadChip® ver-
sion 3 (Illumina, San Diego, USA). In total, 5974 samples met quality control 
inclusion criteria, as previously described [24]. We selected tagging SNPs for 
IGF-I based on HapMap Phase II, using the pairwise tagging mode [25]. We 
selected a minimal set of SNPs of the IGF-I gene, such that all alleles to be 
captured would be correlated at r2 > 0.99 with a minor allele frequency > 5%. 
We surveyed genetic variation across the IGF-I gene from 20 kb upstream of 
transcription to 10 kb downstream. 
SNP genotyping was accomplished using the GeneChip Human Mapping 
500K Array Set HumanHap 550 v3.0 array (Illumina, San Diego, USA) for thir-
teen SNPs. TaqMan allelic discrimination assays were used for fi ve other SNPs 
which were not available in Illumina platform (information on primers and 
probes is available in the supplementary Table (Table S2)). In total eighteen 
SNPs were selected for genetic characterization and these for were success-
fully genotyped in 5970 subjects (Table S1). Primer and probe sequences are 
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available on request. Individuals blinded to the individual’s status performed 
all assays. All SNPs conformed to Hardy-Weinberg equilibrium (P<0.05).
Seven thousand and twelve participants of the Rotterdam study were previ-
ously genotyped for an IGF-I (CA repeat) promoter polymorphism [26]. Data 
from these prior studies were used to investigate whether there was linkage 
disequilibrium (LD) between this IGF-I gene promoter polymorphism and 
SNPs of the IGF-I gene.
Statistical analysis
Hardy-Weinberg equilibrium was tested with the chi-square test. We used 
t-tests (for continuous variables) and chi-square tests (for categorical vari-
ables) to compare baseline characteristics of subjects in both gender.
Total IGF-I was normal distributed. The natural log-transformed values for 
IGF-I bioactivity yielded a normal distribution. To investigate associations 
between genetic variations of IGF-I gene with circulating total IGF-I and 
IGF-I bioactivity, we used general linear regression models. The data were 
stratifi ed by gender. All analyses were adjusted for age and gender except 
where otherwise mentioned. Additional adjustments were made (model 3) 
for systolic blood pressure (SBP), diastolic blood pressure (DBP), body mass 
index (BMI), diabetes mellitus (DM), total and HDL-cholesterol, prevalence of 
CVD, and current smoking.
Haplotype blocks for the IGF-I gene were defi ned using the confi dence 
interval method of Gabriel et al. [27], which implemented in haploview [28]. 
LD between SNPs, as expressed by Dʹ, was calculated in Haploview (29). 
(Figure 1). LD between neighboring SNPs with the IGF-I gene (CA repeat) 
promoter polymorphism was also calculated in Haploview [29].
We used the Haplo.Stats package running for R to estimate the IGF-I 
haplotypes [30] and to investigate associations of inferred haplotypes with 
circulating total IGF-I levels and IGF-I bioactivity [31]. This method assigns 
the probability for each haplotype pair in each individual and then models 
an individual’s phenotype as a function of each inferred haplotype pair, 
weighted by their estimated posterior probability so as to account for haplo-
type ambiguity. We used the Haplo.glm function, which is based on a general-
ized linear model [32,33]. Regression coeffi cients were estimated with haplo.
glm for each haplotypes per blocks. We restricted the analyses to haplotypes 
with an inferred frequency >5%. The haplotype (H1), which was the most 
frequent, was used as the reference group. Coeffi cients refl ect differences in 
mean total IGF-I and back transformed natural logarithm (circulating IGF1 
bioactivity) per copy relative to H1. To evaluate the associations between the 
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single SNPs and haplotypes with circulating total IGF-I levels and IGF-I bio-
activity, we performed analysis of variance. Analysis of covariance was used 
to adjust for gender and age. In case of a consistent trend, we performed a 
linear regression analysis to quantify the association. In order to compare the 
mean of each haplotypes with the most common haplotypes we extracted the 
haplotypes from haplo.stats. To examine associations between single SNPs 
and haplotypes with circulating total IGF-I levels and IGF-I bioactivity, we 
Polymorphisms in the Human IGF-I Gene
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Figure 1. The IGF-I gene is shown schematically at the top to illustrate the relative posi-
tions of the 18 SNPs among the IGF-I gene. LD pattern of eighteen SNPs in the IGF-I gene 
region is shown at the bottom. Dark squares (black) represent high LD values between 
SNPs while the white ones low. The numbers inside the squares indicate the SNP pair wise 
D’ values (in empty squares LD=1). Light squares show SNPs with high D’ values but a low 
measure of confi dence.
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performed analysis of variance. Analysis of covariance was used to adjust for 
gender and age. In case of a consistent trend, we performed a liner regression 
analysis to quantify the association. 
To examine whether susceptibility to MI and AP were associated with 
single variants in the IGF-I gene, we evaluated the relationship between IGF-I 
genotypes and disease risk. Odds ratios (OR) and 95% confi dence intervals 
(95% CI) were estimated by logistic regression for the association between 
genotypes and risk of MI and AP.
Further, to potentially capture other unmeasured variants that may not be 
adequately captured by single SNPs, we evaluated the relationship between 
common IGF-I haplotypes and MI, and AP risk using the haplo.glm function 
of the program haplo Stats [34]. 
RESULTS
In Table 1A clinical characteristics of the study population at baseline are 
shown. There were more female than male participants. Mean age, BMI, total 
cholesterol and HDL cholesterol were signifi cantly higher in women than 
men. Men had signifi cantly higher diastolic BP and were more often smok-
ing than women. In addition, prevalence of CVD was higher in men than in 
women (Table 1A). During follow-up, incidence of MI, AP and coronary heart 
disease was higher in men than in women while incidence of DM type 2 was 
not statistically different (Table 1B).
Eighteen SNPs of the IGF-I gene were selected to characterize the IGF-I 
gene (Figure 1). The IGF-I gene was characterized into 6 haplotype blocks. 
Table 1A. General characteristics of study population of the Rotterdam study at baseline
Total 
population Male Female P -value
  (n=5970) (n=2426) (n=3544)  
Age (years) 69.4 ± 9.1 68.1 ± 8.2 70.3 ± 9.6 < 0.001
Gender (%) 2426 (40.6) 3544 (59.4) < 0.001
Body mass index (kg/m2) 26.3 ± 4.1 25.7 ± 3.8 26.7 ± 4.1 < 0.001
Systolic blood pressure (mmHg) 139.2 ± 22.3 138.7 ± 21.8 139.6 ± 22.6 0.117
Diastolic blood pressure (mmHg) 73.7 ± 11.3 74.6 ± 11.4 73.0 ± 11.2 < 0.001
Total cholesterol (mmol/L) 6.6 ± 1.2 6.3 ± 1.2 6.8 ± 1.2 < 0.001
HDL cholesterol (mmol/L) 1.3 ± 0.4 1.2 ± 0.3 1.5 ± 0.4 < 0.001
Prevalence of cardiovascular disease (%) 886 (22.8) 444 (27.5) 442 (19.5) < 0.001
Current smoking (%) 1343 (23.0) 717 (30.0) 626 (18.2) < 0.001
Values are presented as means ± standard deviation or percentage.
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The level of LD (D') between blocks 1 and 2 of the IGF-I gene was 0.96, while 
the D' between blocks 4 and 5 was 0.88, both refl ecting high LD. The D’s 
of the remaining haplotypes in the IGF-I gene were between 0.37-0.68. The 
previously reported CA repeat in the promoter region of the IGF-I gene was 
mapped between rs2162679 and rs35767 in block 2 of the IGF-I gene. The D' 
between the CA repeat and rs2162679 and rs35767, respectively, was 0.84 and 
0.86.
A. Results on total IGF-I levels
Mean total IGF-I (measured in 430 subjects) was 17.6 nmol/L (SD 7.2). Mean 
total IGF-I levels did not differ between men and women (men: 18.0 nmol/L 
(SD 7.2); women 17.2 nmol/L (SD 7.2); p = 0.13 after adjustment for age).
Single IGF-I gene SNPs and circulating total IGF-I
Regression analyses showed that total IGF-I levels were associated with IGF-I 
gene SNPs located in blocks 1 and 2 (overall, in men and in women). In Table 
2A-C associations between single IGF-I gene SNPs and circulating total IGF-I 
levels are shown. We observed signifi cant relationships between total IGF-I 
and the following SNPs overall (rs35766, rs2162679, rs35767, and rs10860862) 
(Table 2A), in men (rs35766, rs2162679, and rs35767) (Table 2B) and in 
women (rs35766, rs2162679, rs35767, and rs10860862) (Table 2C). Specifi c 
IGF-I SNPs accounted individually for up to 28 % change in total IGF-I levels. 
Table 1B. Overall incidence of cardiovascular disease and type 2 diabetes during follow-up 
from baseline until 1st of January 2006
Total 
population Male Female P -value
(n=5970) (n=2426) (n=3544)
Incidence of myocardial infarction (%) 372 (6.2) 226 (9.3) 146 (4.1) < 0.001
Incidence of angina pectoris (%) 265 (6.7) 111 (6.8) 154 (6.7) 0.894
Incidence of myocardial infarction and angina 
pectoris (%) 468 (11.9) 244 (14.9) 224 (9.7) < 0.001
Incidence of coronary heart disease  (%) 928  (15.5) 517(21.3) 411 (11.6) <0.001
Incidence of type 2 diabetes (%) 562 (10.6) 246 (11.4) 316 (10.1) 0.137
Values are presented as mean ± standard deviation or percentage.
Michael BW2.indd   154 27-11-09   11:12
Total and Bioactive IGF-I and Genetic Variance 155
Table 2A. Associations between circulating total IGF-I and  IGF-I gene polymorphisms in 
the total population
SNP Frequency Model 1 Model 2
      Mean (SE) P % Change Mean (SE) P % Change
Block 1            
rs35766 TT 0.63 18.5 (0.5) 0.003 18.5 (0.5) 0.004
  TC 0.29 17.2 (0.7) -7.1 17.1 (0.7) -7.6
  CC 0.08 14.5 (1.3)* -21.5 14.9 (1.3)* -19.5
rs35765 GG 0.73 18.1 (0.4) 0.151 18.2 (0.4) 0.073
  GT 0.24 16.9 (0.8) -6.6 16.8 (0.8) -7.7
  TT 0.04 16.8 (2.0) -7.4 16.4 (2.0) -9.9
Block 2    
rs2162679 TT 0.63 18.6 (0.5) 0.001 18.6 (0.5) 0.001
  TC 0.28 17.1 (0.7) -8.1 17.1 (0.7) -8.0
  CC 0.08 14.4 (1.3)* -22.6 14.6 (1.3)* -21.5
rs35767 CC 0.63 18.7 (0.5) 0.001 18.6 (0.5) 0.001
  CT 0.28 17.0 (0.7) -9.1 17.0 (0.7)* -8.6
  TT 0.09 14.5 (1.2)* -22.5 14.8 (1.2)* -20.4
Block 3            
rs2033178 GG 0.82 18.1 (0.4) 0.073 18.1 (0.4) 0.042
  GA 0.16 16.5 (0.9) -8.8 16.5 (0.9) -8.8
  AA 0.01 15.2 (3.2) -16.0 14.2 (3.2) -21.5
rs5742632 AA 0.61 17.3 (0.5) 0.121 17.3 (0.5) 0.159
  AG 0.33 18.8 (0.7) 8.7 18.7 (0.6) 8.1
  GG 0.06 18.1 (1.6) 4.6 18.1 (1.5) 4.6
rs5742629 TT 0.53 17.7 (0.5) 0.855 17.7 (0.5) 0.845
  TC 0.39 17.9 (0.6) 1.1 17.9 (0.6) 1.1
  CC 0.08 17.7 (1.3) 0.0 17.9 (1.3) 1.1
rs10778176 CC 0.54 17.7 (0.5) 0.841 17.7 (0.5) 0.830
  CT 0.38 18.0 (0.6) 1.7 17.9 (0.6) 1.1
  TT 0.08 17.7 (1.3) 0.0 18.0 (1.3) 1.7
rs1019731 CC 0.78 17.8 (0.4) 0.781 17.8 (0.4) 0.839
  CA 0.21 17.9 (0.8) 0.6 17.7 (0.8) -0.6
  AA 0.01 19.6 (4.2) 10.1 19.9 (4.1) 11.8
Block 4    
rs2288378 CC 0.56 17.4 (0.5) 0.328 17.5 (0.5) 0.507
  CT 0.38 18.3 (0.6) 5.2 18.2 (0.6) 4.0
  TT 0.06 18.2 (1.5) 4.6 17.9 (1.5) 2.3
rs7136446 TT 0.38 17.2 (0.6) 0.271 17.3 (0.6) 0.325
  CT 0.46 18.1 (0.6) 5.2 18.1 (0.5) 4.6
  CC 0.16 18.3 (0.9) 6.4 18.1 (0.9) 4.6
P for trend is presented for single SNPs; The most frequent  genotype was used as the refer-
ence when comparing total IGF-I levels between genotypes. Model 1: without adjustment. 
Model 2: after adjustment for gender and age. *P ≤ 0.05 compared to the reference.
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Table 2A. Continued
SNP Frequency   Model 1 Model 2
        Mean (SE) P % Change Mean (SE) P % Change
Block 5              
rs6220 AA 0.50   17.6 (0.5) 0.685 17.7 (0.5) 0.918
  AG 0.41   17.9 (0.6) 1.7 17.8 (0.6) 0.6
  GG 0.09   18.0 (1.2) 2.7 17.8 (1.2) 0.6
       
rs978458 CC 0.55   17.5 (0.5) 0.378 17.7 (0.5) 0.588
  CT 0.38   18.2 (0.6) 4.0 18.1 (0.6) 2.3
  TT 0.07   18.1 (1.4) 3.4 18.0 (1.4) 1.7
Block 6      
rs6219 CC 0.82   17.5 (0.4) 0.374 17.6 (0.4) 0.468
  CT 0.16   19.8 (0.9) 13.1 19.7 (0.9) 11.9
  TT 0.02   12.4 (2.9) -29.1 11.7 (2.9)* -33.5
       
rs6214 CC 0.34   18.0 (0.7) 0.827 17.8 (0.6) 0.623
  CT 0.46   17.4 (0.6) -3.3 17.5 (0.5) -1.7
  TT 0.20   18.5 (0.8) 2.8 18.5 (0.8) 3.9
Others
rs2971575 AA 0.35   17.5 (0.6) 0.398 17.6 (0.6) 0.482
  AG 0.46   17.8 (0.6) 1.7 17.7 (0.5) 0.6
  GG 0.18   18.4 (0.9) 5.1 18.4 (0.9) 4.5
       
rs10860862 GG 0.56   18.5 (0.5) 0.002 18.4 (0.5) 0.012
  GT 0.35   17.7 (0.6) -4.3 17.7 (0.6) -3.8
  TT 0.09   14.1 (1.2)* -23.8 14.7 (1.2) * -20.1
       
rs2946834 GG 0.45   17.6 (0.6) 0.824 17.7 (0.6) 0.722
  GA 0.44   18.3 (0.6) 4.0 18.3 (0.6) 3.4
  AA 0.12   16.6 (1.1) -5.7 16.6 (1.1) -6.2
P for trend is presented for single SNPs; The most frequent  genotype was used as the refer-
ence when comparing total IGF-I levels between genotypes. Model 1: without adjustment. 
Model 2: after adjustment for gender and age. *P ≤ 0.05 compared to the reference.
Table 2B. Associations between circulating total IGF-I and IGF-I gene polymorphisms in men
SNP Frequency Model 1 Model 2
      Mean (SE) P % Change Mean (SE) P % Change
Block 1            
rs35766 TT 0.67 18.7 (0.7) 0.043 18.7 (0.7) 0.004
  TC 0.26 17.7 (1.1) -5.3 17.6 (1.1) -5.9
  CC 0.07 13.9 (2.1)* -25.7 15.0 (2.1) -19.8
     
rs35765 GG 0.75 18.5 (0.6) 0.280 18.5 (0.6) 0.073
  GT 0.24 16.9 (1.1) -8.6 17.0 (1.1) -8.1
  TT 0.01 18.8 (5.0) 1.6 18.0 (4.9) -2.7
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SNP Frequency Model 1 Model 2
      Mean (SE) P % Change Mean (SE) P % Change
Block 2    
rs2162679 TT 0.66 19.0 (0.7) 0.019 18.9 (0.7) 0.001
  TC 0.27 17.3 (1.0) -8.9 17.3 (1.0) -8.5
  CC 0.07 14.2 (2.1)* -25.3 15.1 (2.1) -20.1
     
rs35767 CC 0.66 18.9 (0.7) 0.014 18.8 (0.7) 0.001
  CT 0.27 17.3 (1.1) -8.5 17.2 (1.1) -8.5
  TT 0.07 13.7 (2.0)* -27.5 14.8 (2.1) -21.3
Block 3            
rs2033178 GG 0.84 18.6 (0.6) 0.127 18.5 (0.6) 0.042
  GA 0.15 15.8 (1.4) -15.1 15.9 (1.4) -14.0
  AA 0.01 18.8 (5.0) 1.1 18.0 (4.9) -2.7
     
rs5742632 AA 0.63 17.57 (0.7) 0.064 17.6 (0.7) 0.159
  AG 0.31 19.3 (1.0) 9.8 19.0 (1.0) 8.0
  GG 0.06 20.4 (2.2) 16.1 20.5 (2.2) 16.5
     
rs5742629 TT 0.54 18.1 (0.7) 0.701 18.2 (0.7) 0.845
  TC 0.37 17.9 (0.9) -1.1 17.8 (0.9) -2.2
  CC 0.09 19.4 (1.8) 7.2 19.5 (1.8) 7.1
     
rs10778176 CC 0.55 18.0 (0.7) 0.608 18.1 (0.7) 0.830
  CT 0.36 18.0 (0.9) 0.0 17.9 (0.9) -1.1
  TT 0.09 19.4 (1.8) 7.8 19.5 (1.8) 7.7
     
rs1019731 CC 0.76 18.3 (0.6) 0.684 18.3 (0.6) 0.839
  CA 0.24 17.6 (1.1) -3.8 17.6 (1.1) -3..8
  AA 0.01 21.1 (7.1) 15.3 20.8 (7.0) 13.7
Block 4    
rs2288378 CC 0.56 17.9 (0.7) 0.362 18.0 (0.7) 0.507
  CT 0.39 18.1 (0.9) 1.1 18.0 (0.9) 0.0
  TT 0.05 21.3 (2.4) 19.1 20.9 (2.3) 16.1
     
rs7136446 TT 0.37 18.2 (0.9) 0.783 18.1 (0.9) 0.325
  CT 0.45 17.8 (0.8) -2.2 18.0 (0.8) -0.6
  CC 0.18 18.9 (1.3) 3.8 18.7 (1.3) 3.3
Block 5            
rs6220 AA 0.51 18.2 (0.8) 0.671 18.2 (0.8) 0.918
  AG 0.41 17.7 (0.9) -2.7 17.6 (0.8) -3.3
  GG 0.08 20.1 (2.0) 10.4 20.2 (1.9) 11.0
     
rs978458 CC 0.56 17.9 (0.7) 0.439 18.0 (0.7) 0.588
  CT 0.38 18.2 (0.9) 1.7 18.1 (0.9) 0.6
  TT 0.06 20.3 (2.2) 13.4 20.2 (2.2) 12.2
Table 2B. Continued
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Table 2B. Continued
Table 2C. Associations between circulating total IGF-I and  IGF-I gene polymorphisms in 
women
SNP Frequency Model 1 Model 2
      Mean (SE) P % Change Mean (SE) P % Change
Block 1            
rs35766 TT 0.6 18.3 (0.7) 0.037 18.3 (0.7) 0.024
  TC 0.31 16.8 (0.9) -8.2 16.7 (0.9) -8.7
  CC 0.09 14.9 (1.7) -18.6 14.8 (1.6)* -19.1
rs35765 GG 0.71 17.8 (0.6) 0.363 17.9 (0.6) 0.188
  GT 0.24 16.9 (1.1) -5.1 16.6 (1.0) -7.3
  TT 0.05 16.4 (2.2) -7.9 15.9 (2.2) -11.2
Block 2    
rs2162679 TT 0.61 18.3 (0.7) 0.029 18.3 (0.6) 0.013
  TC 0.29 16.9 (1.0) -7.7 17.0 (0.9) -7.1
  CC 0.10 14.6 (1.6)* -20.2 14.1 (1.6)* -23.0
rs35767 CC 0.61 18.4 (0.7) 0.023 18.5 (0.6) 0.012
  CT 0.29 16.8 (1.0) -8.7 16.8 (0.9) -9.2
  TT 0.11 14.9 (1.6)* -19.0 14.7 (1.5)* -20.5
Block 3            
rs2033178 GG 0.81 17.7 (0.6) 0.306 17.8 (0.6) 0.185
  GA 0.17 17.0 (1.2) -4.0 16.8 (1.2) -5.6
  AA 0.01 12.8 (4.3) -27.7 11.7 (4.2) -34.3
SNP Frequency Model 1 Model 2
      Mean (SE) P % Change Mean (SE) P % Change
Block 6    
rs6219 CC 0.80 18.0 (0.6) 0.977 18.0 (0.6) 0.468
  CT 0.18 19.5 (1.3) 8.3 19.3 (1.3) 7.2
  TT 0.02 11.7 (4.1) -35.0 11.0 (4.0) -38.9
     
rs6214 CC 0.33 17.9 (1.0) 0.443 17.6 (0.9) 0.623
  CT 0.48 17.9 (0.8) 0.0 18.0 (0.8) 2.3
  TT 0.19 19.3 (1.3) 7.8 19.5 (1.3) 10.8
 Others    
rs2971575 AA 0.35 18.9 (0.9) 0.746 18.8 (0.9) 0.482
  AG 0.46 17.4 (0.8) -7.9 17.4 (0.8) -7.4
  GG 0.19 18.8 (1.3) -0.5 18.8 (1.2) 0.0
     
rs10860862 GG 0.56 18.4 (0.7) 0.254 18.3 (0.7) 0.012
  GT 0.37 18.6 (0.9) 1.1 18.5 (0.9) 1.1
  TT 0.07 14.3 (2.0) -22.3 15.3 (2.1) -16.4
     
rs2946834 GG 0.43 18.8 (0.8) 0.099 18.8 (0.8) 0.722
  GA 0.45 18.2 (0.8) -3.2 18.2 (0.8) -3.2
  AA 0.13 15.6 (1.5) -17.0 15.7 (1.5) -16.5
P for trend is presented for single SNPs; The most frequent genotype was used as the refer-
ence when comparing total IGF-I levels between genotypes. Model 1: without adjustment. 
Model 2: after adjustment for gender and age. *P ≤ 0.05 compared to the reference.
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Table 2C. Continued
SNP Frequency Model 1 Model 2
      Mean (SE) P % Change Mean (SE) P % Change
rs5742632 AA 0.60 17.1 (0.7) 0.654 17.1 (0.7) 0.622
  AG 0.34 18.4 (0.9) 7.6 18.4 (0.9) 7.6
  GG 0.05 16.0 (2.2) -6.4 16.0 (2.2) -6.4
rs5742629 TT 0.52 17.4 (0.7) 0.928 17.4 (0.7) 0.996
  TC 0.40 18.0 (0.8) 3.4 17.9 (0.8) 2.9
  CC 0.08 16.1 (1.8) -7.5 16.5 (1.8) -5.2
rs10778176 CC 0.53 17.4 (0.7) 0.853 17.4 (0.7) 0.924
  CT 0.39 17.9 (0.8) 2.9 17.8 (0.8) 2.3
  TT 0.08 16.1 (1.8) -7.5 16.5 (1.8) -5.2
rs1019731 CC 0.80 17.3 (0.6) 0.488 17.4 (0.6) 0.559
  CA 0.19 18.2 (1.2) 5.2 18.0 (1.2) 3.4
  AA 0.01 18.9 (5.2) 9.2 19.4 (5.1) 11.5
Block 4    
rs2288378 CC 0.56 17.1 (0.7) 0.604 17.2 (0.7) 0.800
  CT 0.37 18.4 (0.9) 7.6 18.4 (0.8) 7.0
  TT 0.07 16.3 (2.0) -4.7 15.8 (1.9) -8.1
rs7136446 TT 0.39 16.4 (0.8) 0.232 16.6 (0.8) 0.310
  CT 0.46 18.4 (0.8) 12.2 18.3 (0.7) 10.2
  CC 0.15 17.6 (1.3) 7.3 17.5 (1.3) 5.4
Block 5            
rs6220 AA 0.49 17.1 (0.7) 0.832 17.2 (0.7) 0.920
  AG 0.41 18.0 (0.8) 5.3 17.9 (0.8) 4.1
  GG 0.1 16.5 (1.6) -3.5 16.2 (1.6) -5.8
rs978458 CC 0.54 17.17 (0.7) 0.589 17.2 (0.7) 0.823
  CT 0.38 18.38 (0.8) 7.0 18.1 (0.8) 5.2
  TT 0.08 16.9 (1.8) -1.6 16.6 (1.8) -3.5
Block 6    
rs6219 CC 0.84 17.1 (0.6) 0.251 17.1 (0.6) 0.270
  CT 0.14 20.2 (1.4)* 18.1 20.2 (1.3)* 18.1
  TT 0.01 13.0 (4.2) -24.0 12.3 (4.1) -28.1
rs6214 CC 0.34 18.1 (0.9) 0.729 17.9 (0.9) 0.807
  CT 0.45 16.9 (0.8) -6.6 17.1 (0.8) -4.5
  TT 0.21 17.9 (1.1) -1.1 17.7 (1.1) -1.1
Others
rs2971575 AA 0.36 16.4 (0.9) 0.162 16.6 (0.9) 0.262
  AG 0.47 18.1 (0.8) 10.4 18.0 (0.7) 8.4
  GG 0.18 18.2 (1.2) 11.0 18.0 (1.2) 8.4
rs10860862 GG 0.56 18.6 (0.7) 0.004 18.4 (0.7) 0.010
  GT 0.33 16.8 (0.9) -9.7 17.0 (0.9) -7.6
  TT 0.11 14.0 (1.5)* -24.7 14.3 (1.5)* -22.3
rs2946834 GG 0.46 16.6 (0.8) 0.261 16.8 (0.8) 0.376
  GA 0.43 18.5 (0.8) 11.4 18.3 (0.8) 8.9
  AA 0.11 17.4 (1.5) 4.8 17.4 (1.5) 3.6
P for trend is presented for single SNPs; The most frequent genotype was used as the refer-
ence when comparing total IGF-I levels between genotypes. Model 1: without adjustment. 
Model 2: after adjustment for gender and age. *P ≤ 0.05 compared to the reference.
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IGF-I gene haplotype blocks and total IGF-I
In the whole study population and in women haplotypes in block 1 and 2 of 
the IGF-I gene were signifi cantly related to total IGF-I (Table 3A-C). These 
signifi cant relationships remained signifi cant after adjustments for age (Table 
3A and C). In men haplotypes in block 1 and 2 of the IGF-I gene were also 
signifi cantly related to total IGF-I, but only when unadjusted. After adjustment 
for age, haplotypes in block 1 showed borderline signifi cance with total IGF-I 
levels in men (Table 3B). No relationships were observed between blocks 3-6 
of the IGF-I gene and total IGF-I (Table3A-C).
Table 3A. Associations between circulating total IGF-I and IGF-I gene haplotypes in the 
total population
Haplotype Frequency   Model 1  
 
Model 2
        Mean (SE) P % Change Mean (SE) P % Change
Block 1                
H1 TG 0.78   18.3 (0.3) 0.000 18.2 (0.3) 0.001
H2 CT 0.15   16.9 (0.7) -7.7 16.7 (0.7) -8.2
H3 CG 0.07   14.8 (1.0)* -19.1 15.4 (1.0) -15.4
Block 2
H1 TC 0.76   18.3 (0.3) 0.002 18.3 (0.3) 0.005
H2 CT 0.22   16.0 (0.6)* -12.6 16.1 (0.6)* -12.0
H3 <0.05 0.02   18.1 (2.0) -1.1 18.9 (1.9) 3.3
Block 3                
H1 GATCC 0.52   18.0 (0.4) 0.646 18.0 (0.4) 0.626
H2 AATCC 0.09   16.4 (0.9) -8.9 16.2 (0.8) -10.0
H3 GATCA 0.11   18.0 (0.8) 0.0 17.9 (0.8) -0.6
H4 GGCTC 0.22   18.6 (0.6) 3.3 18.5 (0.6) 2.8
H5 <0.05 0.01   15.2 (1.1) -15.6 15.5 (1.1) -13.9
Block 4      
H1 CT 0.61   17.6 (0.3) 0.255 17.6 (0.3) 0.375
H2 CC 0.14   18.0 (0.7) 2.3 18.1 (0.7) 2.8
H3 TC 0.25   18.2 (0.5) 3.4 18.1 (0.5) 2.8
Block 5
H1 AC 0.70   17.8 (0.3) 0.592 17.8 (0.3) 0.425
H2 GT 0.26   18.2 (0.5) 2.2 18.1 (0.5) 1.7
H3 <0.05 0.04   15.3 (1.4) -14.0 15.3 (1.4) -14.0
Block 6
H1 CC 0.47   17.6 (0.4) 0.315 17.5 (0.4) 0.304
H2 CT 0.43   17.9 (0.4) 1.7 18.0 (0.4) 2.9
H3 TC 0.10   18.6 (0.9) 5.7 18.4 (0.8) 5.1
P for trend is presented for single haplotypes. The most frequent haplotype (H1) was used as 
the reference when comparing total IGF-I levels between haplotypes. Model 1: without ad-
justment. Model 2: after adjustment for gender and age. *P ≤ 0.05 compared to the reference.
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Table 3B. Associations between circulating total IGF-I and IGF-I gene haplotypes in men
Haplotype Frequency Model 1 Model 2
      Mean (SE) P % Change Mean (SE) P % Change
Block 1            
H1 TG 0.80 18.6 (0.4) 0.015 18.5 (0.4) 0.052
H2 CT 0.13 17.1 (1.1) -8.1 17.1 (1.0) -7.6
H3 CG 0.07 15.1 (1.5)* -18.8 16.0 (1.5) -13.5
Block 2
H1 TC 0.76 18.6 (0.4) 0.033 18.5 (0.4) 0.086
H2 CT 0.20 16.2 (0.9)* -12.9 16.5 (0.9)* -10.8
H3 <0.05 0.02 18.3 (2.9) -1.6 18.8 (2.8) 1.6
Block 3            
H1 GATCC 0.52 18.4 (0.5) 0.614 18.5 (0.5) 0.600
H2 AATCC 0.10 16.2 (1.3) -12.0 16.2 (1.3) -12.4
H3 GATCA 0.13 17.7 (1.1) -3.8 17.7 (1.1) -4.3
H4 GGCTC 0.22 19.4 (0.8) 5.4 19.2 (0.8) 3.8
H5 <0.05 0.01 14.2 (1.6) -22.8 14.8 (1.6)* -20.0
Block 4    
H1 CT 0.60 18.1 (0.5) 0.536 18.1 (0.5) 0.594
H2 CC 0.16 17.5 (1.0) -3.3 17.7 (1.0) -2.2
H3 TC 0.25 18.7 (0.8) 3.3 18.6 (0.8) 2.8
Block 5
H1 AC 0.71 18.1 (0.5) 0.812 18.1 (0.4) 0.734
H2 GT 0.25 18.7 (0.8) 3.3 18.6 (0.8) 2.8
H3 <0.05 0.04 16.0 (1.9) -11.6 16.0 (1.9) -11.6
Block 6
H1 CC 0.48 17.8 (0.6) 0.547 17.8 (0.6) 0.528
H2 CT 0.43 18.5 (0.6) 3.9 18.6 (0.6) 4.5
H3 TC 0.11 18.2 (1.2) 2.2 17.9 (1.2) 0.6
P for trend is presented for single haplotypes. The most frequent haplotype (H1) was used 
as the reference when comparing total IGF-I levels between haplotypes. Model 1: without 
adjustment. Model 2: after adjustment for age. *P ≤ 0.05  compared to the reference.
Table 3C. Associations between circulating total IGF-I and IGF-I gene haplotypes in women
Haplotype Frequency Model 1 Model 2
      Mean (SE) P % Change Mean (SE) P % Change
Block 1            
H1 TG 0.75 18.0 (0.4) 0.009 18.0 (0.4) 0.009
H2 CT 0.17 16.7 (0.9) -7.2 16.4 (0.9) -8.9
H3 CG 0.07 14.6 (1.3)* -18.9 15.0 (1.3)* -16.7
Block 2
H1 TC 0.74 18.0 (0.4) 0.033 18.1 (0.4) 0.028
H2 CT 0.24 15.9 (0.7)* -11.7 15.7 (0.7)* -13.3
H3 Rare  0.02 17.9 (2.8) -0.6 19.1 (2.7) 5.5
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Characteristics of participants in which IGF-I bioactivity was measured 
IGF-I bioactivity was measured in 1036 subjects randomly selected from the 
participants of the third survey of the Rotterdam study. Mean IGF-I bioactiv-
ity was 180 pmol/L (SD: 56). Mean IGF-I bioactivity was signifi cantly lower 
in men than in women (men: 170 pmol/L (SD 47); women: 187 pmol/L (SD 
62); age adjusted p < 0.001). In Table 4A clinical characteristics of these 
participants are shown. Women were slightly older than men. BMI, total 
cholesterol and HDL cholesterol were signifi cantly higher in women than in 
men, whilediastolic blood pressure and prevalence of cardiovascular disease 
was higher in men than in women. Incidence of MI, coronary heart disease 
and the combination of MI and AP was higher in men than in women, while 
the incidence of diabetes did not differ between the two genders (Table 4B). 
Single IGF-I gene SNPs, and circulating IGF-I Bioactivity
We did not observe signifi cant relationships between IGF-I bioactivity and 
SNPs that were associated with total IGF-I (Table 5A-C). However several 
Haplotype Frequency Model 1 Model 2
      Mean (SE) P % Change Mean (SE) P % Change
Block 3            
H1 GATCC 0.52 17.6 (0.5) 0.864 17.6 (0.5) 0.850
H2 AATCC 0.10 16.5 (1.2) -6.3 16.2 (1.1) -8.0
H3 GATCA 0.10 18.2 (1.1) 3.4 18.1 (1.1) 2.8
H4 GGCTC 0.22 17.9 (0.8) 1.7 17.9 (0.8) 1.7
H5 <0.05 0.01 15.9 (1.5) -9.7 16.0 (1.5) -9.1
Block 4    
H1 CT 0.62 17.2 (0.5) 0.342 17.2 (0.5) 0.477
H2 CC 0.13 18.5 (1.0) 7.6 18.6 (1.0) 8.1
H3 TC 0.25 17.8 (0.7) 3.5 17.7 (0.7) 2.9
Block 5
H1 AC 0.70 17.5 (0.4) 0.618 17.6 (0.4) 0.442
H2 GT 0.27 17.8 (0.7) 1.7 17.6 (0.7) 0.0
H3 <0.05 0.03 14.6 (2.0) -16.6 14.7 (2.0) -16.5
Block 6
H1 CC 0.48 17.4 (0.5) 0.439 17.4 (0.5) 0.415
H2 CT 0.44 17.4 (0.6) 0.0 17.4 (0.5) 0.0
H3 TC 0.09 18.9 (1.2) 8.6 18.8 (1.2) 8.0
P for trend is presented for single haplotypes. The most frequent haplotype (H1) was used 
as the reference when comparing total IGF-I levels between haplotypes. Model 1: without 
adjustment. Model 2: after adjustment for age. *P ≤ 0.05 compared to the reference.
Table 3C continued
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SNPs in the IGF-I gene located in blocks 3-6 were associated with circulat-
ing IGF-I bioactivity overall and in men (overall: rs5742632, rs2288378 and rs 
978458; Table 5A); in men: rs5742632, 5742629, rs10778176 rs2288378, rs6220, 
rs978458 and rs6219; Table 5B), while in women no associations were found 
between IGF-I bioactivity and IGF-I gene SNPs (Table 5C). Specifi c IGF-I SNPs 
accounted individually for up to 30 % change in IGF-I bioactivity.
IGF-I gene haplotype blocks and IGF-I bioactivity
In the whole study population haplotypes in blocks 3 (H4), block 4 (H3) and 
block 5 (H2) were associated with higher circulating IGF-I bioactivity when 
compared to the reference (H1), but no signifi cant trend was found (Table 6A). 
In men, blocks 3 (H4), block 4 (H3), block 5 (H2) and block 6 (H3) were related 
to signifi cantly higher circulating IGF-I bioactivity than the respective reference 
haplotypes (H1) (Table 6B) and a signifi cant trend was found in blocks 3, 4 and 
5. In women no signifi cant relationships were observed between haplotypes 
and IGF-I bioactivity (Table 6C).
Table 4A. General characteristics of all subjects in which IGF-I boactivity was measured at 
the third round of the Rotterdam study
Characteristics Total population Male Female P-value
Total number 1036 451 585  
Age (years) 72.4 ± 7.3 71.8 ± 6.8 72.8 ± 7.7  0.03
Gender (%) 451 (43.5) 585 (56.5) < 0.001
Body mass index (kg/m2) 26.9 ± 3.9 26.4 ± 3.2 27.3 ± 4.4  0.001
Systolic blood pressure (mmHg) 143.9 ± 21.7 145.7 ± 22.0 142.5 ± 21.3 0.02
Diastolic blood pressure (mmHg) 75.3 ± 11.7 76.8 ± 11.7 74.1 ± 11.5 < 0.001
Total cholesterol (mmol/L) 5.8 ± 1.0 5.5 ± 0.9 6.1 ± 1.0 < 0.001
HDL cholesterol (mmol/L) 1.4 ± 0.4 1.2 ± 0.3 1.5 ± 0.4 < 0.001
Prevalence of cardiovascular disease (%) 173 (23.2) 86 (27.3) 87 (20.2)  0.02
Current smoking (%) 290 (29.0) 208 (48.4) 82 (14.4) < 0.001
Values are presented as mean ± standard deviation or percentage.
Table 4B. Incidence of cardiovascular disease and diabetes during follow-up of all subjects 
in which IGF-I bioactivity was measured at the third round of the Rotterdam study.
Characteristics Total population Male Female P-value
Total number 1036 451 585  
Incidence of myocardial infarction (%) 62 (6.0) 43 (9.5) 19 (3.2) < 0.001
Incidence of angina pectoris (%) 62 (6.0) 29 (6.4) 33 (5.6) 0.123
Incidence of myocardial infarction and angina 
pectoris (%) 118 (11.6) 68 (15.2) 50 (8.8) 0.001
Incidence of coronary heart disease and angina 
pectoris (%) 167 (16.4) 96 (21.5) 71 (12.5) < 0.001
Incidence of type 2 diabetes (%) 208 (20.1) 103 (22.9) 105 (18.0) 0.05
Values are presented as mean ± standard deviation or percentage
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Table 5A. Associations between circulating IGF-I bioactivity and  IGF-I gene polymorphisms 
in the total population
SNP Frequency Model 1 Model 2
      Mean (SE) P % Change Mean (SE) P % Change
Block 1            
rs35766 TT 0.70 181.3 (2.2) 0.170 174.9 (2.1) 0.103
  TC 0.27 164.0 (3.1) -9.5 167.3 (3.2)* -4.3
  CC 0.02 181.3 (12.0) 0.0 174.0 (11.4) -0.5
rs35765 GG 0.78 181.3 (2.1) 0.347 173.8 (2.0) 0.275
  GT 0.21 164.0 (3.6) -9.5 169.2 (3.7) -2.6
  TT 0.01 164.0 (14.7) -9.5 169.7 (15.0) -2.4
Block 2    
rs2162679 TT 0.70 174.6 (2.1) 0.313 174.5 (2.1) 0.232
  TC 0.27 168.0 (3.2) -3.8 168.2 (3.2) -3.6
  CC 0.03 175.0 (10.8) 0.2 176.4 (10.8) 1.1
rs35767 CC 0.70 173.8 (2.1) 0.191 174.9 (2.1) 0.110
  CT 0.27 169.6 (3.3) -2.4 166.7 (3.2)* -4.7
  TT 0.02 171.2 (11.1) -1.5 176.4 (11.4) 0.9
Block 3            
rs2033178 GG 0.86 169.5 (1.8) 0.251 171.9 (1.8) 0.223
  GA 0.13 177.5 (4.9) 4.7 177.9 (4.9) 3.5
  AA 0.00 171.9 (25.5) 1.4 182.7 (26.9) 6.3
rs5742632 AA 0.60 169.3 (2.2) 0.008 168.7 (2.2) 0.007
  AG 0.35 177.8 (3.0)* 5.0 179.1 (3.0)* 6.2
  GG 0.05 173.0 (7.5) 2.2 178.4 (7.7) 5.7
rs5742629 TT 0.54 172.7 (2.4) 0.119 169.4 (2.3) 0.113
  TC 0.39 173.0 (2.8)* 0.2 177.7 (2.8)* 4.9
  CC 0.07 174.0 (6.4) 0.8 171.4 (6.3) 1.2
rs10778176 CC 0.55 174.3 (2.4) 0.074 169.4 (2.3) 0.075
  CT 0.38 168.4 (2.7)* -3.4 177.9 (2.8)* 5.0
  TT 0.07 178.3 (6.8) 2.3 172.4 (6.5) 1.8
rs1019731 CC 0.74 174.5 (2.0) 0.910 172.6 (2.0) 0.787
  CA 0.24 167.3 (3.4) -4.1 173.1 (3.5) 0.3
  AA 0.02 178.4 (13.2) 2.2 176.4 (13.0) 2.2
Block 4    
rs2288378 CC 0.57 172.0 (2.3) 0.017 169.7 (2.2) 0.013
  CT 0.37 177.4 (2.9) 3.1 175.4 (2.9)* 3.4
  TT 0.06 186.0 (7.7)* 8.1 187.5 (7.7) 10.5
rs7136446 TT 0.36 168.7 (2.8) 0.281 170.7 (2.8) 0.222
  CT 0.48 178.8 (2.6) 6.0 172.8 (2.5) 1.2
  CC 0.15 178.9 (4.6) 6.0 177.5 (4.5) 4.0
Block 5            
rs6220 AA 0.52 169.9 (2.4) 0.053 170.2 (2.4) 0.045
  AG 0.41 175.0 (2.8) 3.0 175.2 (2.7) 2.9
  GG 0.07 187.8 (7.0) 10.5 182.4 (6.8) 7.2
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SNP Frequency Model 1 Model 2
      Mean (SE) P % Change Mean (SE) P % Change
rs978458 CC 0.54 171.1 (2.3) 0.015 169.0 (2.3) 0.011
  CT 0.39 172.7 (2.8) 0.9 176.4 (2.8)* 4.4
  TT 0.06 177.2 (7.1) 3.6 183.1 (7.2) 8.3
Block 6    
rs6219 CC 0.82 170.3 (1.9) 0.152 171.6 (1.9) 0.143
  CT 0.17 175.1 (4.2) 2.8 176.8 (4.2) 3.0
  TT 0.01 182.3 (17.1) 7.0 188.7 (17.5) 10.0
rs6214 CC 0.37 169.3 (2.8) 0.325 175.6 (2.9) 0.299
  CT 0.47 176.0 (2.6) 4.0 171.1 (2.5) -2.6
  TT 0.16 183.6 (4.6) 8.4 171.4 (4.2) -2.4
Others    
rs2971575 AA 0.34 171.6 (3.0) 0.692 172.4 (3.0) 0.642
  AG 0.48 173.9 (2.5) 1.3 172.1 (2.5) -0.2
  GG 0.18 173.3 (4.1) 1.0 175.2 (4.1) 1.6
rs10860862 GG 0.67 171.6 (2.1) 0.107 175.6 (2.1) 0.062
  GT 0.29 176.6 (3.3)* 2.9 166.3 (3.0)* -5.3
  TT 0.04 189.8 (10.1) 10.6 175.0 (9.2) -0.3
rs2946834 GG 0.47 175.5 (2.6) 0.602 171.4 (2.5) 0.532
  GA 0.43 171.1 (2.6) -2.5 174.0 (2.6) 1.5
  AA 0.10 171.5 (5.4) -2.3 173.6 (5.4) 1.3
P for trend is presented for single SNPs; The most frequent genotype was used as the refer-
ence when comparing total IGF-I levels between genotypes. Model 1: without adjustment. 
Model 2: after adjustment for gender and age. *P ≤ 0.05 compared to the reference.
Table 5A. Continued
Table 5B. Associations between circulating IGF-I bioactivity and  IGF-I gene polymor-
phisms in men
SNP Frequency Model 1 Model 2
      Mean (SE) P % Change Mean (SE) P % Change
Block 1            
rs35766 TT 0.73 166.7 (2.8) 0.304 167.0 (2.8) 0.204
  TC 0.25 159.1 (4.5) -4.6 158.4 (4.5) -5.2
  CC 0.02 171.4 (17.0) 2.8 169.0 (16.6) 1.2
rs35765 GG 0.79 165.9 (2.7) 0.522 166.2 (2.6) 0.376
  GT 0.20 162.1 (5.2) -2.3 160.9 (5.1) -3.2
  TT 0.01 162.1 (22.7) -2.3 161.7 (22.5) -2.7
Block 2    
rs2162679 TT 0.72 166.1 (2.8) 0.539 166.2 (2.8) 0.448
  TC 0.26 161.1 (4.5) -3.0 160.9 (4.4) -3.2
  CC 0.02 171.4 (17.0) 3.2 169.0 (16.7) 1.7
rs35767 CC 0.73 165.6 (2.8) 0.468 165.8 (2.8) 0.375
  CT 0.25 160.0 (4.6) -3.4 159.7 (4.6) -3.7
  TT 0.02 170.6 (18.1) 3.0 168.5 (17.8) 1.6
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SNP Frequency Model 1 Model 2
      Mean (SE) P % Change Mean (SE) P % Change
Block 3            
rs2033178 GG 0.85 163.4 (2.5) 0.133 163.5 (2.5) 0.149
  GA 0.14 173.7 (6.5) 6.3 173.3 (6.5) 6.0
  AA 0.00 173.0 (48.5) 5.9 173.8 (48.4) 6.3
rs5742632 AA 0.59 158.4 (2.9) 0.001 158.2 (2.9) 0.001
  AG 0.36 174.3 (4.1)* 10.0 174.7 (4.1)* 10.4
  GG 0.05 178.6 (11.4) 12.8 177.7 (11.3) 12.3
rs5742629 TT 0.53 159.0 (3.1) 0.031 158.7 (3.0) 0.025
  TC 0.40 173.2 (3.8)* 8.9 173.5 (3.8)* 9.3
  CC 0.07 163.7 (8.9) 3.0 163.5 (8.8) 3.0
rs10778176 CC 0.54 158.8 (3.0) 0.021 158.7 (3.0) 0.018
  CT 0.39 173.6 (3.9)* 9.3 173.8 (3.9)* 9.5
  TT 0.06 164.6 (9.2) 3.7 164.5 (9.1) 3.7
rs1019731 CC 0.73 164.6 (2.7) 0.945 164.5 (2.7) 0.979
  CA 0.25 166.3 (4.8) 1.0 166.5 (4.7) 1.2
  AA 0.03 159.6 (14.2) -3.0 157.6 (13.9) -4.2
Block 4
rs2288378 CC 0.55 158.0 (3.0) 0.001 158.2 (3.0) 0.001
  CT 0.39 172.5 (3.9)* 9.2 172.1 (3.8)* 8.8
  TT 0.06 182.6 (10.8)* 15.6 182.9 (10.7)* 15.6
rs7136446 TT 0.35 159.6 (3.9) 0.192 159.3 (3.8) 0.147
  CT 0.49 168.1 (3.4) 5.3 168.0 (3.4) 5.5
  CC 0.16 166.5 (5.9) 4.3 167.3 (5.9) 5.0
Block 5            
rs6220 AA 0.51 158.3 (3.1) 0.003 158.4 (3.1) 0.003
  AG 0.41 172.1 (3.8) 8.7 171.9 (3.8)* 8.52
  GG 0.07 176.3 (9.2)* 11.4 177.0 (9.1)* 11.7
rs978458 CC 0.53 157.3 (3.0) 0.000 157.3 (3.0) 0.000
  CT 0.42 172.8 (3.8)* 9.9 172.8 (3.7)* 9.9
  TT 0.06 180.5 (10.4)* 14.7 180.5 (10.3)* 14.8
Block 6    
rs6219 CC 0.81 162.2 (2.5) 0.008 162.2 (2.5) 0.008
  CT 0.18 175.0 (5.8)* 7.9 175.4 (5.8)* 8.1
  TT 0.01 212.9 (29.7)* 31.3 207.3 (28.7) 27.8
rs6214 CC 0.38 166.8 (3.9) 0.214 166.3 (3.8) 0.277
  CT 0.47 166.2 (3.4) -0.4 166.3 (3.4) 0.0
  TT 0.15 156.5 (5.7) -6.2 157.0 (5.6) -5.6
Others    
rs2971575 AA 0.33 159.8 (3.9) 0.504 159.5 (3.9) 0.405
  AG 0.48 169.7 (3.5) 6.2 169.5 (3.4) 6.3
  GG 0.18 161.7 (5.3) 1.2 162.6 (5.3) 1.9
Table 5B. Continued
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Table 5B. Continued
Table 5C. Associations between circulating IGF-I bioactivity and  IGF-I gene polymorphisms 
in women
SNP Frequency Model 1 Model 2
Mean (SE) P % Change Mean (SE) P % Change
Block 1
rs35766 TT 0.68 181.7 (3.0) 0.218 181.6 (3.0) 0.230
TC 0.29 174.3 (4.4) -4.1 174.3 (4.4) -4.0
CC 0.02 177.5 (15.6) -2.3 178.4 (15.6) -1.8
rs35765 GG 0.77 180.6 (2.8) 0.392 180.5 (2.8) 0.403
GT 0.22 175.2 (5.2) -3.0 175.2 (5.2) -2.9
TT 0.01 176.6 (20.3) -2.2 178.2 (20.5) -1.3
Block 2
rs2162679 TT 0.69 181.4 (3.0) 0.313 181.5 (3.0) 0.333
TC 0.28 174.1 (4.5) -4.0 174.0 (4.5) -4.1
CC 0.03 182.0 (14.3) 0.3 183.3 (14.4) 1.0
rs35767 CC 0.68 182.5 (3.1) 0.154 182.4 (3.1) 0.170
CT 0.29 172.5 (4.5) -5.5 172.4 (4.5) -5.5
TT 0.03 182.4 (14.9) -0.1 183.8 (15.0) 0.8
Block 3
rs2033178 GG 0.87 179.1 (2.6) 0.723 179.1 (2.6) 0.680
GA 0.12 180.9 (7.1) 1.0 181.3 (7.1) 1.2
AA 0.01 190.5 (33.5) 6.4 191.1 (33.6) 6.7
rs5742632 AA 0.60 177.2 (3.2) 0.416 177.2 (3.2) 0.403
AG 0.34 182.7 (4.3) 3.1 182.7 (4.3) -4.8
GG 0.06 179.2 (10.5) 1.1 179.3 (10.5) 7.5
rs5742629 TT 0.55 178.3 (3.3) 0.764 178.2 (3.3) 0.747
TC 0.38 181.3 (4.1) 1.7 181.5 (4.1) 1.9
CC 0.08 177.8 (8.8) -0.3 177.7 (8.8) -0.3
rs10778176 CC 0.55 178.1 (3.3) 0.664 178.0 (3.3) 0.643
CT 0.38 181.3 (4.1) 1.8 181.5 (4.1) 2.0
TT 0.07 179.0 (9.1) 0.5 178.9 (9.1) 0.5
SNP Frequency Model 1 Model 2
      Mean (SE) P % Change Mean (SE) P % Change
rs10860862 GG 0.69 167.0  (3.1) 0.228 167.3  (3.1) 0.301
  GT 0.29 159.1  (4.4) -4.7 158.9  (4.6) -4.7
  TT 0.02 177.9  (9.1) 6.5 177.5  (9.3) 6.5
rs2946834 GG 0.45 163.3 (3.5) 0.736 162.9 (3.4) 0.582
  GA 0.44 166.9 (3.6) 2.2 167.2 (3.6) 2.6
  AA 0.11 163.3 (7.1) 0.0 164.0 (7.1) 0.7
P for trend is presented for single SNPs; The most frequent  genotype was used as the refer-
ence when comparing total IGF-I levels between genotypes. Model 1: without adjustment. 
Model 2: after adjustment for gender and age. *P ≤ 0.05 compared to the reference.
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Table 5C. Continued
SNP Frequency Model 1 Model 2
Mean (SE) P % Change Mean (SE) P % Change
rs1019731 CC 0.75 179.2 (2.9) 0.762 179.3 (2.9) 0.777
CA 0.24 178.7 (5.1) -0.3 178.6 (5.1) -0.4
AA 0.01 201.1 (25.0) 12.2 201.5 (25.0) 12.4
Block 4
rs2288378 CC 0.59 179.5 (3.2) 0.656 179.3 (3.2) 0.615
CT 0.35 177.2 (4.1) -1.3 177.3 (4.1) -1.1
TT 0.06 191.8 (10.8) 6.9 192.3 (10.8) 7.3
rs7136446 TT 0.38 180.1 (4.0) 0.609 179.8 (4.0) 0.571
CT 0.47 176.6 (3.6) -1.9 176.8 (3.6) -1.7
CC 0.15 187.0 (6.7) 3.8 187.2 (6.7) 4.1
Block 5
rs6220 AA 0.53 180.0 (3.4) 0.852 179.8 (3.4) 0.805
AG 0.40 177.6 (3.9) -1.3 177.7 (3.9) -1.2
GG 0.07 187.3 (9.8) 4.1 187.5 (9.8) 4.3
rs978458 CC 0.56 178.9 (3.3) 0.657 178.8 (3.3) 0.615
CT 0.37 179.0 (4.0) 0.1 178.9 (4.0) 0.1
TT 0.07 185.8 (10.0) 3.9 186.4 (10.0) 4.3
Block 6
rs6219 CC 0.82 179.5 (2.7) 0.789 179.5 (2.7) 0.859
CT 0.17 178.0 (6.0) -0.8 178.4 (6.0) -0.6
TT 0.01 175.8 (21.8) -2.1 177.0 (22.0) -1.4
rs6214 CC 0.37 182.9 (4.2) 0.726 182.9 (4.1) 0.692
CT 0.47 175.1 (3.5) -4.3 175.4 (3.5) -4.1
TT 0.17 183.6 (6.2) 0.4 183.1 (6.2) 0.1
Others
rs2971575 AA 0.34 183.0 (4.3) 0.964 182.9 (4.3) 0.934
AG 0.48 174.2 (3.5) -4.8 174.2 (3.4) -4.8
GG 0.18 187.0 (6.2) 2.2 187.2 (6.2) 2.4
rs10860862 GG 0.66 182.7 (3.1) 0.119 182.7 (3.1) 0.129
GT 0.30 172.4 (4.4) -5.6 172.4 (4.4) -5.6
TT 0.05 178.1 (11.3) -2.5 178.6 (11.3) -2.2
rs2946834 GG 0.48 178.2 (3.6) 0.589 178.0 (3.6) 0.524
GA 0.43 179.9 (3.8) 1.0 180.0 (3.8) 1.1
AA 0.10 182.7 (8.1) 2.5 183.3 (8.1) 3.0
P for trend is presented for single SNPs; The most frequent genotype was used as the refer-
ence when comparing total IGF-I levels between genotypes. Model 1: without adjustment. 
Model 2: after adjustment for gender and age. *P ≤ 0.05 compared to the reference.
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Table 6A. Associations between circulating IGF-I bioactivity and IGF-I gene haplotypes in 
the total population 
Haplotype Frequency  Model 1 Model 2
Mean (SE) P % Change Mean (SE) P % Change
Block 1    
H1 TG 0.84 173.5 (1.3) 0.178 173.6 (1.3) 0.104
H2 CT 0.12 169.4 (3.5) -2.4 168.8 (3.5) -2.8
H3 <0.05 0.04 167.9 (5.8) -3.2 166.7 (5.7) -4.0
Block 2    
H1 TC 0.83 173.5 (1.3) 0.238 173.6 (1.3) 0.165
H2 CT 0.16 169.3 (3.0) -2.4 168.8 (3.0) -2.8
H3 <0.05 0.01 170.7 (11.6) -1.6 170.2 (11.5) -2.0
Block 3            
H1 GATCC 0.53 170.5 (1.7) 0.138 170.4 (1.6) 0.112
H2 AATCC 0.07 177.5 (4.8) 4.1 177.7 (4.7) 4.3
H3 GATCA 0.14 173.1 (3.3) 1.5 173.6 (3.3) 1.9
H4 GGCTC 0.23 178.7 (2.6)* 4.8 178.8 (2.6)* 4.9
H5 <0.05 0.04 161.2 (5.7) -5.5 161.1 (5.7) -5.5
Block 4    
H1 CT 0.61 171.7 (1.6) 0.069 171.6 (1.5) 0.050
H2 CC 0.15 168.8 (3.1) -1.7 169.0 (3.0) -1.5
H3 TC 0.24 178.0 (2.6)* 3.7 178.2 (2.5)* 3.8
Block 5  
H1 AC 0.72 171.3 (1.4) 0.193 171.2 (1.4) 0.175
H2 GT 0.25 177.9 (2.5)* 3.9 178.0 (2.5)* 4.0
H3 <0.05 0.03 164.3 (7.2) -4.1 164.2 (7.1) -4.1
Block 6
H1 CC 0.51 172.9 (1.7) 0.591 172.9 (1.7) 0.596
H2 CT 0.39 171.3 (1.9) -0.9 171.2 (1.9) -1.0
H3 TC 0.09 178.1 (4.0) 3.0 178.2 (4.0) 3.1
P for trend is presented for single haplotypes. The most frequent haplotype (H1) was used as 
the reference when comparing total IGF-I levels between haplotypes.  Model 1: without ad-
justment. Model 2: after adjustment for gender and age. *P ≤ 0.05 compared to the reference.
Table 6B. Associations between circulating IGF-I bioactivity with IGF-I gene haplotypes in men
Haplotype Frequency  Model 1 Model 2
Mean (SE) P % Change Mean (SE) P % Change
Block 1    
H1 TG 0.86 165.6 (1.8) 0.305 165.7 (1.8) 0.220
H2 CT 0.11 161.2 (4.9) -2.7 160.1 (4.8) -3.4
H3 <0.05 0.03 159.4 (8.6) -3.7 159.0 (8.5) -4.0
Block 2    
H1 TC 0.84 165.3 (1.8) 0.712 165.5 (1.8) 0.572
H2 CT 0.14 161.3 (4.3) -2.4 160.8 (4.2) -2.8
H3 Rare  0.01 178.7 (17.7) 8.1 176.4 (17.4) 6.6
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Haplotype Frequency  Model 1 Model 2
Mean (SE) P % Change Mean (SE) P % Change
Block 3            
H1 GATCC 0.52 160.7 (2.2) 0.038 160.8 (2.2) 0.032
H2 AATCC 0.07 172.7 (6.4) 7.5 172.1 (6.4) 7.0
H3 GATCA 0.14 165.1 (4.3) 2.7 165.0 (4.2) 2.6
H4 GGCTC 0.23 174.5 (3.6)* 8.6 174.5 (3.6)* 8.5
H5 <0.05 0.04 150.2 (7.6) -6.5 151.3 (7.6) -5.9
Block 4    
H1 CT 0.59 163.1 (2.1) 0.014 162.9 (2.1) 0.012
H2 CC 0.16 156.3 (4.0) -4.2 157.3 (4.0) -3.4
H3 TC 0.25 174.7 (3.5)* 7.1 174.5 (3.4)* 7.1
Block 5  
H1 AC 0.71 161.8 (1.9) 0.024 161.7 (1.9) 0.019
H2 GT 0.26 174.6 (3.4)* 7.9 174.5 (3.4)* 7.9
H3 <0.05 0.03 154.7 (9.6) -4.4 156.5 (9.7) -3.2
Block 6
H1 CC 0.51 164.3 (2.3) 0.140 164.0 (2.3) 0.113
H2 CT 0.39 162.3 (2.6) -1.2 162.6 (2.6) -0.9
H3 TC 0.10 178.6 (5.7)* 8.7 178.4 (5.6)* 8.8
P for trend is presented for single haplotypes. The most frequent haplotype (H1) was used 
as the reference when comparing total IGF-I levels between haplotypes. Model 1: without 
adjustment. Model 2: after adjustment for age. *P ≤ 0.05 compared to the reference.
Table 6C. Associations between circulating IGF-I bioactivity with IGF-I gene  haplotypes in 
women 
Haplotype Frequency Model 1 Model 2
Mean (SE) P % Change Mean (SE) P % Change
Block 1    
H1 TG 0.83 180.3 (1.9) 0.218 180.4 (1.9) 0.231
H2 CT 0.12 175.5 (4.9) -2.7 175.6 (4.9) -2.7
H3 <0.05 0.05 173.0 (7.7) -4.0 173.1 (7.7) -4.0
Block 2    
H1 TC 0.82 180.5 (1.9) 0.149 180.4 (1.9) 0.163
H2 CT 0.17 175.1 (4.2) -3.0 175.2 (4.2) -2.9
H3 <0.05 0.01 165.2 (15.1) -8.5 165.5 (15.1) -8.3
Block 3            
H1 GATCC 0.54 178.3 (2.4) 0.728 178.2 (2.4) 0.713
H2 AATCC 0.07 181.7 (6.8) 1.9 182.2 (6.8) 2.2
H3 GATCA 0.13 180.7 (4.9) 1.3 180.5 (4.9) 1.3
H4 GGCTC 0.23 182.1 (3.7) 2.1 182.2 (3.7) 2.2
H5 <0.05 0.04 170.2 (8.3) -4.5 170.0 (8.3) -4.6
Block 4    
H1 CT 0.62 178.7 (2.2) 0.604 178.6 (2.2) 0.560
H2 CC 0.15 180.0 (4.6) 0.7 180.0 (4.6) 0.8
H3 TC 0.24 180.8 (3.6) 1.2 180.9 (3.6) 1.3
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C. IGF-I gene SNPs, IGF-I gene haplotype blocks, and myocardial infarction 
In the whole study population and in men, but not in women several SNPs 
of the IGF-I gene were signifi cantly associated with risk of MI/AP. One SNP 
(rs35766) located in block 1 and two SNPs located in block 2 (rs2162679 and 
rs35767) were signifi cantly related to an increased risk of MI/AP (Table 7A-C). 
In addition, only in men SNPs rs35765 (block 1) and rs10860862 (others) were 
also associated with risk of MI/AP (Table 7B). After adjustments for age, BMI, 
systolic and diastolic BP, total and HDL-cholesterol, incidence of DM type 2, 
prevalence of CVD and current smoking these relationships remained signifi -
cant for all these SNPs in men, and for rs35766 and 35767 in the total study 
population (Table 7B and 7A respectively).
In the whole study population and in men there was a signifi cantly increased 
risk for MI/AP for carriers of haplotype 2 in both block 1 and block 2, odds 
ratios were 1.23 and 1.22 in the whole study population and 1.40 and 1.46 in 
men, respectively (Table 8A and 8B). These relationships remained signifi cant 
in men after adjustments for age, BMI, systolic and diastolic BP, total and 
HDL-cholesterol, incidence of DM type 2, prevalence of CVD and current 
smoking, while overall these relationships became borderline signifi cant after 
these adjustments (Tabel 8B and 8A: models 2 and 3). In women no such 
relationships were found (Table 8C). 
None of the IGF-I SNPs or haplotypes of the IGF-I gene that were associ-
ated with circulating IGF-I bioactivity were signifi cantly associated with an 
increased risk on MI and/or AP (Table 7A-C and Table 8A-C). No signifi cant 
relationships were found between SNPs/haplotypes of the IGF-I gene and 
coronary heart disease (data not shown).
Haplotype Frequency Model 1 Model 2
Mean (SE) P % Change Mean (SE) P % Change
Block 5  
H1 AC 0.72 179.2 (2.1) 0.917 179.1 (2.0) 0.955
H2 GT 0.25 180.6 (3.5) 0.8 180.7 (3.5) 0.9
H3 <0.05 0.03 172.0 (10.2) -4.0 171.9 (10.2) -4.0
Block 6
H1 CC 0.51 180.3 (2.5) 0.590 180.4 (2.5) 0.624
H2 CT 0.40 178.6 (2.8) -0.9 178.6 (2.8) -1.0
H3 TC 0.10 177.7 (5.6) -1.4 178.2 (5.6) -1.2
P for trend is presented for single haplotypes. The most frequent haplotype (H1) was used 
as the reference when comparing total IGF-I levels between haplotypes. Model 1: without 
adjustment. Model 2: after adjustment for age. *P ≤ 0.05 compared to the reference.
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Table 7A. Risk of myocardial infarction and angina pectoris across IGF-I gene polymor-
phisms in the total population
SNP Frequency Model 1 Model 2 Model 3
    Control Case OR (95% CI) P OR (95% CI) P OR (95% CI) P
Block 1              
rs35766 TT 0.71 0.66 1 (Ref.) 0.012 1 (Ref.) 0.011 1 (Ref.) 0.032
  TC 0.26 0.30 1.20 (0.97-1.49) 1.20 (0.97-1.49) 1.17 (0.94-1.46)
  CC 0.03 0.04 1.75 (1.06-2.88)* 1.81 (1.09-2.99)* 1.69 (1.00-2.86)
               
rs35765 GG 0.78 0.74 1 (Ref.) 0.078 1 (Ref.) 0.076 1 (Ref.) 0.162
  GT 0.21 0.23 1.19 (0.95-1.50) 1.18 (0.94-1.49) 1.16 (0.91-1.48)
  TT 0.02 0.02 1.41 (0.73-2.70) 1.50 (0.78-2.90) 1.31 (0.65-2.66)
Block 2              
rs2162679 TT 0.71 0.67 1 (Ref.) 0.050 1 (Ref.) 0.050 1 (Ref.) 0.111
  TC 0.26 0.29 1.18 (0.95-1.46) 1.16 (0.94-1.44) 1.14 (0.92-1.43)
  CC 0.03 0.04 1.46 (0.87-2.45) 1.55 (0.92-2.61) 1.42 (0.82-2.44)
               
rs35767 CC 0.71 0.66 1 (Ref.) 0.016 1 (Ref.) 0.015 1 (Ref.) 0.041
  CT 0.26 0.29 1.20 (0.96-1.49) 1.18 (0.95-1.47) 1.16 (0.92-1.45)
  TT 0.03 0.04 1.71 (1.04-2.82)* 1.82 (1.10-3.01)* 1.69 (1.00-2.87)*
Block 3              
rs2033178 GG 0.87 0.85 1 (Ref.) 0.149 1 (Ref.) 0.189 1 (Ref.) 0.363
  GA 0.12 0.15 1.26 (0.95-1.65) 1.23 (0.93-1.62) 1.21 (0.91-1.61)
  AA 0.005 0.004 0.90 (0.21-3.90) 0.97 (0.22-4.25) 0.70 (0.15-3.23)
               
rs5742632 AA 0.60 0.60 1 (Ref.) 0.614 1 (Ref.) 0.678 1 (Ref.) 0.632
  AG 0.35 0.35 1.00 (0.82-1.23) 1.01 (0.82-1.24) 0.99 (0.80-1.23)
  GG 0.05 0.04 0.82 (0.51-1.31) 0.83 (0.52-1.33) 0.84 (0.52-1.36)
               
rs5742629 TT 0.54 0.55 1 (Ref.) 0.738 1 (Ref.) 0.815 1 (Ref.) 0.768
  TC 0.39 0.39 0.99 (0.81-1.21) 1.00 (0.82-1.23) 1.00 (0.81-1.23)
  CC 0.07 0.07 0.92 (0.62-1.37) 0.93 (0.63-1.39) 0.91 (0.60-1.38)
               
rs10778176 CC 0.55 0.55 1 (Ref.) 0.749 1 (Ref.) 0.848 1 (Ref.) 0.772
  CT 0.38 0.39 1.01 (0.82-1.24) 1.03 (0.84-1.26) 1.02 (0.83-1.26)
  TT 0.07 0.06 0.89 (0.59-1.33) 0.90 (0.59-1.35) 0.87 (0.57-1.34)
rs1019731 CC 0.73 0.73 1 (Ref.) 0.947 1 (Ref.) 0.870 1 (Ref.) 0.799
  CA 0.24 0.25 1.03 (0.82-1.29) 1.03 (0.82-1.29) 1.07 (0.85-1.34)
  AA 0.02 0.02 0.81 (0.39-1.68) 0.77 (0.37-1.61) 0.85 (0.40-1.82)
Block 4                  
rs2288378 CC 0.57 0.57 1 (Ref.) 0.883 1 (Ref.) 0.821 1 (Ref.) 0.997
  CT 0.37 0.38 1.05 (0.85-1.28) 1.04 (0.85-1.28) 1.02 (0.83-1.26)
  TT 0.06 0.05 0.95 (0.61-1.47) 0.98 (0.63-1.53) 0.95 (0.60-1.51)
                   
rs7136446 TT 0.37 0.36 1 (Ref.) 0.605 1 (Ref.) 0.599 1 (Ref.) 0.274
  CT 0.47 0.50 1.09 (0.88-1.34) 1.07 (0.87-1.33) 1.00 (0.80-1.24)
  CC 0.17 0.14 0.87 (0.64-1.17) 0.87 (0.64-1.18) 0.81 (0.59-1.11)
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SNP Frequency Model 1 Model 2 Model 3
    Control Case OR (95% CI) P OR (95% CI) P OR (95% CI) P
Block 5                  
rs6220 AA 0.52 0.50 1 (Ref.) 0.760 1 (Ref.) 0.748 1 (Ref.) 0.940
  AG 0.4 0.43 1.10 (0.90-1.34) 1.10 (0.90-1.35) 1.08 (0.88-1.33)
  GG 0.08 0.07 0.93 (0.63-1.38) 0.93 (0.63-1.38) 0.89 (0.59-1.35)
                   
rs978458 CC 0.55 0.54 1 (Ref.) 0.679 1 (Ref.) 0.670 1 (Ref.) 0.867
  CT 0.38 0.41 1.09 (0.89-1.33) 1.08 (0.88-1.32) 1.06 (0.86-1.30)
  TT 0.06 0.06 0.95 (0.63-1.45) 0.98 (0.64-1.49) 0.94 (0.61-1.46)
Block 6                  
rs6219 CC 0.81 0.82 1 (Ref.) 0.658 1 (Ref.) 0.732 1 (Ref.) 0.951
  CT 0.17 0.18 1.00 (0.78-1.30) 1.01 (0.78-1.30) 1.03 (0.79-1.35)
  TT 0.01 0.01 0.54 (0.17-1.75) 0.58 (0.18-1.89) 0.67 (0.20-2.22)
                   
rs6214 CC 0.34 0.32 1 (Ref.) 0.833 1 (Ref.) 0.810 1 (Ref.) 0.956
  CT 0.50 0.53 1.12 (0.90-1.39) 1.11 (0.89-1.38) 1.13 (0.90-1.41)
  TT 0.16 0.15 0.99 (0.73-1.33) 0.99 (0.74-1.34) 0.93 (0.68-1.27)
Others                  
rs2971575 AA 0.33 0.33 1 (Ref.) 0.510 1 (Ref.) 0.483 1 (Ref.) 0.234
  AG 0.48 0.51 1.08 (0.87-1.34) 1.07 (0.86-1.33) 1.00 (0.80-1.25)
  GG 0.19 0.16 0.87 (0.65-1.16) 0.86 (0.65-1.16) 0.81 (0.60-1.10)
                   
rs10860862 GG 0.66 0.64  1 (Ref.) 0.468 1 (Ref.) 0.368 1 (Ref.) 0.266
  GT 0.31 0.33 1.12 (0.91-1.37) 1.12 (0.91-1.38) 1.18 (0.95-1.46)
  TT 0.04 0.03 0.97 (0.57-1.66) 1.04 (0.61-1.77) 1.00 (0.58-1.74)
                   
rs2946834 GG 0.48 0.46 1 (Ref.) 0.713 1 (Ref.) 0.634 1 (Ref.) 0.377
  GA 0.41 0.46 1.19 (0.97-1.46) 1.17 (0.95-1.43) 1.11 (0.90-1.37)
  AA 0.11 0.08 0.74 (0.52-1.06) 0.74 (0.51-1.06) 0.70 (0.48-1.02)
P for trend is presented for single SNPs; The most frequent genotype was used as the refer-
ence when comparing incidence of myocardial infarction and angina pectoris between geno-
types. Model 1: without adjustment; Model 2: after adjustment for gender and age; Model 3: 
adjusted for gender, age and cardiovascular risk factors. *P ≤ 0.05 compared to the reference.
Table 7A. Continued
Table 7B. Risk of myocardial infarction and angina pectoris across IGF-I gene polymor-
phisms in men
SNP Frequency Model 1 Model 2 Model 3
    Control Case OR (95% CI) P OR (95% CI) P OR (95% CI) P
Block 1                  
rs35766 TT 0.71 0.62 1 (Ref.) 0.004 1 (Ref.) 0.003 1 (Ref.) 0.005
  TC 0.27 0.34 1.44 (1.07-1.93)* 1.46 (1.08-1.96)* 1.45 (1.07-1.96)*
  CC 0.02 0.04 1.97 (0.95-4.09) 2.06 (0.99-4.28)* 1.99 (0.93-4.27)
rs35765 GG 0.77 0.70 1 (Ref.) 0.025 1 (Ref.) 0.020 1 (Ref.) 0.029
  GT 0.22 0.27 1.36 (0.99-1.85) 1.38 (1.01-1.88)* 1.36 (0.99-1.89)
  TT 0.01 0.02 1.87 (0.74-4.73) 1.92 (0.76-4.87) 1.92 (0.71-5.16)
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SNP Frequency Model 1 Model 2 Model 3
    Control Case OR (95% CI) P OR (95% CI) P OR (95% CI) P
Block 2                  
rs2162679 TT 0.71 0.62 1 (Ref.) 0.006 1 (Ref.) 0.005 1 (Ref.) 0.011
  TC 0.27 0.34 1.40 (1.05-1.88)* 1.40 (1.05-1.89)* 1.38 (1.01-1.87)*
  CC 0.02 0.04 2.02 (0.97-4.19) 2.10 (1.01-4.39)* 2.00 (0.93-4.30)
rs35767 CC 0.71 0.61 1 (Ref.) 0.002 1 (Ref.) 0.002 1 (Ref.) 0.004
  CT 0.27 0.35 1.50 (1.12-2.02)* 1.50 (1.12-2.02)* 1.47 (1.08-2.00)*
  TT 0.02 0.04 2.09 (1.00-4.35)* 2.15 (1.03-4.51)* 2.08 (0.96-4.50)
Block 3                  
rs2033178 GG 0.86 0.84 1 (Ref.) 0.291 1 (Ref.) 0.283 1 (Ref.) 0.210
  GA 0.14 0.16 1.20 (0.82-1.74) 1.20 (0.82-1.75) 1.23 (0.83-1.82)
  AA 0.002 0.00 1.96 (0.20-18.89) 2.17 (0.22-21.11) 3.44 (0.34-34.50)
rs5742632 AA 0.60 0.61 1 (Ref.) 0.526 1 (Ref.) 0.476 1 (Ref.) 0.361
  AG 0.34 0.36 1.04 (0.78-1.39) 1.04 (0.78-1.38) 0.98 (0.73-1.32)
  GG 0.05 0.03 0.60 (0.28-1.27) 0.58 (0.27-1.23) 0.59 (0.28-1.28)
rs5742629 TT 0.55 0.55 1 (Ref.) 0.931 1 (Ref.) 0.907 1 (Ref.) 0.706
  TC 0.38 0.39 1.01 (0.76-1.35) 1.01 (0.76-1.35) 0.98 (0.73-1.32)
  CC 0.07 0.07 0.94 (0.54-1.65) 0.93 (0.53-1.64) 0.86 (0.47-1.58)
rs10778176 CC 0.56 0.55 1 (Ref.) 0.972 1 (Ref.) 0.989 1 (Ref.) 0.763
  CT 0.37 0.38 1.03 (0.77-1.37) 1.03 (0.77-1.37) 0.99 (0.74-1.33)
  TT 0.07 0.07 0.97 (0.55-1.69) 0.96 (0.54-1.68) 0.88 (0.48-1.62)
rs1019731 CC 0.73 0.72 1 (Ref.) 0.998 1 (Ref.) 0.916 1 (Ref.) 0.786
  CA 0.25 0.26 1.04 (0.76-1.42) 1.02 (0.75-1.40) 1.09 (0.79-1.51)
  AA 0.02 0.02 0.85 (0.33-2.19) 0.81 (0.31-2.12) 0.86 (0.32-2.30)
Block 4                  
rs2288378 CC 0.57 0.54 1 (Ref.) 0.742 1 (Ref.) 0.771 1 (Ref.) 0.850
  CT 0.38 0.42 1.18 (0.89-1.56) 1.17 (0.88-1.54) 1.14 (0.85-1.53)
  TT 0.05 0.04 0.74 (0.36-1.52) 0.75 (0.36-1.53) 0.73 (0.34-1.59)
rs7136446 TT 0.35 0.34 1 (Ref.) 0.837 1 (Ref.) 0.813 1 (Ref.) 0.533
  CT 0.49 0.52 1.08 (0.80-1.46) 1.08 (0.80-1.46) 0.97 (0.71-1.33)
  CC 0.16 0.14 0.91 (0.59-1.39) 0.90 (0.59-1.38) 0.86 (0.55-1.33)
Block 5                  
rs6220 AA 0.52 0.48 1 (Ref.) 0.566 1 (Ref.) 0.600 1 (Ref.) 0.722
  AG 0.40 0.45 1.22 (0.92-1.62) 1.21 (0.91-1.61) 1.19 (0.89-1.60)
  GG 0.08 0.07 0.90 (0.51-1.58) 0.90 (0.51-1.57) 0.84 (0.46-1.55)
rs978458 CC 0.55 0.51 1 (Ref.) 0.702 1 (Ref.) 0.781 1 (Ref.) 0.902
  CT 0.39 0.45 1.23 (0.93-1.63) 1.21 (0.91-1.60) 1.17 (0.87-1.57)
  TT 0.06 0.04 0.71 (0.36-1.41) 0.71 (0.36-1.40) 0.69 (0.33-1.42)
Block 6                        
rs6219 CC 0.82 0.83   1 (Ref.) 0.457   1 (Ref.) 0.411   1 (Ref.) 0.342
  CT 0.17 0.16   0.92 (0.64-1.33)   0.91 (0.63-1.31)   0.87 (0.59-1.28)
  TT 0.01 0.00   0.43 (0.06-3.30)   0.42 (0.05-3.23)   0.46 (0.06-3.57)
Table 7B. Continued
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Table 7B. Continued
SNP Frequency Model 1 Model 2 Model 3
    Control Case OR (95% CI) P OR (95% CI) P OR (95% CI) P
rs6214 CC 0.34 0.30   1 (Ref.) 0.104   1 (Ref.) 0.112   1 (Ref.) 0.320
  CT 0.51 0.51   1.13 (0.83-1.54)   1.12 (0.82-1.53)   1.08 (0.78-1.49)
  TT 0.15 0.19   1.41 (0.94-2.10)   1.41 (0.94-2.10)   1.25 (0.82-1.89)
Others                        
rs2971575 AA 0.32 0.31   1 (Ref.) 0.963     0.914   1 (Ref.) 0.654
  AG 0.49 0.51   1.07 (0.78-1.45)   1.06 (0.77-1.44)   0.98 (0.71-1.35)
  GG 0.19 0.18   0.97 (0.65-1.45)   0.96 (0.64-1.44) 0.90 (0.59-1.38)
rs10860862 GG 0.67 0.61   1 (Ref.) 0.025   1 (Ref.) 0.020   1 (Ref.) 0.037
  GT 0.3 0.35   1.29 (0.96-1.72)   1.29 (0.97-1.73)   1.30 (0.96-1.76)
  TT 0.03 0.05   1.83 (0.92-3.66)   1.95 (0.97-3.90)   1.72 (0.83-3.55)
rs2946834 GG 0.46 0.44   1 (Ref.) 0.792   1 (Ref.) 0.735   1 (Ref.) 0.504
  GA 0.43 0.47   1.13 (0.85-1.50)   1.11 (0.84-1.48)   1.04 (0.78-1.40)
  AA 0.11 0.09   0.79 (0.48-1.30)   0.78 (0.47-1.29)   0.75 (0.45-1.25)
P for trend is presented for single SNPs; The most frequent genotype was used as the refer-
ence when comparing incidence of myocardial infarction and angina pectoris between geno-
types. Model 1: without adjustment;  Model 2: after adjustment for gender and age; Model 3: 
adjusted for gender, age and cardiovascular risk factors. *P ≤ 0.05 compared to the reference.
Table 7C. Risk of myocardial infarction and angina pectoris across IGF-I gene polymor-
phisms in women.
SNP Frequency Model 1 Model 2 Model 3
    Control Case OR (95% CI) P OR (95% CI) P OR (95% CI) P
Block 1              
rs35766 TT 0.71 0.71 1 (Ref.) 0.552 1 (Ref.) 0.540 1 (Ref.) 0.762
  TC 0.26 0.25 0.96 (0.70-1.33) 0.97 (0.70-1.33) 0.95 (0.68-1.32)
  CC 0.03 0.04 1.61 (0.81-3.22) 1.61 (0.81-3.23) 1.44 (0.69-3.03)
rs35765 GG 0.78 0.78 1 (Ref.) 0.949 1 (Ref.) 0.876 1 (Ref.) 0.823
  GT 0.20 0.19 0.98 (0.69-1.39) 0.99 (0.70-1.41) 0.98 (0.68-1.41)
  TT 0.02 0.02 1.13 (0.44-2.92) 1.20 (0.47-3.08) 0.88 (0.30-2.54)
Block 2                  
rs2162679 TT 0.71 0.72 1 (Ref.) 0.944 1 (Ref.) 0.848 1 (Ref.) 0.775
  TC 0.26 0.25 0.95 (0.69-1.30) 0.94 (0.68-1.30) 0.94 (0.67-1.31)
  CC 0.03 0.04 1.13 (0.53-2.40) 1.17 (0.55-2.48) 0.99 (0.44-2.24)
rs35767 CC 0.71 0.72 1 (Ref.) 0.830 1 (Ref.) 0.805 1 (Ref.) 0.995
  CT 0.26 0.24 0.90 (0.65-1.25) 0.90 (0.65-1.25) 0.89 (0.64-1.26)
  TT 0.03 0.05 1.51 (0.76-3.00) 1.56 (0.78-3.12) 1.37 (0.65-2.87)
Block 3                  
rs2033178 GG 0.88 0.86 1 (Ref.) 0.432 1 (Ref.) 0.433 1 (Ref.) 0.825
  GA 0.11 0.13 1.25 (0.83-1.88) 1.26 (0.84-1.90) 1.17 (0.76-1.79)
  AA 0.01 0.004 0.68 (0.09-5.20) 0.63 (0.08-4.88) 0.43 (0.05-3.45)
rs5742632 AA 0.59 0.60 1 (Ref.) 0.998 1 (Ref.) 0.902 1 (Ref.) 0.816
  AG 0.35 0.34 0.97 (0.73-1.31) 0.98 (0.73-1.32) 1.00 (0.74-1.35)
  GG 0.05 0.06 1.06 (0.58-1.93) 1.10 (0.60-2.02) 1.13 (0.61-2.09)
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Table 7C. Continued
SNP Frequency Model 1 Model 2 Model 3
    Control Case OR (95% CI) P OR (95% CI) P OR (95% CI) P
rs5742629 TT 0.54 0.54 1 (Ref.) 0.759 1 (Ref.) 0.827 1 (Ref.) 0.960
  TC 0.39 0.39 0.98 (0.73-1.30) 0.99 (0.74-1.32) 1.02 (0.76-1.38)
  CC 0.07 0.07 0.91 (0.52-1.61) 0.93 (0.53-1.63) 0.98 (0.55-1.75)
rs10778176 CC 0.54 0.54 1 (Ref.) 0.696 1 (Ref.) 0.771 1 (Ref.) 0.983
  CT 0.39 0.40 1.01 (0.76-1.35) 1.02 (0.77-1.37) 1.06 (0.78-1.42)
  TT 0.07 0.06 0.82 (0.45-1.49) 0.83 (0.46-1.52) 0.89 (0.48-1.63)
rs1019731 CC 0.74 0.74 1 (Ref.) 0.829 1 (Ref.) 0.894 1 (Ref.) 0.989
  CA 0.24 0.25 1.02 (0.74-1.40) 1.03 (0.75-1.42) 1.03 (0.74-1.44)
  AA 0.02 0.01 0.69 (0.21-2.27) 0.70 (0.21-2.30) 0.79 (0.24-2.62)
Block 4                  
rs2288378 CC 0.58 0.59 1 (Ref.) 0.881 1 (Ref.) 0.982 1 (Ref.) 0.916
  CT 0.37 0.34 0.90 (0.67-1.21) 0.92 (0.68-1.24) 0.90 (0.66-1.23)
  TT 0.06 0.07 1.15 (0.65-2.02) 1.19 (0.67-2.09) 1.15 (0.65-2.06)
rs7136446 TT 0.38 0.38 1 (Ref.) 0.508 1 (Ref.) 0.609 1 (Ref.) 0.388
  CT 0.45 0.48 1.05 (0.78-1.41) 1.07 (0.79-1.45) 1.01 (0.74-1.38)
  CC 0.17 0.14 0.82 (0.53-1.26) 0.84 (0.55-1.29) 0.78 (0.50-1.22)
Block 5                  
rs6220 AA 0.52 0.53 1 (Ref.) 0.838 1 (Ref.) 0.939 1 (Ref.) 0.940
  AG 0.40 0.40 0.98 (0.73-1.31) 1.00 (0.75-1.34) 0.99 (0.73-1.33)
  GG 0.07 0.07 0.95 (0.55-1.65) 0.97 (0.56-1.68) 0.99 (0.56-1.74)
rs978458 CC 0.56 0.56 1 (Ref.) 0.873 1 (Ref.) 0.753 1 (Ref.) 0.853
  CT 0.38 0.36 0.94 (0.70-1.26) 0.96 (0.71-1.29) 0.94 (0.70-1.28)
  TT 0.06 0.08 1.19 (0.70-2.04) 1.23 (0.72-2.12) 1.19 (0.69-2.07)
Block 6                        
rs6219 CC 0.81 0.80   1 (Ref.) 0.855   1 (Ref.) 0.750   1 (Ref.) 0.391
  CT 0.17 0.19   1.10 (0.77-1.57)   1.12 (0.78-1.60)   1.21 (0.84-1.75)
  TT 0.01 0.01   0.67 (0.16-2.84)   0.71 (0.17-3.03)   0.93 (0.22-4.01)
rs6214 CC 0.34 0.35   1 (Ref.) 0.169   1 (Ref.) 0.207   1 (Ref.) 0.244
  CT 0.49 0.54   1.09 (0.81-1.47)   1.11 (0.82-1.50)   1.18 (0.87-1.62)
  TT 0.17 0.11   0.63 (0.39-1.01)   0.64 (0.40-1.03)   0.63 (0.38-1.02)
Others                        
rs2971575 AA 0.34 0.350   1 (Ref.) 0.319   1 (Ref.) 0.375   1 (Ref.) 0.280
  AG 0.46 0.5   1.07 (0.79-1.45)   1.08 (0.80-1.47)   1.02 (0.74-1.39)
  GG 0.19 0.15   0.76 (0.49-1.16)   0.77 (0.50-1.18)   0.75 (0.48-1.16)
rs10860862 GG 0.65 0.670   1 (Ref.) 0.309   1 (Ref.) 0.314   1 (Ref.) 0.562
  GT 0.31 0.31   0.97 (0.72-1.31)   0.97 (0.72-1.31)   1.06 (0.78-1.44)
  TT 0.04 0.02   0.51 (0.20-1.28)   0.51 (0.20-1.28)   0.52 (0.20-1.31)
rs2946834 GG 0.49 0.47   1 (Ref.) 0.683   1 (Ref.) 0.734   1 (Ref.) 0.684
  GA 0.39 0.46   1.21 (0.91-1.61)   1.22 (0.92-1.63)   1.18 (0.88-1.60)
  AA 0.12 0.08   0.68 (0.40-1.16)   0.69 (0.40-1.17)   0.69 (0.39-1.19)
P for trend is presented for single SNPs; The most frequent genotype was used as the refer-
ence when comparing incidence of myocardial infarction and angina pectoris between geno-
types. Model 1: without adjustment; Model 2: after adjustment for gender and age; Model 3: 
adjusted for gender, age and cardiovascular risk factors. *P ≤ 0.05 compared to the reference.
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Table 8A. Risk of myocardial infarction and angina pectoris across IGF-I gene haplotypes in 
the total population
Haplotype Frequency Model 1 Model 2 Model 3
Control Case OR (95% CI) P OR (95% CI) P OR (95% CI) P
Block 1
H1 TG 0.84 0.81 1 (Ref.) 1 (Ref.) 1 (Ref.)
H2 CT 0.12 0.14 1.23 (1.01-1.49) 0.038 1.23 (1.01-1.50) 0.037 1.19 (0.97-1.46) 0.091
H3 <0.05  0.04 0.05 1.32 (0.95-1.85) 0.101 1.33 (0.95-1.86) 0.100 1.30 (0.92-1.84) 0.130
Block 2
H1 TC 0.84 0.81 1 (Ref.) 1 (Ref.) 1 (Ref.)
H2 CT 0.15 0.18 1.22 (1.02-1.46) 0.026 1.23 (1.02-1.46) 0.026 1.19 (0.99-1.43) 0.060
H3 <0.05  0.01 0.01 1.04 (0.52-2.08) 0.915 1.07 (0.53-2.15) 0.861 1.01 (0.50-2.06) 0.973
Block 3
H1 GATCC 0.53 0.52 1 (Ref.) 1 (Ref.) 1 (Ref.)
H2 AATCC 0.06 0.08 1.22 (0.93-1.59) 0.151 1.20 (0.92-1.58) 0.185 1.14 (0.86-1.51) 0.363
H3 GATCA 0.14 0.14 1.01 (0.82-1.23) 0.943 1.00 (0.81-1.22) 0.979 1.04 (0.84-1.28) 0.743
H4 GGCTC 0.23 0.22 0.98 (0.83-1.17) 0.835 0.99 (0.83-1.17) 0.873 0.98 (0.82-1.17) 0.825
H5 <0.05  0.03 0.04 1.08 (0.75-1.55) 0.682 1.08 (0.75-1.56) 0.667 1.09 (0.75-1.60) 0.643
Block 4
H1 CT 0.60 0.61 1 (Ref.) 1 (Ref.) 1 (Ref.)
H2 CC 0.16 0.15 0.92 (0.76-1.12) 0.418 0.92 (0.75-1.11) 0.377 0.86 (0.71-1.06) 0.155
H3 TC 0.24 0.24 0.99 (0.84-1.17) 0.934 1.00 (0.84-1.18) 0.977 0.96 (0.81-1.15) 0.683
Block 5
H1 AC 0.72 0.71 1 (Ref.) 1 (Ref.) 1 (Ref.)
H2 GT 0.25 0.26 1.02 (0.87-1.20) 0.790 1.02 (0.87-1.20) 0.772 1.00 (0.85-1.18) 0.992
H3 <0.05 0.03 0.03 1.09 (0.73-1.65) 0.671 1.10 (0.73-1.66) 0.646 1.12 (0.73-1.72) 0.597
Block 6
H1 AC 0.72 0.71 1 (Ref.) 1 (Ref.) 1 (Ref.)
H2 GT 0.25 0.26 1.02 (0.87-1.20) 0.790 1.02 (0.87-1.20) 0.772 1.00 (0.85-1.18) 0.992
H3 <0.05 0.03 0.03 1.09 (0.73-1.65) 0.671 1.10 (0.73-1.66) 0.646 1.12 (0.73-1.72) 0.597
P for trend is presented for single haplotypes. The most frequent haplotype (H1) was used as 
the reference when comparing total IGF-I levels between haplotypes. Model 1: without ad-
justment. Model 2: after adjustment for gender and age. Model 3: after adjustment for gender, 
age and cardiovascular risk factors.
Table 8B. Risk of myocardial infarction and angina pectoris across IGF-I gene haplotypes in 
men
Haplotype Frequency Model 1 Model 2 Model 3
Control Case OR (95% CI) P OR (95% CI) P OR (95% CI) P
Block 1
H1 TG 0.84 0.79 1 (Ref.) 1 (Ref.) 1 (Ref.)
H2 CT 0.12 0.16 1.40 (1.07-1.84) 0.014 1.42 (1.09-1.87) 0.011 1.42 (1.07-1.88) 0.016
H3 Rare  0.03 0.05 1.50 (0.94-2.39) 0.089 1.52 (0.95-2.42) 0.083 1.47 (0.90-2.38) 0.122
Block 2
H1 TC 0.84 0.78 1 (Ref.) 1 (Ref.) 1 (Ref.)
H2 CT 0.15 0.21 1.46 (1.15-1.87) 0.002 1.48 (1.15-1.89) 0.002 1.45 (1.12-1.88) 0.004
H3 Rare  0.00 0.01 0.95 (0.33-2.76) 0.927 0.97 (0.33-2.85) 0.958 0.87 (0.29-2.62) 0.808
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Haplotype Frequency Model 1 Model 2 Model 3
Control Case OR (95% CI) P OR (95% CI) P OR (95% CI) P
Block 3
H1 GATCC 0.52 0.52 1 (Ref.) 1 (Ref.) 1 (Ref.)
H2 AATCC 0.07 0.08 1.23 (0.84-1.80) 0.279 1.23 (0.84-1.81) 0.284 1.27 (0.85-1.88) 0.242
H3 GATCA 0.15 0.14 1.02 (0.77-1.36) 0.871 1.01 (0.76-1.34) 0.963 1.06 (0.79-1.41) 0.714
H4 GGCTC 0.22 0.21 0.96 (0.75-1.24) 0.764 0.95 (0.74-1.22) 0.695 0.93 (0.72-1.21) 0.607
H5 Rare  0.03 0.04 1.34 (0.83-2.15) 0.229 1.37 (0.85-2.20) 0.197 1.38 (0.83-2.29) 0.220
Block 4
H1 CT 0.59 0.60 1 (Ref.) 1 (Ref.) 1 (Ref.)
H2 CC 0.17 0.16 0.94 (0.72-1.22) 0.632 0.94 (0.72-1.22) 0.629 0.88 (0.67-1.17) 0.377
H3 TC 0.24 0.25 1.01 (0.80-1.28) 0.921 1.01 (0.79-1.28) 0.952 0.98 (0.76-1.26) 0.891
Block 5
H1 AC 0.72 0.71 1 (Ref.) 1 (Ref.) 1 (Ref.)
H2 GT 0.25 0.26 1.05 (0.84-1.32) 0.660 1.04 (0.83-1.30) 0.728 1.02 (0.80-1.29) 0.871
H3 <0.05 0.03 0.03 1.12 (0.64-1.95) 0.692 1.16 (0.67-2.03) 0.597 1.14 (0.63-2.06) 0.654
Block 6
H1 CC 0.49 0.47 1 (Ref.) 1 (Ref.) 1 (Ref.)
H2 CT 0.41 0.45 1.17 (0.95-1.44) 0.142 1.16 (0.94-1.43) 0.158 1.09 (0.88-1.35) 0.447
H3 TC 0.10 0.09 0.94 (0.66-1.34) 0.746 0.93 (0.65-1.33) 0.682 0.87 (0.60-1.27) 0.475
P for trend is presented for single haplotypes. The most frequent haplotype (H1) was used as 
the reference when comparing total IGF-I levels between haplotypes. Model 1: without ad-
justment. Model 2: after adjustment for gender and age. Model 3: after adjustment for gender, 
age and cardiovascular risk factors.
Table 8B continued
Table 8C. Risk of myocardial infarction and angina pectoris across IGF-I gene haplotypes 
in women
Haplotype Frequency Model 1 Model 2 Model 3
Control Case OR (95% CI) P OR (95% CI) P OR (95% CI) P
Block 1
H1 TG 0.84 0.83 1 (Ref.) 1 (Ref.) 1 (Ref.)
H2 CT 0.12 0.12 1.05 (0.78-1.40) 0.759 1.06 (0.79-1.42) 0.704 1.00 (0.73-1.35) 0.984
H3 <0.05 0.04 0.05 1.20 (0.74-1.94) 0.463 1.17 (0.72-1.89) 0.530 1.20 (0.73-1.96) 0.474
Block 2
H1 TC 0.83 0.83 1 (Ref.) 1 (Ref.) 1 (Ref.)
H2 CT 0.16 0.16 1.00 (0.77-1.31) 0.976 1.01 (0.77-1.31) 0.966 0.97 (0.74-1.28) 0.842
H3 <0.05 0.01 0.01 1.13 (0.45-2.83) 0.795 1.14 (0.45-2.86) 0.786 1.14 (0.45-2.87) 0.783
Block 3
H1 GATCC 0.53 0.53 1 (Ref.) 1 (Ref.) 1 (Ref.)
H2 AATCC 0.06 0.07 1.16 (0.79-1.71) 0.444 1.17 (0.79-1.72) 0.431 1.06 (0.71-1.58) 0.784
H3 GATCA 0.14 0.14 0.98 (0.73-1.31) 0.868 0.99 (0.73-1.33) 0.942 1.01 (0.74-1.37) 0.965
H4 GGCTC 0.23 0.23 1.00 (0.79-1.28) 0.988 1.02 (0.80-1.30) 0.881 1.03 (0.80-1.32) 0.807
H5 <0.05 0.03 0.03 0.82 (0.46-1.46) 0.494 0.81 (0.45-1.44) 0.472 0.89 (0.50-1.61) 0.710
Block 4
H1 CT 0.61 0.62 1 (Ref.) 1 (Ref.) 1 (Ref.)
H2 CC 0.15 0.14 0.89 (0.67-1.18) 0.414 0.89 (0.67-1.19) 0.441 0.84 (0.63-1.13) 0.260
H3 TC 0.24 0.24 0.97 (0.77-1.22) 0.779 0.99 (0.78-1.25) 0.919 0.96 (0.75-1.22) 0.736
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DISCUSSION
The main fi nding in our study was that in men several SNPs/ haplotypes of 
the IGF-I gene were related to circulating total IGF-I levels ànd to MI/AP. 
All these SNPs/haplotypes were present in block 1 and 2 of the IGF-I gene. 
Although in women the same SNPs/haplotypes of the IGF-I gene were related 
to circulating IGF-I levels, no associations were found with MI/AP.
We previously examined within the Rotterdam study the role of a cytosine-
adenosine (CA) repeat in the promoter region of the IGF-I gene in relation 
to circulating IGF-I levels and MI [12]. We observed that participants who did 
not carry the wild-type (192-bp) allele had lower circulating total IGF-I con-
centrations and an increased risk of MI [12]. In addition, this IGF-I promoter 
polymorphism was associated with excess mortality in elderly subjects with MI 
[13]. However, subsequent studies failed to fi nd any consistent functional asso-
ciations between these IGF-I gene variant and circulating levels of total IGF-I 
[35,36]. In concurrence with previous fi ndings our study confi rms that the less 
common repeat length CA repeat polymorphism in the promoter region of 
the IGF-I gene is in LD with the minor alleles of rs35767 in haplotype block 
1 [37]. In our study there was not only high linkage equilibrium between this 
polymorphism and rs35767 but also with rs2162679. The minor alleles of both 
SNPs were associated with signifi cantly lower total IGF-I levels and with an 
increased risk for MI/AP during follow-up of the Rotterdam study. 
The so-called Mendelian randomization method is considered a powerful 
approach, which is useful to overcome the effects of confounding and reverse 
causality in epidemiological studies (10). When a polymorphism of the IGF-I 
Table 8C continued
Haplotype Frequency Model 1 Model 2 Model 3
Control Case OR (95% CI) P OR (95% CI) P OR (95% CI) P
Block 5
H1 CC 0.49 0.52 1 (Ref.) 1 (Ref.) 1 (Ref.)
H2 CT 0.41 0.38 0.86 (0.70-1.06) 0.167 0.88 (0.71-1.08) 0.221 0.90 (0.72-1.11) 0.326
H3 TC 0.10 0.10 0.97 (0.70-1.34) 0.839 0.99 (0.72-1.38) 0.975 1.10 (0.78-1.54) 0.593
Block 6
H1 CC 0.49 0.52 1 (Ref.) 1 (Ref.) 1 (Ref.)
H2 CT 0.41 0.38 0.86 (0.70-1.06) 0.167 0.88 (0.71-1.08) 0.221 0.90 (0.72-1.11) 0.326
H3 TC 0.10 0.10 0.97 (0.70-1.34) 0.839 0.99 (0.72-1.38) 0.975 1.10 (0.78-1.54) 0.593
P for trend is presented for single haplotypes. The most frequent haplotype (H1) was used as 
the reference when comparing total IGF-I levels between haplotypes. Model 1: without ad-
justment. Model 2: after adjustment for gender and age. Model 3: after adjustment for gender, 
age and cardiovascular risk factors.
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gene is related to low levels of circulating (total) IGF-I levels, and when low 
levels of circulating (total) IGF-I are indeed a causal risk for MI/AP, then one 
would expect that individuals with IGF-I genotypes/haplotypes associated 
with low (total) IGF-I levels have a higher risk to develop MI/AP. We found 
indeed that subjects with some genetic variants (SNPs, haplotypes) in block 
1 and in block 2 of the IGF-I gene - compared to subjects with the wild-type 
- are life-long exposed to lower total IGF-I levels as well as have an increased 
risk to develop MI/AP. 
Recent results suggest that IGF-I is a protective factor against endothelial 
dysfunction, atherosclerotic plaque development, the metabolic syndrome, 
clinical instability, and ischemic myocardial damage [38]. Some of these effects 
are related to the induction of constitutive nitric oxide (NO) production by 
IGF-I [38]. When total IGF-I levels are decreased below a critical threshold, 
vascular risk factors (like hypertension, cholesterol and glucose) may fully 
exert their detrimental effects, through unopposed endothelial dysfunction, 
endothelial apoptosis, and development of unstable plaques (38. 
Circulating total IGF-I levels in large part determine body reserves of 
IGF-I [39]. The size of these reserves will become important in conditions 
of reduced IGF-I synthesis and/or increased IGF-I demands. We hypothesize 
that with aging circulating total IGF-I levels will earlier decline below a critical 
threshold value in subjects with some variant forms of SNPs of the IGF-I gene. 
This will impair the role of IGF-I as vascular protective factor and thereby 
increase the risk on MI/AP. 
Although circulating IGF-I in women was related to the same genetic vari-
ants of the IGF-I gene as found in men, we did not fi nd signifi cant associations 
between these gene variants and MI/AP. How to explain this important gender 
difference? There is evidence that pathophysiology of coronary artery disease 
is different between men and women [40]. In the Framingham Heart Studied 
it was shown that women experience coronary artery disease events approxi-
mately 10 years later than men [41]. Moreover, it is increasingly being realized 
that hormonal differences between men and women go beyond the obvious 
differences in reproductive physiology. Although generally circulating total 
IGF-I levels do not differ between men and women, spontaneous growth hor-
mone (GH) secretion has been reported to be approximately twofold higher in 
females [42,43]. Thus, both gender-specifi c differences in pathophysiology of 
coronary artery disease as well as gender-specifi c differences in the regulation 
of the GH-IGF-I axis may have played a role in the observed gender-specifi c 
associations between IGF-I gene variants and MI/AP.
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We and others previously observed a weak correlation between circulating 
total IGF-I levels and IGF-I bioactivity suggesting that the IGF-I KIRA produces 
new information about the IGF-I system, which essentially differs from that 
obtained by IGF-I immunoassays [14,15,44,45]. In line with this, circulating 
IGF-I bioactivity was not associated with the risk for MI/ AP. 
Mean circulating IGF-I bioactivity was higher in women than in men, while 
SNPs/haplotypes in blocks 3, 4, and 5 of the IGF-I gene showed gender-
specifi c associations with circulating IGF-I bioactivity. As above discussed, a 
sexually dimorphic pattern of GH secretion may have infl uenced the circulat-
ing concentrations and actions of IGF-I bioactivity in a gender-specifi c way 
[46]. An alternative explanation for the observed differences in IGF-I bioactiv-
ity between men and women is gender-specifi c effects of sex hormones on 
the GH-IGF-I axis [46]. 
Specifi c IGF-I SNPs and haplotypes individually accounted in generally 
less for changes in circulating IGF-I bioactivity than for circulating total IGF-I. 
This suggests that IGF-I bioactivity is less dependent on genetic factors than 
circulating total IGF-I. In men SNPs/haplotypes closely related to circulating 
IGF-I bioactivity were observed in blocks 3-6 of the IGF-I gene. Blocks 3-6 of 
the IGF-I gene encode transcripts involved in size variation in IGF-I mRNAs 
and alternative splicing forms of the IGF-I gene [47]. This opens the possibility 
that differential processing of the IGF-I protein by posttranscriptional and/or 
posttranslational events is responsible for the observed relationships between 
genetic variants in blocks 3-6 of the IGF-I gene and circulating IGF-I bioactivity.
A limitation of our study was that circulating IGF-I bioactivity was not 
measured at baseline but after the third round of the Rotterdam study. This 
may have introduced a prevalence bias since the “worst” cases may have died 
in the intervening years. In favor of this latter option, the frequency of geno-
types/haplotypes of participants in the third round of the Rotterdam study 
was almost similar to that of the controls at baseline. Another limitation of 
our study was that we combined MI and AP as a measure for coronary heart 
disease to increase power of our study. This may have introduced gender-
specifi c differences, since women have higher rates of functional disability 
and a lower prevalence of obstructive coronary heart disease, as evidenced 
by coronary angiogram, than men [48]. In addition, information on AP was 
obtained at the third survey but there was no information available about 
the incidence of AP in the remaining period. Thus the incidence of AP was 
probably underrated. There are yet no data on the effects of long-term storage 
on sample IGF-I bioactivity in the KIRA. However, because all samples were 
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analyzed after an equal period of storage, any variable effect of storage time 
is likely removed. 
Another limitation of our study is that total IGF-I and IGF-I bioactivity were 
only measured in a subsample of the population. In addition, we did not 
measure in the study IGFBPs or other factors that can modify IGF-I levels or 
action.
In conclusion, we observed gender specifi c effects of the IGF-I gene. In 
men but not in women there was an impact of genetic variation in the IGF-I 
gene on circulating total IGF-I levels and risk on MI/AP. In addition, genetic 
variations of the IGF-I gene were also related to circulating IGF-I bioactivity 
in men but not in women. However, these latter genetic variations in the IGF-I 
gene did not substantially infl uence the risk on MI/AP in this study.
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Table S1. General information of the 18 SNPs used to cover the genetic information of the 
human IGF-I gene
No. SNP Position HWE %Genotype MAF Alleles Genotyping method
1 rs2971575 101305009 0.21 100 0.12 G:T Illumina 550K Chip
2 rs10860862 101310202 0.21 100 0.16 T:C Illumina 550K Chip
3 rs2946834 101311944 0.24 97.3 0.16 C:T Illumina 550K Chip
4 rs6219 101314322 0.11 100 0.16 T:C TaqMan*
5 rs6214 101317699 0.91 99.8 0.14 C:A TaqMan*
6 rs6220 101318645 0.22 100 0.26 C:T TaqMan*
7 rs978458 101326369 0.19 100 0.27 T:C Illumina 550K Chip
8 rs2288378 101354138 0.10 99.4 0.23 A:G Illumina 550K Chip
9 rs7136446 101362645 0.53 100 0.07 G:A Illumina 550K Chip
10 rs2033178 101371206 0.09 99.9 0.40 T:C Illumina 550K Chip
11 rs5742632 101380604 0.67 100 0.24 C:T Illumina 550K Chip
12 rs5742629 101381393 0.88 100 0.26 C:T Illumina 550K Chip
13 rs10778176 101387109 0.75 98.2 0.28 A:G Illumina 550K Chip
14 rs1019731 101388555 0.34 100 0.41 C:T Illumina 550K Chip
15 rs2162679 101395389 0.31 99.9 0.10 C:T Illumina 550K Chip
16 rs35767 101399699 0.08 100 0.32 G:A TaqMan*
17 rs35766 101404603 0.63 100 0.19 G:T Illumina 550K Chip
18 rs35765 101405826 0.17 100 0.43 A:G TaqMan*
HWE = Hardy-Weinberg Equilibrium, MAF = Minor allele frequency
*Sequences of designed primers and probes  used in these Taqman assays are shown in Table 
S2.
Table S2. Primers and probes designed for Taqman assays to genotype specifi c IGF-I SNPs
No. SNPs Primer Fw (5’> 3’) Primer Rev (5’> 3’) Probes (5’> 3’)
4 rs6219 GTACCCGCTGCTAAA-
CACACT
TGAATAGACATTTTCA-
TGATACACAGACACA
VIC-
CTGAAACCTCAAGCTGTCTA
FAM-CTGAAACCTCAAACTGTCTA
5 rs6214 CCTCTCAACAAAACT-
TTATAGGCAGTCT
AGTGAAGGAAATAAG-
TCATAGACACTCTTAGA
VIC-
AGACTTAACGTGTTTTC
FAM-
CAGACTTAACATGTTTTC
6 rs6220 GAAAAGAAGGAATC-
ATTGTGTTTTTCAAA-
ATGAA
GCACTCACTGACTCTT-
CTATGCA
VIC-TCTAGTAAAACCTCGTTTAAT
FAM-ATCTAGTAAAACCTTGTTTAAT
16 rs35767 GGATTTCAAGCAGA-
ACTGTGTTTTCA
GGTGGAAATAACCTG-
GACCTTGAAT
VIC-
CCTGAGAGTCATGTGGAAA
FAM-
CTGAGAGTCATGCGGAAA
18 rs35765 GCCAAGTCAAGTGG-
TCACAAC
GCTCCTGCACTTACTG-
TTTCTTG
VIC-
TTCTCTTTGGAAATGAT 
FAM-
CTCTTTGGCAATGAT
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The general aim of the research presented in this thesis was to evaluate 
whether circulating IGF-I bioactivity measured by the IGF-I-KIRA has the 
potential to produce new insights in the functional properties of the circulat-
ing IGF system in relation to human aging, health and disease.
8.1 The general aim of the thesis; what lies beneath?
One of the major challenges in the fi eld of IGF research is to clarify how IGF-I 
bioactivity is regulated in vivo. At the basis of this challenge lies the fascinat-
ing but highly complex structure of the molecular network that comprises the 
IGF system of which IGF-I is a major determinant. Classically the IGF system 
includes two growth factors (IGF-I and IGF-II), six IGF-binding proteins 
(IGFBP-1 to -6), nine IGFBP-related proteins (IGFBP-rPs), two cell surface 
receptors (IGF-IR and the IGF-II mannose-6-phosphate receptor (M-6-PR) 
and several IGFBP specifi c proteases [1,2]. When compared to other hormone 
systems, IGFs are thus enclosed by a large number of regulatory proteins, 
suggesting tight and complex regulation of their actions.
In addition to the sophisticated structure of the IGF system itself, a good 
insight in the regulation of IGF-I bioactivity in vivo is further complicated 
by the direct or indirect interactions between the IGF system and other hor-
mones/factors. These interactions could have various impact on IGF-I bioac-
tivity. One of the most striking examples is the interaction between IGFs and 
insulin (actions), which is in part due to the structural and functional overlap 
between IGFs and insulin including those of their cognate receptors. From 
an evolutionary point of view - IGFs and insulin can be interpreted as being 
complementary players in one large biological functional system. 
IGF-I immunoassays: The history of the development of assays with the 
aim to estimate IGF-I bioactivity in vivo has followed a process that is highly 
comparable to that for other (endocrine) factors. The last thirty years the main 
focus in the design of IGF-I assays has been primarily on the highly specifi c 
and accurate determination of the circulating ligand concentration. This has 
been performed by means of sophisticated immunological methods and by 
use of highly specifi c (monoclonal) IGF-I antibodies that show little to no cross 
reactivity with IGF-II and (pro)insulin. Nowadays these IGF-I immunoassays 
are used widely in daily clinical routine as a tool to screen for, to diagnose 
and to evaluate treatment of GH disorders (e.g. acromegaly and GHD) [3-7]. 
Although the type of technique applied in IGF-I immunoassays has evolved 
from competitive binding strategies (IGF-I RIA) towards two antibody capture 
techniques (IRMA, CLIA), their underlying ‘ligand based’ design has not been 
altered. Nevertheless, it should be realized that the presence of IGFBPs in 
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plasma was encountered to negatively infl uence accuracy of IGF-I immunoas-
says. The last, as a result of binding competition that exists between IGF-I 
antibodies and IGFBPs. In order to overcome this interference in IGF-I immu-
noassays a set of various pre-analytical methods have been developed serving 
the general aim of complete IGFBP removal and/or inhibition of their IGF-I 
binding capacities. Indeed, from a technical point of view this has resulted in 
highly specifi c assays for measurements of total circulating IGF-I levels. How-
ever, not all sample preparation methods effi ciently remove all IGFBPs or BP 
fragments, and there is currently no reference method for IGF-I measurement 
against which these IGF-I assays can be calibrated [8].
In line with the idea that the circulating ligand concentration is a direct 
derivate of hormone activity, results of total IGF-I immunoassays are gener-
ally interpreted as good estimates of circulating IGF-I bioactivity. However, in 
the paragraph that follows several arguments will be discussed why the IGF-I 
KIRA probably refl ects IGF-I bioactivity better than (immunoreactive) total 
IGF-I levels: 1. Although occurring in large quantities in the circulation (up to 
100 nM), over 99% of IGF-I is bound to IGFBPs. This means that only a small 
amount of circulating total IGF-I is actually in a free (uncomplexed) form. Only 
free IGF-I is assumed to be bioactive, as being available for IGF-IR binding. 
In this respect, immunoassays that measure total IGF-I levels probably do not 
provide information about the direct bioavailability of IGF-I at the receptor 
level. Indeed, this given course has lead to the development of immunological 
methods to measure free IGF-I (in line with e.g. measurements of free estro-
gens/androgens and free thyroid hormones). Although the rational of measur-
ing free IGF-I has been questioned, it has been shown that free IGF-I can 
give biologically meaningful information which could not be established by 
measurement of total IGF-I. In healthy fasting individuals Chen et al. showed 
that free IGF-I but not total IGF-I had a reciprocal relation with increasing 
GH levels, suggesting free rather than total IGF-I levels as determinant of 
the negative feedback loop on GH release [9]. 2. In addition to IGF transport 
functions and protection from degradation, IGFBPs are important modulators 
of IGF system activity [10]. Both inhibitory as well as potentiating effects of 
IGFBPs on IGF actions have been reported. Though, as a consequence of 
their design the infl uence of IGFBPs is eliminated in IGF-I immunoassays. 
Therefore these assays do not detect and thus ignore the modifying effects of 
IGFBPs and/or proteases on IGF-I bioactivity. Thus, the concession made in 
IGF-I immunoassays (IGFBP removal) to guarantee high assay accuracy may 
lead to loss of biological information on how IGF-I bioactivity is regulated in 
vivo. 3. Another argument aims at the possibility of the limited value of single 
Michael BW2.indd   192 27-11-09   11:12
Conclusions and General Discussion 193
immunological measurements of IGF-I (or other members of the IGF system) 
in relation to IGF-I bioactivity. Due to the complex structure of the IGF system 
it is diffi cult to understand and defi ne what impact individual variability in 
circulating levels of IGF-I and/or IGFBPs eventually have on overall IGF-I 
bioactivity, since this is dependent on the context of these changes in relation 
to other determinants of IGF bioactivity. Theoretically changes in circulating 
total IGF-I levels can but do not necessarily lead to variation in bioactivity, 
since they could also represent a compensatory mechanism in order to keep 
hormone bioactivity unchanged refl ecting system redundancy. Thus, although 
in several pathological conditions (DM type 2, CVD, cancer) relative changes 
in the composition of the IGF system have been recognized, the degree of 
the actual impact of these changes on IGF-I bioactivity itself is not known. 
4. IGF-I immunoassays only determine the immunoreactive properties of the 
IGF-I molecule, rather than its actual biological effect. Theoretically, frag-
ments of the IGF-I molecule that are not recognized by IGF-I antibodies could 
(still) be biologically active. Or vice versa, fragments of IGF-I that have no 
biological effects could still harbor epitopes that are bound by IGF-I antibod-
ies and thus measured. 5. Antibody interactions can be disturbed by presence 
of heterophilic antibodies in serum, resulting in falsely higher or lower total 
IGF-I levels. Although this phenomenon has been well described for several 
immunoassays (e.g. for thyroid stimulating hormone (TSH) and luteinizing 
hormone (LH)), for IGF-I immunoassays this has not. Here, in chapter 5, we 
described the fi rst case in the literature in which falsely low total IGF-I levels 
were measured due to the presence of heterophilic antibodies. As the IGF-I 
KIRA was not affected by the presence of heterophilic antibodies we demon-
strated that no effects on IGF-I bioactivity were present. This study therefore 
nicely shows the consequence of methodological differences between IGF-I 
immuno- and bioassay. 
Of note, it must be clear to the reader of this thesis that it is not the aim of the 
author to undermine the use of immunoassays to determine circulating levels 
of IGF system parameters. Conversely, IGF-I immunoassays (in combination 
with others designed for IGF-II and IGFBPs) have indeed yielded important 
and meaningful information about the IGF system in general. Nevertheless, 
today’s visions, ideas and knowledge about the function of the circulating 
IGF system in health and disease are (almost) completely dictated by informa-
tion gathered by use of a single type of method (immunoassays). As is the 
case for almost every method, immunoassays have limitations, and within 
their strength a weakness may be enclosed; When using immunoassays, con-
cessions are made to the original structure of the IGF system (as discussed 
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above), to guarantee full accessibility of highly specifi c antibodies to respec-
tive targets of interest. This could lead to both loss of information enclosed in 
the regulatory network of the IGF system itself and misinterpretation of data. 
Recognition and acceptance of this limitation however also creates a new 
fi eld to study the possible added value of alternative methods to measure IGF 
system activity next to (and not instead of) IGF-I immunoassays and others. 
Last has been the general aim and drive using the IGF-I KIRA method in the 
studies included in this thesis.
The elegance of the IGF-I KIRA is that it is designed to detect IGF-IR activity 
in a biological system of human origin without interrupting the physiological 
structure (and thus most likely function) of the IGF system [11].
8.2 Performance and downscaling of the IGF-I KIRA
The IGF-I KIRA employs a two-plate system, one (plate 1) for cell culture 
and stimulation of intact human 293 EBNA cells transfected with cDNA of the 
human IGF-IR, followed by receptor solublization, and one (plate 2) for spe-
cifi c capture and analysis of IGF-IR phosphorylation status by ELISA [11,12]. 
Sensitivity and specifi city: Compared to the IGF-I KIRA developed by 
Sadick et al., which uses untransfected MCF-7 cells [12], the IGF-I KIRA uses 
IGF-IR tranfected 293 EBNA cells and shows higher sensitivity and specifi city 
for IGFs, especially for IGF-I. Chen et al. reported that the sensitivity of the 
IGF-I KIRA for IGF-I was 0.08 µg/L which equals 10.4 pmol/L. In addition 
the standard curve was shown to be best fi tted by a linear model between 
0.1 – 10 µg/L (13.0 – 1370 pmol/L). At our laboratory we were able to replicate 
these fi ndings. Concentrations of recombinant IGF-I used in standard curves 
in the studies presented in our studies ranged from 62.5 – 1000 pmol/L. Con-
cerning assay sensitivity, the lowest concentration used in IGF-I standards 
(62.5 pmol/L) gave results that easily exceeded those of non-stimulated cells, 
serving as non-specifi c background. We also found a linear relationship of the 
observed points within the specifi ed concentration range of IGF-I standards, 
which covered over 99% of all measured serum samples in which circulating 
IGF-I bioactivity was obtained (Figure 1A).
Since the IGF-IR can also bind IGF-II and insulin no absolute specifi city for 
IGF-I was to be expected. Specifi city for IGF-I was reported about 10- and 
200-fold higher for IGF-I than for IGF-II and insulin, respectively. Figure 1B 
shows the relative contribution of recombinant IGF-II to the IGF-I KIRA at 
equal concentrations measured at our laboratory. Insulin was also tested but 
showed no activity within this concentration range (data not shown).
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Accuracy: For the IGF-I KIRA in MCF-7 cells intra- and inter-assay coef-
fi cients of variation (respectively CVintra and CVinter) were studied by Sadick 
et al. for samples with relatively low (∼1.10 ng/mL or ∼151 pmol/L), mid 
(∼5.3 ng/mL or ∼693 pmol/L) and high (∼22.3 ng/mL or ∼ 2914 pmol/L) IGF-I 
bioactivity. They found CVintra of 7.2%, 5.0% and 9.5% (n=24) and CVinter 
of 10.5%, 6.5% and 11.8% (n=11) for the three samples tested respectively. 
Chen et al. found for the IGF-I KIRA in transfected 293 EBNA cells that CVs of 
IGF-I standards on 1 plate averaged 7%. Furthermore, CVinter was estimated 
by repetitive measurements of a (non-specifi ed) control sample assayed 34 
times on 6 different days and averaged 13%. Together, these fi ndings suggest 
that the IGF-I KIRA’s precision is an appropriate method to measure IGF-I 
bioactivity in larger settings, e.g. in population based studies. One could 
argue, however, that the calculated CVintra and CVinter in these studies were 
based on relatively low numbers, meaning that the experiments from which 
these data were obtained could have been performed in a small number of 
cell culture passages thereby limiting between assay variability. In the last fi ve 
years, however, several studies have been performed in which IGF-I bioactiv-
ity was determined using the IGF-I KIRA with acceptable sample numbers, 
including those presented in this thesis. From these studies the conclusion 
can be drawn that the originally estimated CV’s also hold in larger settings. 
Of note, although the absolute number of counts per second obtained in the 
read-out system did vary between assays that were run at different time points 
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Figure 1: (A) IGF-I KIRA reference line as used in the studies in this thesis. Within the 
range of 63 – 1000 pMol/L the reference showed a lineair relationship with the num-
ber of counts. Serum levels of almost all samples measured were within this range. (B) 
Comparison of equal concentrations of recombinant IGF-I and IGF-II in the IGF-I KIRA. At 
a concentration of 1*10-9 Mol/L (1000 pMol/L) IGF-II reached about 11-15% of activity of 
IGF-I, while it reached equal activity at 1*10-8 Mol/L when compared to IGF-I at 1*10-9.
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(e.g. different weeks), this did not infl uence assay accuracy. Retrospectively, 
we can also conclude that the (arbitrary) chosen level of acceptance (<10%) 
for intra-sample variation of duplicates has been reasonable. Using this cut-off 
value, in our hands, the IGF-I KIRA showed 92-96% effi ciency in the studies 
described, meaning that about 4-8% of samples when measured in duplicate 
showed over 10% variation per run and therefore had to be measured again. 
For a bioassay this level of effi ciency is remarkably high. Explanations for the 
4-8% failure are most probably multifactorial, being both of technical origin 
(cell culture techniques, antibody coating/binding, plate blocking, sample 
storage (conditions) etc.) and of human origin (errors made in sample dilu-
tions or sample misplacement on plates during stimulation, learning curves 
etc.). In chapter 2 we described that CV of the IGF-I KIRA within the study 
population (a standardized measure of relative spread in data) was compa-
rable and actually slightly lower than that for IGF-I immunoassays. Because 
a lower magnitude of this variability is considered to refl ect better reliability 
(precision) of measurements, this suggests that the IGF-I KIRA in this respect 
performs at least as well as IGF-I immunoassays. When one considers that 
the IGF-I KIRA assay is actually both a bioassay and an ELISA, and that in its 
current form most of the methodology is done by hand, the level of precision 
that can be reached is quite remarkable.
Assay downscaling: In the original design of the IGF-I KIRA a 24 well cell 
culture plate (plate 1) was used. Chen et al. validated the IGF-I KIRA as such 
for this measurement of IGF-I bioactivity in human serum. However, when 
using a 24 well plate, this design largely limited the number of unknown 
serum samples that could be run per assay when all measurements, including 
those of standard preparations and control samples, should be performed in 
duplicate. Measurements of IGF-I bioactivity in this thesis were performed 
by use of 48 well culture plates. Using 48 well plates and starting with half of 
the number of plated cells results did not differ when compared to 24 well 
plates (Figure 2). This means that no information was lost due to downscal-
ing of the assay as such. Next to the ability of sample number enlargement 
per assay, this adaptation had also positive effects on the cost effectiveness 
of the IGF-I KIRA. Volumes of needed materials and serum could be largely 
reduced. The use of 96 well plates was also evaluated, but this encountered 
some problems as assay sensitivity for IGF-I was less than when using 24 or 
48 wells plates (data not shown). This is probably due to the lower number 
of cells and thus of IGF-IRs. It is in line with the fi nding of Chen et al, who 
reported the use of transfected cells probably explained that higher sensitivity 
could be reached than when using cells with endogenous IGF-IR expression. 
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In addition, because cell stimulation in the IGF-I KIRA is done by hand, higher 
sample variability was found when using 96 wells plates. In addition, since 
the stimulation of cells in the IGF-I KIRA occurs only during 15 minutes, after 
which the cells are lysed, the use of 96 wells introduced diffi culties in a good 
time management of all procedures. 
8.3 IGF-I bioactivity in relation to health and IGF-I immunoassays
In chapter 2 we have described a study with the aim to determine normal val-
ues of circulating IGF-I bioactivity. These age-specifi c normative ranges can 
be helpful in future to interpret whether IGF-I bioactivity is normal, increased 
and/or decreased in subjects with pathological conditions like acromegaly 
and GH defi ciency. Circulating IGF-I bioactivity was measured in a population 
which consisted of 426 healthy blood donor individuals. In this population 
Ranke et al. earlier had determined normal values for total IGF-I levels using 
fi ve different immunoassays, three IGF-I immunometric asssays and two IGF-I 
RIAs. Our second aim was to analyze correlation coeffi cients between IGF-I 
bioactivity and measurements of total IGF-I, in order to estimate to which 
degree IGF-I bioactivity measured by the IGF-I KIRA can be explained by 
immunoreactive measurements of total IGF-I. 
Concerning assay outcomes, we found that distribution of circulating IGF-I 
bioactivity came close to a normal Gaussian curve which contrasted to the 
distribution of total IGF-I levels measured by all IGF-I immunoassays. This 
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Figure 2: IGF-I KIRA outcomes for serial dilutions of recombinant IGF-I and serum sam-
ples. (A) outcomes using a 24 well culture plate; 400.000 cells per well were cultured on 
day 1 of the assay. (B) outcomes using a 48 well culture plate; 200.000 cells per well were 
cultured on day 1 of the assay. Outcomes for serum samples of a patient with acromegaly 
(ACRO) and of a normal control subject did not differ from each other when IGF-I bioactiv-
ity levels were calculated by use of the respective reference.
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means that while levels of total IGF-I are not, circulating IGF-I bioactivity is 
normally distributed in the healthy population. Although one might expect 
hormone activity to be normally distributed in the population, this was previ-
ously not demonstrated by use of immunoassays for total IGF-I. In the study 
presented in chapter 3 circulating IGF-I bioactivity also showed a normal 
distribution in the study population of elderly men, while such distribution 
was absent for total and free IGF-I. Thogether these fi ndings suggest that the 
IGF-I KIRA more closely resembles the physiological IGF system activity in 
vivo than do immunoreactive measurements of total and free IGF-I.
As expected correlations observed between circulating IGF-I bioactivity 
and total IGF-I levels reached signifi cance (p < 0.001), however r2 ranged from 
0.25 to 0.31 in the study described in chapter 2. This means that in general 
70-75% of the variation in IGF-I bioactivity could not be explained by levels of 
total IGF-I, being independent of the type of IGF-I immunoassay used.
In chapter 3 we also observed that the correlation between bioactive and 
free IGF-I was signifi cant, however it was lower than that observed for total 
IGF-I. Similar correlation coeffi cients between IGF-I bioactivity and total IGF-I 
and free levels have been reported by others, although some variability is to 
be expected due to differences in the populations studied [13]. Of interest in 
this setting are observations by Karl et al., who demonstrated that in healthy 
young women immunoreactive levels of total and free IGF-I in combination 
with those of IGFBP-1, 2 and 3 could explain on average only 61% of the 
variation observed in circulating IGF-I bioactivity in a multiple regression 
model [14]. Interestingly, other factors like age, sex-hormones, selenium and 
alcohol intake also were associated with circulating IGF-I bioactivity. From 
these fi ndings the conclusion can be drawn that circulating IGF-I bioactivity 
differs considerably from measurements of immunoreactive IGF-I (or other 
IGF related parameters) and thus cannot (always) be estimated by these 
methods. 
Another interesting fi nding, described in chapter 3 is that bioactive IGF-I 
levels were found to be signifi cantly higher than levels of free IGF-I and that 
correlation between these two measures is relatively poor. This fi nding is 
supported by others [15]. Theoretically one might expect that both measures 
determine that part of total IGF-I that comes available for receptor activation. 
Several arguments however support that the differences found could actually 
be realistic. First, the IGF-I KIRA not only determines the part of circulating 
IGF-I that is in a free form and thus able to bind the IGF-IR, but it is also sensi-
tive to the part of IGF-I that actively (due to protease activity or IGFBP (cell-) 
binding) or passively (due to dissociation) comes free from IGFBPs. Second, 
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measures of free IGF-I do only represent the immunoreactive properties of 
unbound IGF-I molecules harboring the epitope required to be bound by the 
specifi c IGF-I antibody and thus not whether this molecule also has bioactive 
properties. In addition, as argued before not only IGF-I but also IGF-II is able 
to activate the IGF-IR which next to IGF-I can contributes to the IGF-I KIRA 
output (see also next alinea) [11].
In line with circulating total IGF-I levels we found that circulating IGF-I 
bioactivity declined with age in both men and women. Interestingly, we 
observed that the fraction of IGF-I bioactivity over total IGF-I increased with 
age (chapter 2: fi gure 5A-E). This observation suggests that the degree of 
decline of total IGF-I levels with age is not translated in proportion to that 
of IGF-I bioactivity. Explanations for this observation could be at the level 
of difference in GH dependency, adaptation of IGF-I bioactivity to increas-
ing insulin resistance with age or the relative increase of the contribution of 
IGF-II to the IGF-I KIRA outcome with age as is described in chapter 2. A 
notable remark on this is however that our cross-sectional study design does 
not refl ect the rate of individual changes in IGF-I bioactivity with aging. 
Age is a major determinant of circulating total IGF-I concentrations, with a 
decrease in circulating total IGF-I concentrations with aging. Part of this decre-
ment is believed to be due to the known age-related decrease in GH secretion 
[16]. However, circulating IGF-I becomes less and less GH-dependent with 
age, ultimately leading to a situation in which circulating IGF-I concentrations 
become more and more infl uenced by nutrition, liver function, sex steroid 
levels and insulin [17]. One also has to consider that circulating concentrations 
of IGF-II are generally around two- to four-fold higher than those of IGF-I in 
adults and IGF-II levels most likely do not decline with age [18]. As both IGFs 
appear to activate the IGF-IR, IGF-II can potentially elicit the same actions 
as IGF-I at the cellular level. These arguments could substantially affect the 
slope of decline with age for circulating IGF-I bioactivity. Interesting are also 
the fi ndings of Frystyk et al. who reported that although absolute measures 
of total and bioactive IGF-I where lower, percent IGF-I bioactivity was higher 
in obese subjects compared to both lean and overweight subjects [19]. It is 
well-known that with increasing age risk of obesity and insulin resistance 
increases.
A fi nding of major interest is the suggestion that there exists a sexual dimor-
phism for circulating IGF-I Bioactivity (Chapter 2). In women we found a 
remarkable profi le for IGF-I bioactivity levels with age, as circulating IGF-I 
bioactivity dropped disproportionally around the age range of 55. This fi nd-
ing suggests that IGF-I bioactivity is directly or indirectly positively driven 
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by sex-hormones (e.g. estrogens or progestagens). This suggestion should 
be presented with appropriate caution, however, because the cross-sectional 
design of the study does not allow to claim causation. Furthermore there was 
a lack of information in the individuals studied about the use of oral estro-
gens and/or menstrual status in the study population. We could not detect a 
direct effect of estrogens on IGF-I bioactivity; when estrogen was added at 
physiological circulating concentrations (in females) to male serum or to the 
reference this did not differ from controls (chapter 2: Table 4). However, a 
couple of studies demonstrated increased serum total IGF-I concentrations 
during the luteal phase of the menstrual cycle, possibly concomitant with 
elevated estradiol concentrations [20,21]. Second, in case of measures of IGF-I 
bioactivity by the IGF-I KIRA Karl et al. recently reported signifi cant positive 
associations with circulating levels of estradiol and progesterone in young 
healthy women [14]. These fi ndings strengthen our own suggestions, linking 
IGF-I bioactivity to female sex-hormones. It is not unthinkable that in men 
testosterone is also associated with circulating IGF-I bioactivity and that this 
results in a similar decline later in life. This is, however, speculative and at this 
moment we do not have any data to support this suggestion.
In chapters 6 and 7 we have described results of circulating IGF-I bioactiv-
ity in elderly individuals aged 55 years and over that were included in the Rot-
terdam study. Interestingly, mean circulating levels of IGF-I bioactivity were 
again higher in women than in men. Furthermore, circulating IGF-I bioactivity 
decreased signifi cantly with age in men, but it did not in women. It is well 
known that the growth hormone (GH)/insulin-like growth factor (IGF)-I axis 
exhibits gender-specifi c differences. One of these differences is the pattern 
of the pulsatile GH release by the pituitary [22,23]. These gender-specifi c 
differences may be related to multiple factors that occur during aging and 
that strongly infl uence neuro-endocrine activity of the GH-IGF-I axis. Factors 
like visceral fat, accompanying changes in body composition during aging, 
varying sex-steroid hormone concentrations and unequal physical fi tness may 
result in gender-specifi c differences in the activity of the GH-IGF-I axis and 
thereby IGF-I bioactivity. Of interest are results of IGF-I bioactivity reported 
by Karl et al. that indicate factors involved in the observed sex differences in 
IGF-I bioactivity [14]. The authors reported that in contrast to measures of free 
and total IGF-I circulating IGF-I bioactivity in young women was positively 
associated with percent body fat, a parameter which is characterized by sexual 
dimorphism. It has been shown that cultured human adipocytes secrete sub-
stantial amounts of IGF-I, IGF-II and IGFBP-3 into the cell medium [24]. Thus, 
it is conceivable that part of the circulating IGFs and IGFBPs originate from 
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adipose tissues and that thus their contribution to the circulating pool might 
substantially differ between the sexes.
8.4 IGF-I bioactivity in relation to human longevity and cardiovascular disease
The insulin/IGF signaling pathways have been linked to aging and longev-
ity. From studies obtained in nematodes, fl ies and rodents direct and indirect 
evidence exists that low insulin/IGF signaling may result in extended life 
expectancy. Findings in humans, however, are controversial and studies are 
limited or show indirect evidence due to ethic considerations. A number of 
epidemiological studies suggest that low-IGF-I activity, at least at advanced 
age, is not associated with longevity in humans [25]. We speculated that, due 
to its different methodological character when compared to IGF-I immunoas-
says, the IGF-I KIRA might be an interesting tool to study circulating IGF-I 
bioactivity in relation to human longevity.
In chapter 3 we have described a prospective study in which we studied 
circulating IGF-I bioactivity next to free and total IGF-I in relation to survival in 
elderly men. We found that circulating IGF-I bioactivity measured by the IGF-I 
KIRA showed a profi le in relation to survival, that differed considerably from 
that obtained by free and total IGF-I. We found relatively high, rather than low 
circulating IGF-I bioactivity to be related with longer survival in elderly men. 
Interestingly, in a sub-analysis in which we stratifi ed for presence or absence 
of cardiovascular disease (CVD) and/or evidence for a high CVD risk profi le 
based on CRP levels (a measure of subclinical systemic infl ammation), we 
observed that low circulating IGF-I bioactivity was an independent risk factor 
for mortality especially in individuals with CVD and/or a high infl ammatory 
risk profi le.
The precise interactions of all factors (e.g. genetic diversity/ DNA damage 
(repair), food, environment and disease) that play a role in the process of 
organism aging and longevity is extremely complex. In humans this process is 
even more diffi cult to study due to our capacity to actively infl uence several 
of such factors. On one hand this capacity could create substantial bias. On 
the other hand, however, some of these infl uences might also help to gain 
more insight into the (pathological) processes that determine human longev-
ity, and of the biological factors/systems that play a role in these processes. 
To illustrate this with an example: there exists both a well-known relationship 
between smoking and risk of death from CVD by atherosclerosis as well as 
from cancer by DNA damage. Smoking is probably not only a causative factor 
in these relationships but mainly acts as a modulator, accelerating two major 
processes that determine human survival, namely vascular infl ammation/
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atherosclerosis giving rise to a high risk to die from CVD and DNA damage 
resulting in death from cancer or more progressive aging. 
When this reasoning is applied to our fi ndings than how should we inter-
pret our results in relation to the role of IGF signaling in relation to human 
longevity? We speculate that IGF-I bioactivity could substantially infl uence 
human survival by modulating / limiting the risk of death by CVD. Due to 
factors specifi ed to (changes in) human lifestyle CVD is a major determinant 
of human survival, especially through the process of atherosclerosis (an 
infl ammatory disease of the artery wall) [26-28]. Although results of the IGF-I 
KIRA may not necessarily refl ect IGF-I bioactivity at the local tissue level, a 
notable exception to this is formed by the vascular endothelium, however. 
This tissue is in direct contact with the blood from which IGF-I bioactivity is 
determined. Indeed IGF-I has been suggested to have strong vascular protec-
tive properties [29]. A potential mechanism by which IGF-I could prevent CVD 
is the maintenance of normal NO bioavailability and consequent activation of 
anti-atherogenic mechanisms to maintain normal function of vascular endo-
thelium cells. As an additional mechanism IGF-I also activates cell survival 
signaling pathways and has been shown to stimulate stem cell survival and 
their homing to damaged tissue, including that of endothelial progenitor cells 
to the heart and vascular endothelium [30-32]. Through such mechanisms, indi-
viduals with a relatively high circulating IGF-I bioactivity might be relatively 
protected from endothelial damage by infl ammatory processes and thus have 
a lower risk of CVD than those with low IGF-I bioactivity. A third mechanism 
that could be of signifi cance is insulin resistance. There is increasing evidence 
that preservation of insulin sensitivity is one of the essential conditions to 
maintain health and promote longevity in humans. Most striking evidence 
comes from longitudinal studies in centenarians [25,33]. In general, the preva-
lence of insulin resistance increases with age and thus has a relatively high 
prevalence in the elderly. It has been shown that insulin resistance is strongly 
associated with risk of CVD [28]. Therefore a mechanism that might explain or 
might have contributed to the fi ndings in this study is the effect of circulating 
IGF-I bioactivity on insulin sensitivity. It could thus be that relatively high 
IGF-I bioactivity represent individuals that can still overcome or at least in 
part compensate for insulin resistance, whereas those with relative lower 
circulating IGF-I bioactivity have lost this ability. In this respect it should be 
remembered that IGFs have some biological actions, which in some aspects 
are indistinguishable from those of insulin. IGF-I has also been shown to be a 
determinant of insulin sensitivity. However, in the study described in chapter 
3 we did not determine insulin sensitivity. (Note: In chapter 6 we presented 
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a study in which we focused on the relationship between IGF-I bioactivity, 
insulin sensitivity and the metabolic syndrome (see paragraph 8.5 below)).
We realize that it cannot be claimed from the study described in chapter 
3 that circulating IGF-I bioactivity is substantially involved in the process 
of human aging (longevity) as such. Our study stands on its own, since no 
previously performed other study has studied circulating IGF-I bioactivity in 
relation to human survival. As stated earlier, it remains to be seen whether 
reduced IGF-I bioactivity is an endocrine contributor to mortality risk or an 
epiphenomenon related to overall health/resistance to infl ammation. Another 
aspect is that the study participants were all men. Whether this relationship is 
also present in women, however, is at present unknown.
Low circulating total IGF-I levels have been associated before with higher 
risk on CVD in longitudinal studies [34]. However in our study direct com-
parison between levels of immunoreactive IGF-I and IGF-I bioactivity clearly 
showed a different profi le with human survival and risk on CVD. This suggests 
that bioactive IGF-I probably is more sensitive than immunoreactive param-
eters to study the IGF system in relation to these outcomes. Of interest in this 
respect is a recently published prospective study by Friedrich et al. which 
supports our fi ndings. These authors showed that after 8.5 years of follow-up 
in 1988 men that men with low total IGF-I levels at baseline compared to men 
with high total IGF-I levels at baseline had an almost 2-fold higher risk of 
all-cause mortality (IGF-I: HR 1.9 (1.3-2.7) and CVD mortality (IGF-I: HR 1.9 
(1.0 -3.71). This association was not found in 2069 women.
We believe that the fi ndings in our study could be of major interest since for 
the fi rst time they provide direct insights in the function of the circulating IGF 
system in relation to human survival. In addition, these fi ndings could be of 
importance in the fi eld of CVD. Hence, future studies are needed to replicate, 
expand and clarify these fi ndings into further detail. This in order to answer 
the question whether and how circulating IGF-I bioactivity may infl uence the 
risk of death from CVD (in man). 
8.5 IGF-I bioactivity as a marker of nutritional status in chronic kidney disease
Nutrition, in particular calorie and protein intake, is known to affect the IGF 
system [35-37]. From this perspective IGF-I could be an interesting protein to 
study as a marker of nutritional status. Chronic renal failure (CRF) is a disease 
prone for development of protein and energy malnutrition (PEM). Especially 
individuals with CRF on dialysis are prone to develop PEM [38]. Several fac-
tors are thought to contribute to PEM in CRF, e.g. infl ammation, metabolic 
acidosis, uremia, protein loss and anorexia [39,40]. To compensate for PEM in 
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CRF patients dialysate solutions that contain glucose (G) and/or aminoacids 
(AA) have been studied both in the fasting and in the fed state [41,42]. In CRF 
patient on dialysis circulating total IGF-I has been proposed as a valid marker 
of (mal) nutrition in subjects on dialysis [43-45].
The IGF system and the kidney infl uence each other’s function. IGF-I is 
known to increase renal glomerular fi ltration rate and plasma fl ow [46]. In 
addition, the GH-induced positive phosphate balance by enhanced renal 
absorption, is thought to be mediated entirely by IGF-I [47]. Most studies that 
have focused on circulating total IGF-I levels in CRF found normal or even 
elevated levels in subjects with CRF [48]. It is thought however that in CRF 
IGF-I bioavailability is actually decreased, thus opposite to what total IGF-I 
levels might suggest [49]. Interestingly – about three decades ago - Phillips et 
al. reported when using a ‘classic’ IGF-I bioassay that circulating IGF-I bioac-
tivity was low in adults with CRF, and they suggested ‘somatomedin inhibitory 
factors’ to be present in the blood in excess [50,51]. When compared to healthy 
controls Frystyk et al. found in non-dialyzed CRF patients that mean serum 
free IGF-I levels were signifi cantly decreased (-53%), whereas levels of total 
IGF-II, IGFBP-1 and IGFBP-2 were increased (40%, 546%, 270%, respectively) 
[52]. Total circulating IGF-I levels were unaffected, as were intact IGFBP-3 
levels. Of note, there were however increased levels of IGFBP-3 fragments 
in CRF patients, suggesting higher IGFBP protease activity. Together these 
fi ndings support the suggestion that impaired kidney function severely affects 
IGF system activity. 
In chapter 4 we described results of circulating IGF-I bioactivity and total 
IGF-I measurements performed in a randomized cross-over study in 12 
patients who were on continuous ambulatory peritoneal dialysis (CAPD) [42]. 
Two different dialysis solutions were used; either enriched with glucose (G) 
or glucose plus amino acids (AAG). IGF-I bioactivity and total IGF-I were 
measured at baseline and after the respective dialysis program, about 9 hours 
later. Previously the metabolic effects of AAG and G dialysate were evalu-
ated in this study. It was observed that the AAG dialysate improved protein 
metabolism in the fed state [42]. 
While mean circulating total IGF-I levels in CAPD subjects were in the 
upper half of the normal range with good (SGA A) nutritional status and even 
exceeding the normal range in 4 subjects with moderate (SGA B) nutritional 
status, mean circulating IGF-I bioactivity was in the lower half of the normal 
range. Based on the observed circulating total IGF-I levels one would expect 
relatively high or at least unchanged IGF-I activity in CAPD subjects, when 
compared to healthy controls. Our fi ndings on circulating IGF-I bioactivity 
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confi rm however what has been previously suggested by Philips et al. [50], 
namely that circulating IGF-I bioactivity is low rather than high in CRF sub-
jects. This better fi ts the clinical phenotype of CRF subjects, which are gener-
ally characterized by an underfed status.
The question rises how to explain the discrepancy between measures of 
total and bioactive IGF-I? It could be that total IGF-I levels are falsely elevated 
in CRF subjects due to interference of IGFBPs in the IGF-I immunoassays. On 
the other hand levels of total IGF-I may be truly elevated, but as a result of 
hampered kidney function next to IGF-I also IGFBP clearance is sub-optimal 
eventually leading to a relative low bioavailability of IGF-I. Both explanations 
are in line with fi ndings of Frystyk et al. described above [52]. In addition, 
although Frystyk et al. observed in CRF patients that there might be a higher 
IGFBP protease activity, our results show that this does lead to a relatively 
high IGF-I bioactivity in these subjects, as might be expected. An explanation 
could be that protease activity in these subjects is indeed increased, but that 
this does not result in effective release of IGFs from IGFBPs. Another explana-
tion could be that there is no increased IGFBP protease activity  in vivo in 
these patients, but that this observation is an artifact due to sample collection, 
storage and preparation methods in vitro. Since we did not measure IGFBP 
fragments in this study we do not know whether an altered protease activity 
was present in our study participants.
Circulating IGF-I bioactivity did not differ between SGA A and B. Most 
probably this is explained by the low number of SGA B patients, since our 
study was not adequately powered to detect differences between both SGA 
categories. In addition, SGA may not reliably identify CRF patients with an 
abnormal nutritional state and misclassify a large number of subjects [53]. 
No differences in circulating total IGF-I levels could be found after AAG 
nor G dialysis when compared to baseline measures. [54]. In contrast, when 
using the IGF-I KIRA we were able to detect acute increases in circulating 
IGF-I bioactivity in CRF patients on CAPD upon AAG and G dialysis. For AAG 
dialysis this difference reached statistically signifi cant difference, whereas the 
lack of a signifi cant rise in IGF-I bioactivity after G dialysis is probably due to 
the small number of patients. 
The observed differences in the dynamics of circulating total and bioactive 
IGF-I levels in response to nutritional intake are of interest. Our study suggests 
that IGF-I bioactivity even in the fed state can be readily changed (refl ecting 
system dynamics) having a causative relationship with AAG uptake. It also 
shows that the IGF-I KIRA is sensitive enough to observe small differences in 
IGF-I bioactivity which might have biological importance and also enlarges 
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insight in the system functionality. The changes in IGF-I bioactivity were how-
ever independent on variability in levels of total IGF-I upon nutritional intake. 
This means that other dymamical changes upon nutrition in the IGF system 
are responsible for variability in IGF-I bioactivity. We think that changes in 
levels and phosphorylation status of IGFBPs and/or IGFBP protease activity 
upon nutritional intake are most likely responsible for the changes in IGF-I 
bioactivity. One of the mechanisms that could be involved is the insulin driven 
down regulation of IGFBP-1 upon nutrition. 
An advantage of our study is its randomized cross-over design, enlarging 
statistical power by limiting inter-individual variance. Second, implementation 
of measurements in time enabled us to study causative relationships. Third, 
the short time schedule during which this study was performed also limited 
intra-individual variance (e.g. day to day variance, or bias due to unknown 
infection or progression of state of disease). On the other hand, because of 
the short time period no conclusions can be drawn concerning the effects of 
AAG or G dialysis on IGF-I bioactivity in relation to nutritional status and kid-
ney function over time. Prospective data spanning at least several months is 
essential to study this aspect in future. Nevertheless, this is the fi rst study that 
provides a mechanistic insight into the function of the circulating IGF system 
in subjects on CAPD. Our results indicate that in CAPD patients bioactive but 
not total IGF-I is sensitive to acute changes in nutritional intake. 
In conclusion: We believe that levels of total IGF-I may not be informative 
in subjects on CAPD in relation to their nutritional status nor when used as 
a marker of (acute) metabolic responses to nutrition. Total IGF-I levels may 
be falsely elevated and do not well represent the IGF system activity in these 
subjects. In contrast, circulating IGF-I bioactivity may be a new promising 
marker to study in this fi eld of research. 
8.6 IGF-I bioactivity in relation to insulin sensitivity and the metabolic syndrome
8.6.1 IGF-I bioactivity and its relation to insulin sensitivity
The IGF system, GH and insulin are thought to play complementary roles in 
the maintenance of glucose homeostasis. This interplay between GH, insulin 
and IGF-I is, however, complex. IGF-I probably plays an important role to 
balance the well-recognized contrasting metabolic actions of GH and insulin, 
which both affect IGF-I (bioactivity). Hepatic IGF-I production is driven by 
both GH and insulin, whereas IGF-I negatively feeds back on both pituitary 
GH and pancreatic insulin release. In addition, IGF-I is thought to increase 
peripheral insulin sensitivity by both GH-dependent and –independent 
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mechanisms. Furthermore, GH and insulin also regulate levels of circulating 
IGFBPs. GH stimulates hepatic IGFBP-3 production, whereas insulin inhibits 
that of IGFBP-1, and to a lesser degree of IGFBP-2 [10,55,56].
In chapter 6 we described a cross-sectional study in 1036 elderly individuals 
that focused on the relationship between circulating IGF-I bioactivity, insulin 
sensitivity and the metabolic syndrome (MS). A fi nding of interest was that 
mean circulating levels of IGF-I bioactivity progressively rose with increasing 
fasting glucose and insulin levels (and thereby HOMA-IR), while it abruptly 
declined in individuals that met criteria for DM type 2. Although no direct 
causality can be concluded as a consequence of the cross-sectional study 
design, and also no measures of total IGF-I, free IGF-I, IGF-II and IGFBPs 
were performed, these fi ndings might be of value in the fi eld of IGF research 
which concerns the role played by the human IGF system in the pathophysi-
ological process of insulin resistance towards type 2 DM. As stated before, the 
history of this fi eld of research is characterized by controversial outcomes. 
Recently, Rajpathak et al. published a review about this subject, in which the 
authors claim that circulating total IGF-I levels in general have been reported 
normal in subjects with obesity and (pre-)diabetes [57]. However evidence is 
also available that in subjects with type 2 DM circulating total IGF-I levels are 
decreased [58,59]. An explanation for the controversy in literature concerning 
total IGF-I levels may be related to methodological problems to measure IGF-I 
by immunoassays, especially in diabetic subjects. Chestnut et al. evaluated 9 
different IGF-I immunoassays and sample preparation methods using samples 
from healthy donors and from donors with type 1 and type 2 DM [8]. The 
authors reported that assays compared poorly when samples from type 1 and 
type 2 DM were used. Dependent on the IGF-I immunoassay used, levels of 
total circulating IGF-I were high, normal or decreased in subjects with type 1 
or type 2 DM compared to controls. The authors suggested that interference 
by remaining IGFBPs or of their fragments were the cause of the differences 
observed between these immunoassays. These assay differences may explain 
some of the differences seen in the literature on IGF-I levels in diabetes.
For free IGF-I relatively high levels have been found in subjects with type 
2 DM. Thus, in type 2 DM there may be a response to increase free IGF-I 
concentrations to compensate for reduced insulin bioactivity. Unfortunately 
to date very limited prospective data are available. Sandhu et al. found an 
inverse relationship between circulating total IGF-I levels and risk of DM type 
2 [60]. However, the total follow-up time of this study (4.5 years) was rela-
tively short in relation to the developmental process from disturbed glucose 
homeostasis towards DM type 2 (≥10-15 years). Also this study was hampered 
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by a low number of subjects that developed impaired glucose tolerance (IGT) 
(N=44) or DM type 2 (N=7), resulting in low statistical power. IGT and type 
2 DM subjects had to be analyzed together, which might have created bias. 
It can thus be stated that to date suggestive but no hard evidence has been 
provided that links IGF-I clearly to the pathophysiological process of insulin 
resistance and type 2 DM. 
Interesting fi ndings come from studies in which IGFBP-1 was studied in 
relation to glucose homeostasis and risk of DM type 2. In white Europeans 
Cruickshank et al. found a U-shape curve fore mean fasting IGFBP-1 levels in 
individuals with respectively normal (NGT) and impaired glucose tolerance 
(IGT) and DM type 2, with NGT and diabetic subjects having higher fasting 
IGFBP-1 levels than those with IGT [61]. Fasting proinsulin levels were lower 
in NGT individuals and higher in diabetics. Mean circulating total IGF-I levels 
did not signifi cantly differ among individuals with NGT, IGT and type 2 DM. 
In another longitudinal (incident case-control) study performed in Swedish 
white men aged 35-56 years, Lewitt et al. followed individuals for 10 years 
to develop IGT and/or type 2 DM [62]. All subjects had normal oral glucose 
tolerance tests (OGTT) at baseline. Interestingly, baseline levels of IGFBP-1 
appeared to discriminate between individuals that were still NGT (highest) 
and those that developed IGT and type 2 DM (lowest). At 10 years of follow-
up mean IGFBP-1 levels in those who developed DM type 2 rose 32%, up to 
the level in those that still had NGT, whereas in individuals with IGT at ten 
years IGFBP-1 levels did not change. Lewitt et al. concluded that low IGFBP-1 
levels could be used as a predictive marker for risk of DM type 2, whereas 
total IGF-I levels could not.
Although not being studied in a prospective setting, our fi ndings for circu-
lating IGF-I bioactivity in relation to glucose homeostasis is in agreement with 
the prospective observations for IGFBP-1. The profi le in our study observed 
for circulating IGF-I bioactivity in relation to glucose homeostasis and insulin 
sensitivity is inverse to that previously reported for IGFBP-1. This is in line 
with the thought that IGFBP-1 is a modulator of circulating IGF-I bioactivity. 
Although we did not measure IGFBP-1 levels in our study, the decline in IGF-I 
bioactivity in subjects with FG levels > 7.0 mmol/L may be directly related to 
(increasing) inhibitory effects of elevated IGFBP-1 levels on IGF-I bioactivity. 
Our study, however, is the fi rst that provides data on circulating IGF-I bioac-
tivity in relation to glucose homeostasis and insulin sensitivity/resistance. 
The IGF-I KIRA is sensitive to modulations of IGFBPs on IGF-IR activation 
[11,13]. This opens the possibility that the observed alterations in IGFBP-1 
levels in relation to glucose homeostasis are not only a marker of hepatic 
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insulin sensitivity [63], but most likely also affects circulating IGF-I bioactiv-
ity itself. Of note, we can only speculate on this since we did not measure 
IGFBP-1 in our study.
An important discriminative aspect of our study is that we did not only study 
circulating IGF-I bioactivity according to (crude) groups of NGT, IGT and 
type 2 DM, but also (and especially) according to increases of HOMA-IR. An 
advantage of this design is that it enlarges the insight on how IGF-I bioactivity 
is related to the relative degree of insulin resistance. This strategy is in agree-
ment with the generally accepted concept that type 2 DM is an endpoint status 
of a probably decade’s spanning pathophysiological process characterized by 
progressive loss of insulin sensitivity in time. By using HOMA-IR as an indi-
cator of a time-dependent pathophysiological process, one creates a model 
within a cross-sectional study that to some degree shows similarity with that of 
a prospective design. Of course it does not inform about direct causality, but 
it is more informative to gain insight into the (possible) mechanistic adapta-
tions of a biologal system in relation to these pathophysiological processes. 
Essential requirements for this are a large study population, which creates 
enough statistical power to stratify individuals according to subgroups of the 
pathophysiological indicator (in this case HOMA-IR) and the use of a detection 
method that covers the biological system. We think that we met these require-
ments by studying the relation between the IGF system and insulin resistance/
glucose homeostasis, as IGF-I KIRA measurements were performed in more 
than 1000 individuals to assess circulating IGF-I bioactivity.
We believe that the suggestive rise in circulating IGF-I bioactivity with 
increasing HOMA-IR could be part of a compensating mechanism trying to 
overcome insulin resistance through insulin like actions of IGFs on glucose 
uptake and on peripheral insulin sensitivity. A prominent candidate for 
the driving force in this could be insulin itself, by simultaneously stimulat-
ing hepatic IGF-I production and suppressing IGFBP-1 and -2. In addition, 
insulin also appears to be necessary for normal liver responsiveness to GH 
[64]. On the other hand the observed increase of circulating IGF-I bioactivity 
with increasing HOMA-IR could also be the consequence of an compensa-
tory adaptation to an increased IGF-IR resistance. Although this could explain 
the relative increase in mean IGF-I bioactivity in parallel with the increase in 
fasting glucose/HOMA-IR, it does however not explain the abrupt decline in 
IGF-I bioactivity in individuals with type 2 DM. When being independent of 
insulin resistance, one would expect a further (disproportional) increase in 
IGF-I bioactivity (or at least in IGF-I levels) in type 2 DM as is observed for 
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insulin. Our fi ndings thus support the idea that insulin, the IGF system and 
GH are dependent on each other for optimal biological activity/performance. 
The disproportional high fasting insulin levels observed in individuals that 
met criteria for type 2 DM (based on fasting glucose levels >7.0 mmol/L) most 
probably resemble the existence of hepatic insulin resistance (Hep-IR). Hep-
IR has been associated with reduced hepatic insulin clearance [65], being one 
of the mechanisms leading to chronic hyperinsulinaemia. Chronic hyperinsu-
linaemia has been shown to reduce GHR expression and signaling in the liver 
and has also been associated with increased IGFBP-1 levels [66]. In support 
with this are the fi ndings by Chen et al. in patients with liver cirrhosis. They 
hypothesized that the lower fasting levels of bioactive IGF-I together with 
the 2-fold increase in IGFBP-1 levels in these patients in coexistence with 
an abnormal glucose metabolism was due to liver cirrhosis-related insulin 
resistance [13].
The abrupt decline in circulating IGF-I bioactivity observed in diabetics in 
our study are consistent with the rise in IGFBP-1 levels after development of 
type 2 DM observed by Lewitt et al. [62], referring to the probable dependency 
of circulating IGF-I bioactivity on isulin actions. On the other hand, the decline 
of IGF-I bioactivity in type 2 DM might even deteriorate insulin resistance 
in the peripheral tissues by several mechanisms (e.g. impairment of: insulin 
sensitivity by muscle tissue [67], anti-infl ammatory effects [57,68], uptake of 
FFA and pancreatic β-cell function and survival [69]). Although causation can-
not be claimed from our study design, the results of Lewitt et al. support the 
idea that changes in circulating IGF-I bioactivity most probably precede those 
of detectable insulin resistance as a decrease in IGFBP-1 levels was already 
present before abnormal fasting or post OGTT glucose levels. This indicates 
that the IGF system plays a crucial and causative role in the development of 
insulin resistance and DM type 2. However, it has to be acknowledged that 
these hypotheses remain to be tested in prospective studies.
8.6.2 IGF-I bioactivity and its relation to the Metabolic Syndrome
The metabolic syndrome (MS) is a condition characterized by a cluster of 
evidence-based cardiovascular risk factors, known as MS components (1. 
abdominal obesity, 2. hypertriglyceridemia, 3. low-serum high-density lipo-
protein (HDL) cholesterol, 4. elevated blood pressure, 5. glucose intolerance) 
and a pro-infl ammatory state [70]. Presence of MS has been defi ned as having 
3 or more components, regardless of the components that contribute to this. 
The MS has been strongly associated with an increased risk of CVD [71], and 
type 2 DM [72].
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Insulin-resistance is thought to be the most important denominator of the 
MS [72,73] and has been called ‘the cornerstone abnormality’. Based on our 
observations as described in paragraph 8.5.1, we also studied IGF-I bioactiv-
ity in relation to the MS. We found a non-linear inverse u-shaped (parabolic) 
relation between IGF-I bioactivity and the number of present MS components. 
Mean circulating IGF-I bioactivity raised gradually up to the level of three 
present MS components (and thus presence of MS), but it declined when all 
5 MS components were present. This pattern substantially differs, however, 
from that reported for circulating total IGF-I levels in relation to MS compo-
nents by others (discussed below).
In the last decade IGF-I has been studied and with raising interest in rela-
tion to MS. With some degree of inconsistency, circulating total IGF-I levels 
have been reported decreased in relation to individual components of the 
MS [60,74]. Two well documented cross-sectional studies on this subject have 
been published recently (data was derived from the Third Nutrition Examina-
tion Survey (NHANES III)) [75,76]. In almost 3400 healthy adults (aged 20-50 
yrs) Sierra-Johnson et al. [76] showed that subjects in the lowest quartile of 
the IGF-I/IGFFBP3 ratio – which was assumed as an reliable estimate of IGF-I 
bioavailability - were more likely to meet the NCEP ATP-III criteria for MS than 
those in the 2th-4th quartile (OR (95% CI): for men 3.1 (2.0-5.1), for women 
3.6 (2.4-5.5)). This was also signifi cant for insulin resistance (2.1 (1.3-3.3) 
and 2.1 (1.5-3.0), respectively), arbitrarily defi ned as the upper quartile of the 
HOMA2 distribution. Interestingly, mean IGF-I/IGFBP-3 ratio decreased in a 
linear fashion as the number of MS components increased. Saydah et al. [75] 
studied these parameters in relation to MS in 5900 participants of NHANES III, 
also including elderly subjects and diabetics. They showed to some degree 
overlapping results to those reported by Sierra-Johnson et al. Independent 
of diabetic status, all individual MS components were associated with lower 
mean levels of total IGF-I and IGFBP-3, a lower IGF-I/IGFBP-3 ratio and with 
higher levels of insulin. Only in non-diabetic subjects mean levels of circulat-
ing total IGF-I and the IGF-I/IGFBP-3 ratio decreased signifi cantly in a linear 
fashion in subjects with either 0, 1-2 or 3-5 components of MS, whereas insulin 
levels showed an opposite pattern. Participants with diabetes had lower mean 
total IGF-I and IGFBP-3 levels and a lower mean IGF-I/IGFBP-3 ratio than 
non-diabetic subjects, regardless of the number of MS components.
Unfortunately, no data of circulating total IGF-I and/or IGFBPs levels 
are available in the third survey of the Rotterdam study, and thus no direct 
comparisons could be made between these IGF parameters and circulating 
IGF-I bioactivity, nor with MS components. We do recognize this limitation of 
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our study. We believe, however, that the results reported in the NHANES III 
studies can be used instead to discuss similarities and differences that seem to 
exist between measurements of circulating bioactive and total IGF-I in relation 
to the MS. This is possible because of the relatively high number of parallels 
between our study and the NHANES III studies (arguments: in all studies data 
were derived from well-characterized longitudinal population-based studies 
with large sample sizes and identical models were used to defi ne MS (NCEP 
ATP-III) and to calculate insulin sensitivity/resistance (HOMA2 model). 
As insulin resistance is the most important denominator of the MS, it can 
therefore be used to validate the outcome of the MS criteria used. Using the 
NCEP ATP III criteria for MS we observed a disproportional rise in insulin lev-
els in subjects that met all 5 MS criteria and a signifi cant rise of mean HOMA-IR 
with increasing MS components. Similarity of these results with other studies, 
including those of the NHANES III studies, means that the population studied 
was representative for our study aim. As IGF-I bioactivity was low in subjects 
with 5 MS components, this confi rms the suggestion that IGF-I bioavailability 
is relatively low in these subjects. However, we also showed that mean IGF-I 
bioactivity in these individuals did not signifi cantly differ from those having 0 
or 1 components but only from those having 2 or 3. In contrast, as the IGF-I/
IGFBP-3 ratio had a stronger association with MS than measures of IGF-I 
or IGFBP-3 alone, Sierra-Johnson et al. suggested that IGF-I bioavailability 
decreased linearly with increasing MS components [76]. 
With the appropriate respect to observations done and suggestions made 
by others, several conclusions can be drawn from the in part confl icting 
results. 1. It appears that IGF-I bioactivity has an inverse U-shaped rather 
than a linear relationship with the development of the MS and thus cardio-
vascular risk. We believe that this observed pattern fi ts better to what is to be 
expected from a biological system, namely harboring dynamic buffer capacity 
or system redundancy. Buffering capacity is, however, only possible within a 
certain range. This could explain why mean IGF-I bioactivity seems to show 
a linear increase rather than an decrease up to the level of 3 MS components. 
One of the mechanisms involved could be adaptation of IGF-I bioactivity in 
an attempt to overcome the degree of insulin resistance, although with the 
requirement that Hep-IR is still absent (a mechanism described in paragraph 
8.5.1). 2. The IGF-I/IGFBP-3 ratio is probably not a very sensitive measure as 
estimate of IGF-I bioavailability (an observation that we analyzed ourselves 
in chapter 3). By use of the IGF-I/IGFBP-3 ratio a parabolic pattern between 
MS components and IGF-I bioactivity - which we believe is more plausible 
when approached from a biological point of view - was not observed. An 
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explanation could be within the range of the study limitations recognized 
by the authors themselves, namely the absence of measurements of other 
determinants of IGF-I bioavailability (e.g. IGFBP-1 and 2). Although not 
much data are available, it was recently reported in a cohort of 163 patients 
with type 2 DM that a low level of IGFBP-2 was independently associated 
with an increased risk of the MS (OR 0.31 [95 % CI 0.11 - 0.90]; p = 0.03) 
[77], suggesting that other determinants could be of importance as well in 
relation to IGF-I bioactivity. Of course one could argue that we also did not 
measure IGFBPs. However, the elegance of the IGF-I KIRA is that it has been 
shown to be sensitive for IGFBPs [11] and outcomes can be interpreted as an 
integral of all and not a subset of factors that determine IGF-I bioactivity. This 
means that by use of the IGF-I/IGFBP-3 ratio probably information about IGF 
system functionality is missed, as data in relation to the MS were discrepant 
when compared to those of IGF-I bioactivity. Thus, although the possibility 
still exists that the IGF-I/IGFP3 ratio could be a marker to monitor risk of 
development of the MS, our study provides data that this ratio is too limited 
to provide a full mechanistic insight into the MS, as the authors proclaimed. 
3. In healthy individuals with absent components of the MS a relatively high 
circulating total IGF-I level seems to be present, but circulating IGF-I bioactiv-
ity seems to be relatively low. This supports the fi ndings discussed in chapter 
2; high immunoreactive levels of total IGF-I do not necessarily represent high 
IGF-I bioactivity. 4. Low levels of circulating IGF-I bioactivity seem to be 
present both in the healthy state as well as when severe insulin resistance has 
developed. Thus, this means that a low circulating IGF-I bioactivity as such 
is not informative about health status, but should be interpreted in relation to 
insulin sensitivity and other markers of CVD.
In conclusion: It is of our belief that the strength of the study described 
in chapter 6 is that it is the only study so far that provides direct measure-
ments of circulating IGF-I bioactivity which were studied in relation to insulin 
sensitivity and the MS. It provides new information about the possible role 
and/or dynamics of the IGF system in relation to the pathophysiological 
process of insulin resistance and the MS. This information is in part unique as 
it seems to differ from information in this fi eld gathered by immunoreactive 
measurements of IGF-I. From our data we conclude that IGF-I bioactivity rises 
in parallel to insulin resistance up to the level that Hep-IR develops, after 
which IGF-I bioactivity drops and insulin levels increase disproportionately. 
Nonetheless, we do recognize that an important limitation of our study is 
the cross-sectional design. This means that we cannot determine whether the 
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association between IGF-I bioactivity and insulin resistance is causal, and 
thus we can only speculate about the direction of causation. Nevertheless, we 
think that this study provides new insights about the relationships between 
the IGF-I system and insulin resistance. Prospective data are needed, how-
ever, to test our hypotheses.
8.7 IGF-I gene polymorphisms in relation to variance in total and bioactive IGF-I 
levels and risk of cardiovascular disease
Twin studies have revealed that total IGF-I levels are heritable, with a high 
degree of heritability at birth (maybe even up to 93%), but a lower degree 
in middle aged and elderly twin subjects ranging from about 40-60% [78-80]. 
However, although family-based studies suggest that genetic variation could 
substantially contribute to circulating levels of IGF-I and IGFBPs, analyses 
of associations with multiple SNPs preferentially located within the regions 
of their genes have been only subtle for circulating levels and even less for 
risk on complex diseases. Restricted to the possible contribution of genetic 
variability itself, it is to be expected however that not only polymorphic 
variation in IGF (related) genes themselves but also that at multiple other loci 
infl uence their gene transcription and thus levels (e.g. activity of transcription 
factors, hormones, inhibitors of transcription (silencing RNA) etcetera). Thus, 
although the contribution of an individual genetic variable is expected to be 
low, a large number of infl uencing variables together could be of substantial 
importance. On the other hand one must be aware that the infl uence of genetic 
variability on the IGF system may be substantially overruled by environmental 
factors such as nutritional status, life style factors and others, thereby referring 
to the classic ‘Nature versus Nurture’ debate. 
In chapter 7 we have described a study in which we analyzed whether 
genetic variance at the human IGF-I gene locus was associated with circulat-
ing levels of total and bioactive IGF-I; 18 SNPs giving rise to 6 haplotype 
blocks were studied. In addition we studied the relationship between these 
IGF-I gene SNPs/haplotypes and the risk of myocardial infarction (MI) and/
or  angina pectoris (AP). Study participants in which circulating total (N=430) 
and bioactive IGF-I levels (N=1036) were determined were randomly selected 
from the fi rst and third survey of Rotterdam study, respectively.
In both men and women mean levels of circulating total IGF-I were sig-
nifi cantly associated with individual SNPs that were mainly located within 
haplotype blocks (1 and 2) covering the genetic variance of the promoter 
regions from which IGF-I gene transcription is initiated (P1 and P2) and further 
5’ upstream. Haplotypes in blocks 1 and 2 were also associated with mean 
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levels of circulating total IGF-I. Genotypes within haplotype blocks 1 and 2 
that were associated with a lower mean total IGF-I level were also associated 
with an increased risk of myocardial MI/AP tested for the total population of 
the fi rst survey of the Rotterdam study for which genotyping was performed 
(N=5974). However, this last association was only found in men. In individuals 
in which we determined circulating IGF-I bioactivity we also found signifi cant 
associations, but with a different profi le. Individual SNPs were signifi cantly 
associated with mean levels of IGF-I bioactivity but this was only observed in 
men. Second these SNPs were located within haplotype blocks 3 to 6, cover-
ing genetic variance of introns 1 to 5 and of the 3’ untranslated region (3’UTR). 
Haplotypes within blocks 3 to 5 also reached signifi cance in men. We could 
not fi nd associations for haplotypes in blocks 3-6 and risk of MI/AP.
A systematic step by step interpretation of our results probably best fi ts 
this study as several fi ndings are of interest but they were not all observed in 
the same individuals (e.g. total IGF-I was measured in 430 individuals of fi rst 
survey, whereas IGF-I bioactivity was measured in 1036 of the third survey of 
the Rotterdam study). We do recognize this study limitation. However, as no 
measurements of circulating IGF-I bioactivity were (nor could be) performed 
in the fi rst survey of the Rotterdam study and no fi nancial resources were 
available to measure total IGF-I in the third study survey we were not able 
to analyze these parameters together. This makes both measurements were 
not fully comparable and thus the results should be interpreted separately. Of 
interest is the association of mean total IGF-I levels and genetic variance at 
the locus of the IGF-I gene promoters. The total circulating level of IGF-I is a 
result of gene transcription initiated from exons 1 (P1) and 2 (P2) of the IGF-I 
gene. It is known that several transcription factors bind to the 5’ UTR region 
of the IGF-I gene [81]. By use of a computer program designed to predict 
transcription factor binding sites especially at gene promoter loci (MatInspec-
tor: http://www.sigmaplot.com/products/genomatix/ matinspector.php) we 
found that SNPs rs35765 and rs35767 are located within predicted binding 
sites at the 5’UTR of the human IGF-I gene for hepatocyte nuclear transcrip-
tion factor 1 alpha (HNF-1a) and the of oncogene TFE3 [82], respectively. 
Although no literature is available to support the last prediction, the human 
IGF-I gene has been shown to be trans-activated by HNF-1a in reporter gene 
cotransfection assays from at a locus close to P1 [83]. Interestingly, HNF-1a 
has also been clearly linked to the occurrence of maturity-onset diabetes 
of the young (MODY) in humans [84]. Although this mechanism could be 
involved currently no functional data is available about whether this SNP is 
indeed functional. Therefore, it must be clear that this possible explanation 
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for the associations found between individual IGF-I SNPs and genotypes 
within blocks 1 and 2 that cover genetic variance at the IGF-I gene promoter 
and mean total IGF-I levels are speculative. Another possibility is that SNPs 
located within haplotype blocks 1 and 2 are themselves not functional, but 
that they are in high linkage disequilibrium with other polymorphisms that 
are functional. In this respect we also looked at the linkage between the 
polymorphisms in blocks 1 and 2 and a VNTR CA repeat at -1 Kb of exon 
1 that has been associated in the Rotterdam study with levels of total IGF-I, 
height and risk on DM type 2, MI, heart failure, stroke and others including 
risk on proteinuria in diabetics [85-89]. Linkage disequilibrium (D’) between 
the CA repeat and rs2162679 and rs35767, respectively, was 0.84 and 0.86. 
Although the CA repeat has been used in several studies for years to study 
genetic variance at the human IGF-I locus today no functional data is available 
for this VNTR. It probably means that this VNTR itself is not functional and 
that publication bias have to be taken into consideration as an explanation for 
this absence of data; IGF-I promoter activation studies have been performed 
in other settings and with success [81].
Interestingly, SNPs located within blocks 1 and 2, as well as haplotypes 
within these blocks were not only associated with mean total IGF-I levels in a 
subset of individuals, but also with risk of MI/AP in the total study population 
of the Rotterdam study, however only in men. Genotypes/haplotypes associ-
ated with lower mean IGF-I levels at baseline showed higher risk at follow-
up, which is in line with fi ndings reported by others: this counts both for the 
link between IGF-I and CVD, as well as for the sexual dimorphism observed 
in this. The question rises how this sexual dimorphism should be explained? 
In relation to CVD IGF-I may have different functions in men and women, or 
being a vascular protective agent in both sexes but far more pronounced in 
men compared to women. In addition, the absence of associations with IGF-I 
gene polymorphisms and CVD in women could also be due to the fact that the 
highest incidence of CVD is at older age (about a decade later) than in men.
Quite surprisingly we observed that mean levels of IGF-I bioactivity were 
associated with SNPs and haplotypes located within other regions of the IGF-I 
gene than total IGF-I levels, and only in men. Although one cannot ignore 
the high linkage between certain SNPs, more associations reached signifi -
cance than one would expect by chance only, suggesting that these fi ndings 
actually have physiological meaning. Of most interest is that mean levels of 
IGF-I bioactivity in men were also associated with SNPs located within other 
functional regions of the IGF-I gene than total IGF-I, namely spanning that 
from exon 3 up to the 3’UTR region. This last region, including exon 5 and 
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exon 6 is known to be subjected to tissue specifi c alternative splicing giving 
rise to different IGF-I mRNA transcripts and IGF-I precursor peptides [90,91]. 
Exon 6 gives rise to the Ea-domain, Exon 5 to the Eb-domain (being both 
regulated by hormonal factors) and a part of both exons to the Ec domain 
[92,93]. This last domain is present in an isoform of IGF-I (Mechano Growth 
Factor), which is produced by muscle tissue upon stretch or damage [93,94]. 
Alignment of the Ea domain among different species shows that the sequence 
is highly conserved, suggesting a biological function for this region, whereas 
sequences for the Eb and Ec-domain are more variable [95]. SNPs in the 3’UTR 
region may thus be associated with differential transcription of IGF-I precur-
sors. Today not much is known about the different IGF-I precursor peptides 
nor about the function of the E-domains in vivo as only one ‘identical’ mature 
IGF-I protein is produced from all precursors. However, our results at least 
indicate that there could be a link between the genetic variability at the locus 
of the IGF-I 3’UTR gene, IGF-I precursors and circulating IGF-I bioactivity. If 
this speculation holds, the observed sexual dimorphism for the associations 
observed might be explained by differences in hormone factors and/or muscle 
mass. In addition it could also be that mRNA stability of IGF-I transcripts is 
affected by genetic variability at the 3’UTR region, thus leading to differences 
in posttranslational modifi cations. We realize that at this moment we cannot 
present data to support these suggestions. 
Another observation of interest comes from our search in the MatInspec-
tor database to predict whether SNPs analyzed change transcription binding 
sites. By use of the MatInspector programme we observed that SNP rs6220 is 
located within a recognized DNA binding site of FOXO proteins. This could 
mean that the 3’ regulatory region of the human IGF-I gene might be targeted 
by these forkhead transcription factors. This might infl uence IGF-I bioactivity. 
Again there is at present no literature that supports this fi nding and therefore 
studies are needed to test this hypothesis.
In our study we did not observe any signifi cant associations between SNP 
and/or haplotypes located within blocks 3-6 and risk of MI and/or AP. Several 
explanations can be considered for this; First it could be that this gene region 
indeed is associated with levels of circulating IGF-I bioactivity but not with 
risk of MI and/or AP. On the other hand we have shown in chapter 3 that IGF-I 
bioactivity was strongly associated with survival in men especially with risk 
of death from CVD. Differences in the defi nition of disease outcome could be 
of infl uence (CVD in chapter 3 was differently defi ned than MI and/or AP in 
chapter 7). Furthermore, we also showed in the same individuals (chapter 6) 
that IGF-I bioactivity had a non-linear inverse u-shaped relationship with the 
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number of components of the MS, a condition characterized by a cluster of 
cardiovascular risk factors. It is of importance to realize that this pattern exists, 
as the overall distribution of individuals within this spectrum can greatly 
infl uence statistical outcomes based on linear models. This means that if the 
majority of individuals is at the left side of the inverse u-shaped curve of IGF-I 
bioactivity one might fi nd that high levels of IGF-I bioactivity are associated 
with risk CVD, whereas if the majority of individuals is at the right side of the 
inverse u-shaped curve, this is true for low levels. Second, if individuals are 
equally spread one might not fi nd any relationship with CVD risk. 
A limitation of our study was that circulating IGF-I bioactivity was not mea-
sured at baseline but only after the third round of the Rotterdam study. This 
may have introduced a prevalence bias since the “worst” cases may have died 
in the intervening years between the fi rst and the third survey. More likely, 
however, is that the genetic contribution to IGF-I bioactivity is far less than 
that of non-genetic factors, whereas total IGF-I levels are more genetically 
determined.
In conclusion: Although having some recognizable limitations, we do think 
that the study presented in chapter 7, gives new insight in the relationship 
between levels of circulating total and bioactive IGF-I and human genetics. 
It is of large interest that again we observed a sexual dimorphism. This study 
also contributes to the data that link the IGF-I system to risk of cardiovascular 
disease. Furthermore our study is the fi rst that suggests that polymorphic vari-
ability at the locus of the IGF-I gene differentially affects levels of total and 
bioactive IGF-I. Where polymorphisms at the 5’UTR region probably affect 
total circulating IGF-I levels, those at the 3’UTR region of the human IGF-I 
gene might affect circulating IGF-I bioactivity (in men). Of course future stud-
ies are necessary to further investigate these fi ndings.
8.8 General refl ection and future perspectives
It is of the authors believe that the general ‘Aim of the Thesis’ has been met 
by the studies included in the thesis. First, our results indeed suggest that 
measurements of circulating IGF-I bioactivity by use of the IGF-I KIRA can 
substantially differ from those obtained by immunoreactive measurements 
of total IGF-I levels, even when obtained in combination with measures of 
IGFBPs. This has been confi rmed by others and is most likely explained by 
the different type of methodology on which the IGF-I KIRA is based when 
compared to immunoassay measurements of circulating levels; Namely, a 
specifi c response produced by living cells (IGF-IR activation) upon exposure 
to an intact biological system. Beforehand, we therefore speculated that this 
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method has the potential to enlarge insight in the function and responses of 
the IGF system in relation to health and disease. 
We have shown for the fi rst time that the IGF-I KIRA can be easily used in 
relatively large population based settings. When one considers that the KIRA 
assay is actually both a bioassay and an ELISA, the level of assay performance 
that could be reached was quite remarkable. We have established normal val-
ues for circulating IGF-I bioactivity in healthy adults, which could and can be 
used in other studies. We observed a sexual dimorphism in circulating levels 
for bioactive IGF-I, with most obvious a signifi cant drop in IGF-I bioactivity 
around the expected age of menopause in women. This could mean that in 
women sex-hormones affect IGF-I bioactivity in vivo, a fi nding of interest in 
relation to for instance the development of (breast) cancer. 
In a prospective study circulating IGF-I bioactivity was found as an inde-
pendent predictor of survival in elderly men, especially when focusing on 
cardiovascular risk. For an IGF-I bioassay this has not been shown previ-
ously. Next to its prospective design, strength of this study was that direct 
comparisons could be made with measures of total and free IGF-I, for which 
in this study we could not fi nd these relationships. Although one might 
expect measures of free and bioactive IGF-I to be closely related – both aim 
to determine direct available IGF-I for IGF-IR activation – outcomes of both 
methods seemed to differ extensively. Probably effects of IGFBP and protease 
activity, involvement of IGF-II and other biological factors important for IGF-I 
bioactivity as well as differences in the methodology and type of population 
studied are involved in this.
In a cross-sectional setting we found that IGF-I bioactivity was related to 
glucose homeostasis and insulin sensitivity as mean levels gradually raised 
with increasing HOMA-IR and dropped exactly at the level when type 2 DM 
was present. Furthermore, mean IGF-I bioactivity showed a parabolic rela-
tionship with the number of MS components present. This type of data is 
new in the fi eld of IGF research and clearly enhances insight in the function 
of the IGF system in relation to insulin resistance. We hope that these results 
in future can be studied in a prospective setting. This is obviously needed 
to obtain information about causality of the observed changes in circulating 
IGF-I bioactivity: are they cause or consequence of insulin resistance? 
In the Rotterdan study we observed that levels of IGF-I bioactivity were 
associated with genetic variation at the IGF-I gene locus. Again we observed a 
sexual dimorphism, as signifi cant associations were only observed in men. Of 
most interest, the polymorphisms that were associated with IGF-I bioactivity 
in men were located in another functional region of the IGF-I gene (3’UTR 
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region), than those that were associated with levels of total IGF-I (promoter 
region). This fi nding opens the possibility that IGF-I bioactivity in part is 
determined by genetic variability at the 3’UTR region of the IGF-I gene, a 
region which is known to be subject to mRNA alternative splicing and post-
translational modifi cation. This fi nding for IGF-I bioactivity is unique, but 
whether it also has physiological consequences remains to be seen.
A limitation at this moment is that the IGF-I KIRA is fully processed by 
hand. However it is not unthinkable that because of its design (at least) a 
large part of the assay is easily adapted to automation. This means that larger 
numbers of samples can be separately run at one time, making this assay more 
time- and economically-effi cient. 
It should be emphasized that the IGF-I KIRA is not developed to replace 
immunoassay measures of IGF-I (or those of other IGF system parameters). 
However, by using both types of techniques the IGF-I KIRA can be of interest 
to clarify how IGF-I bioactivity is regulated in vivo. At this moment the IGF-I 
KIRA has not been used in clinical studies (e.g. GH disorders). Future studies 
are thus of major interest and need to determine the additive value that the 
IGF-I KIRA may have in the clinical setting next to immunoassay measures.
In theory the KIRA design is applicable to all cell surface receptors harbor-
ing kinase receptor activity upon specifi c ligand binding. As next to insulin 
and IGFs also the IR and the IGF-IR share high structure homology it is of 
interest to design identical KIRA bioassays for insulin. By use of comparable 
bioassays this may help to further unravel the functional overlap and differ-
ences between IGFs and insulin. We are currently developing insulin bioassays 
with an identical design as the IGF-I KIRA at our laboratory. This opens the 
possibility to study both parameters (IGF-I and insulin bioactivity) in parallel 
with full comparison.
Last, when interpreting the IGF-I KIRA outcomes one should consider the 
following: when using this method to determine circulating IGF-I bioactivities 
of individuals, outcomes are plotted against a universal background, namely 
an artifi cially IGF-IR transfected cell system. This means that outcomes may 
not necessarily refl ect the actual circulating IGF-I bioactivity of a certain 
individual generated through its own IGF-IRs (e.g. this opens the possibility 
that a relatively high IGF-I bioactivity level measured by the IGF-I KIRA is 
actually an indicator of a low in vivo IGF-IR signaling activity). Therefore an 
interesting future perspective may be to study whether it is possible exists to 
design IGF bioassays that even better refl ect an individual’s IGF-I bioactivity.
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SUMMARY
One of the major challenges in the fi eld of IGF research is to clarify how IGF-I 
bioactivity is regulated in vivo. The highly complex molecular network that 
comprises the IGF system together with its dynamic interactions with other 
factors lies at the basis of this interesting challenge. Classically, the IGF sys-
tem includes two growth factors (IGF-I and IGF-II), six IGF-binding proteins 
(IGFBP-1 to -6), nine IGFBP-related proteins (IGFBP-rPs), two cell surface 
receptors (IGF-IR and the IGF-II mannose-6-phosphate receptor (M-6-PR) and 
several IGFBP specifi c proteases. From this it can be concluded that IGFs are 
enclosed by a large number of regulatory proteins and factors, suggesting 
tight, complex as well as dynamic regulation of their actions.
To date immunoassays are used for measurement of circulating levels of 
individual components of the IGF system in order to estimate IGF activity 
in vivo. Especially IGF-I immunoassays for measures of total IGF-I are used 
in the clinic to screen for, diagnose and evaluate treatment of GH disorders 
(e.g. acromegaly and GHD). It should, however, be realized that in IGF-I 
immunoassays large concessions are made to the structure of the IGF system. 
To guarantee full accessibility of highly specifi c antibodies for IGF-I binding 
IGFBPs are removed, thereby ignoring their substantial infl uences on IGF-I 
activity. Second, although the type of technique applied in IGF-I immunoas-
says has evolved from competitive binding strategies (IGF-I RIA) towards two 
antibody capture techniques (IRMA, CLIA), their underlying ‘ligand based’ 
design has not been altered. However, circulating hormone levels may not 
necessarily refl ect IGF bioavailability (which may also be true for measures 
of circulating free IGF-I). Third, even if levels determined by immunoassay 
techniques are highly accurate it is still extremely diffi cult to defi ne the impact 
of individual circulating levels of IGF-I and/or IGFBPs on IGF-I bioactivity. 
This is dependent on the context of these changes in relation to each other 
and to other determinants of IGF-I bioactivity. Thus, although immunoassays 
without any doubt have yielded important information about the IGF system, 
meaningful information about the IGF system may still not be detected.
In 2003 Frystyk at al. developed a highly specifi c and sensitive bioassay 
to measure circulating IGF-I bioactivity in human serum (IGF-I KIRA). This 
assay quantifi es IGF-IR phosphorylation of living human cells upon stimula-
tion with serum as a direct measure of circulating IGF system activity, defi ned 
as IGF-I bioactivity. Important discriminative features of the IGF-I KIRA in 
relation to immunoassays are that it uses a highly specifi c biological response 
as outcome, and that the IGF system from which this response is derived is 
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kept intact. Thus, the IGF-I KIRA may more naturally refl ect IGF-I bioactivity 
in vivo as IGF-IR activation is the fi rst and biologically most specifi c response 
of all factors that directly infl uence IGF-I bioactivity (it is the level at which all 
extracellular information is integrated into a cellular response).
In the studies included in this thesis the IGF-I KIRA was used to study IGF-I 
bioactivity in relation to aging, health and disease. Our general aim was to 
evaluate whether measures of circulating IGF-I bioactivity have the potential 
to produce new insights in the functional properties of the circulating IGF 
system.
In chapter 2 we have described a cross-sectional study in which normal 
values for the IGF-I KIRA were determined. Circulating IGF-I bioactivity was 
measured in 426 healthy blood donor individuals. Ranke et al. had recently 
determined values for circulating total IGF-I levels within this population 
using 5 different immunoassays. We found that the distribution of circulat-
ing IGF-I bioactivity came close to a normal Gaussian curve, contrasting the 
distribution of total IGF-I levels. The age-specifi c normative ranges can be 
helpful in future to interpret whether IGF-I bioactivity is normal, increased 
and/or decreased in subjects with pathological conditions like acromegaly 
and GH defi ciency. In women circulating IGF-I bioactivity signifi cantly 
dropped around the age range of 55. This suggests that IGF-I bioactivity is in 
part driven by sex hormones. Correlations observed between IGF-I bioactivity 
and measurements of total IGF-I reached signifi cance (p<0.001), however r2 
ranged from 0.25 to 0.31. This means that 70-75% of the variability in IGF-I 
bioactivity could not be explained by levels of total IGF-I. We observed that 
IGF-I bioactivity declined with age, while the fraction of IGF-I bioactivity over 
total IGF-I increased with age.
In chapter 3 we have described a prospective study in which we analyzed 
circulating IGF-I bioactivity next to free and total IGF-I in relation to overall 
survival in a population of about 400 elderly men. Correlations between levels 
of IGF-I bioactivity and those of total and free IGF-I were signifi cant but weak 
and mean IGF-I bioactivity was about 2-3 times higher than free IGF-I levels. 
We found that of the composed survival models only that for circulating IGF-I 
bioactivity reached signifi cance. A relatively high, rather than low circulating 
IGF-I bioactivity was related with longer survival. In a sub-analysis we strati-
fi ed for presence or absence of cardiovascular disease (CVD) and/or evidence 
of a high CVD risk profi le based on CRP levels (a measure of subclinical 
systemic infl ammation). We observed that low circulating IGF-I bioactivity 
was an independent risk factor for mortality and especially in individuals with 
CVD and/or a high infl ammatory risk profi le. We believe that these fi ndings 
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could be of interest since for the fi rst time they provide direct insights in the 
function of the circulating IGF system in relation to human survival.
In chapter 4 we have described results of circulating IGF-I bioactivity and 
total IGF-I measurements performed in a randomized cross-over study in 12 
fed patients who were on continuous ambulatory peritoneal dialysis (CAPD) 
as kidney replacement therapy. Two different dialysis solutions were used; 
either enriched with glucose (G) or glucose plus amino acids (AAG). IGF-I 
bioactivity and total IGF-I were measured at baseline and after the dialysis 
program (9 hours later). We found that the mean circulating total IGF-I levels 
in CAPD subjects were in the upper half of the normal range, whereas mean 
circulating IGF-I bioactivity levels were in the lower half of the normal range 
however. No differences in circulating total IGF-I levels could be found after 
AAG or G dialysis when compared to baseline. IGF-I bioactivity increased 
in CRF patients on CAPD upon both AAG and G dialysis, but only for AAG 
dialysis this difference reached signifi cant difference. This means that IGF-I 
bioactivity even in the fed state can be readily changed (refl ecting system 
dynamics), having a causative relationship with AAG uptake. We concluded 
that bioactive rather than total IGF-I is involved in acute responses to nutri-
tional interventions in CAPD patients.
In chapter 5 we have described a case report of a relatively healthy patient 
with low serum total IGF-I levels, eventually recognized to be caused by 
interference from heterophilic antibodies in the IGF-I immunoassay. IGF-I 
immunoassays are dependent on the highly specifi c interaction between 
the IGF-I protein and the IGF-I antibody. This interaction can (theoretically) 
be disturbed by so-called heterophilic antibodies present in serum. Such 
interference, well-known for other immunoassays, has however never been 
described for IGF-I immunoassays. Here we report the fi rst case in the litera-
ture. Our observation implicates that in some cases heterophilic antibodies 
could be a pitfall in the interpretation of levels of total IGF-I especially when 
used in the diagnosis or treatment of GH disorders. We showed that IGF-I 
bioactivity in this patient was within the mid-normal range for age and sex. 
Using the scantibody technique with the aim to eliminate heterophilic anti-
body interference we observed that the total IGF-I level in this patient was 
within the mid-normal range. This study thus also adds to the data showing 
that measures of IGF-I bioactivity can substantially differ from those obtained 
by immunoassays.
In chapter 6 a cross-sectional study (N=1036) in elderly individuals is 
described. We focused on the relationship between circulating IGF-I bioactiv-
ity, insulin resistance (HOMA-IR) and the metabolic syndrome (MS). Mean 
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circulating IGF-I bioactivity levels progressively rose with increasing mean 
fasting glucose and insulin levels (and thereby HOMA-IR), but it declined 
when undiagnosed type 2 DM was present. We believe that the rise in circulat-
ing IGF-I bioactivity with increasing HOMA-IR could be part of a compensat-
ing mechanism to overcome insulin resistance through insulin like actions of 
IGFs on glucose uptake and on peripheral insulin sensitivity. Hepatic insulin 
resistance could be the cause of the decline in circulating IGF-I bioactivity 
in diabetics. This study supports the idea that the IGF system is involved in 
the pathogenesis of type 2 DM. Causality cannot be obtained from this study 
however.
The metabolic syndrome (MS) is a condition characterized by a cluster 
of evidence based cardiovascular risk factors of which insulin resistance is 
thought to be ‘the corner stone’. A non-linear (inversed U-shaped) relation 
between IGF-I bioactivity and the number of MS components present was 
observed. Circulating IGF-I bioactivity raised gradually up to the level of 
three present MS components (and thus the presence of MS), but it declined 
when all 5 MS components were present. These data contrast to the relation 
between total IGF-I and the total number of MS components reported by oth-
ers in which a linear decreasing relationship was reported. We speculated that 
there could exist a Starling Curve for circulating IGF-I bioactivity.
In chapter 7 we have described a study in which we analyzed whether 
genetic variance at the human IGF-I gene locus was associated with circulating 
levels of total and bioactive IGF-I; 18 SNPs giving rise to 6 haplotype blocks 
were studied. In addition we studied the relationship between these IGF-I 
gene SNPs/haplotypes and risk of MI and/or AP. Study participants in which 
circulating total (N=430) and bioactive IGF-I levels (N=1036) were determined 
were randomly selected from the fi rst and third survey of Rotterdam study 
respectively. Mean levels of circulating total IGF-I were signifi cantly associ-
ated with individual SNPs that were mainly located within haplotype blocks 
(1 and 2) covering the genetic variance of the promoter regions. Indeed, hap-
lotypes in blocks 1 and 2 were also associated with mean levels of circulating 
total IGF-I. These haplotypes were also associated with risk of MI/AP, but only 
in men. 
Individual SNPs were signifi cantly associated with mean levels of IGF-I bio-
activity but this was only observed in men. These SNPs were located within 
haplotype blocks 3 to 6, covering genetic variance of introns 2 to 5 and of the 
3’ untranslated region (3’UTR). Haplotypes within blocks 3 to 5 also reached 
signifi cance in men. We did not observe associations for genotypes/haplo-
tyes in blocks 3-6 and risk of MI/AP. We believe that this study provides new 
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insight in the relationship between levels of circulating total and bioactive 
IGF-I and human genetics. Furthermore levels of IGF-I bioactivity may be less 
determined by genetic variability than total circulating levels.
Overall we believe that by the use of the IGF-I KIRA to asses circulating 
IGF-I bioactivity we have been able to demonstrate that this technique indeed 
provides information about the IGF-I system, that differs from that obtained 
by immunoassays. Therefore the IGF-I KIRA is an interesting technique that 
in future can be used next to (and not instead of) immunoassays to further 
unravel the functions of the IGF system in health and disease.
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SAMENVATTING
Een van de grote uitdagingen in het veld van onderzoek dat zich toespitst op 
‘insulin-like growth factors’ (IGFs) is te verklaren hoe de IGF-I bioactiviteit 
wordt gereguleerd in vivo. Aan de basis van deze uitdaging ligt het complexe 
netwerk van het IGF systeem, alsmede de dynamische interacties die het heeft 
met andere factoren. Het klassieke IGF systeem bestaat uit twee groeifactoren 
(IGF-I en IGF-II), zes IGF bindende eiwitten (IGFBP-1 t/m -6, negen IGFBP 
gerelateerde eiwitten (IGFBP-rPs), twee cel receptoren (de IGF-IR en de IGF-
II mannose-6-fosfaat receptor (M-6-PR) en verschillende IGFBP specifi eke 
proteasen. Hieruit kan geconcludeerd worden dat IGFs omringd worden 
door een groot aantal regulatoire eiwitten en factoren. Dit suggereert zowel 
stringente, complexe als dynamische regulatie van de acties die door IGFs 
worden bewerkstelligd.
Tegenwoordig wordt gebruik gemaakt van immunoassays ter bepaling 
van circulerende concentraties van de individuele componenten van het IGF 
systeem. Met name IGF-I immunoassays, ter bepaling van de totale IGF-I 
spiegels, worden gebruikt in de kliniek met betrekking tot het screenen naar, 
het diagnosticeren van, en het evalueren van de behandeling van groeihor-
moon (GH) gerelateerde ziekten (bijvoorbeeld acromegalie en groeihormoon 
defi ciëntie). Men moet zich echter realiseren dat inherent aan het gebruik van 
IGF-I immunoassays concessies moeten worden gedaan ten aanzien van de 
structuur van het IGF systeem. IGFBPs worden verwijderd uit het bloedmon-
ster om volledige toegankelijkheid te garanderen van specifi eke antilichamen 
voor IGF-I, met als gevolg dat de invloeden van IGFBPs op de IGF-I activiteit 
dus worden genegeerd. Ten tweede, ondanks dat de toegepaste technieken 
in IGF-I immunoassays zijn geëvolueerd van competitieve bindingsstra-
tegieën (IGF-I RIA) naar bindingsmethoden berustend op het gebruik van 
twee antilichamen (IRMA, CLIA), is het algemene principe – de focus ligt 
op de ligand concentratie – onveranderd gebleven. Echter, de circulerende 
hormoon spiegels hoeven niet per se de biologische beschikbaarheid van 
IGFs te vertegenwoordigen (iets wat ook geldt voor de bepaling van vrij IGF-
I). Ten derde, zelfs indien spiegels middels immunoassay technieken zeer 
accuraat bepaald zouden worden, geldt alsnog dat het bijzonder moeizaam 
is de individuele invloed van IGF-I en/of IGFBPs spiegels (of veranderingen 
daarin) op de IGF-I bioactiviteit te defi niëren. Dit laatste is namelijk mede 
afhankelijk van de context van deze spiegels / veranderingen ten opzichte 
van elkaar, alsmede van andere factoren die van invloed zijn op de IGF-I 
bioactiviteit. Resumerend, ondanks het feit dat immunoassays zonder enige 
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twijfel belangrijke informatie over het IGF systeem aan het licht hebben 
gebracht, sluit dit geenszins de mogelijkheid uit dat waardevolle informatie 
over het IGF systeem nog steeds niet wordt gedetecteerd.
In 2003 is door Chen et al. een zeer specifi eke en sensitieve bioassay 
ontwikkelt ter bepaling van de circulerende IGF-I bioactiviteit in humaan 
serum (IGF-I KIRA). Deze assay kwantifi ceert de IGF-IR fosforylering in 
levende cellen na stimulatie met serum als een directe afgeleide van de circu-
lerende IGF systeem activiteit, gedefi nieerd als IGF-I bioactiviteit. Belangrijke 
onderscheidende eigenschappen van de IGF-I KIRA in relatie tot IGF-I imm-
munoassays zijn dat het als meetbare uitkomst gebruik maakt van een zeer 
specifi eke biologische respons, en dat het IGF systeem, waardoor deze res-
pons gegenereerd wordt, geheel intact blijft. Daarom zou de IGF-I KIRA een 
meer natuurlijke afspiegeling kunnen geven van de in vivo IGF-I bioactiviteit, 
aangezien activatie van de IGF-IR de eerste en biologisch meest specifi eke 
respons is van alle factoren die direct de IGF-I bioactiviteit beïnvloeden (het 
vertegenwoordigt het niveau waarbij alle extracellulaire informatie wordt 
geïntegreerd en vertaald naar een intracellulaire response). 
In de studies opgenomen in dit proefschrift is gebruikt gemaakt van de IGF-I 
KIRA ter bestudering van de IGF-I bioactiviteit in relatie veroudering, gezond-
heid en ziekte. Onze algemene doelstelling was te evalueren of bepalingen 
van de circulerende IGF-I bioactiviteit de potentie hebben nieuwe inzichten te 
verschaffen over de eigenschappen van het circulerende IGF systeem. 
In hoofdstuk 2 hebben wij een cross-sectionele studie beschreven waarin 
normaalwaarden voor de IGF-I KIRA methode zijn bepaald. De circulerende 
IGF-I bioactiviteit is hierbij gemeten in bloed van 426 gezonde bloeddonoren. 
Recent heeft Ranke et al. totale IGF-I waarden bepaald in deze populatie, 
waarbij gebruik is gemaakt van vijf verschillende IGF-I immunoassays. Onze 
bevindingen waren dat de distributie van de circulerende IGF-I bioactiviteit 
in de studie populatie dicht in de buurt kwam van een normale Gaussiaanse 
curve. Dit staat in contrast tot de distributies gevonden in de populatie voor 
totaal IGF-I. De leeftijdsspecifi eke normaal waarden vormen een houvast bij 
de interpretatie van toekomstige IGF-I bioactiviteit metingen of deze normaal, 
verhoogd en/of verlaagd zijn bij individuen met onderliggende pathologische 
aandoeningen zoals acromegalie en GH defi ciëntie. Bij vrouwen rond de leef-
tijd van 55 jaar daalde de circulerende IGF-I bioactiviteit signifi cant. Dit sug-
gereert dat de IGF-I bioactiviteit ten dele wordt gedreven door oestrogenen/
prostagenen. Wij vonden signifi cante correlaties tussen de IGF-I bioactiviteit 
en metingen van totaal IGF-I (P<0,001), echter de r2 varieerde van 0.25 tot 
0.31. Dit betekent dat 70-75% van de variatie in de IGF-I bioactiviteit niet 
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kon worden verklaard door spiegels van totaal IGF-I. Ook vonden wij dat de 
IGF-I bioactiviteit daalde met de leeftijd, maar dat de ratio tussen de IGF-I 
bioactiviteit en totaal IGF-I, uitgedrukt in percentage, steeg met de leeftijd. 
In hoofdstuk 3 hebben wij een prospectieve studie beschreven waarin de 
circulerende IGF-I bioactiviteit naast vrij en totaal IGF-I zijn geanalyseerd in 
relatie tot overleving in een populatie van nagenoeg 400 oudere mannen. 
Correlaties tussen de spiegels van IGF-I bioactiviteit en die van totaal en vrij 
IGF-I waren signifi cant, doch zwak, en de gemiddelde IGF-I bioactiviteit was 
2 tot 3 maal hoger dan die van vrij IGF-I. Wij vonden dat alleen de samenge-
stelde overlevingsmodellen voor de IGF-I bioactiviteit signifi cantie bereikten. 
Relatief hoge, in plaats van een lage IGF-I bioactiviteit, was geassocieerd met 
een langere overleving. In een sub-analyse hebben wij de populatie gestra-
tifi ceerd voor de aan- danwel afwezigheid van hart- en vaatziekte (CVD) en/
of bewijs voor een hoog CVD risico profi el gebaseerd op CRP spiegels (een 
maat voor subklinische sytemische infl ammatie). Wij vonden dat een lage 
IGF-I bioactiviteit een onafhankelijke risico factor was voor mortaliteit en met 
name bij individuen met CVD en/of een hoog infl ammatoir risico profi el. Wij 
veronderstellen dat deze bevindingen van belang kunnen zijn aangezien zij 
directe inzichten geven in de functie van het circulerend IGF syteem in relatie 
tot humane overleving.
In hoofdstuk 4 hebben wij onze resultaten beschreven van de circulerende 
IGF-I bioactiviteit en totaal IGF-I bepaald in een gerandomiseerde cross-over 
studie met 12 gevoede nierpatiënten, gebruik makend van continue ambulante 
peritoneale dialyse (CAPD) als nier vervangende therapie. Twee verschillende 
dialyse oplossingen zijn gebruikt; verrijkt met alleen glucose (G) dan wel met 
glucose en aminozuren (AAG). De IGF-I bioaciviteit en totaal IGF-I werden 
voorafgaand en na het dialyse programma (9 uur later) bepaald. We vonden 
dat de gemiddelde circulerende totaal IGF-I spiegels zich bevonden in boven-
ste helft van de normaal waarden, terwijl de gemiddelde IGF-I bioactiviteit 
spiegels zich echter in de onderste helft van de normaalwaarden bevonden. 
Wij vonden geen verschillen in circulerende totaal IGF-I spiegels na AAG of 
G dialyse wanneer deze werden vergeleken met de waarden voorafgaand 
aan dialyse. De IGF-I bioactiviteit steeg in de CAPD patiënten na zowel AAG 
als G dialyse, echter dit bereikte alleen signifi cantie in de AAG dialyse groep. 
Dit betekent dat zelfs in een gevoede toestand de IGF-I bioactiviteit snel kan 
worden aangepast (dit als refl ectie van systemische dynamiek), daarbij een 
causale relatie met AAG opname hebbende. Wij concludeerden dat bioactief 
maar niet totaal IGF-I betrokken is bij de acute responsen op voedingsinter-
venties bij CAPD patiënten. 
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In hoofdstuk 5 hebben wij een case report beschreven van een relatief 
gezonde patient met lage totaal IGF-I spiegels die uiteindelijk gebaseerd 
bleek op interferentie van de gebruikte IGF-I immunoassay door heterofi ele 
antilichamen. IGF-I immunoassays zijn afhankelijk van de specifi eke inter-
actie tussen het IGF-I proteïne en het IGF-I antilichaam. Deze interactie kan 
theoretisch worden verstoord door in serum aanwezig zijnde heterofi ele 
antilichamen. Een dergelijke interferentie, een bekend fenomeen in andere 
immunoassays, was tot op heden niet beschreven voor IGF-I immunoassays. 
Alhier rapporteren wij de eerste ‘case’ in de literatuur. Onze observatie zou 
kunnen impliceren dat in sommige gevallen heterofi ele antilichamen een val-
kuil kunnen vormen bij de interpretatie van totale IGF-I spiegels, met name bij 
gebruik in de diagnostiek of behandeling van GH aandoeningen. Wij toonden 
aan dat de IGF-I bioactiviteit bij deze patiënt zich bevond in de mid-normale 
waarden rekening houdend met leeftijd en geslacht. Gebruik makend van de 
‘scantibody’ techniek, met als doel de interferentie door hetrofi ele antilicha-
men te elimineren, vonden wij dat de totale IGF-I spiegel van deze patiënt 
zich bevond in de mid-normale range. Deze studie vormt een aanvulling op 
de data die aantonen dat bepalingen van de IGF-I bioactiviteit substantieel 
kunnen verschillen van die verkregen met immunoassay technieken.
In hoofdstuk 6 wordt een cross-sectionele studie beschreven, verricht in 
oudere individuen (N=1036). In deze studie hebben wij ons toegespitst op de 
relatie tussen de circulerende IGF-I bioactiviteit, insuline resistentie (HOMA-
IR) en het metabool syndroom (MS). De circulerende IGF-I bioactiviteit steeg 
progressief, parallel aan de gemiddelde nuchtere glucose en insuline waar-
den (en daarmee de HOMA-IR), maar daalde wanneer type 2 DM aanwezig 
was. Wij veronderstellen dat de stijging van de IGF-I bioactiviteit parallel aan 
de toename in de HOMA-IR ten gevolge van een compensatoir mechanisme 
kan zijn; dit ter overwinning van de heersende insuline resistentie middels de 
insulineachtige effecten van IGFs op de cellulaire glucose opname en op de 
perifere insuline gevoeligheid. Het bestaan van hepatische insuline resistentie 
zou de oorzaak kunnen zijn van het verval van de circulerende IGF-I bioac-
tiviteit bij diabetici. Deze studie ondersteunt het idee dat het IGF systeem 
betrokken is in de pathogenese van DM type 2. Een oorzakelijk verband kan 
echter niet verkregen worden uit de opzet van deze studie.
Het MS is een toestand die wordt gekarakteriseerd door een kluster van 
vijf bewezen cardiovasculaire risico factoren waarbij wordt verondersteld 
dat insuline resistentie de zogenaamde hoeksteen vormt van het syndroom. 
Wij vonden een parabole relatie tussen de IGF-I bioactiviteit en het aantal 
aanwezige componenten van het MS. De gemiddelde IGF-I bioactiviteit steeg 
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gradueel tot op het niveau van 3 aanwezige MS componenten, maar het daalde 
bij aanwezigheid van alle 5 de componenten. Deze data staat in contrast tot 
de relatie tussen totaal IGF-I spiegels en het aantal componenten van het 
MS die is beschreven door anderen, waarbij een afnemend lineair verband is 
gevonden. Wij speculeren dat er een Straling Curve zou kunnen bestaan voor 
de circulerende IGF-I bioactiviteit.
In hoofdstuk 7 hebben wij een studie beschreven waarin de associatie tussen 
de genetische variatie ter plaatse van het humane IGF-I locus en circulerende 
spiegels van totaal en bioactief IGF-I is geanalyseerd; 18 SNPs werden bestu-
deerd welke tevens zijn gebruikt ter samenstelling van 6 haplotype blokken. 
Daarnaast hebben we de relatie bestudeerd tussen deze SNPs/haplotypen en 
het risico op een hart infarct en/of angina pectoris (MI/AP). Studie participan-
ten waarbij circulerend totaal (N=430) en bioactief IGF-I (N=1036) werden 
bepaald werden at random geselecteerd vanuit respectievelijk de eerste en 
derde onderzoeksronde van de Rotterdam studie. Spiegels van circulerend 
totaal IGF-I waren signifi cant geassocieerd met individuele SNPs die voorna-
melijk gelokaliseerd waren in haplotype blokken (1 en 2) die de genetische 
variatie van de promotor regionen van het IGF-I gen omvatten. Haplotypen 
in blok 1 en 2 waren ook geassocieerd met spiegels van totaal IGF-I. Deze 
haplotypen waren tevens signifi cant geassocieerd met het risico op MI/AP, 
echter alleen in mannen.
Individuele SNPs waren signifi cant geassocieerd met spiegels van de IGF-I 
bioactiviteit, doch dit werd alleen gevonden in mannen. Deze SNPs waren 
gelokaliseerd in haplotype blokken 3 tot en met 6, welke de genetische vari-
atie omvatten van intron 2 tot en met 5 alsmede van de 3’ untranslated region 
(3’UTR). Haplotypen in blokken 3 tot en met 5 bereikten ook signifi cantie in 
mannen. We vonden geen signifi cante associaties voor haplotypen in blokken 
3 tot en met 6 en het risico op MI/AP. We veronderstellen dat deze studie 
nieuwe inzichten geeft in de relatie tussen spiegels van circulerend totaal en 
bioactief IGF-I en humane genetica. Verder zouden spiegels van bioactief 
IGF-I minder onder invloed van genetische variatie kunnen staan dan spiegels 
van circulerend totaal IGF-I. 
In het algemeen vinden wij dat met behulp van de IGF-I KIRA methode, 
ter bepaling van de IGF-I bioactiviteit, wij in staat zijn geweest om aan te 
tonen dat deze techniek informatie over het IGF systeem kan verschaffen die 
verschilt van die verkregen met immunoassays. Dit maakt de IGF-I KIRA een 
interessante techniek die in de toekomst kan worden toegepast naast (en niet 
in plaats van) immunoassays om de functie van het IGF systeem bij gezond-
heid en ziekte verder te ontrafelen.
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Aangekomen bij het Dankwoord van het proefschrift wordt ik aangegrepen 
door tegenstrijdige emoties. Enerzijds overheerst een gevoel van vreugde - 
ten dele gekenmerkt door opluchting - bij het tot stand komen van het boekje 
als geheel. Anderzijds bestaat het gevoel van afscheid moeten nemen van 
een levensfase waar ik mij met volle passie voor heb ingezet, een passie die 
verslavend is.
Een groot aantal personen hebben een belangrijke bijdrage geleverd aan 
de studies opgenomen in dit proefschrift. Graag wil ik hier een ieder daarvoor 
bedanken, waarvan een aantal in het bijzonder.
Professor Lamberts, mijn Promotor, hartelijk dank voor het geheel aan 
geboden kansen, vertrouwen, stimuli en professionele begeleiding tijdens 
mijn periode als uw promovendus. Ik ben zeer vereerd dat ik mag aansluiten 
in de rij met promovendi die onder uw inspirerende supervisie het hebben 
mogen brengen tot doctor. Het was en is mij een waar genoegen.
Dr. Janssen, maar veel liever gezegd ‘Joop’, met woorden kan ik niet omvat-
ten wat ik aan jou te danken heb. Van begin tot eind ben jij zeer trouw, betrok-
ken en enthousiast gebleken in je taak als co-promoter. Jouw onovertroffen 
kennis en visie op het gebied van IGF en insuline werking, in combinatie met 
je passionele behulpzaamheid, is meer dan bewonderenswaardig en vormt 
de drijvende kracht van veel (nieuw) relevant wetenschappelijk onderzoek 
aan onze universiteit. Ik heb dan ook zeer veel van je geleerd. Tevens besef 
ik dat je mij veel vrijheid hebt gegeven om mezelf te kunnen ontplooien. Ik 
hoop dat onze samenwerking nog lang voort mag duren. Het ‘Bloed’, het 
‘Zweet’ en de Tranen’ waren het meer dan waard; BEDANKT Joop!
Professor van der Lely, Professor Visser en Professor van Saase, hartelijk 
dank voor het plaats nemen in de kleine commissie van mijn promotie.
Dr. Frystyk, dear Jan, here I would like to thank you for your support and 
efforts concerning the integration and development of the IGF-I KIRA at our 
laboratory. I am honoured that I have been able to work and publish with 
you, in this more than interesting fi eld of research. I truely hope that we can 
continue and augment our cooperation in the near future.
Beste Aimee en Christiaan, mijn paranimfen! Mijn keuze om juist jullie te 
vragen voor deze taak was verreweg de minst moeilijke keuze van het gehele 
promotie traject. 
Christiaan, geworden van collega tot geliefde vriend! Veel steun en goede 
herrinneringen heb ik over gehouden aan onze overlappende werk periode 
op het lab, waarin vooral humor en onderling respect de boventoon voerden. 
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Daar waar ik jouw paranimf mocht zijn voelt het goed dat jij dat nu bij mij wilt 
zijn! Lieve Aimee, binnen gekomen als ‘mijn studente’ en tevens geworden 
tot lieve vriendin. Zeer vastberaden was je om na je keuze onderzoek meteen 
terug te stromen naar de kliniek. Ik vind het geweldig echter hoe ik nu bij 
jouw terug zie dat de ‘KIRA feeling’ zich inmiddels diep heeft geworteld. We 
hebben reeds mooi werk samen verricht – om daarbij ook Jeanette zeker niet 
te vergeten (bedankt Jean!) – en ik weet zeker dat daar nog veel meer aan 
toegevoegd gaat worden, uiteindelijk leidend tot een prachtig proefschrift 
’You go Girl!’.
Lieve collegae en vrienden van het lab Neuro-Endo, mijn thuishaven op 
het Erasmus MC, dank voor de mooie tijd op ‘ons’ lab. Beste Leo, wat heb 
ik veel steun aan jou gehad, op werk-gebied, maar zeker ook op persoon-
lijk vlak. Zonder jouw drijvende en structurerende invloed had veel KIRA 
werk waarschijnlijk nimmer tot stand kunnen komen. Net als Joop, heb jij 
mij veel vertrouwen en wetenschappelijke vrijheid gegeven, bedankt daar-
voor! Marlijn, Peter en Diane, onze ‘back bone’ van het lab, dank voor de 
fi jne samenwerking. Marlijn, bedankt voor je inzet tijdens de laatste fase van 
mijn practisch werk met de IGF-I KIRA en opzet van de insuline KIRA. Katy, 
bedankt voor de samenwerking, uiteindelijk heb jij mij de funesses van de 
bioassay bijgebracht. Ik ben het nimmer vergeten! ‘Neuro-endo collegae’ - 
Jan-Willem, Henk, Joost, Pauline, Manon, Fadime, Ramona, Davine, Roxanne 
en Laura – dank voor de gezelligheid en de helpende hand wanneer nodig. 
Veel succes in jullie verdere loopbaan. Cristina e Giovanni, grazie! Rogier, 
kerel, als laatste van ‘het trio’ nog fl ink aan het buffelen in het lab. Ik wens je 
alle goeds toe en heb er alle vertrouwen in!
Collegae van het laboratorium van de interne geneeskunde, ‘de 5e verdie-
ping’, bedankt voor de prettige werksfeer, de gezelligheid in het algemeen, 
tijdens de lab-dagen en de congressen. Piet Uitterlinden, beste Piet, dank voor 
je behulpzaamheid o.a. met het verzamelen van ‘controles’ en je verzette werk 
voor het heterofi ele antilichamen paper. IGF-I (en Joop niet te vergeten) heeft 
ons aan elkaar doen verbinden; ‘Immunoassay vs. Bioassay’ zullen we maar 
zeggen, ‘the story continues’. Dank voor de leuke tijd en je vaak wijze raad! 
Bas Karels, ‘buurman’, klein van postuur maar groot qua persoonlijkheid. De 
metroritten van en naar het werk waren altijd leuk, de gesprekken altijd goed, 
en de grappen altijd fantastisch! Ik zie je in de supermarkt!
Mojgan thank you so much for all your efforts and the extra hours that 
you spent, even when I already had left the laboratory. Chapter 7 of the the-
sis - together with the publications that will be written - couldn’t have been 
adchieved without your help. I wish you and your sister all the best in Canada.
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Beste collegae op de RIDE projecten, Marieke, Wendy, Nadia en Lisette, als 
club van 5 zijn we gestart, dank voor de gezellige tijd en de gedeelde smart. 
De meesten van jullie zal ik ongetwijfeld weer tegen komen in de kliniek, en 
wie weet wederom als directe collega. Marieke waar was ik geweest zonder 
jouw know how van de epidemiologie! Lisette, bedankt voor de introductie 
en je behulpzaamheid in het doolhof van informatiestromen die je kennelijk 
moet beheersen om iets te SNaPpen van polymorfi smen. Zonder jouw was 
dat zeker niet gelukt! 
Collegae van de epidemiologie, bedankt voor de prettige samenwerking. 
Dames van het ERGO centrum, ook jullie ben ik zeker niet vergeten (Aneke, 
bedankt het was een leuke ervaring als ERGO-arts in jouw team!).
Beste Collegae in het Ikazia ziekenhuis (in de ruimste zin van het woord), 
dank voor de prettige werksfeer, jullie collegialiteit en jullie betrokkenheid.
Lieve familie, te weten Pa, Ma, Edwin en Dewie, Frans, Mariet, Mireille en 
Daan, alhoewel jullie geen directe relatie hebben met het werk beschreven 
in dit proefschrift, is jullie indirecte bijdrage desalniettemin van groot belang 
geweest. Dit in de vorm van een onuitputtelijke morele steun. Jullie betrok-
kenheid bij mij als persoon, in combinatie met de liefde, warmte en humor 
die ik van jullie heb mogen (en nog steeds mag) ontvangen, vormden een 
belangrijk drijfveer om dit boekje tot een succes te maken. Dank hiervoor!
Lianne, mijn lieve vrouw inmiddels, wat heb ik veel te danken aan jouw 
onvoorwaardelijke steun, liefde, doorzettingsvermogen en inzet. Veel heb je 
moeten laten, en veel heb je juist alleen moeten doen, in de lange periode dat 
ik mij voornamelijk bezig hield met het schrijven van dit proefschrift, in afwis-
seling met mijn werkzaamheden in de kliniek. Dat was niet altijd makkelijk 
voor je, dat besef ik ter dege. Je hebt me zelfs geholpen met pipetteren op 
het lab toen ik qua tijdsplanning moeilijk kwam te zitten; welke echtgenoot 
kan dat zeggen, je bent een schat! Het proefschrift ligt er nu – en dus zeker 
mede namens jou! - en ik weet dat je trots op me bent! Daar waar ik stond te 
glunderen toen jij promoveerde, weet ik dat jij dat zult doen nu ik daar ben 
aangekomen. Lieve schat, BEDANKT!, ik had het niet zonder jou willen doen! 
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